<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml producer="poppler" version="0.62.0">
<page number="1" position="absolute" top="0" left="0" height="918" width="1512">
	<fontspec id="0" size="15" family="Times" color="#000000"/>
	<fontspec id="1" size="19" family="Times" color="#000000"/>
	<fontspec id="2" size="15" family="Times" color="#000000"/>
	<fontspec id="3" size="19" family="Times" color="#000000"/>
	<fontspec id="4" size="14" family="Times" color="#000000"/>
	<fontspec id="5" size="14" family="Times" color="#000000"/>
	<fontspec id="6" size="14" family="Times" color="#000000"/>
	<fontspec id="7" size="12" family="Times" color="#000000"/>
	<fontspec id="8" size="12" family="Times" color="#0000ff"/>
<text top="59" left="108" width="4" height="15" font="0"> </text>
<text top="59" left="459" width="4" height="15" font="0"> </text>
<text top="59" left="810" width="4" height="15" font="0"> </text>
<text top="59" left="864" width="4" height="15" font="0"> </text>
<text top="59" left="918" width="4" height="15" font="0"> </text>
<text top="59" left="972" width="4" height="15" font="0"> </text>
<text top="59" left="1026" width="4" height="15" font="0"> </text>
<text top="59" left="1080" width="4" height="15" font="0"> </text>
<text top="59" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="108" width="613" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="825" left="810" width="4" height="15" font="0"> </text>
<text top="825" left="864" width="4" height="15" font="0"> </text>
<text top="825" left="918" width="4" height="15" font="0"> </text>
<text top="825" left="972" width="4" height="15" font="0"> </text>
<text top="825" left="1026" width="4" height="15" font="0"> </text>
<text top="825" left="1080" width="4" height="15" font="0"> </text>
<text top="825" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="1188" width="4" height="15" font="0"> </text>
<text top="825" left="1242" width="13" height="15" font="0">1 </text>
<text top="847" left="108" width="4" height="15" font="0"> </text>
<text top="113" left="408" width="701" height="19" font="1"><b>2012 ACCF/AHA Stable Ischemic Heart Disease Guideline Data Supplements </b></text>
<text top="136" left="101" width="4" height="16" font="2"><b> </b></text>
<text top="158" left="101" width="269" height="19" font="1"><b>Data Supplement 1 - Imaging<i> </i></b></text>
<text top="181" left="79" width="95" height="15" font="4"><b>Study Name, </b></text>
<text top="201" left="75" width="103" height="15" font="4"><b>Author, Year, </b></text>
<text top="219" left="96" width="62" height="15" font="4"><b>Citation </b></text>
<text top="181" left="222" width="52" height="15" font="4"><b>Aim of </b></text>
<text top="201" left="226" width="45" height="15" font="4"><b>Study </b></text>
<text top="181" left="307" width="46" height="15" font="4"><b>Study </b></text>
<text top="201" left="309" width="40" height="15" font="4"><b>Type </b></text>
<text top="181" left="377" width="46" height="15" font="4"><b>Study </b></text>
<text top="201" left="384" width="33" height="15" font="4"><b>Size </b></text>
<text top="181" left="457" width="136" height="15" font="4"><b>Patient Population </b></text>
<text top="181" left="686" width="77" height="15" font="4"><b>Endpoints </b></text>
<text top="181" left="858" width="74" height="15" font="4"><b>Statistical </b></text>
<text top="201" left="863" width="64" height="15" font="4"><b>Analysis </b></text>
<text top="219" left="862" width="66" height="15" font="4"><b>(Results) </b></text>
<text top="181" left="965" width="84" height="15" font="4"><b>P Values &amp; </b></text>
<text top="201" left="977" width="60" height="15" font="4"><b>95% CI </b></text>
<text top="181" left="1064" width="69" height="15" font="4"><b>OR: HR: </b></text>
<text top="201" left="1084" width="28" height="15" font="4"><b>RR </b></text>
<text top="181" left="1176" width="46" height="15" font="4"><b>Study </b></text>
<text top="201" left="1156" width="86" height="15" font="4"><b>Limitations </b></text>
<text top="181" left="1301" width="70" height="15" font="4"><b>Findings/ </b></text>
<text top="201" left="1296" width="80" height="15" font="4"><b>Comments </b></text>
<text top="239" left="55" width="4" height="15" font="5"> </text>
<text top="239" left="443" width="69" height="15" font="6"><i><b>Inclusion </b></i></text>
<text top="258" left="449" width="57" height="15" font="6"><i><b>Criteria </b></i></text>
<text top="239" left="532" width="73" height="15" font="6"><i><b>Exclusion </b></i></text>
<text top="258" left="540" width="57" height="15" font="6"><i><b>Criteria </b></i></text>
<text top="239" left="645" width="60" height="15" font="6"><i><b>Primary </b></i></text>
<text top="258" left="642" width="67" height="15" font="6"><i><b>Endpoint </b></i></text>
<text top="239" left="746" width="76" height="15" font="6"><i><b>Secondary </b></i></text>
<text top="258" left="750" width="67" height="15" font="6"><i><b>Endpoint </b></i></text>
<text top="239" left="838" width="4" height="15" font="5"> </text>
<text top="278" left="55" width="251" height="16" font="2"><b>Standard Exercise ECG Testing</b> </text>
<text top="314" left="55" width="49" height="16" font="2"><b>RCTs </b></text>
<text top="335" left="55" width="133" height="14" font="7">A randomized trial of </text>
<text top="352" left="55" width="111" height="14" font="7">exercise treadmill </text>
<text top="369" left="55" width="141" height="14" font="7">ECG vs. stress SPECT </text>
<text top="386" left="55" width="103" height="14" font="7">MPI as an initial </text>
<text top="404" left="55" width="132" height="14" font="7">diagnostic strategy in </text>
<text top="421" left="55" width="119" height="14" font="7">stable patients with </text>
<text top="438" left="55" width="89" height="14" font="7">chest pain and </text>
<text top="455" left="55" width="129" height="14" font="7">suspected CAD: cost </text>
<text top="472" left="55" width="126" height="14" font="7">analysis, Sabharwal, </text>
<text top="490" left="55" width="38" height="14" font="7">2007, </text>
<text top="490" left="93" width="18" height="14" font="8">(1)</text>
<text top="490" left="110" width="7" height="14" font="7">  </text>
<text top="335" left="211" width="59" height="14" font="7">Compare </text>
<text top="352" left="211" width="75" height="14" font="7">Ex ECG vs. </text>
<text top="369" left="211" width="30" height="14" font="7">MPI </text>
<text top="335" left="298" width="33" height="14" font="7">RCT </text>
<text top="335" left="373" width="26" height="14" font="7">457 </text>
<text top="335" left="440" width="64" height="14" font="7">Suspected </text>
<text top="352" left="440" width="35" height="14" font="7">CAD </text>
<text top="335" left="528" width="30" height="14" font="7">N/A </text>
<text top="335" left="622" width="47" height="14" font="7">Cost to </text>
<text top="352" left="622" width="60" height="14" font="7">diagnosis </text>
<text top="335" left="741" width="30" height="14" font="7">N/A </text>
<text top="335" left="838" width="30" height="14" font="7">N/A </text>
<text top="335" left="964" width="39" height="14" font="7">p=NS </text>
<text top="352" left="1005" width="4" height="14" font="7"> </text>
<text top="335" left="1062" width="30" height="14" font="7">N/A </text>
<text top="335" left="1146" width="87" height="14" font="7">No Sens/Spec </text>
<text top="352" left="1197" width="4" height="14" font="7"> </text>
<text top="335" left="1264" width="139" height="14" font="7">Costs similar per ECG </text>
<text top="352" left="1264" width="46" height="14" font="7">&amp; MPI </text>
<text top="508" left="55" width="81" height="14" font="7">Comparative </text>
<text top="525" left="55" width="98" height="14" font="7">effectiveness of </text>
<text top="542" left="55" width="53" height="14" font="7">exercise </text>
<text top="560" left="55" width="123" height="14" font="7">electrocardiography </text>
<text top="577" left="55" width="96" height="14" font="7">with or without </text>
<text top="594" left="55" width="131" height="14" font="7">myocardial perfusion </text>
<text top="611" left="55" width="142" height="14" font="7">SPECT in women with </text>
<text top="629" left="55" width="101" height="14" font="7">suspected CAD, </text>
<text top="646" left="55" width="139" height="14" font="7">Women’s Trial, Shaw, </text>
<text top="663" left="55" width="30" height="14" font="7">2011</text>
<text top="663" left="85" width="21" height="14" font="8"> (2)</text>
<text top="663" left="107" width="4" height="14" font="7"> </text>
<text top="508" left="211" width="59" height="14" font="7">Compare </text>
<text top="525" left="211" width="75" height="14" font="7">Ex ECG vs. </text>
<text top="542" left="211" width="46" height="14" font="7">MPI in </text>
<text top="560" left="211" width="51" height="14" font="7">Women </text>
<text top="508" left="298" width="33" height="14" font="7">RCT </text>
<text top="508" left="373" width="26" height="14" font="7">824 </text>
<text top="508" left="440" width="64" height="14" font="7">Suspected </text>
<text top="525" left="440" width="35" height="14" font="7">CAD </text>
<text top="508" left="528" width="30" height="14" font="7">N/A </text>
<text top="508" left="622" width="100" height="14" font="7">2 y incidence of </text>
<text top="525" left="622" width="47" height="14" font="7">MACE </text>
<text top="542" left="622" width="87" height="14" font="7">(composite of </text>
<text top="560" left="622" width="87" height="14" font="7">cardiac death, </text>
<text top="577" left="622" width="91" height="14" font="7">nonfatal MI or </text>
<text top="594" left="622" width="51" height="14" font="7">hospital </text>
<text top="611" left="622" width="86" height="14" font="7">admission for </text>
<text top="629" left="622" width="77" height="14" font="7">ACS or HF) </text>
<text top="508" left="741" width="69" height="14" font="7">Diagnostic </text>
<text top="525" left="741" width="57" height="14" font="7">accuracy </text>
<text top="508" left="838" width="83" height="14" font="7">ETT 98% vs. </text>
<text top="525" left="838" width="83" height="14" font="7">exercise MPI </text>
<text top="542" left="838" width="42" height="14" font="7">97.7% </text>
<text top="560" left="838" width="4" height="14" font="7"> </text>
<text top="508" left="964" width="46" height="14" font="7">p=0.59 </text>
<text top="508" left="1062" width="30" height="14" font="7">N/A </text>
<text top="508" left="1146" width="79" height="14" font="7">Limited stat. </text>
<text top="525" left="1146" width="41" height="14" font="7">power </text>
<text top="508" left="1264" width="33" height="14" font="7">.N/A </text>
<text top="682" left="55" width="116" height="16" font="2"><b>Meta-Analysis </b></text>
<text top="703" left="55" width="104" height="14" font="7">Meta-analysis of </text>
<text top="720" left="55" width="112" height="14" font="7">exercise testing to </text>
<text top="737" left="55" width="142" height="14" font="7">detect CAD in women, </text>
<text top="754" left="55" width="78" height="14" font="7">Kwok, 1999 </text>
<text top="754" left="133" width="17" height="14" font="8">(3)</text>
<text top="754" left="151" width="4" height="14" font="7"> </text>
<text top="703" left="211" width="69" height="14" font="7">Diagnostic </text>
<text top="720" left="211" width="73" height="14" font="7">accuracy of </text>
<text top="737" left="211" width="58" height="14" font="7">Ex ECG, </text>
<text top="754" left="211" width="60" height="14" font="7">MPI, and </text>
<text top="771" left="211" width="50" height="14" font="7">Echo in </text>
<text top="789" left="211" width="48" height="14" font="7">women </text>
<text top="703" left="298" width="36" height="14" font="7">Meta-</text>
<text top="720" left="298" width="52" height="14" font="7">analysis </text>
<text top="703" left="373" width="19" height="14" font="7">27 </text>
<text top="720" left="373" width="45" height="14" font="7">studies </text>
<text top="737" left="373" width="43" height="14" font="7">(4,113 </text>
<text top="754" left="373" width="26" height="14" font="7">pts) </text>
<text top="703" left="440" width="64" height="14" font="7">Suspected </text>
<text top="720" left="440" width="37" height="14" font="7">CAD-</text>
<text top="737" left="440" width="51" height="14" font="7">Women </text>
<text top="703" left="528" width="30" height="14" font="7">N/A </text>
<text top="703" left="622" width="35" height="14" font="7">CAD </text>
<text top="703" left="733" width="30" height="14" font="7">N/A </text>
<text top="703" left="838" width="98" height="14" font="7">ECG: Sens=61; </text>
<text top="720" left="838" width="94" height="14" font="7">Spec=70           </text>
<text top="737" left="838" width="98" height="14" font="7">Echo: Sens=86, </text>
<text top="754" left="838" width="98" height="14" font="7">Spec=79;           </text>
<text top="771" left="838" width="94" height="14" font="7">MPI: Sens=61, </text>
<text top="789" left="838" width="56" height="14" font="7">Spec=70 </text>
<text top="703" left="964" width="30" height="14" font="7">N/A </text>
<text top="703" left="1062" width="30" height="14" font="7">N/A </text>
<text top="703" left="1146" width="95" height="14" font="7">Planar imaging </text>
<text top="703" left="1264" width="126" height="14" font="7">Moderate diagnostic </text>
<text top="720" left="1264" width="120" height="14" font="7">accuracy in women </text>
</page>
<page number="2" position="absolute" top="0" left="0" height="918" width="1512">
<text top="59" left="108" width="4" height="15" font="0"> </text>
<text top="59" left="459" width="4" height="15" font="0"> </text>
<text top="59" left="810" width="4" height="15" font="0"> </text>
<text top="59" left="864" width="4" height="15" font="0"> </text>
<text top="59" left="918" width="4" height="15" font="0"> </text>
<text top="59" left="972" width="4" height="15" font="0"> </text>
<text top="59" left="1026" width="4" height="15" font="0"> </text>
<text top="59" left="1080" width="4" height="15" font="0"> </text>
<text top="59" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="108" width="613" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="825" left="810" width="4" height="15" font="0"> </text>
<text top="825" left="864" width="4" height="15" font="0"> </text>
<text top="825" left="918" width="4" height="15" font="0"> </text>
<text top="825" left="972" width="4" height="15" font="0"> </text>
<text top="825" left="1026" width="4" height="15" font="0"> </text>
<text top="825" left="1080" width="4" height="15" font="0"> </text>
<text top="825" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="1188" width="4" height="15" font="0"> </text>
<text top="825" left="1242" width="13" height="15" font="0">2 </text>
<text top="847" left="108" width="4" height="15" font="0"> </text>
<text top="112" left="55" width="129" height="14" font="7">Exercise-induced ST </text>
<text top="129" left="55" width="105" height="14" font="7">depression in the </text>
<text top="147" left="55" width="116" height="14" font="7">diagnosis of CAD, </text>
<text top="164" left="55" width="99" height="14" font="7">Gianrossi, 1989 </text>
<text top="164" left="154" width="18" height="14" font="8">(4)</text>
<text top="164" left="172" width="4" height="14" font="7"> </text>
<text top="112" left="211" width="69" height="14" font="7">Diagnostic </text>
<text top="129" left="211" width="73" height="14" font="7">accuracy of </text>
<text top="147" left="211" width="54" height="14" font="7">Ex ECG </text>
<text top="112" left="298" width="36" height="14" font="7">Meta-</text>
<text top="129" left="298" width="52" height="14" font="7">analysis </text>
<text top="112" left="373" width="26" height="14" font="7">150 </text>
<text top="129" left="373" width="36" height="14" font="7">study </text>
<text top="147" left="373" width="44" height="14" font="7">groups </text>
<text top="164" left="373" width="50" height="14" font="7">(24,074 </text>
<text top="181" left="373" width="26" height="14" font="7">pts) </text>
<text top="112" left="440" width="64" height="14" font="7">Suspected </text>
<text top="129" left="440" width="35" height="14" font="7">CAD </text>
<text top="112" left="528" width="30" height="14" font="7">N/A </text>
<text top="112" left="622" width="35" height="14" font="7">CAD </text>
<text top="112" left="733" width="30" height="14" font="7">N/A </text>
<text top="112" left="838" width="59" height="14" font="7">Sens=61, </text>
<text top="129" left="838" width="56" height="14" font="7">Spec=77 </text>
<text top="112" left="964" width="30" height="14" font="7">N/A </text>
<text top="112" left="1062" width="30" height="14" font="7">N/A </text>
<text top="112" left="1146" width="30" height="14" font="7">N/A </text>
<text top="112" left="1264" width="126" height="14" font="7">Moderate diagnostic </text>
<text top="129" left="1264" width="57" height="14" font="7">accuracy </text>
<text top="200" left="55" width="485" height="16" font="2"><b>Pharmacologic Echocardiography, Radionuclide MPI, or MRI </b></text>
<text top="225" left="55" width="445" height="16" font="2"><b>Clinical Practice Guideline/Expert Consensus Statements </b></text>
<text top="246" left="55" width="133" height="14" font="7">Myocardial perfusion </text>
<text top="263" left="55" width="104" height="14" font="7">scintigraphy: the </text>
<text top="281" left="55" width="139" height="14" font="7">evidence, Underwood, </text>
<text top="298" left="55" width="38" height="14" font="7">2004, </text>
<text top="298" left="93" width="13" height="14" font="8">(5</text>
<text top="298" left="105" width="7" height="14" font="7">, </text>
<text top="298" left="113" width="13" height="14" font="8">6)</text>
<text top="298" left="125" width="4" height="14" font="7"> </text>
<text top="246" left="211" width="69" height="14" font="7">Systematic </text>
<text top="263" left="211" width="66" height="14" font="7">Review of </text>
<text top="281" left="211" width="31" height="14" font="7">Cost </text>
<text top="298" left="211" width="69" height="14" font="7">Effectivene</text>
<text top="315" left="211" width="65" height="14" font="7">ss of ECG </text>
<text top="332" left="211" width="56" height="14" font="7">and MPI </text>
<text top="246" left="298" width="51" height="14" font="7">Consens</text>
<text top="263" left="298" width="17" height="14" font="7">us </text>
<text top="281" left="298" width="52" height="14" font="7">conferen</text>
<text top="298" left="298" width="21" height="14" font="7">ce; </text>
<text top="315" left="298" width="45" height="14" font="7">review </text>
<text top="246" left="373" width="51" height="14" font="7">Consens</text>
<text top="263" left="373" width="17" height="14" font="7">us </text>
<text top="281" left="373" width="48" height="14" font="7">Confere</text>
<text top="298" left="373" width="51" height="14" font="7">nce;  48 </text>
<text top="315" left="373" width="45" height="14" font="7">studies </text>
<text top="332" left="373" width="43" height="14" font="7">(7,002 </text>
<text top="350" left="373" width="26" height="14" font="7">pts) </text>
<text top="246" left="440" width="64" height="14" font="7">Suspected </text>
<text top="263" left="440" width="35" height="14" font="7">CAD </text>
<text top="246" left="528" width="30" height="14" font="7">N/A </text>
<text top="246" left="622" width="69" height="14" font="7">Diagnostic </text>
<text top="263" left="622" width="34" height="14" font="7">costs </text>
<text top="246" left="730" width="30" height="14" font="7">N/A </text>
<text top="246" left="838" width="30" height="14" font="7">N/A </text>
<text top="246" left="964" width="30" height="14" font="7">N/A </text>
<text top="246" left="1062" width="30" height="14" font="7">N/A </text>
<text top="246" left="1146" width="30" height="14" font="7">N/A </text>
<text top="246" left="1265" width="103" height="14" font="7">Diagnostic costs </text>
<text top="368" left="55" width="133" height="14" font="7">Relationship between </text>
<text top="385" left="55" width="131" height="14" font="7">obstructive CAD and </text>
<text top="402" left="55" width="141" height="14" font="7">abnormal stress testing </text>
<text top="419" left="55" width="96" height="14" font="7">in patients with </text>
<text top="436" left="55" width="90" height="14" font="7">paroxysmal or </text>
<text top="454" left="55" width="88" height="14" font="7">persistent AF, </text>
<text top="471" left="55" width="95" height="14" font="7">Nucifora, 2011 </text>
<text top="471" left="150" width="18" height="14" font="8">(7)</text>
<text top="471" left="167" width="4" height="14" font="7"> </text>
<text top="368" left="211" width="69" height="14" font="7">Diagnostic </text>
<text top="385" left="211" width="73" height="14" font="7">accuracy of </text>
<text top="402" left="211" width="70" height="14" font="7">ECG in pts </text>
<text top="419" left="211" width="30" height="14" font="7">with </text>
<text top="436" left="211" width="60" height="14" font="7">abnormal </text>
<text top="454" left="211" width="34" height="14" font="7">ECG </text>
<text top="471" left="246" width="4" height="14" font="7"> </text>
<text top="368" left="302" width="89" height="14" font="7">Registry   87 </text>
<text top="368" left="440" width="44" height="14" font="7">AF pts </text>
<text top="368" left="528" width="30" height="14" font="7">N/A </text>
<text top="368" left="622" width="69" height="14" font="7">Diagnostic </text>
<text top="385" left="622" width="61" height="14" font="7">Accuracy </text>
<text top="368" left="730" width="30" height="14" font="7">N/A </text>
<text top="368" left="838" width="30" height="14" font="7">N/A </text>
<text top="368" left="964" width="30" height="14" font="7">N/A </text>
<text top="368" left="1062" width="30" height="14" font="7">N/A </text>
<text top="368" left="1146" width="30" height="14" font="7">N/A </text>
<text top="368" left="1265" width="96" height="14" font="7">Low diagnostic </text>
<text top="385" left="1265" width="141" height="14" font="7">accuracy of ETT in pts </text>
<text top="402" left="1265" width="125" height="14" font="7">with abnormal ECG </text>
<text top="490" left="55" width="116" height="16" font="2"><b>Meta-Analysis </b></text>
<text top="510" left="55" width="129" height="14" font="7">Exercise-induced ST </text>
<text top="528" left="55" width="105" height="14" font="7">depression in the </text>
<text top="545" left="55" width="116" height="14" font="7">diagnosis of CAD, </text>
<text top="562" left="55" width="99" height="14" font="7">Gianrossi, 1989 </text>
<text top="562" left="154" width="18" height="14" font="8">(4)</text>
<text top="562" left="172" width="4" height="14" font="7"> </text>
<text top="510" left="211" width="69" height="14" font="7">Diagnostic </text>
<text top="528" left="211" width="73" height="14" font="7">accuracy of </text>
<text top="545" left="211" width="54" height="14" font="7">Ex ECG </text>
<text top="510" left="298" width="36" height="14" font="7">Meta-</text>
<text top="528" left="298" width="52" height="14" font="7">analysis </text>
<text top="510" left="373" width="26" height="14" font="7">150 </text>
<text top="528" left="373" width="36" height="14" font="7">study </text>
<text top="545" left="373" width="44" height="14" font="7">groups </text>
<text top="562" left="373" width="50" height="14" font="7">(24,074 </text>
<text top="579" left="373" width="26" height="14" font="7">pts) </text>
<text top="510" left="440" width="64" height="14" font="7">Suspected </text>
<text top="528" left="440" width="35" height="14" font="7">CAD </text>
<text top="510" left="528" width="30" height="14" font="7">N/A </text>
<text top="510" left="622" width="35" height="14" font="7">CAD </text>
<text top="510" left="748" width="30" height="14" font="7">N/A </text>
<text top="510" left="838" width="105" height="14" font="7">Meta-regression: </text>
<text top="528" left="838" width="88" height="14" font="7">Reduced Sens </text>
<text top="545" left="838" width="77" height="14" font="7">with LBBB, </text>
<text top="562" left="838" width="52" height="14" font="7">digitalis </text>
<text top="510" left="964" width="53" height="14" font="7">p=0.002 </text>
<text top="510" left="1062" width="30" height="14" font="7">N/A </text>
<text top="510" left="1146" width="30" height="14" font="7">N/A </text>
<text top="510" left="1264" width="126" height="14" font="7">Moderate diagnostic </text>
<text top="528" left="1264" width="57" height="14" font="7">accuracy </text>
<text top="598" left="55" width="165" height="16" font="2"><b>Multicenter Registry</b> </text>
<text top="619" left="55" width="132" height="14" font="7">Economics of MPI in </text>
<text top="636" left="55" width="139" height="14" font="7">Europe—the EMPIRE </text>
<text top="653" left="55" width="118" height="14" font="7">study, Underwood, </text>
<text top="671" left="55" width="30" height="14" font="7">1999</text>
<text top="671" left="85" width="21" height="14" font="8"> (8)</text>
<text top="671" left="107" width="4" height="14" font="7"> </text>
<text top="619" left="211" width="59" height="14" font="7">Compare </text>
<text top="636" left="211" width="58" height="14" font="7">Ex ECG, </text>
<text top="653" left="211" width="55" height="14" font="7">MPI, vs. </text>
<text top="671" left="211" width="41" height="14" font="7">Angio </text>
<text top="619" left="298" width="54" height="14" font="7">Registry </text>
<text top="619" left="373" width="26" height="14" font="7">396 </text>
<text top="619" left="440" width="64" height="14" font="7">Suspected </text>
<text top="636" left="440" width="35" height="14" font="7">CAD </text>
<text top="619" left="528" width="30" height="14" font="7">N/A </text>
<text top="619" left="622" width="106" height="14" font="7">Diagnostic Costs </text>
<text top="619" left="748" width="30" height="14" font="7">N/A </text>
<text top="619" left="838" width="30" height="14" font="7">N/A </text>
<text top="619" left="964" width="30" height="14" font="7">N/A </text>
<text top="619" left="1062" width="30" height="14" font="7">N/A </text>
<text top="619" left="1146" width="30" height="14" font="7">N/A </text>
<text top="619" left="1264" width="100" height="14" font="7">Costs higher for </text>
<text top="636" left="1264" width="135" height="14" font="7">imaging; emphasis on </text>
<text top="653" left="1264" width="120" height="14" font="7">ECG for lower-risk </text>
<text top="671" left="1264" width="50" height="14" font="7">patients </text>
<text top="690" left="55" width="884" height="16" font="2"><b>Exercise Echocardiography or MPI with patients who can and cannot exercise and Standard Exercise ECG testing </b></text>
<text top="723" left="55" width="445" height="16" font="2"><b>Clinical Practice Guideline/Expert Consensus Statements </b></text>
<text top="744" left="55" width="120" height="14" font="7">Clinical value, cost-</text>
<text top="761" left="55" width="107" height="14" font="7">effectiveness and </text>
<text top="778" left="55" width="127" height="14" font="7">safety of myocardial </text>
<text top="744" left="211" width="69" height="14" font="7">Diagnostic </text>
<text top="761" left="211" width="61" height="14" font="7">Accuracy </text>
<text top="778" left="211" width="72" height="14" font="7">of MPI and </text>
<text top="744" left="298" width="36" height="14" font="7">Meta-</text>
<text top="761" left="298" width="56" height="14" font="7">analysis  </text>
<text top="744" left="373" width="19" height="14" font="7">19 </text>
<text top="761" left="373" width="45" height="14" font="7">studies </text>
<text top="778" left="373" width="43" height="14" font="7">(1,405 </text>
<text top="744" left="440" width="53" height="14" font="7">Suspecte</text>
<text top="761" left="440" width="47" height="14" font="7">d CAD </text>
<text top="744" left="510" width="30" height="14" font="7">N/A </text>
<text top="744" left="622" width="35" height="14" font="7">CAD </text>
<text top="744" left="748" width="30" height="14" font="7">N/A </text>
<text top="744" left="838" width="82" height="14" font="7">Pharm: MPI: </text>
<text top="761" left="838" width="59" height="14" font="7">Sens=87, </text>
<text top="778" left="838" width="64" height="14" font="7">Spec=90;  </text>
<text top="744" left="964" width="30" height="14" font="7">N/A </text>
<text top="744" left="1062" width="30" height="14" font="7">N/A </text>
<text top="744" left="1146" width="30" height="14" font="7">N/A </text>
<text top="744" left="1264" width="99" height="14" font="7">High diagnostic </text>
<text top="761" left="1264" width="57" height="14" font="7">accuracy </text>
</page>
<page number="3" position="absolute" top="0" left="0" height="918" width="1512">
	<fontspec id="9" size="12" family="Times" color="#131213"/>
<text top="59" left="108" width="4" height="15" font="0"> </text>
<text top="59" left="459" width="4" height="15" font="0"> </text>
<text top="59" left="810" width="4" height="15" font="0"> </text>
<text top="59" left="864" width="4" height="15" font="0"> </text>
<text top="59" left="918" width="4" height="15" font="0"> </text>
<text top="59" left="972" width="4" height="15" font="0"> </text>
<text top="59" left="1026" width="4" height="15" font="0"> </text>
<text top="59" left="1080" width="4" height="15" font="0"> </text>
<text top="59" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="108" width="613" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="825" left="810" width="4" height="15" font="0"> </text>
<text top="825" left="864" width="4" height="15" font="0"> </text>
<text top="825" left="918" width="4" height="15" font="0"> </text>
<text top="825" left="972" width="4" height="15" font="0"> </text>
<text top="825" left="1026" width="4" height="15" font="0"> </text>
<text top="825" left="1080" width="4" height="15" font="0"> </text>
<text top="825" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="1188" width="4" height="15" font="0"> </text>
<text top="825" left="1242" width="13" height="15" font="0">3 </text>
<text top="847" left="108" width="4" height="15" font="0"> </text>
<text top="112" left="55" width="142" height="14" font="7">perfusion scintigraphy: </text>
<text top="129" left="55" width="124" height="14" font="7">a position statement </text>
<text top="147" left="55" width="102" height="14" font="7">Marcassa, 2008, </text>
<text top="147" left="157" width="21" height="14" font="8">(9) </text>
<text top="164" left="55" width="4" height="14" font="7"> </text>
<text top="112" left="211" width="35" height="14" font="7">Echo </text>
<text top="112" left="373" width="26" height="14" font="7">pts) </text>
<text top="112" left="838" width="98" height="14" font="7">Echo: Sens=85, </text>
<text top="129" left="838" width="98" height="14" font="7">Spec=85;           </text>
<text top="147" left="838" width="59" height="14" font="7">Ex: MPI: </text>
<text top="164" left="838" width="59" height="14" font="7">Sens=82, </text>
<text top="181" left="838" width="64" height="14" font="7">Spec=88;  </text>
<text top="198" left="838" width="98" height="14" font="7">Echo: Sens=70, </text>
<text top="215" left="838" width="56" height="14" font="7">Spec=89 </text>
<text top="233" left="55" width="133" height="14" font="7">Myocardial perfusion </text>
<text top="251" left="55" width="104" height="14" font="7">scintigraphy: the </text>
<text top="268" left="55" width="139" height="14" font="7">evidence, Underwood, </text>
<text top="285" left="55" width="34" height="14" font="7">2004 </text>
<text top="285" left="89" width="13" height="14" font="8">(5</text>
<text top="285" left="102" width="8" height="14" font="7">, </text>
<text top="285" left="109" width="13" height="14" font="8">6)</text>
<text top="285" left="121" width="4" height="14" font="7"> </text>
<text top="302" left="55" width="4" height="14" font="7"> </text>
<text top="233" left="211" width="69" height="14" font="7">Diagnostic </text>
<text top="251" left="211" width="61" height="14" font="7">Accuracy </text>
<text top="268" left="211" width="47" height="14" font="7">of MPI </text>
<text top="233" left="298" width="51" height="14" font="7">Consens</text>
<text top="251" left="298" width="17" height="14" font="7">us </text>
<text top="268" left="298" width="52" height="14" font="7">conferen</text>
<text top="285" left="298" width="21" height="14" font="7">ce; </text>
<text top="302" left="298" width="45" height="14" font="7">review </text>
<text top="233" left="373" width="46" height="14" font="7">Concen</text>
<text top="251" left="373" width="23" height="14" font="7">sus </text>
<text top="268" left="373" width="45" height="14" font="7">confere</text>
<text top="285" left="373" width="51" height="14" font="7">nce:  48 </text>
<text top="302" left="373" width="45" height="14" font="7">studies </text>
<text top="320" left="373" width="43" height="14" font="7">(7,002 </text>
<text top="337" left="373" width="26" height="14" font="7">pts) </text>
<text top="233" left="440" width="53" height="14" font="7">Suspecte</text>
<text top="251" left="440" width="47" height="14" font="7">d CAD </text>
<text top="233" left="510" width="30" height="14" font="7">N/A </text>
<text top="233" left="622" width="35" height="14" font="7">CAD </text>
<text top="233" left="748" width="30" height="14" font="7">N/A </text>
<text top="233" left="838" width="84" height="14" font="7">Ex: Sens=88, </text>
<text top="251" left="838" width="98" height="14" font="7">Spec=70;           </text>
<text top="268" left="838" width="97" height="14" font="7">Dipy: Sens=91, </text>
<text top="285" left="838" width="102" height="14" font="7">Spec=75;            </text>
<text top="302" left="838" width="85" height="14" font="7">Ad: Sens=87, </text>
<text top="320" left="838" width="56" height="14" font="7">Spec=81 </text>
<text top="233" left="964" width="30" height="14" font="7">N/A </text>
<text top="233" left="1062" width="30" height="14" font="7">N/A </text>
<text top="233" left="1146" width="30" height="14" font="7">N/A </text>
<text top="233" left="1264" width="99" height="14" font="7">High diagnostic </text>
<text top="251" left="1264" width="57" height="14" font="7">accuracy </text>
<text top="356" left="55" width="111" height="16" font="2"><b>Meta-analysis </b></text>
<text top="376" left="55" width="135" height="14" font="7">Ex echo or ex SPECT </text>
<text top="394" left="55" width="108" height="14" font="7">imaging? A meta-</text>
<text top="411" left="55" width="134" height="14" font="7">analysis of diagnostic </text>
<text top="428" left="55" width="108" height="14" font="7">test performance, </text>
<text top="445" left="55" width="118" height="14" font="7">Fleischmann, 1998,</text>
<text top="445" left="173" width="4" height="14" font="8"> </text>
<text top="463" left="55" width="25" height="14" font="8">(10)</text>
<text top="463" left="80" width="4" height="14" font="7"> </text>
<text top="376" left="211" width="69" height="14" font="7">Diagnostic </text>
<text top="394" left="211" width="73" height="14" font="7">accuracy of </text>
<text top="411" left="211" width="55" height="14" font="7">Ex Echo </text>
<text top="428" left="211" width="56" height="14" font="7">and MPI </text>
<text top="376" left="298" width="36" height="14" font="7">Meta-</text>
<text top="394" left="298" width="52" height="14" font="7">analysis </text>
<text top="376" left="373" width="19" height="14" font="7">44 </text>
<text top="394" left="373" width="47" height="14" font="7">articles </text>
<text top="411" left="373" width="43" height="14" font="7">(5,830 </text>
<text top="428" left="373" width="26" height="14" font="7">pts) </text>
<text top="376" left="440" width="64" height="14" font="7">Suspected </text>
<text top="394" left="440" width="35" height="14" font="7">CAD </text>
<text top="376" left="552" width="30" height="14" font="7">N/A </text>
<text top="376" left="643" width="35" height="14" font="7">CAD </text>
<text top="376" left="748" width="30" height="14" font="7">N/A </text>
<text top="376" left="838" width="98" height="14" font="7">Echo: Sens=85, </text>
<text top="394" left="838" width="139" height="14" font="7">Spec=77;                      </text>
<text top="411" left="838" width="94" height="14" font="7">MPI: Sens=87, </text>
<text top="428" left="838" width="56" height="14" font="7">Spec=64 </text>
<text top="376" left="964" width="30" height="14" font="7">N/A </text>
<text top="376" left="1062" width="30" height="14" font="7">N/A </text>
<text top="376" left="1146" width="30" height="14" font="7">N/A </text>
<text top="376" left="1264" width="30" height="14" font="7">N/A </text>
<text top="481" left="55" width="131" height="14" font="7">Cost-effectiveness of </text>
<text top="498" left="55" width="91" height="14" font="7">alternative test </text>
<text top="515" left="55" width="142" height="14" font="7">strategies for diagnosis </text>
<text top="532" left="55" width="138" height="14" font="7">of CAD, Garber, 1999 </text>
<text top="550" left="55" width="25" height="14" font="8">(11)</text>
<text top="550" left="80" width="4" height="14" font="7"> </text>
<text top="481" left="211" width="69" height="14" font="7">Diagnostic </text>
<text top="498" left="211" width="73" height="14" font="7">accuracy of </text>
<text top="515" left="211" width="60" height="14" font="7">Echo and </text>
<text top="532" left="211" width="25" height="14" font="7">MP </text>
<text top="481" left="298" width="36" height="14" font="7">Meta-</text>
<text top="498" left="298" width="56" height="14" font="7">analysis  </text>
<text top="481" left="373" width="19" height="14" font="7">27 </text>
<text top="498" left="373" width="45" height="14" font="7">studies </text>
<text top="515" left="373" width="43" height="14" font="7">(2,753 </text>
<text top="532" left="373" width="26" height="14" font="7">pts) </text>
<text top="481" left="440" width="64" height="14" font="7">Suspected </text>
<text top="498" left="440" width="35" height="14" font="7">CAD </text>
<text top="481" left="552" width="30" height="14" font="7">N/A </text>
<text top="481" left="643" width="35" height="14" font="7">CAD </text>
<text top="481" left="748" width="30" height="14" font="7">N/A </text>
<text top="481" left="838" width="98" height="14" font="7">Echo: Sens=76, </text>
<text top="498" left="838" width="76" height="14" font="7">Spec=88;     </text>
<text top="515" left="838" width="112" height="14" font="7">SPECT: Sens=87, </text>
<text top="532" left="838" width="98" height="14" font="7">Spec=76;           </text>
<text top="550" left="838" width="94" height="14" font="7">PET: Sens=88, </text>
<text top="567" left="838" width="56" height="14" font="7">Spec=81 </text>
<text top="481" left="964" width="30" height="14" font="7">N/A </text>
<text top="481" left="1062" width="30" height="14" font="7">N/A </text>
<text top="481" left="1146" width="30" height="14" font="7">N/A </text>
<text top="481" left="1264" width="99" height="14" font="7">High diagnostic </text>
<text top="498" left="1264" width="57" height="14" font="7">accuracy </text>
<text top="585" left="55" width="85" height="14" font="7">Head-to-head </text>
<text top="602" left="55" width="90" height="14" font="7">comparison of </text>
<text top="619" left="55" width="141" height="14" font="7">dipyridamole echo and </text>
<text top="637" left="55" width="97" height="14" font="7">stress perfusion </text>
<text top="654" left="55" width="121" height="14" font="7">scintigraphy for the </text>
<text top="671" left="55" width="114" height="14" font="7">detection of CAD, </text>
<text top="688" left="55" width="77" height="14" font="7">Imran, 2003 </text>
<text top="688" left="132" width="25" height="14" font="8">(12)</text>
<text top="688" left="157" width="4" height="14" font="7"> </text>
<text top="585" left="211" width="69" height="14" font="7">Diagnostic </text>
<text top="602" left="211" width="73" height="14" font="7">accuracy of </text>
<text top="619" left="211" width="64" height="14" font="7">Pharmacol</text>
<text top="637" left="211" width="64" height="14" font="7">ogic Echo </text>
<text top="654" left="211" width="56" height="14" font="7">and MPI </text>
<text top="585" left="298" width="36" height="14" font="7">Meta-</text>
<text top="602" left="298" width="52" height="14" font="7">analysis </text>
<text top="619" left="327" width="4" height="14" font="7"> </text>
<text top="585" left="373" width="19" height="14" font="7">10 </text>
<text top="602" left="373" width="45" height="14" font="7">studies </text>
<text top="619" left="373" width="31" height="14" font="7">(651 </text>
<text top="637" left="373" width="26" height="14" font="7">pts) </text>
<text top="585" left="440" width="64" height="14" font="7">Suspected </text>
<text top="602" left="440" width="35" height="14" font="7">CAD </text>
<text top="585" left="552" width="30" height="14" font="7">N/A </text>
<text top="585" left="643" width="35" height="14" font="7">CAD </text>
<text top="585" left="748" width="30" height="14" font="7">N/A </text>
<text top="585" left="838" width="98" height="14" font="7">Echo: Sens=70; </text>
<text top="602" left="838" width="113" height="14" font="7">Spec=90;               </text>
<text top="619" left="838" width="94" height="14" font="7">MPI: Sens=88, </text>
<text top="637" left="838" width="56" height="14" font="7">Spec=67 </text>
<text top="585" left="964" width="30" height="14" font="7">N/A </text>
<text top="585" left="1062" width="33" height="14" font="7">N/A  </text>
<text top="585" left="1146" width="30" height="14" font="7">N/A </text>
<text top="585" left="1264" width="30" height="14" font="7">N/A </text>
<text top="706" left="55" width="77" height="14" font="7">Accuracy of </text>
<text top="724" left="55" width="76" height="14" font="7">noninvasive </text>
<text top="741" left="55" width="89" height="14" font="7">techniques for </text>
<text top="758" left="55" width="137" height="14" font="7">diagnosis of CAD and </text>
<text top="775" left="55" width="128" height="14" font="7">prediction of cardiac </text>
<text top="793" left="55" width="138" height="14" font="7">events in patients with </text>
<text top="706" left="211" width="69" height="14" font="7">Diagnostic </text>
<text top="724" left="211" width="72" height="14" font="7">accuracy in </text>
<text top="741" left="211" width="51" height="14" font="7">Patients </text>
<text top="758" left="211" width="73" height="14" font="7">with LBBB </text>
<text top="706" left="298" width="36" height="14" font="7">Meta-</text>
<text top="724" left="298" width="52" height="14" font="7">analysis </text>
<text top="706" left="373" width="19" height="14" font="7">55 </text>
<text top="724" left="373" width="49" height="14" font="7">studies; </text>
<text top="741" left="373" width="38" height="14" font="7">1,432 </text>
<text top="758" left="373" width="50" height="14" font="7">patients </text>
<text top="706" left="440" width="64" height="14" font="7">Suspected </text>
<text top="724" left="440" width="94" height="14" font="7">CAD in LBBB </text>
<text top="706" left="552" width="30" height="14" font="7">N/A </text>
<text top="706" left="643" width="78" height="14" font="7">Detection of </text>
<text top="724" left="643" width="61" height="14" font="7">CAD and </text>
<text top="741" left="643" width="81" height="14" font="7">prediction of </text>
<text top="758" left="643" width="89" height="14" font="7">cardiac events </text>
<text top="775" left="643" width="67" height="14" font="7">in pts with </text>
<text top="793" left="643" width="47" height="14" font="7">LBBB; </text>
<text top="793" left="690" width="43" height="14" font="9"> &gt;50% </text>
<text top="706" left="748" width="30" height="14" font="7">N/A </text>
<text top="706" left="838" width="98" height="14" font="7">Echo: Sens=75; </text>
<text top="724" left="838" width="113" height="14" font="7">Spec=89;               </text>
<text top="741" left="838" width="94" height="14" font="7">MPI: Sens=89, </text>
<text top="758" left="838" width="56" height="14" font="7">Spec=41 </text>
<text top="706" left="964" width="30" height="14" font="7">N/A </text>
<text top="706" left="1062" width="30" height="14" font="7">N/A </text>
<text top="706" left="1146" width="30" height="14" font="7">N/A </text>
<text top="706" left="1264" width="30" height="14" font="7">N/A </text>
</page>
<page number="4" position="absolute" top="0" left="0" height="918" width="1512">
<text top="59" left="108" width="4" height="15" font="0"> </text>
<text top="59" left="459" width="4" height="15" font="0"> </text>
<text top="59" left="810" width="4" height="15" font="0"> </text>
<text top="59" left="864" width="4" height="15" font="0"> </text>
<text top="59" left="918" width="4" height="15" font="0"> </text>
<text top="59" left="972" width="4" height="15" font="0"> </text>
<text top="59" left="1026" width="4" height="15" font="0"> </text>
<text top="59" left="1080" width="4" height="15" font="0"> </text>
<text top="59" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="108" width="613" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="825" left="810" width="4" height="15" font="0"> </text>
<text top="825" left="864" width="4" height="15" font="0"> </text>
<text top="825" left="918" width="4" height="15" font="0"> </text>
<text top="825" left="972" width="4" height="15" font="0"> </text>
<text top="825" left="1026" width="4" height="15" font="0"> </text>
<text top="825" left="1080" width="4" height="15" font="0"> </text>
<text top="825" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="1188" width="4" height="15" font="0"> </text>
<text top="825" left="1242" width="13" height="15" font="0">4 </text>
<text top="847" left="108" width="4" height="15" font="0"> </text>
<text top="112" left="55" width="132" height="14" font="7">LBBB, Biagini, 2006 </text>
<text top="129" left="55" width="29" height="14" font="7">(13) </text>
<text top="112" left="643" width="56" height="14" font="9">or &gt;70% </text>
<text top="129" left="643" width="57" height="14" font="9">coronary </text>
<text top="147" left="643" width="90" height="14" font="9">artery stenosis </text>
<text top="164" left="643" width="19" height="14" font="9">on </text>
<text top="181" left="643" width="75" height="14" font="9">angiography</text>
<text top="181" left="718" width="4" height="14" font="7"> </text>
<text top="199" left="55" width="69" height="14" font="7">Diagnostic </text>
<text top="216" left="55" width="133" height="14" font="7">performance of stress </text>
<text top="233" left="55" width="127" height="14" font="7">CMR imaging in the </text>
<text top="251" left="55" width="125" height="14" font="7">detection of CAD: a </text>
<text top="268" left="55" width="86" height="14" font="7">meta-analysis </text>
<text top="285" left="55" width="97" height="14" font="7">Nandular, 2007 </text>
<text top="285" left="152" width="25" height="14" font="8">(14)</text>
<text top="285" left="177" width="4" height="14" font="7"> </text>
<text top="199" left="211" width="69" height="14" font="7">Diagnostic </text>
<text top="216" left="211" width="73" height="14" font="7">accuracy of </text>
<text top="233" left="211" width="37" height="14" font="7">CMR </text>
<text top="251" left="211" width="67" height="14" font="7">WMA and </text>
<text top="268" left="211" width="60" height="14" font="7">perfusion </text>
<text top="199" left="298" width="36" height="14" font="7">Meta-</text>
<text top="216" left="298" width="52" height="14" font="7">analysis </text>
<text top="233" left="327" width="4" height="14" font="7"> </text>
<text top="199" left="373" width="19" height="14" font="7">37 </text>
<text top="216" left="373" width="45" height="14" font="7">studies </text>
<text top="233" left="373" width="43" height="14" font="7">(2,191 </text>
<text top="251" left="373" width="26" height="14" font="7">pts) </text>
<text top="199" left="440" width="64" height="14" font="7">Suspected </text>
<text top="216" left="440" width="35" height="14" font="7">CAD </text>
<text top="199" left="552" width="30" height="14" font="7">N/A </text>
<text top="199" left="643" width="35" height="14" font="7">CAD </text>
<text top="199" left="748" width="30" height="14" font="7">N/A </text>
<text top="199" left="838" width="105" height="14" font="7">WMA: Sens=83, </text>
<text top="216" left="838" width="83" height="14" font="7">Spec=86;       </text>
<text top="233" left="838" width="65" height="14" font="7">Perfusion: </text>
<text top="251" left="838" width="59" height="14" font="7">Sens=91, </text>
<text top="268" left="838" width="56" height="14" font="7">Spec=81 </text>
<text top="199" left="964" width="30" height="14" font="7">N/A </text>
<text top="199" left="1062" width="30" height="14" font="7">N/A </text>
<text top="199" left="1146" width="30" height="14" font="7">N/A </text>
<text top="199" left="1264" width="30" height="14" font="7">N/A </text>
<text top="303" left="55" width="134" height="14" font="7">DSE for the detection </text>
<text top="320" left="55" width="119" height="14" font="7">of CAD in women, </text>
<text top="338" left="55" width="98" height="14" font="7">Geleijnse, 2007 </text>
<text top="338" left="153" width="25" height="14" font="8">(15)</text>
<text top="338" left="178" width="7" height="14" font="7">  </text>
<text top="303" left="211" width="69" height="14" font="7">Diagnostic </text>
<text top="320" left="211" width="73" height="14" font="7">accuracy of </text>
<text top="338" left="211" width="47" height="14" font="7">DSE in </text>
<text top="355" left="211" width="48" height="14" font="7">women </text>
<text top="303" left="298" width="36" height="14" font="7">Meta-</text>
<text top="320" left="298" width="52" height="14" font="7">analysis </text>
<text top="338" left="327" width="4" height="14" font="7"> </text>
<text top="303" left="373" width="19" height="14" font="7">14 </text>
<text top="320" left="373" width="45" height="14" font="7">studies </text>
<text top="338" left="373" width="50" height="14" font="7">(91 pts) </text>
<text top="303" left="440" width="64" height="14" font="7">Suspected </text>
<text top="320" left="440" width="99" height="14" font="7">CAD in women </text>
<text top="303" left="552" width="30" height="14" font="7">N/A </text>
<text top="303" left="643" width="35" height="14" font="7">CAD </text>
<text top="303" left="748" width="35" height="14" font="7">CAD </text>
<text top="303" left="838" width="93" height="14" font="7">Sens=72% and </text>
<text top="320" left="838" width="69" height="14" font="7">Spec=88% </text>
<text top="338" left="838" width="4" height="14" font="7"> </text>
<text top="355" left="893" width="4" height="14" font="7"> </text>
<text top="303" left="964" width="30" height="14" font="7">N/A </text>
<text top="303" left="1062" width="30" height="14" font="7">N/A </text>
<text top="303" left="1146" width="30" height="14" font="7">N/A </text>
<text top="303" left="1264" width="30" height="14" font="7">N/A </text>
<text top="373" left="55" width="92" height="14" font="7">The diagnostic </text>
<text top="390" left="55" width="73" height="14" font="7">accuracy of </text>
<text top="408" left="55" width="141" height="14" font="7">pharmacological stress </text>
<text top="425" left="55" width="75" height="14" font="7">echo for the </text>
<text top="442" left="55" width="137" height="14" font="7">assessment of CAD: a </text>
<text top="459" left="55" width="141" height="14" font="7">meta–analysis, Picano, </text>
<text top="476" left="55" width="34" height="14" font="7">2008 </text>
<text top="476" left="89" width="25" height="14" font="8">(16)</text>
<text top="476" left="114" width="4" height="14" font="7"> </text>
<text top="373" left="211" width="69" height="14" font="7">Diagnostic </text>
<text top="390" left="211" width="73" height="14" font="7">accuracy of </text>
<text top="408" left="211" width="64" height="14" font="7">Pharmacol</text>
<text top="425" left="211" width="64" height="14" font="7">ogic Echo </text>
<text top="373" left="298" width="36" height="14" font="7">Meta-</text>
<text top="390" left="298" width="52" height="14" font="7">analysis </text>
<text top="408" left="327" width="4" height="14" font="7"> </text>
<text top="373" left="373" width="11" height="14" font="7">5 </text>
<text top="390" left="373" width="45" height="14" font="7">studies </text>
<text top="408" left="373" width="31" height="14" font="7">(435 </text>
<text top="425" left="373" width="26" height="14" font="7">pts) </text>
<text top="373" left="440" width="64" height="14" font="7">Suspected </text>
<text top="390" left="440" width="35" height="14" font="7">CAD </text>
<text top="373" left="552" width="30" height="14" font="7">N/A </text>
<text top="373" left="643" width="35" height="14" font="7">CAD </text>
<text top="373" left="748" width="35" height="14" font="7">CAD </text>
<text top="373" left="838" width="72" height="14" font="7">Sens=85%, </text>
<text top="390" left="838" width="69" height="14" font="7">Spec=89% </text>
<text top="373" left="964" width="30" height="14" font="7">N/A </text>
<text top="373" left="1062" width="30" height="14" font="7">N/A </text>
<text top="373" left="1146" width="30" height="14" font="7">N/A </text>
<text top="373" left="1264" width="99" height="14" font="7">High diagnostic </text>
<text top="390" left="1264" width="57" height="14" font="7">accuracy </text>
<text top="494" left="55" width="142" height="14" font="7">Diagnostic accuracy of </text>
<text top="512" left="55" width="125" height="14" font="7">MPI and stress echo </text>
<text top="529" left="55" width="120" height="14" font="7">for the diagnosis of </text>
<text top="546" left="55" width="127" height="14" font="7">LM and triple vessel </text>
<text top="563" left="55" width="128" height="14" font="7">CAD: a comparative </text>
<text top="581" left="55" width="94" height="14" font="7">meta-analysis,  </text>
<text top="598" left="55" width="94" height="14" font="7">Mahajan, 2010 </text>
<text top="598" left="149" width="25" height="14" font="8">(17)</text>
<text top="598" left="174" width="4" height="14" font="7"> </text>
<text top="494" left="211" width="69" height="14" font="7">Diagnostic </text>
<text top="512" left="211" width="73" height="14" font="7">accuracy of </text>
<text top="529" left="211" width="60" height="14" font="7">Echo and </text>
<text top="546" left="211" width="52" height="14" font="7">MPI for </text>
<text top="563" left="211" width="60" height="14" font="7">3VD/LM </text>
<text top="494" left="298" width="36" height="14" font="7">Meta-</text>
<text top="512" left="298" width="52" height="14" font="7">analysis </text>
<text top="529" left="327" width="4" height="14" font="7"> </text>
<text top="494" left="373" width="19" height="14" font="7">32 </text>
<text top="512" left="373" width="45" height="14" font="7">studies </text>
<text top="529" left="373" width="43" height="14" font="7">(3,533 </text>
<text top="546" left="373" width="26" height="14" font="7">pts) </text>
<text top="494" left="440" width="64" height="14" font="7">Suspected </text>
<text top="512" left="440" width="35" height="14" font="7">CAD </text>
<text top="494" left="552" width="30" height="14" font="7">N/A </text>
<text top="494" left="643" width="63" height="14" font="7">3 VD/LM </text>
<text top="494" left="748" width="30" height="14" font="7">N/A </text>
<text top="494" left="838" width="98" height="14" font="7">Echo: Sens=94, </text>
<text top="512" left="838" width="64" height="14" font="7">Spec=40;  </text>
<text top="529" left="838" width="94" height="14" font="7">MPI: Sens=75, </text>
<text top="546" left="838" width="56" height="14" font="7">Spec=48 </text>
<text top="494" left="964" width="30" height="14" font="7">N/A </text>
<text top="494" left="1062" width="30" height="14" font="7">N/A </text>
<text top="494" left="1146" width="30" height="14" font="7">N/A </text>
<text top="494" left="1264" width="66" height="14" font="7">High Sens </text>
<text top="617" left="55" width="429" height="16" font="2"><b>CCTA for patients who are and are not able to exercise </b></text>
<text top="654" left="55" width="202" height="16" font="2"><b>Controlled Clinical Trials </b></text>
<text top="674" left="55" width="69" height="14" font="7">Diagnostic </text>
<text top="692" left="55" width="116" height="14" font="7">performance of 64-</text>
<text top="709" left="55" width="127" height="14" font="7">multidetector row of </text>
<text top="726" left="55" width="131" height="14" font="7">CCTA for evaluation </text>
<text top="744" left="55" width="112" height="14" font="7">of coronary artery </text>
<text top="761" left="55" width="137" height="14" font="7">stenosis in individuals </text>
<text top="778" left="55" width="134" height="14" font="7">without known CAD: </text>
<text top="674" left="211" width="69" height="14" font="7">Diagnostic </text>
<text top="692" left="211" width="73" height="14" font="7">accuracy of </text>
<text top="709" left="211" width="52" height="14" font="7">64-slide </text>
<text top="726" left="211" width="44" height="14" font="7">CCTA </text>
<text top="674" left="298" width="56" height="14" font="7">Prospecti</text>
<text top="692" left="298" width="22" height="14" font="7">ve, </text>
<text top="709" left="298" width="53" height="14" font="7">blinded, </text>
<text top="726" left="298" width="35" height="14" font="7">MCS </text>
<text top="674" left="373" width="26" height="14" font="7">230 </text>
<text top="674" left="440" width="54" height="14" font="7">a) ≥18 y </text>
<text top="692" left="440" width="80" height="14" font="7">b) chest pain </text>
<text top="709" left="440" width="66" height="14" font="7">(typical or </text>
<text top="726" left="440" width="56" height="14" font="7">atypical) </text>
<text top="744" left="440" width="97" height="14" font="7">c) nonemergent </text>
<text top="761" left="440" width="30" height="14" font="7">ICA </text>
<text top="674" left="552" width="60" height="14" font="7">a) known </text>
<text top="692" left="552" width="35" height="14" font="7">CAD </text>
<text top="709" left="552" width="50" height="14" font="7">b) renal </text>
<text top="726" left="552" width="43" height="14" font="7">failure </text>
<text top="744" left="552" width="15" height="14" font="7">c) </text>
<text top="761" left="552" width="70" height="14" font="7">arrhythmia </text>
<text top="778" left="552" width="76" height="14" font="7">d) HR &gt;100 </text>
<text top="674" left="643" width="55" height="14" font="7">a) ≥50% </text>
<text top="692" left="643" width="56" height="14" font="7">diameter </text>
<text top="709" left="643" width="70" height="14" font="7">stenosis on </text>
<text top="726" left="643" width="35" height="14" font="7">QCA </text>
<text top="744" left="643" width="56" height="14" font="7">b) ≥70% </text>
<text top="761" left="643" width="56" height="14" font="7">diameter </text>
<text top="778" left="643" width="70" height="14" font="7">stenosis on </text>
<text top="674" left="748" width="30" height="14" font="7">N/A </text>
<text top="674" left="838" width="83" height="14" font="7">Patient based </text>
<text top="692" left="838" width="91" height="14" font="7">analysis ≥50% </text>
<text top="709" left="838" width="51" height="14" font="7">stenosis </text>
<text top="726" left="838" width="67" height="14" font="7">Sens: 95% </text>
<text top="744" left="838" width="68" height="14" font="7">Spec: 83% </text>
<text top="761" left="838" width="67" height="14" font="7">PPV: 64% </text>
<text top="778" left="838" width="69" height="14" font="7">NPV: 99% </text>
<text top="674" left="964" width="83" height="14" font="7">Patient based </text>
<text top="692" left="964" width="91" height="14" font="7">analysis ≥50% </text>
<text top="709" left="964" width="51" height="14" font="7">stenosis </text>
<text top="726" left="964" width="88" height="14" font="7">(85% to 99%) </text>
<text top="744" left="964" width="88" height="14" font="7">(76% to 88%) </text>
<text top="761" left="964" width="88" height="14" font="7">(53% to 75%) </text>
<text top="778" left="964" width="95" height="14" font="7">(96% to 100%) </text>
<text top="674" left="1088" width="30" height="14" font="7">N/A </text>
<text top="674" left="1146" width="77" height="14" font="7">Referred for </text>
<text top="692" left="1146" width="30" height="14" font="7">ICA </text>
<text top="675" left="1264" width="8" height="11" font="7">≥</text>
<text top="674" left="1272" width="82" height="14" font="7">50% stenosis </text>
<text top="692" left="1264" width="121" height="14" font="7">AUC=0.96 (0.94 to </text>
<text top="709" left="1264" width="35" height="14" font="7">0.98) </text>
<text top="726" left="1264" width="4" height="14" font="7"> </text>
<text top="745" left="1264" width="8" height="11" font="7">≥</text>
<text top="744" left="1272" width="82" height="14" font="7">70% stenosis </text>
<text top="761" left="1264" width="121" height="14" font="7">AUC=0.95 (0.92 to </text>
<text top="778" left="1264" width="39" height="14" font="7">0.97)  </text>
</page>
<page number="5" position="absolute" top="0" left="0" height="918" width="1512">
<text top="59" left="108" width="4" height="15" font="0"> </text>
<text top="59" left="459" width="4" height="15" font="0"> </text>
<text top="59" left="810" width="4" height="15" font="0"> </text>
<text top="59" left="864" width="4" height="15" font="0"> </text>
<text top="59" left="918" width="4" height="15" font="0"> </text>
<text top="59" left="972" width="4" height="15" font="0"> </text>
<text top="59" left="1026" width="4" height="15" font="0"> </text>
<text top="59" left="1080" width="4" height="15" font="0"> </text>
<text top="59" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="108" width="613" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="825" left="810" width="4" height="15" font="0"> </text>
<text top="825" left="864" width="4" height="15" font="0"> </text>
<text top="825" left="918" width="4" height="15" font="0"> </text>
<text top="825" left="972" width="4" height="15" font="0"> </text>
<text top="825" left="1026" width="4" height="15" font="0"> </text>
<text top="825" left="1080" width="4" height="15" font="0"> </text>
<text top="825" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="1188" width="4" height="15" font="0"> </text>
<text top="825" left="1242" width="13" height="15" font="0">5 </text>
<text top="847" left="108" width="4" height="15" font="0"> </text>
<text top="112" left="55" width="98" height="14" font="7">results from the </text>
<text top="129" left="55" width="73" height="14" font="7">prospective </text>
<text top="147" left="55" width="72" height="14" font="7">multicenter </text>
<text top="164" left="55" width="141" height="14" font="7">ACCURACY, Budoff, </text>
<text top="181" left="55" width="34" height="14" font="7">2008 </text>
<text top="181" left="89" width="25" height="14" font="8">(18)</text>
<text top="181" left="114" width="4" height="14" font="7"> </text>
<text top="112" left="552" width="49" height="14" font="7">mm Hg </text>
<text top="129" left="552" width="46" height="14" font="7">e) SBP </text>
<text top="147" left="552" width="62" height="14" font="7">&lt;100 mm </text>
<text top="164" left="552" width="22" height="14" font="7">Hg </text>
<text top="181" left="552" width="65" height="14" font="7">f) contrast </text>
<text top="198" left="552" width="45" height="14" font="7">allergy </text>
<text top="215" left="552" width="50" height="14" font="7">g) CI to </text>
<text top="233" left="552" width="76" height="14" font="7">BB’s, CCB; </text>
<text top="250" left="552" width="32" height="14" font="7">nitro </text>
<text top="267" left="552" width="16" height="14" font="7">h) </text>
<text top="284" left="552" width="66" height="14" font="7">pregnancy </text>
<text top="112" left="643" width="35" height="14" font="7">QCA </text>
<text top="112" left="838" width="4" height="14" font="7"> </text>
<text top="130" left="838" width="8" height="11" font="7">≥</text>
<text top="129" left="847" width="88" height="14" font="7">70% stensosis </text>
<text top="147" left="838" width="67" height="14" font="7">Sens: 94% </text>
<text top="164" left="838" width="68" height="14" font="7">Spec: 83% </text>
<text top="181" left="838" width="70" height="14" font="7">PPV:  48% </text>
<text top="198" left="838" width="69" height="14" font="7">NPV: 99% </text>
<text top="215" left="838" width="4" height="14" font="7"> </text>
<text top="233" left="838" width="4" height="14" font="7"> </text>
<text top="112" left="964" width="4" height="14" font="7"> </text>
<text top="130" left="964" width="8" height="11" font="7">≥</text>
<text top="129" left="973" width="82" height="14" font="7">70% stenosis </text>
<text top="147" left="964" width="88" height="14" font="7">(79% to 99%) </text>
<text top="164" left="964" width="88" height="14" font="7">(77% to 88%) </text>
<text top="181" left="964" width="88" height="14" font="7">(35% to 62%) </text>
<text top="198" left="964" width="95" height="14" font="7">(96% to 100%) </text>
<text top="302" left="55" width="69" height="14" font="7">Diagnostic </text>
<text top="320" left="55" width="96" height="14" font="7">performance of </text>
<text top="337" left="55" width="135" height="14" font="7">coronary angiography </text>
<text top="354" left="55" width="137" height="14" font="7">by 64-row CT, Miller, </text>
<text top="372" left="55" width="34" height="14" font="7">2008 </text>
<text top="372" left="89" width="25" height="14" font="8">(19)</text>
<text top="372" left="114" width="4" height="14" font="7"> </text>
<text top="302" left="211" width="69" height="14" font="7">Diagnostic </text>
<text top="320" left="211" width="73" height="14" font="7">accuracy of </text>
<text top="337" left="211" width="52" height="14" font="7">64-slide </text>
<text top="354" left="211" width="58" height="14" font="7">MDCTA </text>
<text top="302" left="298" width="56" height="14" font="7">Prospecti</text>
<text top="320" left="298" width="22" height="14" font="7">ve, </text>
<text top="337" left="298" width="53" height="14" font="7">blinded, </text>
<text top="354" left="298" width="57" height="14" font="7">internatio</text>
<text top="372" left="298" width="61" height="14" font="7">nal, MCS </text>
<text top="302" left="373" width="26" height="14" font="7">291 </text>
<text top="302" left="440" width="57" height="14" font="7">a)  ≥40 y </text>
<text top="320" left="440" width="80" height="14" font="7">b) chest pain </text>
<text top="337" left="440" width="97" height="14" font="7">c) nonemergent </text>
<text top="354" left="440" width="30" height="14" font="7">ICA </text>
<text top="372" left="440" width="45" height="14" font="7">d) neg. </text>
<text top="389" left="440" width="91" height="14" font="7">pregnancy test </text>
<text top="302" left="552" width="60" height="14" font="7">a) known </text>
<text top="320" left="552" width="45" height="14" font="7">CABG </text>
<text top="337" left="552" width="63" height="14" font="7">b) PCI &lt;6 </text>
<text top="354" left="552" width="23" height="14" font="7">mo </text>
<text top="372" left="552" width="38" height="14" font="7">c) AF </text>
<text top="389" left="552" width="50" height="14" font="7">d) renal </text>
<text top="406" left="552" width="43" height="14" font="7">failure </text>
<text top="423" left="552" width="67" height="14" font="7">e) contrast </text>
<text top="440" left="552" width="45" height="14" font="7">allergy </text>
<text top="458" left="552" width="48" height="14" font="7">f) CI to </text>
<text top="475" left="552" width="35" height="14" font="7">BB’s </text>
<text top="492" left="552" width="50" height="14" font="7">g) heart </text>
<text top="509" left="552" width="43" height="14" font="7">failure </text>
<text top="527" left="552" width="76" height="14" font="7">h) BMI &gt;40 </text>
<text top="544" left="552" width="51" height="14" font="7">i) aortic </text>
<text top="561" left="552" width="51" height="14" font="7">stenosis </text>
<text top="579" left="552" width="67" height="14" font="7">j) multiple </text>
<text top="596" left="552" width="60" height="14" font="7">myeloma </text>
<text top="302" left="643" width="55" height="14" font="7">a) ≥50% </text>
<text top="320" left="643" width="56" height="14" font="7">diameter </text>
<text top="337" left="643" width="70" height="14" font="7">stenosis on </text>
<text top="354" left="643" width="35" height="14" font="7">QCA </text>
<text top="302" left="748" width="30" height="14" font="7">N/A </text>
<text top="302" left="838" width="101" height="14" font="7">Visual MCDTA </text>
<text top="320" left="838" width="67" height="14" font="7">Sens: 83% </text>
<text top="337" left="838" width="68" height="14" font="7">Spec: 91% </text>
<text top="354" left="838" width="67" height="14" font="7">PPV: 92% </text>
<text top="372" left="838" width="69" height="14" font="7">NPV: 81% </text>
<text top="389" left="838" width="4" height="14" font="7"> </text>
<text top="406" left="838" width="98" height="14" font="7">Quant MDCTA </text>
<text top="423" left="838" width="67" height="14" font="7">Sens: 85% </text>
<text top="440" left="838" width="68" height="14" font="7">Spec: 90% </text>
<text top="458" left="838" width="67" height="14" font="7">PPV: 91% </text>
<text top="475" left="838" width="69" height="14" font="7">NPV: 83% </text>
<text top="302" left="964" width="101" height="14" font="7">Visual MDCTA </text>
<text top="320" left="964" width="88" height="14" font="7">(76% to 88%) </text>
<text top="337" left="964" width="88" height="14" font="7">(85% to 96%) </text>
<text top="354" left="964" width="88" height="14" font="7">(87% to 96%) </text>
<text top="372" left="964" width="88" height="14" font="7">(73% to 87%) </text>
<text top="389" left="964" width="4" height="14" font="7"> </text>
<text top="406" left="964" width="98" height="14" font="7">Quant MDCTA </text>
<text top="423" left="964" width="92" height="14" font="7">(79% to 90%)  </text>
<text top="440" left="964" width="88" height="14" font="7">(83% to 94%) </text>
<text top="458" left="964" width="88" height="14" font="7">(86% to 95%) </text>
<text top="475" left="964" width="88" height="14" font="7">(75% to 89%) </text>
<text top="302" left="1088" width="4" height="14" font="7"> </text>
<text top="302" left="1146" width="77" height="14" font="7">Referred for </text>
<text top="320" left="1146" width="30" height="14" font="7">ICA </text>
<text top="302" left="1264" width="101" height="14" font="7">Visual MDCTA </text>
<text top="320" left="1264" width="121" height="14" font="7">AUC=0.93 (0.89 to </text>
<text top="337" left="1264" width="35" height="14" font="7">0.95) </text>
<text top="354" left="1264" width="4" height="14" font="7"> </text>
<text top="372" left="1264" width="98" height="14" font="7">Quant MDCTA </text>
<text top="389" left="1264" width="121" height="14" font="7">AUC=0.93 (0.90 to </text>
<text top="406" left="1264" width="35" height="14" font="7">0.96) </text>
<text top="423" left="1264" width="4" height="14" font="7"> </text>
</page>
<page number="6" position="absolute" top="0" left="0" height="918" width="1512">
	<fontspec id="10" size="12" family="Times" color="#000000"/>
<text top="59" left="108" width="4" height="15" font="0"> </text>
<text top="59" left="459" width="4" height="15" font="0"> </text>
<text top="59" left="810" width="4" height="15" font="0"> </text>
<text top="59" left="864" width="4" height="15" font="0"> </text>
<text top="59" left="918" width="4" height="15" font="0"> </text>
<text top="59" left="972" width="4" height="15" font="0"> </text>
<text top="59" left="1026" width="4" height="15" font="0"> </text>
<text top="59" left="1080" width="4" height="15" font="0"> </text>
<text top="59" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="108" width="613" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="825" left="810" width="4" height="15" font="0"> </text>
<text top="825" left="864" width="4" height="15" font="0"> </text>
<text top="825" left="918" width="4" height="15" font="0"> </text>
<text top="825" left="972" width="4" height="15" font="0"> </text>
<text top="825" left="1026" width="4" height="15" font="0"> </text>
<text top="825" left="1080" width="4" height="15" font="0"> </text>
<text top="825" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="1188" width="4" height="15" font="0"> </text>
<text top="825" left="1242" width="13" height="15" font="0">6 </text>
<text top="847" left="108" width="4" height="15" font="0"> </text>
<text top="112" left="55" width="142" height="14" font="7">Diagnostic accuracy of </text>
<text top="129" left="55" width="114" height="14" font="7">64-slice computed </text>
<text top="147" left="55" width="133" height="14" font="7">tomography coronary </text>
<text top="164" left="55" width="93" height="14" font="7">angiography: a </text>
<text top="181" left="55" width="77" height="14" font="7">prospective, </text>
<text top="198" left="55" width="76" height="14" font="7">multicenter, </text>
<text top="215" left="55" width="117" height="14" font="7">multivendor study, </text>
<text top="233" left="55" width="104" height="14" font="7">Meijboom, 2008 </text>
<text top="233" left="159" width="25" height="14" font="8">(20)</text>
<text top="233" left="184" width="4" height="14" font="7"> </text>
<text top="112" left="211" width="69" height="14" font="7">Diagnostic </text>
<text top="129" left="211" width="73" height="14" font="7">accuracy of </text>
<text top="147" left="211" width="52" height="14" font="7">64-slide </text>
<text top="164" left="211" width="44" height="14" font="7">CCTA </text>
<text top="112" left="298" width="56" height="14" font="7">Prospecti</text>
<text top="129" left="298" width="57" height="14" font="7">ve, MCS </text>
<text top="112" left="373" width="26" height="14" font="7">360 </text>
<text top="112" left="440" width="80" height="14" font="7">a) 50 to 70 y </text>
<text top="129" left="440" width="99" height="14" font="7">b) stable angina </text>
<text top="147" left="440" width="51" height="14" font="7">and UA </text>
<text top="164" left="440" width="72" height="14" font="7">referred for </text>
<text top="181" left="440" width="35" height="14" font="7">CCA </text>
<text top="198" left="440" width="80" height="14" font="7">c) chest pain </text>
<text top="215" left="440" width="98" height="14" font="7">d) nonemergent </text>
<text top="233" left="440" width="30" height="14" font="7">ICA </text>
<text top="112" left="552" width="76" height="14" font="7">a) prior PCI </text>
<text top="129" left="552" width="62" height="14" font="7">with stent </text>
<text top="147" left="552" width="65" height="14" font="7">or CABG  </text>
<text top="164" left="552" width="50" height="14" font="7">b) renal </text>
<text top="181" left="552" width="67" height="14" font="7">failure (Cr </text>
<text top="198" left="552" width="35" height="14" font="7">&gt;120 </text>
<text top="216" left="552" width="7" height="13" font="10"><i>µ</i></text>
<text top="215" left="560" width="35" height="14" font="7">M/L) </text>
<text top="233" left="552" width="15" height="14" font="7">c) </text>
<text top="250" left="552" width="70" height="14" font="7">arrhythmia </text>
<text top="267" left="552" width="66" height="14" font="7">d) &lt;15 sec </text>
<text top="284" left="552" width="72" height="14" font="7">breath hold </text>
<text top="302" left="552" width="67" height="14" font="7">e) contrast </text>
<text top="319" left="552" width="45" height="14" font="7">allergy </text>
<text top="113" left="643" width="8" height="11" font="7">≥</text>
<text top="112" left="651" width="31" height="14" font="7">50% </text>
<text top="129" left="643" width="56" height="14" font="7">diameter </text>
<text top="147" left="643" width="70" height="14" font="7">stenosis on </text>
<text top="164" left="643" width="35" height="14" font="7">QCA </text>
<text top="112" left="748" width="30" height="14" font="7">N/A </text>
<text top="112" left="838" width="68" height="14" font="7">Per patient </text>
<text top="129" left="838" width="56" height="14" font="7">analysis: </text>
<text top="147" left="838" width="67" height="14" font="7">Sens: 99% </text>
<text top="164" left="838" width="68" height="14" font="7">Spec: 64% </text>
<text top="181" left="838" width="67" height="14" font="7">PPV: 86% </text>
<text top="198" left="838" width="69" height="14" font="7">NPV: 97% </text>
<text top="112" left="964" width="68" height="14" font="7">Per patient </text>
<text top="129" left="964" width="56" height="14" font="7">analysis: </text>
<text top="147" left="964" width="95" height="14" font="7">(98% to 100%) </text>
<text top="164" left="964" width="88" height="14" font="7">(55% to 73%) </text>
<text top="181" left="964" width="88" height="14" font="7">(82% to 90%) </text>
<text top="198" left="964" width="95" height="14" font="7">(95% to 100%) </text>
<text top="112" left="1088" width="30" height="14" font="7">N/A </text>
<text top="112" left="1146" width="77" height="14" font="7">Referred for </text>
<text top="129" left="1146" width="30" height="14" font="7">ICA </text>
<text top="112" left="1264" width="84" height="14" font="7">Intraobserver </text>
<text top="129" left="1264" width="56" height="14" font="7">(k=0.66) </text>
<text top="147" left="1264" width="4" height="14" font="7"> </text>
<text top="164" left="1264" width="88" height="14" font="7">Iinterobserver </text>
<text top="181" left="1264" width="56" height="14" font="7">(k=0.69) </text>
<text top="198" left="1264" width="4" height="14" font="7"> </text>
<text top="215" left="1264" width="79" height="14" font="7">Multivendor </text>
<text top="348" left="55" width="117" height="14" font="7">64-Slice computed </text>
<text top="365" left="55" width="76" height="14" font="7">tomography </text>
<text top="383" left="55" width="116" height="14" font="7">angiography in the </text>
<text top="400" left="55" width="86" height="14" font="7">diagnosis and </text>
<text top="417" left="55" width="126" height="14" font="7">assessment of CAD: </text>
<text top="435" left="55" width="137" height="14" font="7">systematic review and </text>
<text top="452" left="55" width="90" height="14" font="7">meta-analysis, </text>
<text top="469" left="55" width="84" height="14" font="7">Mowatt, 2008</text>
<text top="469" left="139" width="29" height="14" font="8"> (21)</text>
<text top="469" left="168" width="4" height="14" font="7"> </text>
<text top="348" left="211" width="61" height="14" font="7">Accuracy </text>
<text top="365" left="211" width="67" height="14" font="7">of 64-slice </text>
<text top="383" left="211" width="23" height="14" font="7">CT </text>
<text top="400" left="211" width="67" height="14" font="7">angiograph</text>
<text top="417" left="211" width="74" height="14" font="7">y compared </text>
<text top="435" left="211" width="60" height="14" font="7">with ICA </text>
<text top="348" left="298" width="36" height="14" font="7">Meta-</text>
<text top="365" left="298" width="56" height="14" font="7">analysis  </text>
<text top="348" left="373" width="19" height="14" font="7">18 </text>
<text top="365" left="373" width="45" height="14" font="7">studies </text>
<text top="383" left="373" width="38" height="14" font="7">1,286 </text>
<text top="400" left="373" width="50" height="14" font="7">patients </text>
<text top="348" left="440" width="67" height="14" font="7">a) 64-slice </text>
<text top="365" left="440" width="34" height="14" font="7">CTA </text>
<text top="383" left="440" width="55" height="14" font="7">b) RCTs </text>
<text top="400" left="440" width="15" height="14" font="7">c) </text>
<text top="417" left="440" width="97" height="14" font="7">nonrandomized </text>
<text top="435" left="440" width="78" height="14" font="7">comparative </text>
<text top="452" left="440" width="45" height="14" font="7">studies </text>
<text top="469" left="440" width="84" height="14" font="7">d) case series </text>
<text top="348" left="552" width="30" height="14" font="7">N/A </text>
<text top="349" left="643" width="8" height="11" font="7">≥</text>
<text top="348" left="651" width="31" height="14" font="7">50% </text>
<text top="365" left="643" width="56" height="14" font="7">diameter </text>
<text top="383" left="643" width="51" height="14" font="7">stenosis </text>
<text top="348" left="748" width="30" height="14" font="7">N/A </text>
<text top="348" left="838" width="67" height="14" font="7">Sens: 99% </text>
<text top="365" left="838" width="68" height="14" font="7">Spec: 89% </text>
<text top="383" left="838" width="67" height="14" font="7">PPV: 93% </text>
<text top="400" left="838" width="4" height="14" font="7"> </text>
<text top="417" left="838" width="77" height="14" font="7">NPV: 100% </text>
<text top="348" left="964" width="88" height="14" font="7">(97% to 99%) </text>
<text top="365" left="964" width="88" height="14" font="7">(83% to 94%) </text>
<text top="383" left="964" width="99" height="13" font="10"><i>(Range: 64% to </i></text>
<text top="400" left="964" width="44" height="13" font="10"><i>100%) </i></text>
<text top="417" left="964" width="99" height="13" font="10"><i>(Range: 86% to </i></text>
<text top="435" left="964" width="47" height="13" font="10"><i>100%)  </i></text>
<text top="348" left="1088" width="30" height="14" font="7">N/A </text>
<text top="348" left="1146" width="30" height="14" font="7">N/A </text>
<text top="348" left="1264" width="30" height="14" font="7">N/A </text>
<text top="487" left="55" width="126" height="14" font="7">A systematic review </text>
<text top="504" left="55" width="141" height="14" font="7">on diagnostic accuracy </text>
<text top="521" left="55" width="137" height="14" font="7">of CT-based detection </text>
<text top="539" left="55" width="122" height="14" font="7">of significant CAD, </text>
<text top="556" left="55" width="141" height="14" font="7">Janne d’Othee B, 2008 </text>
<text top="573" left="55" width="25" height="14" font="8">(22)</text>
<text top="573" left="80" width="4" height="14" font="7"> </text>
<text top="487" left="211" width="69" height="14" font="7">Diagnostic </text>
<text top="504" left="211" width="73" height="14" font="7">accuracy of </text>
<text top="521" left="211" width="44" height="14" font="7">CCTA </text>
<text top="487" left="298" width="36" height="14" font="7">Meta-</text>
<text top="504" left="298" width="52" height="14" font="7">analysis </text>
<text top="487" left="373" width="11" height="14" font="7">5 </text>
<text top="504" left="373" width="45" height="14" font="7">studies </text>
<text top="521" left="373" width="31" height="14" font="7">(308 </text>
<text top="539" left="373" width="26" height="14" font="7">pts) </text>
<text top="487" left="440" width="67" height="14" font="7">a) 64-slice </text>
<text top="504" left="440" width="44" height="14" font="7">CCTA </text>
<text top="487" left="552" width="61" height="14" font="7">a) CABG </text>
<text top="504" left="552" width="34" height="14" font="7">CTA </text>
<text top="521" left="552" width="48" height="14" font="7">b) stent </text>
<text top="539" left="552" width="34" height="14" font="7">CTA </text>
<text top="488" left="643" width="8" height="11" font="7">≥</text>
<text top="487" left="651" width="48" height="14" font="7">50% or </text>
<text top="505" left="643" width="8" height="11" font="7">≥</text>
<text top="504" left="651" width="78" height="14" font="7">70% to 75% </text>
<text top="521" left="643" width="56" height="14" font="7">diameter </text>
<text top="539" left="643" width="51" height="14" font="7">stenosis </text>
<text top="487" left="748" width="30" height="14" font="7">N/A </text>
<text top="487" left="838" width="86" height="14" font="7">Fixed effects: </text>
<text top="504" left="838" width="67" height="14" font="7">Sens: 92% </text>
<text top="521" left="838" width="64" height="14" font="7">Spec 98% </text>
<text top="539" left="838" width="4" height="14" font="7"> </text>
<text top="556" left="838" width="102" height="14" font="7">Random effects: </text>
<text top="573" left="838" width="68" height="14" font="7">Spec: 85% </text>
<text top="590" left="838" width="63" height="14" font="7">Sens 99% </text>
<text top="487" left="964" width="30" height="14" font="7">N/A </text>
<text top="487" left="1088" width="30" height="14" font="7">N/A </text>
<text top="487" left="1146" width="30" height="14" font="7">N/A </text>
<text top="487" left="1264" width="30" height="14" font="7">N/A </text>
<text top="608" left="55" width="92" height="14" font="7">Meta-analysis: </text>
<text top="626" left="55" width="133" height="14" font="7">noninvasive coronary </text>
<text top="643" left="55" width="115" height="14" font="7">angiography using </text>
<text top="660" left="55" width="139" height="14" font="7">computed tomography </text>
<text top="678" left="55" width="139" height="14" font="7">vs. MRI, Schuetz GM, </text>
<text top="695" left="55" width="34" height="14" font="7">2010 </text>
<text top="695" left="89" width="25" height="14" font="8">(23)</text>
<text top="695" left="114" width="4" height="14" font="7"> </text>
<text top="608" left="211" width="67" height="14" font="7">Determine </text>
<text top="626" left="211" width="72" height="14" font="7">potential of </text>
<text top="643" left="211" width="44" height="14" font="7">CT for </text>
<text top="660" left="211" width="62" height="14" font="7">ruling out </text>
<text top="678" left="211" width="51" height="14" font="7">CAD in </text>
<text top="695" left="211" width="70" height="14" font="7">adults with </text>
<text top="712" left="211" width="62" height="14" font="7">suspected </text>
<text top="729" left="211" width="61" height="14" font="7">or known </text>
<text top="746" left="211" width="35" height="14" font="7">CAD </text>
<text top="608" left="298" width="36" height="14" font="7">Meta-</text>
<text top="626" left="298" width="52" height="14" font="7">analysis </text>
<text top="608" left="373" width="26" height="14" font="7">109 </text>
<text top="626" left="373" width="45" height="14" font="7">studies </text>
<text top="643" left="373" width="43" height="14" font="7">(8,205 </text>
<text top="660" left="373" width="26" height="14" font="7">pts) </text>
<text top="608" left="440" width="67" height="14" font="7">a) 64-slice </text>
<text top="626" left="440" width="60" height="14" font="7">CCTA (9 </text>
<text top="643" left="440" width="50" height="14" font="7">studies) </text>
<text top="660" left="440" width="75" height="14" font="7">b) 320-slice </text>
<text top="678" left="440" width="60" height="14" font="7">CCTA (1 </text>
<text top="695" left="440" width="41" height="14" font="7">study) </text>
<text top="608" left="552" width="30" height="14" font="7">N/A </text>
<text top="609" left="643" width="8" height="11" font="7">≥</text>
<text top="608" left="651" width="31" height="14" font="7">50% </text>
<text top="626" left="643" width="56" height="14" font="7">diameter </text>
<text top="643" left="643" width="51" height="14" font="7">stenosis </text>
<text top="608" left="748" width="30" height="14" font="7">N/A </text>
<text top="608" left="838" width="67" height="14" font="7">Sens: 98% </text>
<text top="626" left="838" width="68" height="14" font="7">Spec: 89% </text>
<text top="608" left="964" width="92" height="14" font="7">(97% to 99%)  </text>
<text top="626" left="964" width="92" height="14" font="7">(86% to 92%)  </text>
<text top="608" left="1088" width="30" height="14" font="7">N/A </text>
<text top="608" left="1146" width="30" height="14" font="7">N/A </text>
<text top="608" left="1264" width="30" height="14" font="7">N/A </text>
<text top="764" left="55" width="69" height="14" font="7">Diagnostic </text>
<text top="782" left="55" width="96" height="14" font="7">performance of </text>
<text top="764" left="211" width="69" height="14" font="7">Diagnostic </text>
<text top="782" left="211" width="73" height="14" font="7">accuracy of </text>
<text top="764" left="298" width="36" height="14" font="7">Meta-</text>
<text top="782" left="298" width="52" height="14" font="7">analysis </text>
<text top="764" left="373" width="19" height="14" font="7">29 </text>
<text top="782" left="373" width="49" height="14" font="7">studies; </text>
<text top="764" left="440" width="64" height="14" font="7">Suspected </text>
<text top="782" left="440" width="35" height="14" font="7">CAD </text>
<text top="764" left="552" width="30" height="14" font="7">N/A </text>
<text top="764" left="643" width="79" height="14" font="7">CAD; &gt;50% </text>
<text top="782" left="643" width="56" height="14" font="7">diameter </text>
<text top="764" left="748" width="30" height="14" font="7">N/A </text>
<text top="764" left="838" width="67" height="14" font="7">Sens: 96% </text>
<text top="782" left="838" width="68" height="14" font="7">Spec: 74% </text>
<text top="764" left="964" width="30" height="14" font="7">N/A </text>
<text top="764" left="1088" width="30" height="14" font="7">N/A </text>
<text top="764" left="1146" width="30" height="14" font="7">N/A </text>
<text top="764" left="1264" width="30" height="14" font="7">N/A </text>
</page>
<page number="7" position="absolute" top="0" left="0" height="918" width="1512">
<text top="59" left="108" width="4" height="15" font="0"> </text>
<text top="59" left="459" width="4" height="15" font="0"> </text>
<text top="59" left="810" width="4" height="15" font="0"> </text>
<text top="59" left="864" width="4" height="15" font="0"> </text>
<text top="59" left="918" width="4" height="15" font="0"> </text>
<text top="59" left="972" width="4" height="15" font="0"> </text>
<text top="59" left="1026" width="4" height="15" font="0"> </text>
<text top="59" left="1080" width="4" height="15" font="0"> </text>
<text top="59" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="108" width="613" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="825" left="810" width="4" height="15" font="0"> </text>
<text top="825" left="864" width="4" height="15" font="0"> </text>
<text top="825" left="918" width="4" height="15" font="0"> </text>
<text top="825" left="972" width="4" height="15" font="0"> </text>
<text top="825" left="1026" width="4" height="15" font="0"> </text>
<text top="825" left="1080" width="4" height="15" font="0"> </text>
<text top="825" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="1188" width="4" height="15" font="0"> </text>
<text top="825" left="1242" width="13" height="15" font="0">7 </text>
<text top="847" left="108" width="4" height="15" font="0"> </text>
<text top="112" left="55" width="100" height="14" font="7">multislice spiral </text>
<text top="129" left="55" width="139" height="14" font="7">computed tomography </text>
<text top="147" left="55" width="137" height="14" font="7">of coronary arteries as </text>
<text top="164" left="55" width="93" height="14" font="7">compared with </text>
<text top="181" left="55" width="135" height="14" font="7">conventional invasive </text>
<text top="198" left="55" width="139" height="14" font="7">coronary angiography, </text>
<text top="215" left="55" width="103" height="14" font="7">Hamon M, 2006 </text>
<text top="215" left="158" width="25" height="14" font="8">(24)</text>
<text top="215" left="183" width="4" height="14" font="7"> </text>
<text top="112" left="211" width="74" height="14" font="7">CCTA with </text>
<text top="129" left="211" width="54" height="14" font="7">invasive </text>
<text top="147" left="211" width="57" height="14" font="7">coronary </text>
<text top="164" left="211" width="67" height="14" font="7">angiograph</text>
<text top="181" left="211" width="11" height="14" font="7">y </text>
<text top="112" left="373" width="38" height="14" font="7">2,024 </text>
<text top="129" left="373" width="21" height="14" font="7">pts </text>
<text top="112" left="643" width="51" height="14" font="7">stenosis </text>
<text top="112" left="838" width="4" height="14" font="7"> </text>
<text top="233" left="55" width="104" height="14" font="7">Meta-analysis of </text>
<text top="251" left="55" width="78" height="14" font="7">comparative </text>
<text top="268" left="55" width="65" height="14" font="7">diagnostic </text>
<text top="285" left="55" width="128" height="14" font="7">performance of MRI </text>
<text top="302" left="55" width="88" height="14" font="7">and multislice </text>
<text top="320" left="55" width="139" height="14" font="7">computed tomography </text>
<text top="337" left="55" width="97" height="14" font="7">for noninvasive </text>
<text top="354" left="55" width="139" height="14" font="7">coronary angiography, </text>
<text top="372" left="55" width="105" height="14" font="7">Schuijf JD, 2006 </text>
<text top="372" left="160" width="25" height="14" font="8">(25)</text>
<text top="372" left="185" width="4" height="14" font="7"> </text>
<text top="233" left="211" width="69" height="14" font="7">Diagnostic </text>
<text top="251" left="211" width="73" height="14" font="7">accuracy of </text>
<text top="268" left="211" width="74" height="14" font="7">CCTA with </text>
<text top="285" left="211" width="54" height="14" font="7">invasive </text>
<text top="302" left="211" width="57" height="14" font="7">coronary </text>
<text top="320" left="211" width="67" height="14" font="7">angiograph</text>
<text top="337" left="211" width="11" height="14" font="7">y </text>
<text top="233" left="298" width="36" height="14" font="7">Meta-</text>
<text top="251" left="298" width="52" height="14" font="7">analysis </text>
<text top="233" left="373" width="19" height="14" font="7">51 </text>
<text top="251" left="373" width="49" height="14" font="7">studies; </text>
<text top="268" left="373" width="38" height="14" font="7">2,203 </text>
<text top="285" left="373" width="29" height="14" font="7">pts;  </text>
<text top="233" left="440" width="64" height="14" font="7">Suspected </text>
<text top="251" left="440" width="35" height="14" font="7">CAD </text>
<text top="233" left="552" width="30" height="14" font="7">N/A </text>
<text top="233" left="643" width="35" height="14" font="7">CAD </text>
<text top="252" left="643" width="8" height="11" font="7">≥</text>
<text top="251" left="651" width="31" height="14" font="7">50% </text>
<text top="268" left="643" width="56" height="14" font="7">diameter </text>
<text top="285" left="643" width="51" height="14" font="7">stenosis </text>
<text top="233" left="748" width="30" height="14" font="7">N/A </text>
<text top="233" left="838" width="67" height="14" font="7">Sens: 85% </text>
<text top="251" left="838" width="68" height="14" font="7">Spec: 95% </text>
<text top="233" left="964" width="30" height="14" font="7">N/A </text>
<text top="233" left="1088" width="30" height="14" font="7">16.9 </text>
<text top="233" left="1146" width="30" height="14" font="7">N/A </text>
<text top="233" left="1264" width="30" height="14" font="7">N/A </text>
<text top="390" left="55" width="121" height="14" font="7">Diagnostic value of </text>
<text top="407" left="55" width="126" height="14" font="7">multislice computed </text>
<text top="424" left="55" width="76" height="14" font="7">tomography </text>
<text top="441" left="55" width="134" height="14" font="7">angiography in CAD: </text>
<text top="458" left="55" width="127" height="14" font="7">a meta-analysis, Sun </text>
<text top="476" left="55" width="51" height="14" font="7">Z, 2006 </text>
<text top="476" left="106" width="25" height="14" font="8">(26)</text>
<text top="476" left="131" width="4" height="14" font="7"> </text>
<text top="390" left="211" width="69" height="14" font="7">Diagnostic </text>
<text top="407" left="211" width="73" height="14" font="7">accuracy of </text>
<text top="424" left="211" width="74" height="14" font="7">CCTA with </text>
<text top="441" left="211" width="54" height="14" font="7">Invasive </text>
<text top="458" left="211" width="60" height="14" font="7">Coronary </text>
<text top="476" left="211" width="64" height="14" font="7">Angiograp</text>
<text top="493" left="211" width="19" height="14" font="7">hy </text>
<text top="390" left="298" width="36" height="14" font="7">Meta-</text>
<text top="407" left="298" width="52" height="14" font="7">analysis </text>
<text top="390" left="373" width="19" height="14" font="7">47 </text>
<text top="407" left="373" width="49" height="14" font="7">studies; </text>
<text top="424" left="373" width="38" height="14" font="7">3,142 </text>
<text top="441" left="373" width="21" height="14" font="7">pts </text>
<text top="390" left="440" width="64" height="14" font="7">Suspected </text>
<text top="407" left="440" width="35" height="14" font="7">CAD </text>
<text top="390" left="552" width="30" height="14" font="7">N/A </text>
<text top="390" left="643" width="35" height="14" font="7">CAD </text>
<text top="390" left="748" width="30" height="14" font="7">N/A </text>
<text top="390" left="838" width="67" height="14" font="7">Sens: 91% </text>
<text top="407" left="838" width="68" height="14" font="7">Spec: 86% </text>
<text top="390" left="964" width="30" height="14" font="7">N/A </text>
<text top="390" left="1088" width="30" height="14" font="7">N/A </text>
<text top="390" left="1146" width="30" height="14" font="7">N/A </text>
<text top="390" left="1264" width="30" height="14" font="7">N/A </text>
<text top="511" left="55" width="85" height="14" font="7">Multidetector </text>
<text top="528" left="55" width="139" height="14" font="7">computed tomography </text>
<text top="545" left="55" width="120" height="14" font="7">for the diagnosis of </text>
<text top="563" left="55" width="144" height="14" font="7">CAD: a meta-analysis,  </text>
<text top="580" left="55" width="95" height="14" font="7">Stein PD, 2006 </text>
<text top="580" left="150" width="25" height="14" font="8">(27)</text>
<text top="580" left="175" width="4" height="14" font="7"> </text>
<text top="511" left="211" width="69" height="14" font="7">Diagnostic </text>
<text top="528" left="211" width="73" height="14" font="7">accuracy of </text>
<text top="545" left="211" width="74" height="14" font="7">CCTA with </text>
<text top="563" left="211" width="54" height="14" font="7">Invasive </text>
<text top="580" left="211" width="60" height="14" font="7">Coronary </text>
<text top="597" left="211" width="64" height="14" font="7">Angiograp</text>
<text top="615" left="211" width="19" height="14" font="7">hy </text>
<text top="511" left="298" width="36" height="14" font="7">Meta-</text>
<text top="528" left="298" width="52" height="14" font="7">analysis </text>
<text top="511" left="373" width="19" height="14" font="7">33 </text>
<text top="528" left="373" width="49" height="14" font="7">studies; </text>
<text top="545" left="373" width="38" height="14" font="7">1,861 </text>
<text top="563" left="373" width="21" height="14" font="7">pts </text>
<text top="511" left="440" width="64" height="14" font="7">Suspected </text>
<text top="528" left="440" width="35" height="14" font="7">CAD </text>
<text top="511" left="552" width="30" height="14" font="7">N/A </text>
<text top="511" left="643" width="88" height="14" font="7">CAD (50% or </text>
<text top="529" left="643" width="8" height="11" font="7">≥</text>
<text top="528" left="651" width="36" height="14" font="7">50%) </text>
<text top="511" left="748" width="30" height="14" font="7">N/A </text>
<text top="511" left="838" width="67" height="14" font="7">Sens: 98% </text>
<text top="528" left="838" width="68" height="14" font="7">Spec: 88% </text>
<text top="511" left="964" width="30" height="14" font="7">N/A </text>
<text top="511" left="1088" width="30" height="14" font="7">N/A </text>
<text top="511" left="1146" width="30" height="14" font="7">N/A </text>
<text top="511" left="1264" width="30" height="14" font="7">N/A </text>
<text top="633" left="55" width="241" height="16" font="2"><b>Bypass Graft CT Angiography </b></text>
<text top="665" left="55" width="90" height="14" font="7">Multi-detector </text>
<text top="682" left="55" width="139" height="14" font="7">computed tomography </text>
<text top="699" left="55" width="135" height="14" font="7">in CABG assessment: </text>
<text top="717" left="55" width="141" height="14" font="7">a meta-analysis, Jones, </text>
<text top="734" left="55" width="34" height="14" font="7">2007 </text>
<text top="734" left="89" width="25" height="14" font="8">(28)</text>
<text top="734" left="114" width="4" height="14" font="7"> </text>
<text top="665" left="211" width="67" height="14" font="7">Determinat</text>
<text top="682" left="211" width="39" height="14" font="7">ion of </text>
<text top="699" left="211" width="65" height="14" font="7">diagnostic </text>
<text top="717" left="211" width="73" height="14" font="7">accuracy of </text>
<text top="734" left="211" width="67" height="14" font="7">8-slice, 16-</text>
<text top="751" left="211" width="60" height="14" font="7">slice, and </text>
<text top="768" left="211" width="51" height="14" font="7">54-slice </text>
<text top="786" left="211" width="68" height="14" font="7">MDCT vs. </text>
<text top="665" left="298" width="36" height="14" font="7">Meta-</text>
<text top="682" left="298" width="52" height="14" font="7">analysis </text>
<text top="665" left="373" width="46" height="14" font="7">Occlusi</text>
<text top="682" left="373" width="29" height="14" font="7">ons: </text>
<text top="699" left="373" width="19" height="14" font="7">14 </text>
<text top="717" left="373" width="45" height="14" font="7">studies </text>
<text top="734" left="373" width="38" height="14" font="7">1,791 </text>
<text top="751" left="373" width="38" height="14" font="7">grafts </text>
<text top="768" left="373" width="4" height="14" font="7"> </text>
<text top="786" left="373" width="46" height="14" font="7">Stenose</text>
<text top="665" left="440" width="93" height="14" font="7">Comparison of </text>
<text top="682" left="440" width="96" height="14" font="7">CABG patency </text>
<text top="699" left="440" width="87" height="14" font="7">or stenosis, or </text>
<text top="717" left="440" width="53" height="14" font="7">both, on </text>
<text top="734" left="440" width="68" height="14" font="7">MDCT vs. </text>
<text top="751" left="440" width="79" height="14" font="7">angiography </text>
<text top="665" left="552" width="43" height="14" font="7">Use of </text>
<text top="682" left="552" width="74" height="14" font="7">MDCT was </text>
<text top="699" left="552" width="69" height="14" font="7">unconfirme</text>
<text top="717" left="552" width="15" height="14" font="7">d, </text>
<text top="734" left="552" width="66" height="14" font="7">performed </text>
<text top="751" left="552" width="16" height="14" font="7">as </text>
<text top="768" left="552" width="68" height="14" font="7">preoperativ</text>
<text top="786" left="552" width="69" height="14" font="7">e work-up, </text>
<text top="665" left="665" width="47" height="14" font="7">a) graft </text>
<text top="682" left="658" width="61" height="14" font="7">occlusion </text>
<text top="699" left="665" width="48" height="14" font="7">b) graft </text>
<text top="717" left="663" width="51" height="14" font="7">stenosis </text>
<text top="665" left="772" width="30" height="14" font="7">N/A </text>
<text top="665" left="838" width="75" height="14" font="7">Occlusions: </text>
<text top="682" left="838" width="67" height="14" font="7">Sens: 98% </text>
<text top="699" left="838" width="68" height="14" font="7">Spec: 99% </text>
<text top="717" left="838" width="65" height="14" font="7">PPV: 93.6 </text>
<text top="734" left="838" width="77" height="14" font="7">NPV:99.4% </text>
<text top="751" left="838" width="4" height="14" font="7"> </text>
<text top="768" left="838" width="4" height="14" font="7"> </text>
<text top="786" left="838" width="4" height="14" font="7"> </text>
<text top="665" left="964" width="75" height="14" font="7">Occlusions: </text>
<text top="682" left="964" width="52" height="14" font="7">(95% to </text>
<text top="699" left="964" width="36" height="14" font="7">99%) </text>
<text top="717" left="964" width="52" height="14" font="7">(98% to </text>
<text top="734" left="964" width="36" height="14" font="7">99%) </text>
<text top="751" left="964" width="4" height="14" font="7"> </text>
<text top="768" left="964" width="4" height="14" font="7"> </text>
<text top="786" left="964" width="4" height="14" font="7"> </text>
<text top="665" left="1062" width="66" height="14" font="7">Occlusions</text>
<text top="682" left="1062" width="8" height="14" font="7">: </text>
<text top="699" left="1062" width="67" height="14" font="7">OR=934.2 </text>
<text top="717" left="1062" width="58" height="14" font="7">(436.4 to </text>
<text top="734" left="1062" width="50" height="14" font="7">1999.9) </text>
<text top="751" left="1062" width="4" height="14" font="7"> </text>
<text top="768" left="1062" width="4" height="14" font="7"> </text>
<text top="786" left="1062" width="60" height="14" font="7">Stenoses: </text>
<text top="665" left="1146" width="30" height="14" font="7">N/A </text>
<text top="665" left="1264" width="75" height="14" font="7">Occlusions: </text>
<text top="682" left="1264" width="78" height="14" font="7">AUC=0.996 </text>
<text top="699" left="1264" width="4" height="14" font="7"> </text>
<text top="717" left="1264" width="4" height="14" font="7"> </text>
<text top="734" left="1264" width="4" height="14" font="7"> </text>
<text top="751" left="1264" width="4" height="14" font="7"> </text>
<text top="768" left="1264" width="64" height="14" font="7">Stenoses:  </text>
<text top="786" left="1264" width="78" height="14" font="7">AUC=0.867 </text>
</page>
<page number="8" position="absolute" top="0" left="0" height="918" width="1512">
<text top="59" left="108" width="4" height="15" font="0"> </text>
<text top="59" left="459" width="4" height="15" font="0"> </text>
<text top="59" left="810" width="4" height="15" font="0"> </text>
<text top="59" left="864" width="4" height="15" font="0"> </text>
<text top="59" left="918" width="4" height="15" font="0"> </text>
<text top="59" left="972" width="4" height="15" font="0"> </text>
<text top="59" left="1026" width="4" height="15" font="0"> </text>
<text top="59" left="1080" width="4" height="15" font="0"> </text>
<text top="59" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="108" width="613" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="825" left="810" width="4" height="15" font="0"> </text>
<text top="825" left="864" width="4" height="15" font="0"> </text>
<text top="825" left="918" width="4" height="15" font="0"> </text>
<text top="825" left="972" width="4" height="15" font="0"> </text>
<text top="825" left="1026" width="4" height="15" font="0"> </text>
<text top="825" left="1080" width="4" height="15" font="0"> </text>
<text top="825" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="1188" width="4" height="15" font="0"> </text>
<text top="825" left="1242" width="13" height="15" font="0">8 </text>
<text top="847" left="108" width="4" height="15" font="0"> </text>
<text top="112" left="211" width="67" height="14" font="7">angiograph</text>
<text top="129" left="211" width="26" height="14" font="7">y in </text>
<text top="147" left="211" width="60" height="14" font="7">diagnosis </text>
<text top="164" left="211" width="48" height="14" font="7">of graft </text>
<text top="181" left="211" width="61" height="14" font="7">occlusion </text>
<text top="198" left="211" width="25" height="14" font="7">and </text>
<text top="215" left="211" width="57" height="14" font="7">stensosis </text>
<text top="112" left="373" width="14" height="14" font="7">s: </text>
<text top="129" left="373" width="11" height="14" font="7">8 </text>
<text top="147" left="373" width="45" height="14" font="7">studies </text>
<text top="164" left="373" width="26" height="14" font="7">878 </text>
<text top="181" left="373" width="38" height="14" font="7">grafts </text>
<text top="112" left="552" width="16" height="14" font="7">or </text>
<text top="129" left="552" width="66" height="14" font="7">performed </text>
<text top="147" left="552" width="70" height="14" font="7">on pts with </text>
<text top="164" left="552" width="49" height="14" font="7">conduit </text>
<text top="181" left="552" width="67" height="14" font="7">stenting or </text>
<text top="198" left="552" width="73" height="14" font="7">angioplasty </text>
<text top="112" left="838" width="56" height="14" font="7">Stenoses </text>
<text top="129" left="838" width="67" height="14" font="7">Sens: 89% </text>
<text top="147" left="838" width="68" height="14" font="7">Spec: 97% </text>
<text top="164" left="838" width="78" height="14" font="7">PPV: 77.8% </text>
<text top="181" left="838" width="80" height="14" font="7">NPV: 98.8% </text>
<text top="198" left="838" width="4" height="14" font="7"> </text>
<text top="112" left="964" width="60" height="14" font="7">Stenoses: </text>
<text top="129" left="964" width="52" height="14" font="7">(75% to </text>
<text top="147" left="964" width="36" height="14" font="7">95%) </text>
<text top="164" left="964" width="52" height="14" font="7">(96% to </text>
<text top="181" left="964" width="40" height="14" font="7">98%)  </text>
<text top="112" left="1062" width="67" height="14" font="7">OR=152.0 </text>
<text top="129" left="1062" width="51" height="14" font="7">(64.0 to </text>
<text top="147" left="1062" width="42" height="14" font="7">360.7) </text>
<text top="233" left="55" width="69" height="14" font="7">Diagnostic </text>
<text top="251" left="55" width="119" height="14" font="7">performance of 16- </text>
<text top="268" left="55" width="129" height="14" font="7">and 64-section spiral </text>
<text top="285" left="55" width="89" height="14" font="7">CT for CABG </text>
<text top="302" left="55" width="109" height="14" font="7">assessment: meta-</text>
<text top="320" left="55" width="125" height="14" font="7">analysis, Hamon M, </text>
<text top="337" left="55" width="34" height="14" font="7">2008 </text>
<text top="337" left="89" width="25" height="14" font="8">(29)</text>
<text top="337" left="114" width="4" height="14" font="7"> </text>
<text top="233" left="211" width="61" height="14" font="7">Accuracy </text>
<text top="251" left="211" width="65" height="14" font="7">of 16- and </text>
<text top="268" left="211" width="62" height="14" font="7">64- CT to </text>
<text top="285" left="211" width="70" height="14" font="7">help assess </text>
<text top="302" left="211" width="45" height="14" font="7">CABG </text>
<text top="233" left="298" width="36" height="14" font="7">Meta-</text>
<text top="251" left="298" width="52" height="14" font="7">analysis </text>
<text top="233" left="373" width="19" height="14" font="7">15 </text>
<text top="251" left="373" width="45" height="14" font="7">studies </text>
<text top="268" left="373" width="47" height="14" font="7">723 pts </text>
<text top="285" left="373" width="38" height="14" font="7">2,023 </text>
<text top="302" left="373" width="38" height="14" font="7">grafts </text>
<text top="233" left="440" width="55" height="14" font="7">a) use of </text>
<text top="251" left="440" width="78" height="14" font="7">multisection </text>
<text top="268" left="440" width="39" height="14" font="7">CT as </text>
<text top="285" left="440" width="90" height="14" font="7">diagnostic test </text>
<text top="302" left="440" width="56" height="14" font="7">to sasses </text>
<text top="320" left="440" width="67" height="14" font="7">significant </text>
<text top="337" left="440" width="39" height="14" font="7">lesion </text>
<text top="354" left="440" width="82" height="14" font="7">(occlusion or </text>
<text top="372" left="440" width="8" height="11" font="7">≥</text>
<text top="372" left="448" width="87" height="14" font="7">50% stenosis) </text>
<text top="389" left="440" width="62" height="14" font="7">of CABG </text>
<text top="406" left="440" width="88" height="14" font="7">b) used 16- or </text>
<text top="423" left="440" width="66" height="14" font="7">64-section </text>
<text top="440" left="440" width="49" height="14" font="7">scanner </text>
<text top="458" left="440" width="47" height="14" font="7">c) used </text>
<text top="475" left="440" width="57" height="14" font="7">coronary </text>
<text top="492" left="440" width="95" height="14" font="7">angiography as </text>
<text top="509" left="440" width="81" height="14" font="7">the reference </text>
<text top="527" left="440" width="54" height="14" font="7">standard </text>
<text top="233" left="552" width="30" height="14" font="7">N/A </text>
<text top="234" left="643" width="8" height="11" font="7">≥</text>
<text top="233" left="651" width="31" height="14" font="7">50% </text>
<text top="251" left="643" width="56" height="14" font="7">diameter </text>
<text top="268" left="643" width="51" height="14" font="7">stenosis </text>
<text top="233" left="748" width="30" height="14" font="7">N/A </text>
<text top="233" left="838" width="67" height="14" font="7">Sens: 98% </text>
<text top="251" left="838" width="68" height="14" font="7">Spec: 97% </text>
<text top="268" left="838" width="67" height="14" font="7">PPV: 93% </text>
<text top="285" left="838" width="69" height="14" font="7">NPV: 99% </text>
<text top="233" left="964" width="52" height="14" font="7">(96% to </text>
<text top="251" left="964" width="36" height="14" font="7">99%) </text>
<text top="268" left="964" width="52" height="14" font="7">(96% to </text>
<text top="285" left="964" width="36" height="14" font="7">98%) </text>
<text top="302" left="964" width="52" height="14" font="7">(91% to </text>
<text top="320" left="964" width="36" height="14" font="7">95%) </text>
<text top="337" left="964" width="52" height="14" font="7">(97% to </text>
<text top="354" left="964" width="36" height="14" font="7">99%) </text>
<text top="233" left="1062" width="52" height="14" font="7">Positive </text>
<text top="251" left="1062" width="65" height="14" font="7">LR: 23.42 </text>
<text top="268" left="1062" width="58" height="14" font="7">(13.69 to </text>
<text top="285" left="1062" width="50" height="14" font="7">40.07);  </text>
<text top="302" left="1062" width="58" height="14" font="7">Negative </text>
<text top="320" left="1062" width="65" height="14" font="7">LR: 0.045 </text>
<text top="337" left="1062" width="58" height="14" font="7">(0.028 to </text>
<text top="354" left="1062" width="50" height="14" font="7">0.071);  </text>
<text top="372" left="1062" width="69" height="14" font="7">Diagnostic </text>
<text top="389" left="1062" width="29" height="14" font="7">OR: </text>
<text top="406" left="1062" width="45" height="14" font="7">780.32 </text>
<text top="423" left="1062" width="65" height="14" font="7">(379.12 to </text>
<text top="440" left="1062" width="61" height="14" font="7">1,606.01) </text>
<text top="233" left="1146" width="30" height="14" font="7">N/A </text>
<text top="233" left="1264" width="30" height="14" font="7">N/A </text>
<text top="545" left="55" width="117" height="14" font="7">64-Slice computed </text>
<text top="562" left="55" width="76" height="14" font="7">tomography </text>
<text top="579" left="55" width="116" height="14" font="7">angiography in the </text>
<text top="597" left="55" width="86" height="14" font="7">diagnosis and </text>
<text top="614" left="55" width="126" height="14" font="7">assessment of CAD: </text>
<text top="631" left="55" width="137" height="14" font="7">systematic review and </text>
<text top="648" left="55" width="140" height="14" font="7">meta-analysis, Mowatt </text>
<text top="665" left="55" width="52" height="14" font="7">G, 2008 </text>
<text top="665" left="107" width="25" height="14" font="8">(21)</text>
<text top="665" left="132" width="4" height="14" font="7"> </text>
<text top="545" left="211" width="61" height="14" font="7">Accuracy </text>
<text top="562" left="211" width="67" height="14" font="7">of 64-slice </text>
<text top="579" left="211" width="23" height="14" font="7">CT </text>
<text top="597" left="211" width="67" height="14" font="7">angiograph</text>
<text top="614" left="211" width="74" height="14" font="7">y compared </text>
<text top="631" left="211" width="60" height="14" font="7">with ICA </text>
<text top="545" left="298" width="36" height="14" font="7">Meta-</text>
<text top="562" left="298" width="52" height="14" font="7">analysis </text>
<text top="545" left="373" width="19" height="14" font="7">40 </text>
<text top="562" left="373" width="45" height="14" font="7">studies </text>
<text top="579" left="373" width="24" height="14" font="7">(28 </text>
<text top="597" left="373" width="44" height="14" font="7">include</text>
<text top="614" left="373" width="32" height="14" font="7">d) in </text>
<text top="631" left="373" width="34" height="14" font="7">meta-</text>
<text top="648" left="373" width="52" height="14" font="7">analysis </text>
<text top="665" left="373" width="47" height="14" font="7">543 pts </text>
<text top="545" left="440" width="67" height="14" font="7">a) 64-slice </text>
<text top="562" left="440" width="44" height="14" font="7">CCTA </text>
<text top="579" left="440" width="55" height="14" font="7">b) RCTs </text>
<text top="597" left="440" width="43" height="14" font="7">c) non-</text>
<text top="614" left="440" width="74" height="14" font="7">randomized </text>
<text top="631" left="440" width="78" height="14" font="7">comparative </text>
<text top="648" left="440" width="45" height="14" font="7">studies </text>
<text top="665" left="440" width="84" height="14" font="7">d) case series </text>
<text top="545" left="552" width="30" height="14" font="7">N/A </text>
<text top="546" left="643" width="8" height="11" font="7">≥</text>
<text top="545" left="651" width="31" height="14" font="7">50% </text>
<text top="562" left="643" width="56" height="14" font="7">diameter </text>
<text top="579" left="643" width="51" height="14" font="7">stenosis </text>
<text top="545" left="748" width="30" height="14" font="7">N/A </text>
<text top="545" left="838" width="83" height="14" font="7">Patient based </text>
<text top="562" left="838" width="63" height="14" font="7">detection: </text>
<text top="579" left="838" width="67" height="14" font="7">Sens: 99% </text>
<text top="597" left="838" width="68" height="14" font="7">Spec: 89% </text>
<text top="614" left="838" width="67" height="14" font="7">PPV: 93% </text>
<text top="631" left="838" width="77" height="14" font="7">NPV: 100% </text>
<text top="648" left="838" width="4" height="14" font="7"> </text>
<text top="665" left="838" width="95" height="14" font="7">Segment-based </text>
<text top="683" left="838" width="63" height="14" font="7">detection: </text>
<text top="700" left="838" width="104" height="14" font="7">Sens: 90% (85% </text>
<text top="717" left="838" width="55" height="14" font="7">to 94%)  </text>
<text top="734" left="838" width="105" height="14" font="7">Spec: 97% (95% </text>
<text top="752" left="838" width="52" height="14" font="7">to 98%) </text>
<text top="769" left="838" width="103" height="14" font="7">PPV: 76% (44% </text>
<text top="786" left="838" width="55" height="14" font="7">to 93%)  </text>
<text top="545" left="964" width="52" height="14" font="7">(97% to </text>
<text top="562" left="964" width="36" height="14" font="7">99%) </text>
<text top="579" left="964" width="52" height="14" font="7">(83% to </text>
<text top="597" left="964" width="36" height="14" font="7">94%) </text>
<text top="614" left="964" width="52" height="14" font="7">(64% to </text>
<text top="631" left="964" width="44" height="14" font="7">100%) </text>
<text top="648" left="964" width="52" height="14" font="7">(86% to </text>
<text top="665" left="964" width="44" height="14" font="7">100%) </text>
<text top="545" left="1062" width="30" height="14" font="7">N/A </text>
<text top="545" left="1146" width="30" height="14" font="7">N/A </text>
<text top="545" left="1264" width="30" height="14" font="7">N/A </text>
</page>
<page number="9" position="absolute" top="0" left="0" height="918" width="1512">
	<fontspec id="11" size="15" family="Times" color="#000000"/>
<text top="59" left="108" width="4" height="15" font="0"> </text>
<text top="59" left="459" width="4" height="15" font="0"> </text>
<text top="59" left="810" width="4" height="15" font="0"> </text>
<text top="59" left="864" width="4" height="15" font="0"> </text>
<text top="59" left="918" width="4" height="15" font="0"> </text>
<text top="59" left="972" width="4" height="15" font="0"> </text>
<text top="59" left="1026" width="4" height="15" font="0"> </text>
<text top="59" left="1080" width="4" height="15" font="0"> </text>
<text top="59" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="108" width="613" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="825" left="810" width="4" height="15" font="0"> </text>
<text top="825" left="864" width="4" height="15" font="0"> </text>
<text top="825" left="918" width="4" height="15" font="0"> </text>
<text top="825" left="972" width="4" height="15" font="0"> </text>
<text top="825" left="1026" width="4" height="15" font="0"> </text>
<text top="825" left="1080" width="4" height="15" font="0"> </text>
<text top="825" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="1188" width="4" height="15" font="0"> </text>
<text top="825" left="1242" width="13" height="15" font="0">9 </text>
<text top="847" left="108" width="4" height="15" font="0"> </text>
<text top="112" left="838" width="105" height="14" font="7">NPV: 99% (95% </text>
<text top="129" left="838" width="63" height="14" font="7">to 100%)  </text>
<text top="148" left="55" width="157" height="16" font="2"><b>In-Stent Restenosis  </b></text>
<text top="169" left="55" width="142" height="14" font="7">Diagnostic accuracy of </text>
<text top="186" left="55" width="114" height="14" font="7">64-slice computed </text>
<text top="203" left="55" width="76" height="14" font="7">tomography </text>
<text top="220" left="55" width="122" height="14" font="7">angiography for the </text>
<text top="238" left="55" width="124" height="14" font="7">detection of in-stent </text>
<text top="255" left="55" width="112" height="14" font="7">restenosis: a meta-</text>
<text top="272" left="55" width="133" height="14" font="7">analysis, Carrabba N, </text>
<text top="289" left="55" width="34" height="14" font="7">2010 </text>
<text top="289" left="89" width="25" height="14" font="8">(30)</text>
<text top="289" left="114" width="4" height="14" font="7"> </text>
<text top="169" left="211" width="61" height="14" font="7">Accuracy </text>
<text top="186" left="211" width="67" height="14" font="7">of 64-slice </text>
<text top="203" left="211" width="47" height="14" font="7">MDCT </text>
<text top="220" left="211" width="63" height="14" font="7">compared </text>
<text top="238" left="211" width="30" height="14" font="7">with </text>
<text top="255" left="211" width="54" height="14" font="7">invasive </text>
<text top="272" left="211" width="57" height="14" font="7">coronary </text>
<text top="289" left="211" width="67" height="14" font="7">angiograph</text>
<text top="307" left="211" width="66" height="14" font="7">y to detect </text>
<text top="324" left="211" width="27" height="14" font="7">ISR </text>
<text top="169" left="298" width="36" height="14" font="7">Meta-</text>
<text top="186" left="298" width="52" height="14" font="7">analysis </text>
<text top="169" left="373" width="11" height="14" font="7">9 </text>
<text top="186" left="373" width="45" height="14" font="7">studies </text>
<text top="203" left="373" width="47" height="14" font="7">598 pts </text>
<text top="220" left="373" width="26" height="14" font="7">978 </text>
<text top="238" left="373" width="38" height="14" font="7">stents </text>
<text top="169" left="440" width="83" height="14" font="7">a) 64-MDCT </text>
<text top="186" left="440" width="80" height="14" font="7">used for ISR </text>
<text top="203" left="440" width="62" height="14" font="7">b) Values </text>
<text top="220" left="440" width="79" height="14" font="7">available for </text>
<text top="238" left="440" width="77" height="14" font="7">TP, FP, TN, </text>
<text top="255" left="440" width="48" height="14" font="7">and FN </text>
<text top="169" left="552" width="46" height="14" font="7">a) Post-</text>
<text top="186" left="552" width="45" height="14" font="7">CABG </text>
<text top="203" left="552" width="49" height="14" font="7">b) prior </text>
<text top="220" left="552" width="34" height="14" font="7">heart </text>
<text top="238" left="552" width="74" height="14" font="7">transplantati</text>
<text top="255" left="552" width="19" height="14" font="7">on </text>
<text top="169" left="643" width="58" height="14" font="7">&gt;50% by </text>
<text top="186" left="643" width="78" height="14" font="7">angiography </text>
<text top="203" left="643" width="85" height="14" font="7">(invasion and </text>
<text top="220" left="643" width="83" height="14" font="7">quantitative)  </text>
<text top="169" left="748" width="30" height="14" font="7">N/A </text>
<text top="169" left="838" width="67" height="14" font="7">Sens: 86% </text>
<text top="186" left="838" width="68" height="14" font="7">Spec: 93% </text>
<text top="203" left="838" width="79" height="14" font="7">Positive LR: </text>
<text top="220" left="838" width="38" height="14" font="7">12.32 </text>
<text top="238" left="838" width="85" height="14" font="7">Negative LR: </text>
<text top="255" left="838" width="30" height="14" font="7">0.18 </text>
<text top="169" left="964" width="52" height="14" font="7">(80% to </text>
<text top="186" left="964" width="36" height="14" font="7">91%) </text>
<text top="203" left="964" width="52" height="14" font="7">(91% to </text>
<text top="220" left="964" width="40" height="14" font="7">95%)  </text>
<text top="238" left="964" width="51" height="14" font="7">(7.26 to </text>
<text top="255" left="964" width="46" height="14" font="7">20.92)  </text>
<text top="272" left="964" width="4" height="14" font="7"> </text>
<text top="169" left="1062" width="30" height="14" font="7">N/A </text>
<text top="169" left="1146" width="30" height="14" font="7">N/A </text>
<text top="169" left="1264" width="125" height="14" font="7">AUC=0.94 per stent </text>
<text top="186" left="1264" width="111" height="14" font="7">analysis indicated </text>
<text top="203" left="1264" width="99" height="14" font="7">good diagnostic </text>
<text top="220" left="1264" width="140" height="14" font="7">agreement between 64-</text>
<text top="238" left="1264" width="126" height="14" font="7">MDCT and invasive </text>
<text top="255" left="1264" width="136" height="14" font="7">coronary angiography </text>
<text top="342" left="55" width="142" height="14" font="7">Diagnostic accuracy of </text>
<text top="359" left="55" width="105" height="14" font="7">64 multislice CT </text>
<text top="376" left="55" width="116" height="14" font="7">angiography in the </text>
<text top="394" left="55" width="87" height="14" font="7">assessment of </text>
<text top="411" left="55" width="106" height="14" font="7">coronary in-stent </text>
<text top="428" left="55" width="112" height="14" font="7">restenosis: a meta-</text>
<text top="445" left="55" width="137" height="14" font="7">analysis, Sun, Z, 2010 </text>
<text top="463" left="55" width="25" height="14" font="8">(31)</text>
<text top="463" left="80" width="4" height="14" font="7"> </text>
<text top="342" left="211" width="61" height="14" font="7">Accuracy </text>
<text top="359" left="211" width="67" height="14" font="7">of 64-slice </text>
<text top="376" left="211" width="23" height="14" font="7">CT </text>
<text top="394" left="211" width="67" height="14" font="7">angiograph</text>
<text top="411" left="211" width="74" height="14" font="7">y compared </text>
<text top="428" left="211" width="30" height="14" font="7">with </text>
<text top="445" left="211" width="67" height="14" font="7">convention</text>
<text top="463" left="211" width="71" height="14" font="7">al coronary </text>
<text top="480" left="211" width="67" height="14" font="7">angiograph</text>
<text top="497" left="211" width="66" height="14" font="7">y to detect </text>
<text top="514" left="211" width="31" height="14" font="7">ISR  </text>
<text top="342" left="298" width="36" height="14" font="7">Meta-</text>
<text top="359" left="298" width="52" height="14" font="7">analysis </text>
<text top="342" left="373" width="19" height="14" font="7">14 </text>
<text top="359" left="373" width="45" height="14" font="7">studies </text>
<text top="376" left="373" width="47" height="14" font="7">858 pts </text>
<text top="342" left="440" width="93" height="14" font="7">Peer reviewed, </text>
<text top="359" left="440" width="77" height="14" font="7">published in </text>
<text top="376" left="440" width="89" height="14" font="7">English (2004 </text>
<text top="394" left="440" width="58" height="14" font="7">to 2008). </text>
<text top="411" left="440" width="99" height="14" font="7">Prospective and </text>
<text top="428" left="440" width="81" height="14" font="7">retrospective </text>
<text top="445" left="440" width="69" height="14" font="7">studies (10 </text>
<text top="463" left="440" width="44" height="14" font="7">patient </text>
<text top="480" left="440" width="91" height="14" font="7">minimum), 64-</text>
<text top="497" left="440" width="85" height="14" font="7">slice CT used </text>
<text top="514" left="440" width="81" height="14" font="7">for diagnosis </text>
<text top="532" left="440" width="80" height="14" font="7">and invasion </text>
<text top="549" left="440" width="57" height="14" font="7">coronary </text>
<text top="566" left="440" width="95" height="14" font="7">angiography as </text>
<text top="583" left="440" width="60" height="14" font="7">reference </text>
<text top="342" left="552" width="49" height="14" font="7">Review </text>
<text top="359" left="552" width="45" height="14" font="7">article; </text>
<text top="376" left="552" width="64" height="14" font="7">editorials; </text>
<text top="394" left="552" width="69" height="14" font="7">conference </text>
<text top="411" left="552" width="76" height="14" font="7">abstracts; in </text>
<text top="428" left="552" width="48" height="14" font="7">vitro or </text>
<text top="445" left="552" width="70" height="14" font="7">phantomstu</text>
<text top="463" left="552" width="55" height="14" font="7">dies; not </text>
<text top="480" left="552" width="59" height="14" font="7">reporting </text>
<text top="497" left="552" width="71" height="14" font="7">numbers of </text>
<text top="514" left="552" width="76" height="14" font="7">TN, TP, FN </text>
<text top="532" left="552" width="50" height="14" font="7">and FP. </text>
<text top="342" left="643" width="40" height="14" font="7">&gt;50% </text>
<text top="359" left="643" width="55" height="14" font="7">stenosis; </text>
<text top="376" left="643" width="65" height="14" font="7">diagnostic </text>
<text top="394" left="643" width="69" height="14" font="7">sensitivity, </text>
<text top="411" left="643" width="66" height="14" font="7">specificity </text>
<text top="428" left="643" width="81" height="14" font="7">using a fixed </text>
<text top="445" left="643" width="85" height="14" font="7">effects model </text>
<text top="463" left="643" width="82" height="14" font="7">(TP, TN, FP, </text>
<text top="480" left="643" width="32" height="14" font="7">FN)  </text>
<text top="342" left="748" width="30" height="14" font="7">N/A </text>
<text top="342" left="838" width="112" height="14" font="7">Assessable stents: </text>
<text top="359" left="838" width="67" height="14" font="7">Sens: 94% </text>
<text top="376" left="838" width="68" height="14" font="7">Spec: 91% </text>
<text top="394" left="838" width="4" height="14" font="7"> </text>
<text top="411" left="838" width="89" height="14" font="7">Evaluable and </text>
<text top="428" left="838" width="76" height="14" font="7">unevaluable </text>
<text top="445" left="838" width="109" height="14" font="7">stents (5 studies): </text>
<text top="463" left="838" width="67" height="14" font="7">Sens: 79% </text>
<text top="480" left="838" width="68" height="14" font="7">Spec: 81% </text>
<text top="342" left="964" width="69" height="14" font="7">Assessable </text>
<text top="359" left="964" width="78" height="14" font="7">stents: (86% </text>
<text top="376" left="964" width="56" height="14" font="7">to 94%); </text>
<text top="394" left="964" width="52" height="14" font="7">(90% to </text>
<text top="411" left="964" width="40" height="14" font="7">93%); </text>
<text top="428" left="964" width="61" height="14" font="7">evaluable </text>
<text top="445" left="964" width="25" height="14" font="7">and </text>
<text top="463" left="964" width="76" height="14" font="7">unevaluable </text>
<text top="480" left="964" width="54" height="14" font="7">stents (5 </text>
<text top="497" left="964" width="54" height="14" font="7">studies); </text>
<text top="514" left="964" width="52" height="14" font="7">(68% to </text>
<text top="532" left="964" width="77" height="14" font="7">88%); (77% </text>
<text top="549" left="964" width="52" height="14" font="7">to 84%) </text>
<text top="342" left="1062" width="30" height="14" font="7">N/A </text>
<text top="342" left="1146" width="87" height="14" font="7">a) Publication </text>
<text top="359" left="1146" width="60" height="14" font="7">bias (non-</text>
<text top="376" left="1146" width="95" height="14" font="7">English studies </text>
<text top="394" left="1146" width="105" height="14" font="7">excluded, (under </text>
<text top="411" left="1146" width="83" height="14" font="7">way or under </text>
<text top="428" left="1146" width="90" height="14" font="7">review studies </text>
<text top="445" left="1146" width="66" height="14" font="7">excluded;  </text>
<text top="463" left="1146" width="61" height="14" font="7">b) lack of </text>
<text top="480" left="1146" width="98" height="14" font="7">uniform criteria </text>
<text top="497" left="1146" width="87" height="14" font="7">of assessment </text>
<text top="514" left="1146" width="80" height="14" font="7">(reporting of </text>
<text top="532" left="1146" width="55" height="14" font="7">type and </text>
<text top="549" left="1146" width="72" height="14" font="7">diameter of </text>
<text top="566" left="1146" width="38" height="14" font="7">stents </text>
<text top="583" left="1146" width="77" height="14" font="7">implanted);  </text>
<text top="601" left="1146" width="99" height="14" font="7">c) Limitation of </text>
<text top="618" left="1146" width="45" height="14" font="7">pooled </text>
<text top="635" left="1146" width="100" height="14" font="7">sensitivities and </text>
<text top="652" left="1146" width="75" height="14" font="7">specificities </text>
<text top="670" left="1146" width="89" height="14" font="7">(different pos. </text>
<text top="687" left="1146" width="69" height="14" font="7">criteria not </text>
<text top="704" left="1146" width="74" height="14" font="7">considered) </text>
<text top="342" left="1264" width="74" height="14" font="7">64-slice CT </text>
<text top="359" left="1264" width="133" height="14" font="7">angiography has high </text>
<text top="376" left="1264" width="122" height="14" font="7">diagnostic accuracy </text>
<text top="394" left="1264" width="135" height="14" font="7">(&gt;90% sensitivity and </text>
<text top="411" left="1264" width="114" height="14" font="7">specificity) for the </text>
<text top="428" left="1264" width="102" height="14" font="7">detection of ISR </text>
<text top="445" left="1264" width="78" height="14" font="7">compared to </text>
<text top="463" left="1264" width="138" height="14" font="7">conventional coronary </text>
<text top="480" left="1264" width="79" height="14" font="7">angiography </text>
<text top="723" left="108" width="4" height="16" font="11"><i><b> </b></i></text>
<text top="743" left="47" width="1353" height="14" font="7">*Meta-analyses of the diagnostic accuracy of CCTA from 2006 and earlier include predominantly or exclusively studies done with obsolete scanner technology (16-slice or 4-slice MDCT or electron beam CT (EBCT).  These </text>
<text top="760" left="47" width="1249" height="14" font="7">older studies are included here to demonstrate the consistently high diagnostic accuracy of CCTA across all of the available meta-analyses and the evidence and the size of the evidence base supporting its use.</text>
<text top="760" left="1296" width="9" height="16" font="7">&#34; </text>
<text top="778" left="101" width="4" height="16" font="11"><i><b> </b></i></text>
</page>
<page number="10" position="absolute" top="0" left="0" height="918" width="1512">
<text top="59" left="108" width="4" height="15" font="0"> </text>
<text top="59" left="459" width="4" height="15" font="0"> </text>
<text top="59" left="810" width="4" height="15" font="0"> </text>
<text top="59" left="864" width="4" height="15" font="0"> </text>
<text top="59" left="918" width="4" height="15" font="0"> </text>
<text top="59" left="972" width="4" height="15" font="0"> </text>
<text top="59" left="1026" width="4" height="15" font="0"> </text>
<text top="59" left="1080" width="4" height="15" font="0"> </text>
<text top="59" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="108" width="613" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="825" left="810" width="4" height="15" font="0"> </text>
<text top="825" left="864" width="4" height="15" font="0"> </text>
<text top="825" left="918" width="4" height="15" font="0"> </text>
<text top="825" left="972" width="4" height="15" font="0"> </text>
<text top="825" left="1026" width="4" height="15" font="0"> </text>
<text top="825" left="1080" width="4" height="15" font="0"> </text>
<text top="825" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="1188" width="4" height="15" font="0"> </text>
<text top="825" left="1242" width="22" height="15" font="0">10 </text>
<text top="847" left="108" width="4" height="15" font="0"> </text>
<text top="111" left="47" width="1354" height="14" font="7">ACCURACY indicates Assessment by Coronary Computed Tomographic Angiography of Individuals Undergoing Invasive Coronary Angiography; ACS, acute coronary syndrome; AF, atrial fibrillation; Angio, angiography; </text>
<text top="129" left="47" width="1352" height="14" font="7">AUC, area under the curve, BB, beta blocker; BMI; body mass index; bpm, beats per minute; CABG, coronary artery bypass surgery; CAD, coronary artery disease; CCA, conventional coronary angiogram/angioplasty, CCB, </text>
<text top="146" left="47" width="1332" height="14" font="7">calcium channel blocker; CCTA coronary computer tomography angiography; CE-CCT, contrast enhanced coronary computed tomography; CI, confidence interval; CMR, cardiac magnetic resonance, Cr, creatinine, CRF, </text>
<text top="163" left="47" width="1359" height="14" font="7">chronic renal failure; CMR, cardiac magnetic resonance; CT, computed tomography; CTA, computed tomographic angiography; DSE, dobutatmine stress echocardiography; EBCT, electron beam computed tomography; ECG, </text>
<text top="180" left="47" width="1354" height="14" font="7">electrocardiogram; Echo, echocardiography; EMPIRE, Economics of myocardial perfusion imaging in Europe; ETT, exercise tolerance test; Ex, exercise; FN, false negative, FP, false positive, HR, hazard  ratio, ICA, invasive </text>
<text top="197" left="47" width="1306" height="14" font="7">coronary angiography; ISR, in-stent restenosis, LBBB, left bundle brunch block; LM, left main; LR, likelihood ratio; <i>µ</i>M, micromoles MCS, multicenter study; MDCT, multi-detector computed tomography; MDCTA, </text>
<text top="215" left="47" width="1356" height="14" font="7">multidetector CT angiography; MI, myocardial infarction; MPI, myocardial perfusion imaging; MRI, magnetic resonance imaging; N/A not applicable; Neg., negative; NLR, negative likelihood ratio; NPV, negative predictive </text>
<text top="232" left="47" width="1326" height="14" font="7">value; NS, non-significant; NTG, nitroglycerin; OR, odds ratio; PCI, percutaneous coronary intervention; PET, positron emission tomography; PLR, positive likelihood ratio; Pos., positive; PPV, positive predictive value; </text>
<text top="249" left="47" width="1332" height="14" font="7">PTCA, percutaneous transluminal coronary angioplasty; QCA, quantitative coronary angiography; Quant., quantitative; RCT, randomized controlled trial; RR, relative risk; SBP, systolic blood pressure; sec, second; Sens., </text>
<text top="266" left="47" width="1307" height="14" font="7">sensitivity; Spec., specificity; SPECT, single photon emission computed tomography; Stat., statistical; TN, true negative, TP, true positive; UA, unstable angina; VD, vessel disease; vs., versus; and WMA, wall motion </text>
<text top="284" left="47" width="80" height="14" font="7">abnormality. </text>
<text top="302" left="101" width="4" height="16" font="11"><i><b> </b></i></text>
<text top="322" left="101" width="4" height="16" font="11"><i><b> </b></i></text>
<text top="344" left="101" width="269" height="19" font="1"><b>Data Supplement 2 - Imaging<i> </i></b></text>
<text top="377" left="697" width="125" height="15" font="4"><b>Risk Assessment  </b></text>
<text top="416" left="77" width="95" height="15" font="4"><b>Study Name, </b></text>
<text top="435" left="75" width="98" height="15" font="4"><b>Author, Year </b></text>
<text top="416" left="214" width="52" height="15" font="4"><b>Aim of </b></text>
<text top="435" left="219" width="43" height="15" font="4"><b>study </b></text>
<text top="416" left="301" width="46" height="15" font="4"><b>Study </b></text>
<text top="435" left="304" width="40" height="15" font="4"><b>Type </b></text>
<text top="416" left="368" width="46" height="15" font="4"><b>Study </b></text>
<text top="435" left="374" width="33" height="15" font="4"><b>Size </b></text>
<text top="426" left="456" width="136" height="15" font="4"><b>Patient Population </b></text>
<text top="426" left="698" width="77" height="15" font="4"><b>Endpoints </b></text>
<text top="406" left="870" width="74" height="15" font="4"><b>Statistical </b></text>
<text top="426" left="875" width="64" height="15" font="4"><b>Analysis </b></text>
<text top="444" left="874" width="66" height="15" font="4"><b>(Results) </b></text>
<text top="416" left="977" width="88" height="15" font="4"><b>P Values &amp;  </b></text>
<text top="435" left="986" width="65" height="15" font="4"><b>95% CI: </b></text>
<text top="416" left="1097" width="87" height="15" font="4"><b>Main Study </b></text>
<text top="435" left="1107" width="66" height="15" font="4"><b>Findings </b></text>
<text top="416" left="1237" width="50" height="15" font="4"><b> Study </b></text>
<text top="435" left="1219" width="86" height="15" font="4"><b>Limitations </b></text>
<text top="416" left="1351" width="70" height="15" font="4"><b>Findings/ </b></text>
<text top="435" left="1346" width="80" height="15" font="4"><b>Comments </b></text>
<text top="479" left="120" width="8" height="15" font="5">  </text>
<text top="479" left="236" width="8" height="15" font="5">  </text>
<text top="479" left="320" width="8" height="15" font="5">  </text>
<text top="479" left="386" width="8" height="15" font="5">  </text>
<text top="470" left="445" width="69" height="15" font="6"><i><b>Inclusion </b></i></text>
<text top="489" left="451" width="57" height="15" font="6"><i><b>Criteria </b></i></text>
<text top="470" left="543" width="73" height="15" font="6"><i><b>Exclusion </b></i></text>
<text top="489" left="550" width="57" height="15" font="6"><i><b>Criteria </b></i></text>
<text top="470" left="652" width="60" height="15" font="6"><i><b>Primary </b></i></text>
<text top="489" left="649" width="67" height="15" font="6"><i><b>Endpoint </b></i></text>
<text top="470" left="758" width="80" height="15" font="6"><i><b>Secondary  </b></i></text>
<text top="489" left="762" width="67" height="15" font="6"><i><b>Endpoint </b></i></text>
<text top="479" left="903" width="8" height="15" font="5">  </text>
<text top="479" left="1014" width="8" height="15" font="5">  </text>
<text top="479" left="1136" width="8" height="15" font="5">  </text>
<text top="479" left="1257" width="8" height="15" font="5">  </text>
<text top="479" left="1382" width="8" height="15" font="5">  </text>
<text top="529" left="65" width="549" height="16" font="2"><b>Stress Cardiac MRI-prognostic studies in patients with suspected CAD </b></text>
<text top="564" left="65" width="91" height="14" font="7">Assessment of </text>
<text top="582" left="65" width="101" height="14" font="7">myocardial wall </text>
<text top="599" left="65" width="72" height="14" font="7">motion and </text>
<text top="616" left="65" width="64" height="14" font="7">perfusion, </text>
<text top="633" left="65" width="112" height="14" font="7">Korosoglou, 2010 </text>
<text top="651" left="65" width="25" height="14" font="8">(32)</text>
<text top="651" left="90" width="4" height="14" font="7"> </text>
<text top="564" left="195" width="81" height="14" font="7">Prognosis by </text>
<text top="582" left="195" width="74" height="14" font="7">dobutamine </text>
<text top="599" left="195" width="69" height="14" font="7">stress MRI </text>
<text top="564" left="297" width="43" height="14" font="7">Single-</text>
<text top="582" left="297" width="40" height="14" font="7">center </text>
<text top="599" left="297" width="28" height="14" font="7">trial </text>
<text top="564" left="363" width="38" height="14" font="7">1,493 </text>
<text top="564" left="430" width="64" height="14" font="7">Suspected </text>
<text top="582" left="430" width="58" height="14" font="7">Ischemia </text>
<text top="564" left="541" width="32" height="14" font="7">MRI </text>
<text top="582" left="541" width="45" height="14" font="7">related </text>
<text top="599" left="541" width="67" height="14" font="7">exclusions </text>
<text top="564" left="629" width="87" height="14" font="7">Cardiac death </text>
<text top="582" left="629" width="62" height="14" font="7">and AMI  </text>
<text top="564" left="748" width="87" height="14" font="7">Late coronary </text>
<text top="582" left="748" width="87" height="14" font="7">revascularizati</text>
<text top="599" left="748" width="19" height="14" font="7">on </text>
<text top="564" left="856" width="85" height="14" font="7">Multivariable </text>
<text top="582" left="856" width="99" height="14" font="7">Cox Regression </text>
<text top="564" left="971" width="53" height="14" font="7">p&lt;0.001 </text>
<text top="564" left="1079" width="108" height="14" font="7">Adj. HR of stress </text>
<text top="582" left="1079" width="97" height="14" font="7">wall motion for </text>
<text top="599" left="1079" width="117" height="14" font="7">primary endpoints: </text>
<text top="616" left="1079" width="120" height="14" font="7">5.9 (95% CI: 2.5 to </text>
<text top="633" left="1079" width="90" height="14" font="7">13.6); for late  </text>
<text top="651" left="1079" width="106" height="14" font="7">revascularization </text>
<text top="668" left="1079" width="110" height="14" font="7">HR 3.1: (95% CI: </text>
<text top="685" left="1079" width="148" height="14" font="7">1.7 to 5.6)                       </text>
<text top="702" left="1079" width="99" height="14" font="7">Adjusted HR of </text>
<text top="720" left="1079" width="81" height="14" font="7">perfusion for </text>
<text top="737" left="1079" width="117" height="14" font="7">primary endpoints: </text>
<text top="754" left="1079" width="120" height="14" font="7">5.4 (95% CI: 2.3 to </text>
<text top="771" left="1079" width="86" height="14" font="7">12.9); for late </text>
<text top="789" left="1079" width="106" height="14" font="7">revascularization </text>
<text top="564" left="1214" width="82" height="14" font="7">Single center </text>
<text top="582" left="1214" width="84" height="14" font="7">observational </text>
<text top="599" left="1214" width="40" height="14" font="7">study  </text>
<text top="564" left="1321" width="126" height="14" font="7">Very low hard event </text>
<text top="582" left="1321" width="105" height="14" font="7">rates by negative </text>
<text top="599" left="1321" width="74" height="14" font="7">dobutamine </text>
<text top="616" left="1321" width="100" height="14" font="7">combined stress </text>
<text top="633" left="1321" width="79" height="14" font="7">function and </text>
<text top="651" left="1321" width="60" height="14" font="7">perfusion </text>
</page>
<page number="11" position="absolute" top="0" left="0" height="918" width="1512">
<text top="59" left="108" width="4" height="15" font="0"> </text>
<text top="59" left="459" width="4" height="15" font="0"> </text>
<text top="59" left="810" width="4" height="15" font="0"> </text>
<text top="59" left="864" width="4" height="15" font="0"> </text>
<text top="59" left="918" width="4" height="15" font="0"> </text>
<text top="59" left="972" width="4" height="15" font="0"> </text>
<text top="59" left="1026" width="4" height="15" font="0"> </text>
<text top="59" left="1080" width="4" height="15" font="0"> </text>
<text top="59" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="108" width="613" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="825" left="810" width="4" height="15" font="0"> </text>
<text top="825" left="864" width="4" height="15" font="0"> </text>
<text top="825" left="918" width="4" height="15" font="0"> </text>
<text top="825" left="972" width="4" height="15" font="0"> </text>
<text top="825" left="1026" width="4" height="15" font="0"> </text>
<text top="825" left="1080" width="4" height="15" font="0"> </text>
<text top="825" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="1188" width="4" height="15" font="0"> </text>
<text top="825" left="1242" width="22" height="15" font="0">11 </text>
<text top="847" left="108" width="4" height="15" font="0"> </text>
<text top="112" left="1079" width="113" height="14" font="7">adj. HR: 6.2 (95% </text>
<text top="129" left="1079" width="96" height="14" font="7">CI: 3.3 to 11.3) </text>
<text top="162" left="65" width="68" height="14" font="7">Long-term </text>
<text top="179" left="65" width="103" height="14" font="7">prognostic value </text>
<text top="197" left="65" width="91" height="14" font="7">of dobutamine </text>
<text top="214" left="65" width="81" height="14" font="7">stress CMR,  </text>
<text top="231" left="65" width="82" height="14" font="7">Kelle S, 2011</text>
<text top="231" left="147" width="29" height="14" font="8"> (33)</text>
<text top="231" left="176" width="4" height="14" font="7"> </text>
<text top="248" left="65" width="4" height="14" font="7"> </text>
<text top="162" left="195" width="81" height="14" font="7">Prognosis by </text>
<text top="179" left="195" width="74" height="14" font="7">dobutamine </text>
<text top="197" left="195" width="69" height="14" font="7">stress MRI </text>
<text top="162" left="297" width="43" height="14" font="7">Single-</text>
<text top="179" left="297" width="40" height="14" font="7">center </text>
<text top="197" left="297" width="28" height="14" font="7">trial </text>
<text top="162" left="363" width="38" height="14" font="7">1,463 </text>
<text top="162" left="430" width="64" height="14" font="7">Suspected </text>
<text top="179" left="430" width="58" height="14" font="7">Ischemia </text>
<text top="162" left="541" width="32" height="14" font="7">MRI </text>
<text top="179" left="541" width="45" height="14" font="7">related </text>
<text top="197" left="541" width="67" height="14" font="7">exclusions </text>
<text top="162" left="629" width="87" height="14" font="7">Cardiac death </text>
<text top="179" left="629" width="58" height="14" font="7">and AMI </text>
<text top="162" left="748" width="36" height="14" font="7">None </text>
<text top="162" left="856" width="85" height="14" font="7">Multivariable </text>
<text top="179" left="856" width="99" height="14" font="7">Cox Regression </text>
<text top="162" left="971" width="57" height="14" font="7">p&lt;0.001  </text>
<text top="179" left="971" width="70" height="14" font="7">(1.8 to 5.9) </text>
<text top="162" left="1079" width="100" height="14" font="7">HR of inducible </text>
<text top="179" left="1079" width="76" height="14" font="7">wall motion </text>
<text top="197" left="1079" width="97" height="14" font="7">abnormality for </text>
<text top="214" left="1079" width="117" height="14" font="7">primary endpoints: </text>
<text top="231" left="1079" width="30" height="14" font="7">3.31 </text>
<text top="162" left="1214" width="84" height="14" font="7">Single-center </text>
<text top="179" left="1214" width="84" height="14" font="7">observational </text>
<text top="197" left="1214" width="36" height="14" font="7">study </text>
<text top="162" left="1321" width="58" height="14" font="7">Negative </text>
<text top="179" left="1321" width="111" height="14" font="7">dobutamine stress </text>
<text top="197" left="1321" width="90" height="14" font="7">CMR conveys </text>
<text top="214" left="1321" width="104" height="14" font="7">96.8% 6-y event-</text>
<text top="231" left="1321" width="79" height="14" font="7">free survival </text>
<text top="266" left="65" width="75" height="14" font="7">Incremental </text>
<text top="284" left="65" width="67" height="14" font="7">prognostic </text>
<text top="301" left="65" width="92" height="14" font="7">significance of </text>
<text top="318" left="65" width="100" height="14" font="7">combined CMR </text>
<text top="336" left="65" width="56" height="14" font="7">imaging, </text>
<text top="353" left="65" width="101" height="14" font="7">adenosine stress </text>
<text top="370" left="65" width="114" height="14" font="7">perfusion, delayed </text>
<text top="387" left="65" width="112" height="14" font="7">enhancement, and </text>
<text top="404" left="65" width="108" height="14" font="7">LV function over </text>
<text top="422" left="65" width="72" height="14" font="7">preimaging </text>
<text top="439" left="65" width="118" height="14" font="7">information for the </text>
<text top="456" left="65" width="81" height="14" font="7">prediction of </text>
<text top="473" left="65" width="95" height="14" font="7">adverse events. </text>
<text top="491" left="65" width="117" height="14" font="7">Bingham SE, 2011 </text>
<text top="508" left="65" width="25" height="14" font="8">(34)</text>
<text top="508" left="90" width="4" height="14" font="7"> </text>
<text top="266" left="195" width="81" height="14" font="7">Prognosis by </text>
<text top="284" left="195" width="63" height="14" font="7">adenosine </text>
<text top="301" left="195" width="69" height="14" font="7">stress MRI </text>
<text top="266" left="297" width="43" height="14" font="7">Single-</text>
<text top="284" left="297" width="40" height="14" font="7">center </text>
<text top="301" left="297" width="28" height="14" font="7">trial </text>
<text top="266" left="363" width="26" height="14" font="7">908 </text>
<text top="266" left="430" width="64" height="14" font="7">Suspected </text>
<text top="284" left="430" width="58" height="14" font="7">Ischemia </text>
<text top="266" left="541" width="32" height="14" font="7">MRI </text>
<text top="284" left="541" width="45" height="14" font="7">related </text>
<text top="301" left="541" width="67" height="14" font="7">exclusions </text>
<text top="266" left="629" width="105" height="14" font="7">Death, AMI, and </text>
<text top="284" left="629" width="82" height="14" font="7">late coronary </text>
<text top="301" left="629" width="106" height="14" font="7">revascularization </text>
<text top="266" left="748" width="87" height="14" font="7">Cardiac death </text>
<text top="284" left="748" width="47" height="14" font="7">and MI </text>
<text top="266" left="856" width="85" height="14" font="7">Multivariable </text>
<text top="284" left="856" width="99" height="14" font="7">Cox Regression </text>
<text top="266" left="971" width="46" height="14" font="7">p=0.02 </text>
<text top="266" left="1079" width="85" height="14" font="7">HR of 2.2 for </text>
<text top="284" left="1079" width="107" height="14" font="7">primary endpoint </text>
<text top="266" left="1214" width="81" height="14" font="7">Referral bias </text>
<text top="284" left="1214" width="67" height="14" font="7">of a single-</text>
<text top="301" left="1214" width="40" height="14" font="7">center </text>
<text top="318" left="1214" width="84" height="14" font="7">observational </text>
<text top="336" left="1214" width="36" height="14" font="7">study </text>
<text top="266" left="1321" width="124" height="14" font="7">Ventricular volume, </text>
<text top="284" left="1321" width="73" height="14" font="7">aortic flow, </text>
<text top="301" left="1321" width="128" height="14" font="7">myocardial viability, </text>
<text top="318" left="1321" width="123" height="14" font="7">and stress perfusion </text>
<text top="336" left="1321" width="119" height="14" font="7">all add incremental </text>
<text top="353" left="1321" width="122" height="14" font="7">value for prediction </text>
<text top="370" left="1321" width="108" height="14" font="7">of adverse events </text>
<text top="387" left="1321" width="120" height="14" font="7">over pre-CMR data </text>
<text top="404" left="1321" width="68" height="14" font="7">and can be </text>
<text top="422" left="1321" width="123" height="14" font="7">combined to further </text>
<text top="439" left="1321" width="53" height="14" font="7">enhance </text>
<text top="456" left="1321" width="105" height="14" font="7">prognostication.  </text>
<text top="526" left="65" width="104" height="14" font="7">Prognostic value </text>
<text top="543" left="65" width="90" height="14" font="7">of CMR stress </text>
<text top="561" left="65" width="98" height="14" font="7">tests: adenosine </text>
<text top="578" left="65" width="97" height="14" font="7">stress perfusion </text>
<text top="595" left="65" width="100" height="14" font="7">and dobutamine </text>
<text top="612" left="65" width="113" height="14" font="7">stress wall motion </text>
<text top="629" left="65" width="57" height="14" font="7">imaging. </text>
<text top="647" left="65" width="97" height="14" font="7">Jahnke C, 2007 </text>
<text top="664" left="65" width="25" height="14" font="8">(35)</text>
<text top="664" left="90" width="4" height="14" font="7"> </text>
<text top="526" left="195" width="81" height="14" font="7">Prognosis by </text>
<text top="543" left="195" width="63" height="14" font="7">adenosine </text>
<text top="561" left="195" width="69" height="14" font="7">stress MRI </text>
<text top="526" left="297" width="43" height="14" font="7">Single-</text>
<text top="543" left="297" width="40" height="14" font="7">center </text>
<text top="561" left="297" width="28" height="14" font="7">trial </text>
<text top="526" left="363" width="26" height="14" font="7">513 </text>
<text top="526" left="430" width="68" height="14" font="7">Symptoms </text>
<text top="543" left="430" width="82" height="14" font="7">suspicious of </text>
<text top="561" left="430" width="82" height="14" font="7">ischemia and </text>
<text top="578" left="430" width="80" height="14" font="7">no history of </text>
<text top="595" left="430" width="22" height="14" font="7">MI </text>
<text top="526" left="541" width="32" height="14" font="7">MRI </text>
<text top="543" left="541" width="45" height="14" font="7">related </text>
<text top="561" left="541" width="71" height="14" font="7">exclusions  </text>
<text top="526" left="629" width="103" height="14" font="7">Cardiac death or </text>
<text top="543" left="629" width="33" height="14" font="7">AMI </text>
<text top="526" left="748" width="36" height="14" font="7">None </text>
<text top="526" left="856" width="85" height="14" font="7">Multivariable </text>
<text top="543" left="856" width="99" height="14" font="7">Cox Regression </text>
<text top="526" left="971" width="89" height="14" font="7">p&lt;0.001; 95% </text>
<text top="543" left="971" width="80" height="14" font="7">CI: 3.6 to 43 </text>
<text top="526" left="1079" width="92" height="14" font="7">HR of 12.5 for </text>
<text top="543" left="1079" width="107" height="14" font="7">primary endpoint </text>
<text top="526" left="1214" width="84" height="14" font="7">Single-center </text>
<text top="543" left="1214" width="84" height="14" font="7">observational </text>
<text top="561" left="1214" width="36" height="14" font="7">study </text>
<text top="526" left="1321" width="122" height="14" font="7">Both adenosine and </text>
<text top="543" left="1321" width="107" height="14" font="7">dobutamine MRI </text>
<text top="561" left="1321" width="104" height="14" font="7">were effective in </text>
<text top="578" left="1321" width="47" height="14" font="7">cardiac </text>
<text top="595" left="1321" width="127" height="14" font="7">prognostication with </text>
<text top="612" left="1321" width="121" height="14" font="7">high negative event </text>
<text top="629" left="1321" width="30" height="14" font="7">rate. </text>
<text top="682" left="65" width="89" height="14" font="7">Stress MPI by </text>
<text top="699" left="65" width="92" height="14" font="7">CMR provides </text>
<text top="716" left="65" width="108" height="14" font="7">strong prognostic </text>
<text top="734" left="65" width="99" height="14" font="7">value to cardiac </text>
<text top="751" left="65" width="107" height="14" font="7">events regardless </text>
<text top="768" left="65" width="100" height="14" font="7">of patient's sex.  </text>
<text top="786" left="65" width="112" height="14" font="7">Coelho-Filho OR, </text>
<text top="682" left="195" width="81" height="14" font="7">Prognosis by </text>
<text top="699" left="195" width="63" height="14" font="7">adenosine </text>
<text top="716" left="195" width="84" height="14" font="7">stress MRI in </text>
<text top="734" left="195" width="48" height="14" font="7">women </text>
<text top="682" left="297" width="43" height="14" font="7">Single-</text>
<text top="699" left="297" width="40" height="14" font="7">center </text>
<text top="716" left="297" width="28" height="14" font="7">trial </text>
<text top="682" left="363" width="26" height="14" font="7">424 </text>
<text top="682" left="430" width="68" height="14" font="7">Symptoms </text>
<text top="699" left="430" width="82" height="14" font="7">suspicious of </text>
<text top="716" left="430" width="57" height="14" font="7">ischemia </text>
<text top="682" left="541" width="32" height="14" font="7">MRI </text>
<text top="699" left="541" width="45" height="14" font="7">related </text>
<text top="716" left="541" width="67" height="14" font="7">exclusions </text>
<text top="682" left="629" width="89" height="14" font="7">Death or AMI </text>
<text top="682" left="748" width="36" height="14" font="7">None </text>
<text top="682" left="856" width="85" height="14" font="7">Multivariable </text>
<text top="699" left="856" width="99" height="14" font="7">Cox Regression </text>
<text top="682" left="971" width="53" height="14" font="7">p&lt;0.001 </text>
<text top="682" left="1079" width="113" height="14" font="7">Unadjusted HR of </text>
<text top="699" left="1079" width="72" height="14" font="7">presence of </text>
<text top="716" left="1079" width="105" height="14" font="7">ischemia: 6.4 for </text>
<text top="734" left="1079" width="113" height="14" font="7">primary endpoints </text>
<text top="682" left="1214" width="84" height="14" font="7">Single-center </text>
<text top="699" left="1214" width="84" height="14" font="7">observational </text>
<text top="716" left="1214" width="36" height="14" font="7">study </text>
<text top="682" left="1321" width="101" height="14" font="7">Negative annual </text>
<text top="699" left="1321" width="93" height="14" font="7">hard event rate </text>
<text top="716" left="1321" width="109" height="14" font="7">99.4% in women. </text>
<text top="734" left="1321" width="103" height="14" font="7">Stress CMR risk </text>
<text top="751" left="1321" width="94" height="14" font="7">stratify women </text>
<text top="768" left="1321" width="68" height="14" font="7">effectively </text>
</page>
<page number="12" position="absolute" top="0" left="0" height="918" width="1512">
<text top="59" left="108" width="4" height="15" font="0"> </text>
<text top="59" left="459" width="4" height="15" font="0"> </text>
<text top="59" left="810" width="4" height="15" font="0"> </text>
<text top="59" left="864" width="4" height="15" font="0"> </text>
<text top="59" left="918" width="4" height="15" font="0"> </text>
<text top="59" left="972" width="4" height="15" font="0"> </text>
<text top="59" left="1026" width="4" height="15" font="0"> </text>
<text top="59" left="1080" width="4" height="15" font="0"> </text>
<text top="59" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="108" width="613" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="825" left="810" width="4" height="15" font="0"> </text>
<text top="825" left="864" width="4" height="15" font="0"> </text>
<text top="825" left="918" width="4" height="15" font="0"> </text>
<text top="825" left="972" width="4" height="15" font="0"> </text>
<text top="825" left="1026" width="4" height="15" font="0"> </text>
<text top="825" left="1080" width="4" height="15" font="0"> </text>
<text top="825" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="1188" width="4" height="15" font="0"> </text>
<text top="825" left="1242" width="22" height="15" font="0">12 </text>
<text top="847" left="108" width="4" height="15" font="0"> </text>
<text top="112" left="65" width="34" height="14" font="7">2011 </text>
<text top="129" left="65" width="25" height="14" font="8">(36)</text>
<text top="129" left="90" width="4" height="14" font="7"> </text>
<text top="162" left="65" width="104" height="14" font="7">Prognostic value </text>
<text top="179" left="65" width="100" height="14" font="7">of dipyridamole </text>
<text top="197" left="65" width="37" height="14" font="7">stress </text>
<text top="214" left="65" width="91" height="14" font="7">cardiovascular </text>
<text top="231" left="65" width="99" height="14" font="7">MRI in pts with </text>
<text top="248" left="65" width="61" height="14" font="7">known or </text>
<text top="266" left="65" width="101" height="14" font="7">suspected CAD. </text>
<text top="283" left="65" width="89" height="14" font="7">Bodi V, 2007  </text>
<text top="300" left="65" width="25" height="14" font="8">(37)</text>
<text top="300" left="90" width="4" height="14" font="7"> </text>
<text top="318" left="65" width="4" height="14" font="7"> </text>
<text top="162" left="195" width="81" height="14" font="7">Prognosis by </text>
<text top="179" left="195" width="83" height="14" font="7">dipyridamole </text>
<text top="197" left="195" width="69" height="14" font="7">stress MRI </text>
<text top="162" left="297" width="43" height="14" font="7">Single-</text>
<text top="179" left="297" width="40" height="14" font="7">center </text>
<text top="197" left="297" width="28" height="14" font="7">trial </text>
<text top="162" left="363" width="26" height="14" font="7">420 </text>
<text top="162" left="430" width="68" height="14" font="7">Symptoms </text>
<text top="179" left="430" width="82" height="14" font="7">suspicious of </text>
<text top="197" left="430" width="57" height="14" font="7">ischemia </text>
<text top="162" left="541" width="32" height="14" font="7">MRI </text>
<text top="179" left="541" width="45" height="14" font="7">related </text>
<text top="197" left="541" width="67" height="14" font="7">exclusions </text>
<text top="162" left="629" width="87" height="14" font="7">Cardiac death </text>
<text top="179" left="629" width="58" height="14" font="7">and AMI </text>
<text top="162" left="748" width="36" height="14" font="7">None </text>
<text top="162" left="856" width="85" height="14" font="7">Multivariable </text>
<text top="179" left="856" width="99" height="14" font="7">Cox Regression </text>
<text top="162" left="971" width="61" height="14" font="7">p=0.0006 </text>
<text top="162" left="1079" width="115" height="14" font="7">Stress wall motion </text>
<text top="179" left="1079" width="120" height="14" font="7">abnormality carries </text>
<text top="197" left="1079" width="95" height="14" font="7">a OR of 5.3 for </text>
<text top="214" left="1079" width="113" height="14" font="7">primary endpoints </text>
<text top="162" left="1214" width="84" height="14" font="7">Single-center </text>
<text top="179" left="1214" width="84" height="14" font="7">observational </text>
<text top="197" left="1214" width="36" height="14" font="7">study </text>
<text top="162" left="1321" width="30" height="14" font="7">N/A </text>
<text top="336" left="65" width="32" height="14" font="7">MRI </text>
<text top="353" left="65" width="103" height="14" font="7">determination of </text>
<text top="370" left="65" width="116" height="14" font="7">cardiac prognosis.  </text>
<text top="387" left="65" width="92" height="14" font="7">Hundley WG,  </text>
<text top="404" left="65" width="34" height="14" font="7">2002 </text>
<text top="422" left="65" width="25" height="14" font="8">(38)</text>
<text top="422" left="90" width="4" height="14" font="7"> </text>
<text top="336" left="195" width="81" height="14" font="7">Prognosis by </text>
<text top="353" left="195" width="74" height="14" font="7">dobutamine </text>
<text top="370" left="195" width="69" height="14" font="7">stress MRI </text>
<text top="336" left="297" width="43" height="14" font="7">Single-</text>
<text top="353" left="297" width="40" height="14" font="7">center </text>
<text top="370" left="297" width="28" height="14" font="7">trial </text>
<text top="336" left="363" width="26" height="14" font="7">279 </text>
<text top="336" left="430" width="68" height="14" font="7">Symptoms </text>
<text top="353" left="430" width="82" height="14" font="7">suspicious of </text>
<text top="370" left="430" width="57" height="14" font="7">ischemia </text>
<text top="336" left="541" width="32" height="14" font="7">MRI </text>
<text top="353" left="541" width="45" height="14" font="7">related </text>
<text top="370" left="541" width="67" height="14" font="7">exclusions </text>
<text top="336" left="629" width="87" height="14" font="7">Cardiac death </text>
<text top="353" left="629" width="58" height="14" font="7">and AMI </text>
<text top="336" left="748" width="40" height="14" font="7">None  </text>
<text top="336" left="856" width="85" height="14" font="7">Multivariable </text>
<text top="353" left="856" width="99" height="14" font="7">Cox Regression </text>
<text top="336" left="971" width="65" height="14" font="7">p=0.0004; </text>
<text top="353" left="971" width="92" height="14" font="7">95% CI: 1.1 to </text>
<text top="370" left="971" width="22" height="14" font="7">9.7 </text>
<text top="336" left="1079" width="115" height="14" font="7">Stress wall motion </text>
<text top="353" left="1079" width="112" height="14" font="7">abnormality had a </text>
<text top="370" left="1079" width="72" height="14" font="7">HR: 3.3 for </text>
<text top="387" left="1079" width="111" height="14" font="7">primary endpoint, </text>
<text top="404" left="1079" width="93" height="14" font="7">independent of </text>
<text top="422" left="1079" width="41" height="14" font="7">LVEF </text>
<text top="336" left="1214" width="84" height="14" font="7">Single-center </text>
<text top="353" left="1214" width="84" height="14" font="7">observational </text>
<text top="370" left="1214" width="36" height="14" font="7">study </text>
<text top="336" left="1321" width="94" height="14" font="7">First study that </text>
<text top="353" left="1321" width="86" height="14" font="7">illustrated the </text>
<text top="370" left="1321" width="67" height="14" font="7">prognostic </text>
<text top="387" left="1321" width="92" height="14" font="7">significance of </text>
<text top="404" left="1321" width="111" height="14" font="7">dobutamine stress </text>
<text top="422" left="1321" width="32" height="14" font="7">MRI </text>
<text top="440" left="65" width="78" height="14" font="7">Dobutamine </text>
<text top="457" left="65" width="106" height="14" font="7">cardiac magnetic </text>
<text top="474" left="65" width="107" height="14" font="7">resonance results </text>
<text top="491" left="65" width="93" height="14" font="7">predict cardiac </text>
<text top="509" left="65" width="77" height="14" font="7">prognosis in </text>
<text top="526" left="65" width="78" height="14" font="7">women with </text>
<text top="543" left="65" width="61" height="14" font="7">known or </text>
<text top="561" left="65" width="96" height="14" font="7">suspected IHD. </text>
<text top="578" left="65" width="113" height="14" font="7">Wallace EL, 2009 </text>
<text top="595" left="65" width="25" height="14" font="8">(39)</text>
<text top="595" left="90" width="4" height="14" font="7"> </text>
<text top="440" left="195" width="81" height="14" font="7">Prognosis by </text>
<text top="457" left="195" width="74" height="14" font="7">dobutamine </text>
<text top="474" left="195" width="84" height="14" font="7">stress MRI in </text>
<text top="491" left="195" width="48" height="14" font="7">women </text>
<text top="440" left="297" width="43" height="14" font="7">Single-</text>
<text top="457" left="297" width="40" height="14" font="7">center </text>
<text top="474" left="297" width="28" height="14" font="7">trial </text>
<text top="440" left="363" width="26" height="14" font="7">266 </text>
<text top="440" left="430" width="68" height="14" font="7">Symptoms </text>
<text top="457" left="430" width="82" height="14" font="7">suspicious of </text>
<text top="474" left="430" width="61" height="14" font="7">ischemia, </text>
<text top="491" left="430" width="48" height="14" font="7">women </text>
<text top="440" left="541" width="32" height="14" font="7">MRI </text>
<text top="457" left="541" width="45" height="14" font="7">related </text>
<text top="474" left="541" width="67" height="14" font="7">exclusions </text>
<text top="440" left="629" width="87" height="14" font="7">Cardiac death </text>
<text top="457" left="629" width="58" height="14" font="7">and AMI </text>
<text top="440" left="748" width="36" height="14" font="7">None </text>
<text top="440" left="856" width="85" height="14" font="7">Multivariable </text>
<text top="457" left="856" width="99" height="14" font="7">Cox Regression </text>
<text top="440" left="971" width="65" height="14" font="7">p&lt;0.0001; </text>
<text top="457" left="971" width="92" height="14" font="7">95% CI: 1.8 to </text>
<text top="474" left="971" width="22" height="14" font="7">4.3 </text>
<text top="440" left="1079" width="115" height="14" font="7">Stress wall motion </text>
<text top="457" left="1079" width="112" height="14" font="7">abnormality had a </text>
<text top="474" left="1079" width="89" height="14" font="7">HR: of 2.7 for </text>
<text top="491" left="1079" width="117" height="14" font="7">primary endpoints. </text>
<text top="440" left="1214" width="84" height="14" font="7">Single-center </text>
<text top="457" left="1214" width="84" height="14" font="7">observational </text>
<text top="474" left="1214" width="36" height="14" font="7">study </text>
<text top="440" left="1321" width="107" height="14" font="7">Dobtamine stress </text>
<text top="457" left="1321" width="114" height="14" font="7">MRI effectiveness </text>
<text top="474" left="1321" width="100" height="14" font="7">prognosticate in </text>
<text top="491" left="1321" width="48" height="14" font="7">women </text>
<text top="613" left="65" width="104" height="14" font="7">Prognostic value </text>
<text top="630" left="65" width="117" height="14" font="7">of adenosine stress </text>
<text top="647" left="65" width="91" height="14" font="7">cardiovascular </text>
<text top="665" left="65" width="58" height="14" font="7">magnetic </text>
<text top="682" left="65" width="89" height="14" font="7">resonance and </text>
<text top="699" left="65" width="99" height="14" font="7">DSE in pts with </text>
<text top="716" left="65" width="88" height="14" font="7">low-risk chest </text>
<text top="734" left="65" width="107" height="14" font="7">pain. Hartlage G, </text>
<text top="751" left="65" width="34" height="14" font="7">2011 </text>
<text top="768" left="65" width="25" height="14" font="8">(40)</text>
<text top="768" left="90" width="4" height="14" font="7"> </text>
<text top="613" left="195" width="59" height="14" font="7">Compare </text>
<text top="630" left="195" width="81" height="14" font="7">prognosis by </text>
<text top="647" left="195" width="63" height="14" font="7">adenosine </text>
<text top="665" left="195" width="74" height="14" font="7">stress CMR </text>
<text top="682" left="195" width="58" height="14" font="7">and DSE </text>
<text top="613" left="297" width="43" height="14" font="7">Single-</text>
<text top="630" left="297" width="40" height="14" font="7">center </text>
<text top="647" left="297" width="28" height="14" font="7">trial </text>
<text top="613" left="363" width="26" height="14" font="7">255 </text>
<text top="613" left="430" width="64" height="14" font="7">Suspected </text>
<text top="630" left="430" width="57" height="14" font="7">ischemia </text>
<text top="613" left="541" width="30" height="14" font="7">N/A </text>
<text top="613" left="629" width="90" height="14" font="7">Cardiac death, </text>
<text top="630" left="629" width="36" height="14" font="7">AMI, </text>
<text top="647" left="629" width="106" height="14" font="7">obstructive CAD </text>
<text top="665" left="629" width="101" height="14" font="7">on angiography, </text>
<text top="682" left="629" width="25" height="14" font="7">and </text>
<text top="699" left="629" width="104" height="14" font="7">rehospitalization </text>
<text top="613" left="748" width="36" height="14" font="7">None </text>
<text top="613" left="856" width="85" height="14" font="7">Multivariable </text>
<text top="630" left="856" width="99" height="14" font="7">Cox Regression </text>
<text top="613" left="971" width="30" height="14" font="7">N/A </text>
<text top="613" left="1079" width="120" height="14" font="7">Negative event rate </text>
<text top="630" left="1079" width="77" height="14" font="7">(for primary </text>
<text top="647" left="1079" width="94" height="14" font="7">endpoints) was </text>
<text top="665" left="1079" width="97" height="14" font="7">100% for stress </text>
<text top="682" left="1079" width="41" height="14" font="7">CMR. </text>
<text top="613" left="1214" width="84" height="14" font="7">Single-center </text>
<text top="630" left="1214" width="84" height="14" font="7">observational </text>
<text top="647" left="1214" width="36" height="14" font="7">study </text>
<text top="613" left="1321" width="120" height="14" font="7">Negative event rate </text>
<text top="630" left="1321" width="94" height="14" font="7">100% by stress </text>
<text top="647" left="1321" width="112" height="14" font="7">CMR and 99% by </text>
<text top="665" left="1321" width="32" height="14" font="7">DSE </text>
</page>
<page number="13" position="absolute" top="0" left="0" height="918" width="1512">
<text top="59" left="108" width="4" height="15" font="0"> </text>
<text top="59" left="459" width="4" height="15" font="0"> </text>
<text top="59" left="810" width="4" height="15" font="0"> </text>
<text top="59" left="864" width="4" height="15" font="0"> </text>
<text top="59" left="918" width="4" height="15" font="0"> </text>
<text top="59" left="972" width="4" height="15" font="0"> </text>
<text top="59" left="1026" width="4" height="15" font="0"> </text>
<text top="59" left="1080" width="4" height="15" font="0"> </text>
<text top="59" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="108" width="613" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="825" left="810" width="4" height="15" font="0"> </text>
<text top="825" left="864" width="4" height="15" font="0"> </text>
<text top="825" left="918" width="4" height="15" font="0"> </text>
<text top="825" left="972" width="4" height="15" font="0"> </text>
<text top="825" left="1026" width="4" height="15" font="0"> </text>
<text top="825" left="1080" width="4" height="15" font="0"> </text>
<text top="825" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="1188" width="4" height="15" font="0"> </text>
<text top="825" left="1242" width="22" height="15" font="0">13 </text>
<text top="847" left="108" width="4" height="15" font="0"> </text>
<text top="112" left="65" width="100" height="14" font="7">Complementary </text>
<text top="129" left="65" width="109" height="14" font="7">prognostic values </text>
<text top="147" left="65" width="53" height="14" font="7">of stress </text>
<text top="164" left="65" width="71" height="14" font="7">myocardial </text>
<text top="181" left="65" width="111" height="14" font="7">perfusion and late </text>
<text top="198" left="65" width="72" height="14" font="7">gadolinium </text>
<text top="215" left="65" width="83" height="14" font="7">enhancement </text>
<text top="233" left="65" width="108" height="14" font="7">imaging by CMR </text>
<text top="250" left="65" width="111" height="14" font="7">in pts with known </text>
<text top="267" left="65" width="117" height="14" font="7">or suspected CAD. </text>
<text top="284" left="65" width="86" height="14" font="7">Steel K, 2009 </text>
<text top="302" left="65" width="25" height="14" font="8">(41)</text>
<text top="302" left="90" width="4" height="14" font="7"> </text>
<text top="112" left="195" width="81" height="14" font="7">Prognosis by </text>
<text top="129" left="195" width="68" height="14" font="7">combining </text>
<text top="147" left="195" width="37" height="14" font="7">stress </text>
<text top="164" left="195" width="86" height="14" font="7">perfusion and </text>
<text top="181" left="195" width="25" height="14" font="7">late </text>
<text top="198" left="195" width="72" height="14" font="7">gadolinium </text>
<text top="215" left="195" width="83" height="14" font="7">enhancement </text>
<text top="233" left="195" width="53" height="14" font="7">imaging </text>
<text top="112" left="297" width="43" height="14" font="7">Single-</text>
<text top="129" left="297" width="40" height="14" font="7">center </text>
<text top="147" left="297" width="28" height="14" font="7">trial </text>
<text top="112" left="363" width="26" height="14" font="7">254 </text>
<text top="112" left="430" width="68" height="14" font="7">Symptoms </text>
<text top="129" left="430" width="82" height="14" font="7">suspicious of </text>
<text top="147" left="430" width="57" height="14" font="7">ischemia </text>
<text top="112" left="541" width="32" height="14" font="7">MRI </text>
<text top="129" left="541" width="45" height="14" font="7">related </text>
<text top="147" left="541" width="67" height="14" font="7">exclusions </text>
<text top="112" left="629" width="87" height="14" font="7">Cardiac death </text>
<text top="129" left="629" width="58" height="14" font="7">and AMI </text>
<text top="112" left="748" width="30" height="14" font="7">Late </text>
<text top="129" left="748" width="87" height="14" font="7">revascularizati</text>
<text top="147" left="748" width="69" height="14" font="7">on and UA </text>
<text top="164" left="748" width="92" height="14" font="7">hospitalization </text>
<text top="112" left="856" width="85" height="14" font="7">Multivariable </text>
<text top="129" left="856" width="99" height="14" font="7">Cox Regression </text>
<text top="112" left="971" width="61" height="14" font="7">p&lt;0.0001 </text>
<text top="129" left="971" width="93" height="14" font="7">(2.79 to 16.89) </text>
<text top="112" left="1079" width="112" height="14" font="7">Stress CMR had a </text>
<text top="129" left="1079" width="80" height="14" font="7">HR: 6.88 for </text>
<text top="147" left="1079" width="113" height="14" font="7">primary endpoints </text>
<text top="112" left="1214" width="81" height="14" font="7">Referral bias </text>
<text top="129" left="1214" width="67" height="14" font="7">of a single-</text>
<text top="147" left="1214" width="88" height="14" font="7">center clinical </text>
<text top="164" left="1214" width="36" height="14" font="7">study </text>
<text top="112" left="1321" width="114" height="14" font="7">Demonstrated that </text>
<text top="129" left="1321" width="123" height="14" font="7">stress perfusion and </text>
<text top="147" left="1321" width="97" height="14" font="7">late gadolinium </text>
<text top="164" left="1321" width="83" height="14" font="7">enhancement </text>
<text top="181" left="1321" width="102" height="14" font="7">imaging provide </text>
<text top="198" left="1321" width="125" height="14" font="7">complement cardiac </text>
<text top="215" left="1321" width="101" height="14" font="7">prognostication. </text>
<text top="320" left="65" width="104" height="14" font="7">Prognostic value </text>
<text top="337" left="65" width="62" height="14" font="7">of normal </text>
<text top="354" left="65" width="102" height="14" font="7">adenosine-stress </text>
<text top="372" left="65" width="94" height="14" font="7">CMR imaging. </text>
<text top="389" left="65" width="76" height="14" font="7">Pilz G, 2008</text>
<text top="389" left="141" width="29" height="14" font="8"> (42)</text>
<text top="389" left="169" width="4" height="14" font="7"> </text>
<text top="320" left="195" width="81" height="14" font="7">Prognosis by </text>
<text top="337" left="195" width="63" height="14" font="7">adenosine </text>
<text top="354" left="195" width="69" height="14" font="7">stress MRI </text>
<text top="320" left="297" width="43" height="14" font="7">Single-</text>
<text top="337" left="297" width="40" height="14" font="7">center </text>
<text top="354" left="297" width="28" height="14" font="7">trial </text>
<text top="320" left="363" width="26" height="14" font="7">218 </text>
<text top="320" left="430" width="64" height="14" font="7">Suspected </text>
<text top="337" left="430" width="80" height="14" font="7">ischemia but </text>
<text top="354" left="430" width="91" height="14" font="7">negative stress </text>
<text top="372" left="430" width="98" height="14" font="7">CMR perfusion </text>
<text top="320" left="541" width="32" height="14" font="7">MRI </text>
<text top="337" left="541" width="45" height="14" font="7">related </text>
<text top="354" left="541" width="67" height="14" font="7">exclusions </text>
<text top="320" left="629" width="90" height="14" font="7">Cardiac death, </text>
<text top="337" left="629" width="36" height="14" font="7">AMI, </text>
<text top="354" left="629" width="102" height="14" font="7">revascularization</text>
<text top="372" left="629" width="33" height="14" font="7">, and </text>
<text top="389" left="629" width="92" height="14" font="7">hospitalization </text>
<text top="406" left="629" width="56" height="14" font="7">at 12 mo </text>
<text top="320" left="748" width="36" height="14" font="7">None </text>
<text top="320" left="856" width="53" height="14" font="7">Logistic </text>
<text top="337" left="856" width="69" height="14" font="7">regression, </text>
<text top="354" left="856" width="87" height="14" font="7">ROC analysis </text>
<text top="320" left="971" width="30" height="14" font="7">N/A </text>
<text top="320" left="1079" width="120" height="14" font="7">Negative event rate </text>
<text top="337" left="1079" width="77" height="14" font="7">(for primary </text>
<text top="354" left="1079" width="100" height="14" font="7">endpoints) at 12 </text>
<text top="372" left="1079" width="70" height="14" font="7">mo: 99.1% </text>
<text top="320" left="1214" width="75" height="14" font="7">Small study </text>
<text top="337" left="1214" width="65" height="14" font="7">with short-</text>
<text top="354" left="1214" width="94" height="14" font="7">term follow-up </text>
<text top="372" left="1214" width="65" height="14" font="7">composite </text>
<text top="389" left="1214" width="42" height="14" font="7">events </text>
<text top="320" left="1321" width="84" height="14" font="7">CMR 12 mos </text>
<text top="337" left="1321" width="118" height="14" font="7">negative predictive </text>
<text top="354" left="1321" width="79" height="14" font="7">value 99.1% </text>
<text top="424" left="65" width="104" height="14" font="7">Prognostic value </text>
<text top="441" left="65" width="117" height="14" font="7">of adenosine stress </text>
<text top="458" left="65" width="71" height="14" font="7">myocardial </text>
<text top="476" left="65" width="116" height="14" font="7">perfusion by CMR </text>
<text top="493" left="65" width="89" height="14" font="7">imaging in pts </text>
<text top="510" left="65" width="91" height="14" font="7">with known or </text>
<text top="527" left="65" width="101" height="14" font="7">suspected CAD. </text>
<text top="545" left="65" width="80" height="14" font="7">Lo KY, 2011</text>
<text top="545" left="145" width="29" height="14" font="8"> (43)</text>
<text top="545" left="174" width="4" height="14" font="7"> </text>
<text top="424" left="195" width="81" height="14" font="7">Prognosis by </text>
<text top="441" left="195" width="63" height="14" font="7">adenosine </text>
<text top="458" left="195" width="69" height="14" font="7">stress MRI </text>
<text top="424" left="297" width="43" height="14" font="7">Single-</text>
<text top="441" left="297" width="40" height="14" font="7">center </text>
<text top="458" left="297" width="28" height="14" font="7">trial </text>
<text top="424" left="363" width="26" height="14" font="7">203 </text>
<text top="424" left="430" width="64" height="14" font="7">Suspected </text>
<text top="441" left="430" width="57" height="14" font="7">ischemia </text>
<text top="424" left="541" width="30" height="14" font="7">N/A </text>
<text top="424" left="629" width="87" height="14" font="7">Cardiac death </text>
<text top="441" left="629" width="100" height="14" font="7">and nonfatal MI </text>
<text top="424" left="748" width="36" height="14" font="7">None </text>
<text top="424" left="856" width="85" height="14" font="7">Multivariable </text>
<text top="441" left="856" width="99" height="14" font="7">Cox Regression </text>
<text top="424" left="971" width="89" height="14" font="7">p&lt;0.001; 95% </text>
<text top="441" left="971" width="69" height="14" font="7">CI: 3.18 to </text>
<text top="458" left="971" width="30" height="14" font="7">27.3 </text>
<text top="424" left="1079" width="112" height="14" font="7">Stress CMR had a </text>
<text top="441" left="1079" width="92" height="14" font="7">HR of 9.31 for </text>
<text top="458" left="1079" width="93" height="14" font="7">primary events </text>
<text top="424" left="1214" width="87" height="14" font="7">Single-center, </text>
<text top="441" left="1214" width="63" height="14" font="7">small size </text>
<text top="424" left="1321" width="30" height="14" font="7">N/A </text>
<text top="563" left="65" width="82" height="14" font="7">Prediction of </text>
<text top="580" left="65" width="104" height="14" font="7">cardiac events in </text>
<text top="597" left="65" width="103" height="14" font="7">pts with reduced </text>
<text top="615" left="65" width="71" height="14" font="7">LVEF with </text>
<text top="632" left="65" width="74" height="14" font="7">dobutamine </text>
<text top="649" left="65" width="91" height="14" font="7">cardiovascular </text>
<text top="666" left="65" width="58" height="14" font="7">magnetic </text>
<text top="683" left="65" width="63" height="14" font="7">resonance </text>
<text top="701" left="65" width="116" height="14" font="7">assessment of wall </text>
<text top="718" left="65" width="81" height="14" font="7">motion score </text>
<text top="735" left="65" width="45" height="14" font="7">index.  </text>
<text top="752" left="65" width="110" height="14" font="7">Dall'Armellina E, </text>
<text top="770" left="65" width="34" height="14" font="7">2008 </text>
<text top="770" left="99" width="25" height="14" font="8">(44)</text>
<text top="770" left="124" width="4" height="14" font="7"> </text>
<text top="563" left="195" width="81" height="14" font="7">Prognosis by </text>
<text top="580" left="195" width="74" height="14" font="7">dobutamine </text>
<text top="597" left="195" width="85" height="14" font="7">stress MRI as </text>
<text top="615" left="195" width="76" height="14" font="7">modified by </text>
<text top="632" left="195" width="45" height="14" font="7">LVEF. </text>
<text top="563" left="297" width="43" height="14" font="7">Single-</text>
<text top="580" left="297" width="40" height="14" font="7">center </text>
<text top="597" left="297" width="28" height="14" font="7">trial </text>
<text top="563" left="363" width="26" height="14" font="7">200 </text>
<text top="563" left="430" width="64" height="14" font="7">Suspected </text>
<text top="580" left="430" width="61" height="14" font="7">ischemia, </text>
<text top="597" left="430" width="81" height="14" font="7">LVEF ≤55% </text>
<text top="563" left="541" width="32" height="14" font="7">MRI </text>
<text top="580" left="541" width="45" height="14" font="7">related </text>
<text top="597" left="541" width="67" height="14" font="7">exclusions </text>
<text top="563" left="629" width="87" height="14" font="7">Cardiac death </text>
<text top="580" left="629" width="58" height="14" font="7">and AMI </text>
<text top="563" left="748" width="64" height="14" font="7">UA or HF </text>
<text top="580" left="748" width="65" height="14" font="7">admission </text>
<text top="563" left="856" width="85" height="14" font="7">Multivariable </text>
<text top="580" left="856" width="99" height="14" font="7">Cox Regression </text>
<text top="563" left="971" width="53" height="14" font="7">p=0.003 </text>
<text top="563" left="1079" width="112" height="14" font="7">Stress CMR had a </text>
<text top="580" left="1079" width="76" height="14" font="7">HR: 3.01for </text>
<text top="597" left="1079" width="93" height="14" font="7">primary events </text>
<text top="563" left="1214" width="82" height="14" font="7">Single center </text>
<text top="580" left="1214" width="84" height="14" font="7">observational </text>
<text top="597" left="1214" width="36" height="14" font="7">study </text>
<text top="563" left="1321" width="128" height="14" font="7">Induced ischemia by </text>
<text top="580" left="1321" width="111" height="14" font="7">dobutamine stress </text>
<text top="597" left="1321" width="119" height="14" font="7">MRI was primarily </text>
<text top="615" left="1321" width="122" height="14" font="7">in those with LVEF </text>
<text top="632" left="1321" width="40" height="14" font="7">&gt;40% </text>
</page>
<page number="14" position="absolute" top="0" left="0" height="918" width="1512">
<text top="59" left="108" width="4" height="15" font="0"> </text>
<text top="59" left="459" width="4" height="15" font="0"> </text>
<text top="59" left="810" width="4" height="15" font="0"> </text>
<text top="59" left="864" width="4" height="15" font="0"> </text>
<text top="59" left="918" width="4" height="15" font="0"> </text>
<text top="59" left="972" width="4" height="15" font="0"> </text>
<text top="59" left="1026" width="4" height="15" font="0"> </text>
<text top="59" left="1080" width="4" height="15" font="0"> </text>
<text top="59" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="108" width="613" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="825" left="810" width="4" height="15" font="0"> </text>
<text top="825" left="864" width="4" height="15" font="0"> </text>
<text top="825" left="918" width="4" height="15" font="0"> </text>
<text top="825" left="972" width="4" height="15" font="0"> </text>
<text top="825" left="1026" width="4" height="15" font="0"> </text>
<text top="825" left="1080" width="4" height="15" font="0"> </text>
<text top="825" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="1188" width="4" height="15" font="0"> </text>
<text top="825" left="1242" width="22" height="15" font="0">14 </text>
<text top="847" left="108" width="4" height="15" font="0"> </text>
<text top="112" left="65" width="79" height="14" font="7">Prognosis of </text>
<text top="129" left="65" width="58" height="14" font="7">Negative </text>
<text top="147" left="65" width="107" height="14" font="7">Adenosine Stress </text>
<text top="164" left="65" width="60" height="14" font="7">Magnetic </text>
<text top="181" left="65" width="106" height="14" font="7">Resonance in Pts </text>
<text top="198" left="65" width="100" height="14" font="7">Presenting to an </text>
<text top="215" left="65" width="72" height="14" font="7">Emergency </text>
<text top="233" left="65" width="108" height="14" font="7">Department With </text>
<text top="250" left="65" width="72" height="14" font="7">Chest Pain. </text>
<text top="267" left="65" width="105" height="14" font="7">Ingkanisorn WP, </text>
<text top="284" left="65" width="34" height="14" font="7">2006 </text>
<text top="284" left="99" width="25" height="14" font="8">(45)</text>
<text top="284" left="124" width="4" height="14" font="7"> </text>
<text top="112" left="195" width="81" height="14" font="7">Prognosis by </text>
<text top="129" left="195" width="63" height="14" font="7">adenosine </text>
<text top="147" left="195" width="84" height="14" font="7">stress MRI in </text>
<text top="164" left="195" width="87" height="14" font="7">pts with acute </text>
<text top="181" left="195" width="64" height="14" font="7">chest pain </text>
<text top="112" left="297" width="43" height="14" font="7">Single-</text>
<text top="129" left="297" width="40" height="14" font="7">center </text>
<text top="147" left="297" width="28" height="14" font="7">trial </text>
<text top="112" left="363" width="26" height="14" font="7">135 </text>
<text top="112" left="430" width="64" height="14" font="7">Suspected </text>
<text top="129" left="430" width="96" height="14" font="7">ischemia, acute </text>
<text top="147" left="430" width="85" height="14" font="7">chest pain pts </text>
<text top="164" left="430" width="81" height="14" font="7">from the ER, </text>
<text top="181" left="430" width="83" height="14" font="7">with no ECG </text>
<text top="198" left="430" width="77" height="14" font="7">changes and </text>
<text top="215" left="430" width="54" height="14" font="7">negative </text>
<text top="233" left="430" width="85" height="14" font="7">troponins/CK </text>
<text top="112" left="541" width="32" height="14" font="7">MRI </text>
<text top="129" left="541" width="45" height="14" font="7">related </text>
<text top="147" left="541" width="67" height="14" font="7">exclusions </text>
<text top="112" left="629" width="90" height="14" font="7">Cardiac death, </text>
<text top="129" left="629" width="87" height="14" font="7">AMI, and late </text>
<text top="147" left="629" width="106" height="14" font="7">revascularization </text>
<text top="112" left="748" width="36" height="14" font="7">None </text>
<text top="112" left="856" width="53" height="14" font="7">Logistic </text>
<text top="129" left="856" width="69" height="14" font="7">regression, </text>
<text top="147" left="856" width="87" height="14" font="7">ROC analysis </text>
<text top="112" left="971" width="53" height="14" font="7">p&lt;0.002 </text>
<text top="112" left="1079" width="120" height="14" font="7">Negative event rate </text>
<text top="129" left="1079" width="77" height="14" font="7">(for primary </text>
<text top="147" left="1079" width="100" height="14" font="7">endpoints) at 12 </text>
<text top="164" left="1079" width="92" height="14" font="7">mo was 100%. </text>
<text top="112" left="1214" width="84" height="14" font="7">Single-center </text>
<text top="129" left="1214" width="84" height="14" font="7">observational </text>
<text top="147" left="1214" width="36" height="14" font="7">study </text>
<text top="112" left="1321" width="102" height="14" font="7">12 mos negative </text>
<text top="129" left="1321" width="101" height="14" font="7">event rate 100% </text>
<text top="302" left="65" width="104" height="14" font="7">Prognostic value </text>
<text top="320" left="65" width="117" height="14" font="7">of adenosine stress </text>
<text top="337" left="65" width="91" height="14" font="7">cardiovascular </text>
<text top="354" left="65" width="58" height="14" font="7">magnetic </text>
<text top="372" left="65" width="100" height="14" font="7">resonance in pts </text>
<text top="389" left="65" width="84" height="14" font="7">with low-risk </text>
<text top="406" left="65" width="116" height="14" font="7">chest pain. Lerakis </text>
<text top="423" left="65" width="50" height="14" font="7">S, 2009 </text>
<text top="423" left="115" width="25" height="14" font="8">(46)</text>
<text top="423" left="140" width="4" height="14" font="7"> </text>
<text top="302" left="195" width="81" height="14" font="7">Prognosis by </text>
<text top="320" left="195" width="74" height="14" font="7">dobutamine </text>
<text top="337" left="195" width="84" height="14" font="7">stress MRI in </text>
<text top="354" left="195" width="87" height="14" font="7">low risk chest </text>
<text top="372" left="195" width="29" height="14" font="7">pain </text>
<text top="302" left="297" width="43" height="14" font="7">Single-</text>
<text top="320" left="297" width="40" height="14" font="7">center </text>
<text top="337" left="297" width="28" height="14" font="7">trial </text>
<text top="302" left="363" width="26" height="14" font="7">103 </text>
<text top="302" left="430" width="64" height="14" font="7">Suspected </text>
<text top="320" left="430" width="96" height="14" font="7">ischemia, acute </text>
<text top="337" left="430" width="94" height="14" font="7">chest pain with </text>
<text top="354" left="430" width="52" height="14" font="7">no ECG </text>
<text top="372" left="430" width="77" height="14" font="7">changes and </text>
<text top="389" left="430" width="54" height="14" font="7">negative </text>
<text top="406" left="430" width="85" height="14" font="7">troponins/CK </text>
<text top="302" left="541" width="32" height="14" font="7">MRI </text>
<text top="320" left="541" width="45" height="14" font="7">related </text>
<text top="337" left="541" width="67" height="14" font="7">exclusions </text>
<text top="302" left="629" width="90" height="14" font="7">Cardiac death, </text>
<text top="320" left="629" width="36" height="14" font="7">AMI, </text>
<text top="337" left="629" width="102" height="14" font="7">revascularization</text>
<text top="354" left="629" width="33" height="14" font="7">, and </text>
<text top="372" left="629" width="104" height="14" font="7">rehospitalization </text>
<text top="302" left="748" width="40" height="14" font="7">None  </text>
<text top="302" left="856" width="56" height="14" font="7">Logistic  </text>
<text top="320" left="856" width="65" height="14" font="7">regression </text>
<text top="302" left="971" width="30" height="14" font="7">N/A </text>
<text top="302" left="1079" width="120" height="14" font="7">Negative event rate </text>
<text top="320" left="1079" width="77" height="14" font="7">(for primary </text>
<text top="337" left="1079" width="100" height="14" font="7">endpoints) at 12 </text>
<text top="354" left="1079" width="92" height="14" font="7">mo was 100%. </text>
<text top="302" left="1214" width="84" height="14" font="7">Single-center </text>
<text top="320" left="1214" width="84" height="14" font="7">observational </text>
<text top="337" left="1214" width="76" height="14" font="7">study, small </text>
<text top="354" left="1214" width="63" height="14" font="7">study size </text>
<text top="302" left="1321" width="120" height="14" font="7">Negative event rate </text>
<text top="320" left="1321" width="39" height="14" font="7">100% </text>
<text top="441" left="65" width="111" height="14" font="7">Risk stratification </text>
<text top="458" left="65" width="82" height="14" font="7">by adenosine </text>
<text top="476" left="65" width="111" height="14" font="7">stress CMR in pts </text>
<text top="493" left="65" width="87" height="14" font="7">with coronary </text>
<text top="510" left="65" width="108" height="14" font="7">artery stenoses of </text>
<text top="527" left="65" width="79" height="14" font="7">intermediate </text>
<text top="545" left="65" width="82" height="14" font="7">angiographic </text>
<text top="562" left="65" width="103" height="14" font="7">severity. Doesch </text>
<text top="579" left="65" width="51" height="14" font="7">C, 2009 </text>
<text top="579" left="117" width="25" height="14" font="8">(47)</text>
<text top="579" left="141" width="4" height="14" font="7"> </text>
<text top="441" left="195" width="81" height="14" font="7">Prognosis by </text>
<text top="458" left="195" width="84" height="14" font="7">stress MRI in </text>
<text top="476" left="195" width="51" height="14" font="7">pts with </text>
<text top="493" left="195" width="79" height="14" font="7">intermediate </text>
<text top="510" left="195" width="51" height="14" font="7">stenosis </text>
<text top="441" left="297" width="43" height="14" font="7">Single-</text>
<text top="458" left="297" width="40" height="14" font="7">center </text>
<text top="476" left="297" width="28" height="14" font="7">trial </text>
<text top="441" left="363" width="19" height="14" font="7">81 </text>
<text top="441" left="430" width="89" height="14" font="7">Stable angina, </text>
<text top="458" left="430" width="79" height="14" font="7">intermediate </text>
<text top="476" left="430" width="82" height="14" font="7">angiographic </text>
<text top="493" left="430" width="51" height="14" font="7">severity </text>
<text top="441" left="541" width="32" height="14" font="7">MRI </text>
<text top="458" left="541" width="45" height="14" font="7">related </text>
<text top="476" left="541" width="67" height="14" font="7">exclusions </text>
<text top="441" left="629" width="87" height="14" font="7">Death, stroke, </text>
<text top="458" left="629" width="58" height="14" font="7">and ACS </text>
<text top="441" left="748" width="83" height="14" font="7">Target vessel </text>
<text top="458" left="748" width="87" height="14" font="7">revascularizati</text>
<text top="476" left="748" width="70" height="14" font="7">on, angina, </text>
<text top="493" left="748" width="53" height="14" font="7">dyspnea </text>
<text top="441" left="856" width="85" height="14" font="7">Multivariable </text>
<text top="458" left="856" width="99" height="14" font="7">Cox Regression </text>
<text top="441" left="971" width="53" height="14" font="7">p=0.003 </text>
<text top="441" left="1079" width="52" height="14" font="7">Pts who </text>
<text top="458" left="1079" width="76" height="14" font="7">experienced </text>
<text top="476" left="1079" width="72" height="14" font="7">MACE had </text>
<text top="493" left="1079" width="97" height="14" font="7">ischemic extent </text>
<text top="510" left="1079" width="112" height="14" font="7">1.64 fold larger in </text>
<text top="527" left="1079" width="27" height="14" font="7">size </text>
<text top="441" left="1214" width="84" height="14" font="7">Single-center </text>
<text top="458" left="1214" width="84" height="14" font="7">observational </text>
<text top="476" left="1214" width="76" height="14" font="7">study, small </text>
<text top="493" left="1214" width="63" height="14" font="7">study size </text>
<text top="441" left="1321" width="118" height="14" font="7">Evaluate prognosis </text>
<text top="458" left="1321" width="75" height="14" font="7">in setting of </text>
<text top="476" left="1321" width="79" height="14" font="7">intermediate </text>
<text top="493" left="1321" width="108" height="14" font="7">coronary stenosis </text>
<text top="612" left="65" width="498" height="16" font="2"><b>Stress CMR—multicenter or comparative studies to detect CAD </b></text>
<text top="647" left="65" width="66" height="14" font="7">Combined </text>
<text top="665" left="65" width="87" height="14" font="7">assessment of </text>
<text top="682" left="65" width="71" height="14" font="7">myocardial </text>
<text top="699" left="65" width="111" height="14" font="7">perfusion and late </text>
<text top="716" left="65" width="72" height="14" font="7">gadolinium </text>
<text top="734" left="65" width="98" height="14" font="7">enhancement in </text>
<text top="751" left="65" width="52" height="14" font="7">pts after </text>
<text top="768" left="65" width="110" height="14" font="7">percutaneous PCI </text>
<text top="786" left="65" width="113" height="14" font="7">or bypass grafts: a </text>
<text top="647" left="195" width="74" height="14" font="7">Multicenter </text>
<text top="665" left="195" width="55" height="14" font="7">study by </text>
<text top="682" left="195" width="63" height="14" font="7">adenosine </text>
<text top="699" left="195" width="74" height="14" font="7">stress CMR </text>
<text top="716" left="195" width="74" height="14" font="7">in detecting </text>
<text top="734" left="195" width="57" height="14" font="7">coronary </text>
<text top="751" left="195" width="82" height="14" font="7">stenosis after </text>
<text top="768" left="195" width="89" height="14" font="7">PCI or CABG </text>
<text top="647" left="297" width="38" height="14" font="7">Multi-</text>
<text top="665" left="297" width="40" height="14" font="7">center </text>
<text top="682" left="297" width="28" height="14" font="7">trial </text>
<text top="647" left="363" width="11" height="14" font="7">3 </text>
<text top="665" left="363" width="46" height="14" font="7">centers </text>
<text top="682" left="363" width="36" height="14" font="7">(477) </text>
<text top="647" left="430" width="64" height="14" font="7">Suspected </text>
<text top="665" left="430" width="57" height="14" font="7">ischemia </text>
<text top="647" left="541" width="32" height="14" font="7">MRI </text>
<text top="665" left="541" width="45" height="14" font="7">related </text>
<text top="682" left="541" width="67" height="14" font="7">exclusions </text>
<text top="648" left="629" width="8" height="11" font="7">≥</text>
<text top="647" left="637" width="113" height="14" font="7">70% angiographic </text>
<text top="665" left="629" width="108" height="14" font="7">coronary stenosis </text>
<text top="647" left="765" width="30" height="14" font="7">N/A </text>
<text top="647" left="859" width="118" height="14" font="7">Logistic regression </text>
<text top="665" left="859" width="116" height="14" font="7">and ROC, analysis </text>
<text top="647" left="1000" width="30" height="14" font="7">N/A </text>
<text top="647" left="1112" width="87" height="14" font="7">NPV of stress </text>
<text top="665" left="1112" width="58" height="14" font="7">CMR for </text>
<text top="682" left="1112" width="82" height="14" font="7">angiographic </text>
<text top="699" left="1112" width="67" height="14" font="7">significant </text>
<text top="716" left="1112" width="108" height="14" font="7">coronary stenosis </text>
<text top="734" left="1112" width="101" height="14" font="7">was 96%.  Sens. </text>
<text top="751" left="1112" width="84" height="14" font="7">was 94% and </text>
<text top="768" left="1112" width="96" height="14" font="7">spec. was 87%. </text>
<text top="647" left="1236" width="87" height="14" font="7">Selection bias </text>
<text top="665" left="1236" width="75" height="14" font="7">due to entry </text>
<text top="682" left="1236" width="73" height="14" font="7">criteria of a </text>
<text top="699" left="1236" width="48" height="14" font="7">clinical </text>
<text top="716" left="1236" width="85" height="14" font="7">indication for </text>
<text top="734" left="1236" width="96" height="14" font="7">X-ray coronary </text>
<text top="751" left="1236" width="79" height="14" font="7">angiography </text>
<text top="647" left="1349" width="30" height="14" font="7">N/A </text>
</page>
<page number="15" position="absolute" top="0" left="0" height="918" width="1512">
<text top="59" left="108" width="4" height="15" font="0"> </text>
<text top="59" left="459" width="4" height="15" font="0"> </text>
<text top="59" left="810" width="4" height="15" font="0"> </text>
<text top="59" left="864" width="4" height="15" font="0"> </text>
<text top="59" left="918" width="4" height="15" font="0"> </text>
<text top="59" left="972" width="4" height="15" font="0"> </text>
<text top="59" left="1026" width="4" height="15" font="0"> </text>
<text top="59" left="1080" width="4" height="15" font="0"> </text>
<text top="59" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="108" width="613" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="825" left="810" width="4" height="15" font="0"> </text>
<text top="825" left="864" width="4" height="15" font="0"> </text>
<text top="825" left="918" width="4" height="15" font="0"> </text>
<text top="825" left="972" width="4" height="15" font="0"> </text>
<text top="825" left="1026" width="4" height="15" font="0"> </text>
<text top="825" left="1080" width="4" height="15" font="0"> </text>
<text top="825" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="1188" width="4" height="15" font="0"> </text>
<text top="825" left="1242" width="22" height="15" font="0">15 </text>
<text top="847" left="108" width="4" height="15" font="0"> </text>
<text top="112" left="65" width="108" height="14" font="7">multicenter study </text>
<text top="129" left="65" width="98" height="14" font="7">of an integrated </text>
<text top="147" left="65" width="91" height="14" font="7">cardiovascular </text>
<text top="164" left="65" width="58" height="14" font="7">magnetic </text>
<text top="181" left="65" width="63" height="14" font="7">resonance </text>
<text top="198" left="65" width="58" height="14" font="7">protocol. </text>
<text top="215" left="65" width="114" height="14" font="7">Bernhardt P, 2009 </text>
<text top="233" left="65" width="25" height="14" font="8">(48)</text>
<text top="233" left="90" width="4" height="14" font="7"> </text>
<text top="250" left="65" width="4" height="14" font="7"> </text>
<text top="268" left="65" width="92" height="14" font="7">MR-IMPACT, </text>
<text top="285" left="65" width="93" height="14" font="7">Comparison of </text>
<text top="302" left="65" width="99" height="14" font="7">perfusion-CMR </text>
<text top="320" left="65" width="116" height="14" font="7">with single-photon </text>
<text top="337" left="65" width="101" height="14" font="7">emission CT for </text>
<text top="354" left="65" width="97" height="14" font="7">the detection of </text>
<text top="372" left="65" width="61" height="14" font="7">CAD in a </text>
<text top="389" left="65" width="76" height="14" font="7">multicentre, </text>
<text top="406" left="65" width="81" height="14" font="7">multivendor, </text>
<text top="423" left="65" width="106" height="14" font="7">randomized trial. </text>
<text top="440" left="65" width="112" height="14" font="7">Schwitter J, 2008, </text>
<text top="458" left="65" width="25" height="14" font="8">(49)</text>
<text top="458" left="90" width="4" height="14" font="7"> </text>
<text top="268" left="195" width="31" height="14" font="7">First </text>
<text top="285" left="195" width="72" height="14" font="7">multicenter </text>
<text top="302" left="195" width="51" height="14" font="7">study in </text>
<text top="320" left="195" width="66" height="14" font="7">evaluating </text>
<text top="337" left="195" width="65" height="14" font="7">diagnostic </text>
<text top="354" left="195" width="73" height="14" font="7">accuracy of </text>
<text top="372" left="195" width="84" height="14" font="7">stress cardiac </text>
<text top="389" left="195" width="57" height="14" font="7">MRI and </text>
<text top="406" left="195" width="78" height="14" font="7">compared to </text>
<text top="423" left="195" width="49" height="14" font="7">SPECT </text>
<text top="268" left="297" width="38" height="14" font="7">Multi-</text>
<text top="285" left="297" width="40" height="14" font="7">center </text>
<text top="302" left="297" width="28" height="14" font="7">trial </text>
<text top="268" left="363" width="39" height="14" font="7">18 cts </text>
<text top="285" left="363" width="36" height="14" font="7">(241) </text>
<text top="268" left="430" width="68" height="14" font="7">Symptoms </text>
<text top="285" left="430" width="82" height="14" font="7">suspicious of </text>
<text top="302" left="430" width="57" height="14" font="7">ischemia </text>
<text top="268" left="541" width="32" height="14" font="7">MRI </text>
<text top="285" left="541" width="45" height="14" font="7">related </text>
<text top="302" left="541" width="67" height="14" font="7">exclusions </text>
<text top="268" left="629" width="86" height="14" font="7">Angiographic </text>
<text top="285" left="629" width="102" height="14" font="7">significant CAD </text>
<text top="302" left="629" width="49" height="14" font="7">(≥50%) </text>
<text top="268" left="765" width="36" height="14" font="7">None </text>
<text top="268" left="859" width="118" height="14" font="7">Logistic regression </text>
<text top="285" left="859" width="116" height="14" font="7">and ROC analysis  </text>
<text top="268" left="1000" width="46" height="14" font="7">p=0.01 </text>
<text top="268" left="1112" width="98" height="14" font="7">Stress CMR for </text>
<text top="285" left="1112" width="76" height="14" font="7">diagnosis of </text>
<text top="302" left="1112" width="82" height="14" font="7">angiographic </text>
<text top="320" left="1112" width="107" height="14" font="7">significant CAD: </text>
<text top="337" left="1112" width="107" height="14" font="7">Sens. 87%, Spec. </text>
<text top="354" left="1112" width="31" height="14" font="7">86% </text>
<text top="268" left="1236" width="30" height="14" font="7">N/A </text>
<text top="268" left="1349" width="80" height="14" font="7">Vasodilating </text>
<text top="285" left="1349" width="93" height="14" font="7">stress MRI has </text>
<text top="302" left="1349" width="45" height="14" font="7">similar </text>
<text top="320" left="1349" width="65" height="14" font="7">diagnostic </text>
<text top="337" left="1349" width="56" height="14" font="7">utility as </text>
<text top="354" left="1349" width="98" height="14" font="7">SPECT overall, </text>
<text top="372" left="1349" width="57" height="14" font="7">but more </text>
<text top="389" left="1349" width="82" height="14" font="7">sensitive that </text>
<text top="406" left="1349" width="85" height="14" font="7">SPECT in pts </text>
<text top="423" left="1349" width="30" height="14" font="7">with </text>
<text top="440" left="1349" width="72" height="14" font="7">multivessel </text>
<text top="458" left="1349" width="47" height="14" font="7">disease </text>
<text top="476" left="65" width="79" height="14" font="7">Noninvasive </text>
<text top="493" left="65" width="76" height="14" font="7">diagnosis of </text>
<text top="510" left="65" width="109" height="14" font="7">ischemia-induced </text>
<text top="527" left="65" width="76" height="14" font="7">wall motion </text>
<text top="545" left="65" width="116" height="14" font="7">abnormalities with </text>
<text top="562" left="65" width="94" height="14" font="7">the use of high-</text>
<text top="579" left="65" width="106" height="14" font="7">dose dobutamine </text>
<text top="597" left="65" width="73" height="14" font="7">stress MRI: </text>
<text top="614" left="65" width="104" height="14" font="7">comparison with </text>
<text top="631" left="65" width="40" height="14" font="7">DSE.  </text>
<text top="648" left="65" width="90" height="14" font="7">Nagel E, 1999 </text>
<text top="665" left="65" width="25" height="14" font="8">(50)</text>
<text top="665" left="90" width="4" height="14" font="7"> </text>
<text top="476" left="195" width="59" height="14" font="7">Compare </text>
<text top="493" left="195" width="65" height="14" font="7">diagnostic </text>
<text top="510" left="195" width="56" height="14" font="7">utility of </text>
<text top="527" left="195" width="74" height="14" font="7">dobutamine </text>
<text top="545" left="195" width="62" height="14" font="7">MRI with </text>
<text top="562" left="195" width="32" height="14" font="7">DSE </text>
<text top="476" left="297" width="43" height="14" font="7">Single-</text>
<text top="493" left="297" width="40" height="14" font="7">center </text>
<text top="510" left="297" width="28" height="14" font="7">trial </text>
<text top="476" left="363" width="26" height="14" font="7">208 </text>
<text top="476" left="430" width="64" height="14" font="7">Suspected </text>
<text top="493" left="430" width="57" height="14" font="7">ischemia </text>
<text top="476" left="541" width="32" height="14" font="7">MRI </text>
<text top="493" left="541" width="45" height="14" font="7">related </text>
<text top="510" left="541" width="67" height="14" font="7">exclusions </text>
<text top="476" left="629" width="86" height="14" font="7">Angiographic </text>
<text top="493" left="629" width="102" height="14" font="7">significant CAD </text>
<text top="510" left="629" width="101" height="14" font="7">(≥50% diameter </text>
<text top="527" left="629" width="56" height="14" font="7">stenosis) </text>
<text top="476" left="765" width="36" height="14" font="7">None </text>
<text top="476" left="859" width="118" height="14" font="7">Logistic regression </text>
<text top="493" left="859" width="112" height="14" font="7">and ROC analysis </text>
<text top="476" left="1000" width="46" height="14" font="7">p&lt;0.05 </text>
<text top="476" left="1112" width="78" height="14" font="7">Dobutamine </text>
<text top="493" left="1112" width="98" height="14" font="7">stress CMR has </text>
<text top="510" left="1112" width="101" height="14" font="7">higher sens. and </text>
<text top="527" left="1112" width="60" height="14" font="7">speci. for </text>
<text top="545" left="1112" width="76" height="14" font="7">diagnosis of </text>
<text top="562" left="1112" width="102" height="14" font="7">significant CAD </text>
<text top="579" left="1112" width="99" height="14" font="7">than DSE: sens. </text>
<text top="597" left="1112" width="87" height="14" font="7">86% vs. 74%; </text>
<text top="614" left="1112" width="86" height="14" font="7">spec. 86% vs. </text>
<text top="631" left="1112" width="67" height="14" font="7">70% (both </text>
<text top="648" left="1112" width="51" height="14" font="7">p&lt;0.05) </text>
<text top="476" left="1236" width="30" height="14" font="7">N/A </text>
<text top="476" left="1349" width="30" height="14" font="7">N/A </text>
<text top="683" left="65" width="112" height="14" font="7">CE-MARC study. </text>
<text top="701" left="65" width="117" height="14" font="7">Clinical evaluation </text>
<text top="718" left="65" width="75" height="14" font="7">of magnetic </text>
<text top="735" left="65" width="116" height="14" font="7">resonance imaging </text>
<text top="752" left="65" width="106" height="14" font="7">in coronary heart </text>
<text top="770" left="65" width="97" height="14" font="7">disease: the CE-</text>
<text top="787" left="65" width="88" height="14" font="7">MARC study. </text>
<text top="683" left="195" width="59" height="14" font="7">Compare </text>
<text top="701" left="195" width="35" height="14" font="7">CAD </text>
<text top="718" left="195" width="86" height="14" font="7">diagnosis and </text>
<text top="735" left="195" width="81" height="14" font="7">prognosis by </text>
<text top="752" left="195" width="69" height="14" font="7">stress MRI </text>
<text top="770" left="195" width="74" height="14" font="7">and SPECT </text>
<text top="683" left="297" width="43" height="14" font="7">Single-</text>
<text top="701" left="297" width="40" height="14" font="7">center </text>
<text top="718" left="297" width="28" height="14" font="7">trial </text>
<text top="683" left="363" width="26" height="14" font="7">750 </text>
<text top="683" left="430" width="64" height="14" font="7">Suspected </text>
<text top="701" left="430" width="57" height="14" font="7">ischemia </text>
<text top="683" left="541" width="32" height="14" font="7">MRI </text>
<text top="701" left="541" width="45" height="14" font="7">related </text>
<text top="718" left="541" width="67" height="14" font="7">exclusions </text>
<text top="684" left="629" width="8" height="11" font="7">≥</text>
<text top="683" left="637" width="113" height="14" font="7">70% angiographic </text>
<text top="701" left="629" width="108" height="14" font="7">coronary stenosis </text>
<text top="683" left="765" width="36" height="14" font="7">None </text>
<text top="683" left="859" width="118" height="14" font="7">Logistic regression </text>
<text top="701" left="859" width="112" height="14" font="7">and ROC analysis </text>
<text top="683" left="1000" width="30" height="14" font="7">N/A </text>
<text top="683" left="1112" width="81" height="14" font="7">Stress CMR: </text>
<text top="701" left="1112" width="103" height="14" font="7">Sens. 87% (95% </text>
<text top="718" left="1112" width="85" height="14" font="7">CI: 82 to 91), </text>
<text top="735" left="1112" width="108" height="14" font="7">Speci. 83% (95% </text>
<text top="752" left="1112" width="81" height="14" font="7">CI: 80 to 87) </text>
<text top="770" left="1112" width="82" height="14" font="7">SPECT sens. </text>
<text top="787" left="1112" width="109" height="14" font="7">67% (95% CI: 60 </text>
<text top="683" left="1236" width="30" height="14" font="7">N/A </text>
<text top="683" left="1349" width="31" height="14" font="7">First </text>
<text top="701" left="1349" width="74" height="14" font="7">randomized </text>
<text top="718" left="1349" width="96" height="14" font="7">trial comparing </text>
<text top="735" left="1349" width="87" height="14" font="7">the diagnostic </text>
<text top="752" left="1349" width="65" height="14" font="7">utilities of </text>
<text top="770" left="1349" width="99" height="14" font="7">stress CMR and </text>
<text top="787" left="1349" width="86" height="14" font="7">stress SPECT </text>
</page>
<page number="16" position="absolute" top="0" left="0" height="918" width="1512">
<text top="59" left="108" width="4" height="15" font="0"> </text>
<text top="59" left="459" width="4" height="15" font="0"> </text>
<text top="59" left="810" width="4" height="15" font="0"> </text>
<text top="59" left="864" width="4" height="15" font="0"> </text>
<text top="59" left="918" width="4" height="15" font="0"> </text>
<text top="59" left="972" width="4" height="15" font="0"> </text>
<text top="59" left="1026" width="4" height="15" font="0"> </text>
<text top="59" left="1080" width="4" height="15" font="0"> </text>
<text top="59" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="108" width="613" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="825" left="810" width="4" height="15" font="0"> </text>
<text top="825" left="864" width="4" height="15" font="0"> </text>
<text top="825" left="918" width="4" height="15" font="0"> </text>
<text top="825" left="972" width="4" height="15" font="0"> </text>
<text top="825" left="1026" width="4" height="15" font="0"> </text>
<text top="825" left="1080" width="4" height="15" font="0"> </text>
<text top="825" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="1188" width="4" height="15" font="0"> </text>
<text top="825" left="1242" width="22" height="15" font="0">16 </text>
<text top="847" left="108" width="4" height="15" font="0"> </text>
<text top="112" left="65" width="96" height="14" font="7">Greenwood JP, </text>
<text top="129" left="65" width="41" height="14" font="7">2009   </text>
<text top="147" left="65" width="25" height="14" font="8">(51)</text>
<text top="147" left="90" width="4" height="14" font="7"> </text>
<text top="112" left="1112" width="80" height="14" font="7">to 72), Spec. </text>
<text top="129" left="1112" width="99" height="14" font="7">=83% (95% CI: </text>
<text top="147" left="1112" width="58" height="14" font="7">79 to 86) </text>
<text top="180" left="65" width="355" height="16" font="2"><b>Stress CMR-Meta Analysis to Diagnose CAD  </b></text>
<text top="215" left="65" width="69" height="14" font="7">Diagnostic </text>
<text top="232" left="65" width="96" height="14" font="7">performance of </text>
<text top="249" left="65" width="74" height="14" font="7">stress CMR </text>
<text top="266" left="65" width="90" height="14" font="7">imaging in the </text>
<text top="284" left="65" width="114" height="14" font="7">detection of CAD: </text>
<text top="301" left="65" width="100" height="14" font="7">a meta-analysis. </text>
<text top="318" left="65" width="88" height="14" font="7">Nandalur KR, </text>
<text top="336" left="65" width="34" height="14" font="7">2007 </text>
<text top="353" left="65" width="25" height="14" font="8">(14)</text>
<text top="353" left="90" width="4" height="14" font="7"> </text>
<text top="215" left="195" width="74" height="14" font="7">To evaluate </text>
<text top="232" left="195" width="84" height="14" font="7">stress cardiac </text>
<text top="249" left="195" width="69" height="14" font="7">MRI in the </text>
<text top="266" left="195" width="76" height="14" font="7">diagnosis of </text>
<text top="284" left="195" width="35" height="14" font="7">CAD </text>
<text top="301" left="195" width="4" height="14" font="7"> </text>
<text top="215" left="297" width="36" height="14" font="7">Meta-</text>
<text top="232" left="297" width="52" height="14" font="7">analysis </text>
<text top="215" left="363" width="19" height="14" font="7">37 </text>
<text top="232" left="363" width="45" height="14" font="7">studies </text>
<text top="249" left="363" width="43" height="14" font="7">(2,191 </text>
<text top="266" left="363" width="26" height="14" font="7">pts) </text>
<text top="215" left="430" width="64" height="14" font="7">Suspected </text>
<text top="232" left="430" width="86" height="14" font="7">ischemia (use </text>
<text top="249" left="430" width="85" height="14" font="7">of stress MRI </text>
<text top="266" left="430" width="81" height="14" font="7">as diagnostic </text>
<text top="284" left="430" width="81" height="14" font="7">test for CAD </text>
<text top="302" left="430" width="8" height="11" font="7">≥</text>
<text top="301" left="439" width="87" height="14" font="7">50% diameter </text>
<text top="318" left="430" width="76" height="14" font="7">stenosis and </text>
<text top="336" left="430" width="91" height="14" font="7">use of catheter </text>
<text top="353" left="430" width="38" height="14" font="7">X-ray </text>
<text top="370" left="430" width="95" height="14" font="7">angiography as </text>
<text top="387" left="430" width="59" height="14" font="7">reference </text>
<text top="404" left="430" width="54" height="14" font="7">standard </text>
<text top="422" left="430" width="4" height="14" font="7"> </text>
<text top="215" left="541" width="32" height="14" font="7">MRI </text>
<text top="232" left="541" width="45" height="14" font="7">related </text>
<text top="249" left="541" width="67" height="14" font="7">exclusions </text>
<text top="216" left="629" width="8" height="11" font="7">≥</text>
<text top="215" left="637" width="113" height="14" font="7">70% angiographic </text>
<text top="232" left="629" width="108" height="14" font="7">coronary stenosis </text>
<text top="215" left="765" width="36" height="14" font="7">None </text>
<text top="215" left="859" width="118" height="14" font="7">Logistic regression </text>
<text top="232" left="859" width="120" height="14" font="7">and ROC, analysis  </text>
<text top="215" left="1000" width="30" height="14" font="7">N/A </text>
<text top="215" left="1112" width="91" height="14" font="7">Stress induced </text>
<text top="232" left="1112" width="76" height="14" font="7">wall motion </text>
<text top="249" left="1112" width="85" height="14" font="7">abnormalities </text>
<text top="266" left="1112" width="61" height="14" font="7">imaging:  </text>
<text top="284" left="1112" width="106" height="14" font="7">Sens. 0.83, Spec. </text>
<text top="301" left="1112" width="84" height="14" font="7">0.86, Disease </text>
<text top="318" left="1112" width="73" height="14" font="7">prevalence: </text>
<text top="336" left="1112" width="50" height="14" font="7">70.5%.  </text>
<text top="353" left="1112" width="146" height="14" font="7">                                       </text>
<text top="370" left="1112" width="61" height="14" font="7">Perfusion </text>
<text top="387" left="1112" width="61" height="14" font="7">imaging:  </text>
<text top="404" left="1112" width="101" height="14" font="7">Sens. 0.91 (0.88 </text>
<text top="422" left="1112" width="91" height="14" font="7">to 0.94), Spec. </text>
<text top="439" left="1112" width="81" height="14" font="7">0.81 (0.77 to </text>
<text top="456" left="1112" width="89" height="14" font="7">0.85), Disease </text>
<text top="473" left="1112" width="69" height="14" font="7">prevalence </text>
<text top="491" left="1112" width="51" height="14" font="7">=57.4% </text>
<text top="215" left="1236" width="30" height="14" font="7">N/A </text>
<text top="215" left="1349" width="30" height="14" font="7">N/A </text>
<text top="509" left="65" width="104" height="14" font="7">Meta-analysis of </text>
<text top="526" left="65" width="87" height="14" font="7">the diagnostic </text>
<text top="543" left="65" width="96" height="14" font="7">performance of </text>
<text top="561" left="65" width="97" height="14" font="7">stress perfusion </text>
<text top="578" left="65" width="91" height="14" font="7">cardiovascular </text>
<text top="595" left="65" width="58" height="14" font="7">magnetic </text>
<text top="612" left="65" width="85" height="14" font="7">resonance for </text>
<text top="629" left="65" width="114" height="14" font="7">detection of CAD. </text>
<text top="647" left="65" width="103" height="14" font="7">Hamon M, 2010 </text>
<text top="664" left="65" width="25" height="14" font="8">(52)</text>
<text top="664" left="90" width="4" height="14" font="7"> </text>
<text top="509" left="195" width="86" height="14" font="7">Studies (from </text>
<text top="526" left="195" width="74" height="14" font="7">2001-2008) </text>
<text top="543" left="195" width="80" height="14" font="7">presented on </text>
<text top="561" left="195" width="84" height="14" font="7">patient-based </text>
<text top="578" left="195" width="52" height="14" font="7">analysis </text>
<text top="509" left="297" width="36" height="14" font="7">Meta-</text>
<text top="526" left="297" width="52" height="14" font="7">analysis </text>
<text top="509" left="363" width="19" height="14" font="7">35 </text>
<text top="526" left="363" width="45" height="14" font="7">studies </text>
<text top="543" left="363" width="43" height="14" font="7">(2,125 </text>
<text top="561" left="363" width="26" height="14" font="7">pts) </text>
<text top="509" left="430" width="64" height="14" font="7">Suspected </text>
<text top="526" left="430" width="64" height="14" font="7">ischemia.  </text>
<text top="543" left="430" width="84" height="14" font="7">Studies using </text>
<text top="561" left="430" width="87" height="14" font="7">(a) ≥1.5 Tesla </text>
<text top="578" left="430" width="81" height="14" font="7">MR scanner; </text>
<text top="595" left="430" width="84" height="14" font="7">(b) employed </text>
<text top="612" left="430" width="54" height="14" font="7">invasive </text>
<text top="629" left="430" width="57" height="14" font="7">coronary </text>
<text top="647" left="430" width="95" height="14" font="7">angiography as </text>
<text top="664" left="430" width="59" height="14" font="7">reference </text>
<text top="681" left="430" width="76" height="14" font="7">standard for </text>
<text top="698" left="430" width="69" height="14" font="7">diagnosing </text>
<text top="716" left="430" width="67" height="14" font="7">significant </text>
<text top="733" left="430" width="70" height="14" font="7">obstructive </text>
<text top="750" left="430" width="84" height="14" font="7">CAD (≥ 50% </text>
<text top="768" left="430" width="56" height="14" font="7">diameter </text>
<text top="785" left="430" width="85" height="14" font="7">stenosis), and </text>
<text top="509" left="541" width="32" height="14" font="7">MRI </text>
<text top="526" left="541" width="45" height="14" font="7">related </text>
<text top="543" left="541" width="67" height="14" font="7">exclusions </text>
<text top="510" left="629" width="8" height="11" font="7">≥</text>
<text top="509" left="637" width="113" height="14" font="7">70% angiographic </text>
<text top="526" left="629" width="108" height="14" font="7">coronary stenosis </text>
<text top="509" left="765" width="36" height="14" font="7">None </text>
<text top="509" left="859" width="122" height="14" font="7">Logistic regression, </text>
<text top="526" left="859" width="98" height="14" font="7">ROC analysis.   </text>
<text top="543" left="859" width="100" height="14" font="7">Stress perfusion </text>
<text top="561" left="859" width="94" height="14" font="7">CMR: pt based </text>
<text top="578" left="859" width="128" height="14" font="7">analysis:  Sensitivity </text>
<text top="595" left="859" width="98" height="14" font="7">89% (88 to 91), </text>
<text top="612" left="859" width="124" height="14" font="7">Specificity 80% (78 </text>
<text top="629" left="859" width="93" height="14" font="7">to 83), Disease </text>
<text top="647" left="859" width="104" height="14" font="7">prevalence 57%, </text>
<text top="664" left="859" width="112" height="14" font="7">PLR 4.18 (3.31 to </text>
<text top="681" left="859" width="103" height="14" font="7">5.27), NLR 0.15 </text>
<text top="698" left="859" width="124" height="14" font="7">(0.11 to 0.20), AUC </text>
<text top="716" left="859" width="30" height="14" font="7">0.92 </text>
<text top="509" left="1000" width="30" height="14" font="7">N/A </text>
<text top="509" left="1112" width="97" height="14" font="7">Diagnostic OR: </text>
<text top="526" left="1112" width="97" height="14" font="7">33.65 (95% CI: </text>
<text top="543" left="1112" width="95" height="14" font="7">22.09 to 51.27) </text>
<text top="509" left="1236" width="30" height="14" font="7">N/A </text>
<text top="509" left="1349" width="30" height="14" font="7">N/A </text>
</page>
<page number="17" position="absolute" top="0" left="0" height="918" width="1512">
	<fontspec id="12" size="21" family="Times" color="#000000"/>
	<fontspec id="13" size="14" family="Times" color="#0000ff"/>
	<fontspec id="14" size="14" family="Times" color="#000000"/>
	<fontspec id="15" size="15" family="Times" color="#000000"/>
	<fontspec id="16" size="15" family="Times" color="#0000ff"/>
<text top="59" left="108" width="4" height="15" font="0"> </text>
<text top="59" left="459" width="4" height="15" font="0"> </text>
<text top="59" left="810" width="4" height="15" font="0"> </text>
<text top="59" left="864" width="4" height="15" font="0"> </text>
<text top="59" left="918" width="4" height="15" font="0"> </text>
<text top="59" left="972" width="4" height="15" font="0"> </text>
<text top="59" left="1026" width="4" height="15" font="0"> </text>
<text top="59" left="1080" width="4" height="15" font="0"> </text>
<text top="59" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="108" width="613" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="825" left="810" width="4" height="15" font="0"> </text>
<text top="825" left="864" width="4" height="15" font="0"> </text>
<text top="825" left="918" width="4" height="15" font="0"> </text>
<text top="825" left="972" width="4" height="15" font="0"> </text>
<text top="825" left="1026" width="4" height="15" font="0"> </text>
<text top="825" left="1080" width="4" height="15" font="0"> </text>
<text top="825" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="1188" width="4" height="15" font="0"> </text>
<text top="825" left="1242" width="22" height="15" font="0">17 </text>
<text top="847" left="108" width="4" height="15" font="0"> </text>
<text top="112" left="430" width="78" height="14" font="7">(c) provided </text>
<text top="129" left="430" width="89" height="14" font="7">sufficient data </text>
<text top="147" left="430" width="58" height="14" font="7">to permit </text>
<text top="164" left="430" width="56" height="14" font="7">analysis. </text>
<text top="182" left="101" width="1304" height="14" font="7">ACS indicates acute coronary syndrome; Adj, adjusted; AMI; acute myocardial infarction; AUC, area under the curve; CABG, coronary artery bypass graft surgery; CAD, coronary artery disease; CE-MARC, Clinical </text>
<text top="199" left="101" width="1266" height="14" font="7">Evaluation of Magnetic Resonance Imaging in Coronary heart disease; CI, confidence interval; CK, creatine kinase; CMR, contract magnetic resonance; CT, computed tomography; CTA, computed tomography </text>
<text top="216" left="101" width="1259" height="14" font="7">angiography; DSE, dobutatmine stress echo; DSMR, dobutamine stress magnetic resonance; ECG, electrocardiogram; Echo, echocardiogram; ER, emergency room; HF, heart failure; HR, hazard ratio; LV, left </text>
<text top="233" left="101" width="1293" height="14" font="7">ventricular; LVEF, left ventricular ejection fraction; MACE, major adverse cardiac events; MI, myocardial infarction; MR-IMPACT, Magnetic Resonance Imaging for Myocardial Perfusion Assessment in Coronary </text>
<text top="251" left="101" width="1283" height="14" font="7">Artery Disease Trial; MR, magnetic resonance; MRI, magnetic resonance imaging; N/A, not applicable; NLR, negative likelihood ratio; OR, odds ratio; pts, patients; PCI, percutaneous coronary intervention; PLR, </text>
<text top="268" left="101" width="1167" height="14" font="7">positive likelihood ratio; ROC, receiver operator characteristics; Sens., sensitivity; Spec., specificity; SPECT, single-photon emission computed tomography; UA, unstable angina and vs., versus.</text>
<text top="266" left="1268" width="4" height="16" font="11"><i><b> </b></i></text>
<text top="288" left="101" width="6" height="22" font="12"><i><b> </b></i></text>
<text top="315" left="426" width="666" height="22" font="12"><i><b>Data Supplements 3 to 17 pertain to the Revascularization Section  </b></i></text>
<text top="342" left="756" width="5" height="19" font="1"><b> </b></text>
<text top="365" left="108" width="1287" height="16" font="2"><b>Data Supplement 3. Evidence for Survival Benefit After PCI or CABG (With LIMA Grafting to the LAD) in Patients With SIHD Who Are Receiving Medical Therapy </b></text>
<text top="386" left="108" width="401" height="16" font="2"><b>and Are Suitable Candidates for Revascularization  </b></text>
<text top="407" left="167" width="149" height="15" font="4"><b>Anatomic Subgroups</b></text>
<text top="406" left="316" width="4" height="16" font="2"><b> </b></text>
<text top="427" left="242" width="4" height="16" font="2"><b> </b></text>
<text top="407" left="400" width="229" height="15" font="4"><b>Evidence Supporting CABG for </b></text>
<text top="426" left="483" width="60" height="15" font="4"><b>Survival</b></text>
<text top="425" left="542" width="4" height="16" font="2"><b> </b></text>
<text top="407" left="679" width="185" height="15" font="4"><b>Evidence Supporting PCI </b></text>
<text top="406" left="864" width="4" height="16" font="2"><b> </b></text>
<text top="426" left="727" width="85" height="15" font="4"><b>for Survival</b></text>
<text top="425" left="812" width="4" height="16" font="2"><b> </b></text>
<text top="407" left="910" width="237" height="15" font="4"><b>Evidence Supporting Superiority </b></text>
<text top="426" left="930" width="196" height="15" font="4"><b>of Either CABG or PCI for </b></text>
<text top="445" left="997" width="60" height="15" font="4"><b>Survival</b></text>
<text top="444" left="1056" width="4" height="16" font="2"><b> </b></text>
<text top="407" left="1164" width="243" height="15" font="4"><b>Evidence Supporting Equivalence </b></text>
<text top="426" left="1175" width="218" height="15" font="4"><b>of CABG and PCI for Survival</b></text>
<text top="425" left="1392" width="4" height="16" font="2"><b> </b></text>
<text top="465" left="108" width="184" height="15" font="5">Unprotected left main CAD</text>
<text top="464" left="292" width="4" height="16" font="0"> </text>
<text top="484" left="108" width="4" height="16" font="0"> </text>
<text top="505" left="108" width="4" height="16" font="0"> </text>
<text top="525" left="108" width="4" height="16" font="0"> </text>
<text top="546" left="108" width="4" height="16" font="0"> </text>
<text top="567" left="108" width="4" height="16" font="0"> </text>
<text top="587" left="108" width="4" height="16" font="0"> </text>
<text top="608" left="108" width="4" height="16" font="0"> </text>
<text top="629" left="108" width="4" height="16" font="0"> </text>
<text top="649" left="108" width="4" height="16" font="0"> </text>
<text top="670" left="108" width="4" height="16" font="0"> </text>
<text top="691" left="108" width="4" height="16" font="0"> </text>
<text top="712" left="108" width="4" height="16" font="0"> </text>
<text top="732" left="108" width="136" height="15" font="5">SYNTAX score &lt;33</text>
<text top="731" left="244" width="4" height="16" font="0"> </text>
<text top="751" left="108" width="4" height="16" font="0"> </text>
<text top="772" left="108" width="136" height="15" font="5">SYNTAX score ≥33</text>
<text top="771" left="244" width="4" height="16" font="0"> </text>
<text top="465" left="429" width="119" height="15" font="5">CASS Registry* (</text>
<text top="465" left="549" width="17" height="15" font="13">53</text>
<text top="465" left="565" width="8" height="15" font="5">, </text>
<text top="465" left="574" width="16" height="15" font="13">54</text>
<text top="465" left="590" width="6" height="15" font="5">)</text>
<text top="464" left="595" width="4" height="16" font="0"> </text>
<text top="484" left="472" width="54" height="15" font="5">CASS† </text>
<text top="484" left="526" width="22" height="15" font="13">(55</text>
<text top="484" left="548" width="6" height="15" font="5">)</text>
<text top="483" left="553" width="4" height="16" font="0"> </text>
<text top="503" left="426" width="127" height="15" font="5">VA Cooperative† (</text>
<text top="503" left="552" width="17" height="15" font="13">56</text>
<text top="503" left="569" width="8" height="15" font="5">, </text>
<text top="503" left="577" width="17" height="15" font="13">57</text>
<text top="503" left="594" width="6" height="15" font="5">)</text>
<text top="502" left="599" width="4" height="16" font="0"> </text>
<text top="522" left="454" width="89" height="15" font="5">Yusuf et al.† </text>
<text top="522" left="543" width="28" height="15" font="13">(58)</text>
<text top="521" left="571" width="4" height="16" font="0"> </text>
<text top="541" left="451" width="102" height="15" font="5">Dzavik et al.* (</text>
<text top="541" left="552" width="17" height="15" font="13">59</text>
<text top="541" left="569" width="6" height="15" font="5">)</text>
<text top="540" left="574" width="4" height="16" font="0"> </text>
<text top="465" left="731" width="77" height="15" font="14"><i>None found</i></text>
<text top="464" left="808" width="4" height="16" font="15"><i> </i></text>
<text top="465" left="981" width="91" height="15" font="14"><i>CABG better:</i></text>
<text top="464" left="1072" width="4" height="16" font="15"><i> </i></text>
<text top="484" left="995" width="42" height="15" font="5">Wu* (</text>
<text top="484" left="1036" width="17" height="15" font="13">60</text>
<text top="484" left="1053" width="6" height="15" font="5">)</text>
<text top="483" left="1058" width="4" height="16" font="0"> </text>
<text top="503" left="1027" width="4" height="16" font="0"> </text>
<text top="523" left="989" width="75" height="15" font="14"><i>PCI better:</i></text>
<text top="522" left="1064" width="4" height="16" font="15"><i> </i></text>
<text top="542" left="987" width="78" height="15" font="5">None found</text>
<text top="541" left="1066" width="4" height="16" font="0"> </text>
<text top="562" left="1027" width="4" height="16" font="0"> </text>
<text top="582" left="1027" width="4" height="16" font="0"> </text>
<text top="603" left="1027" width="4" height="16" font="0"> </text>
<text top="624" left="1027" width="4" height="16" font="0"> </text>
<text top="644" left="1027" width="4" height="16" font="0"> </text>
<text top="665" left="1027" width="4" height="16" font="0"> </text>
<text top="686" left="1027" width="4" height="16" font="0"> </text>
<text top="706" left="1027" width="4" height="16" font="0"> </text>
<text top="727" left="975" width="75" height="15" font="5">SYNTAX†</text>
<text top="727" left="1050" width="27" height="15" font="13">(61)</text>
<text top="726" left="1078" width="4" height="16" font="0"> </text>
<text top="746" left="1027" width="4" height="16" font="0"> </text>
<text top="768" left="972" width="75" height="15" font="5">SYNTAX†</text>
<text top="767" left="1047" width="4" height="16" font="0"> </text>
<text top="767" left="1052" width="30" height="16" font="16">(61)</text>
<text top="767" left="1081" width="4" height="16" font="0"> </text>
<text top="465" left="1230" width="80" height="15" font="5">SYNTAX† </text>
<text top="465" left="1309" width="27" height="15" font="13">(62)</text>
<text top="464" left="1337" width="4" height="16" font="0"> </text>
<text top="484" left="1228" width="85" height="15" font="5">LE MANS† </text>
<text top="484" left="1312" width="27" height="15" font="13">(63)</text>
<text top="483" left="1339" width="4" height="16" font="0"> </text>
<text top="503" left="1216" width="107" height="15" font="5">Boudriot et al.† </text>
<text top="503" left="1323" width="28" height="15" font="13">(64)</text>
<text top="502" left="1351" width="4" height="16" font="0"> </text>
<text top="522" left="1208" width="105" height="15" font="5">Chieffo et al.* (</text>
<text top="522" left="1313" width="17" height="15" font="13">65</text>
<text top="522" left="1329" width="4" height="15" font="5">,</text>
<text top="522" left="1333" width="21" height="15" font="13"> 66</text>
<text top="522" left="1354" width="6" height="15" font="5">)</text>
<text top="521" left="1359" width="4" height="16" font="0"> </text>
<text top="541" left="1233" width="73" height="15" font="5">Lee et al.* </text>
<text top="541" left="1307" width="27" height="15" font="13">(67)</text>
<text top="540" left="1334" width="4" height="16" font="0"> </text>
<text top="560" left="1233" width="73" height="15" font="5">Lee et al.§ </text>
<text top="560" left="1307" width="27" height="15" font="13">(68)</text>
<text top="559" left="1334" width="4" height="16" font="0"> </text>
<text top="578" left="1229" width="81" height="15" font="5">Naik et al.§ </text>
<text top="578" left="1310" width="27" height="15" font="13">(69)</text>
<text top="577" left="1338" width="4" height="16" font="0"> </text>
<text top="598" left="1225" width="89" height="15" font="5">White et al.* </text>
<text top="598" left="1314" width="28" height="15" font="13">(70)</text>
<text top="597" left="1342" width="4" height="16" font="0"> </text>
<text top="616" left="1213" width="113" height="15" font="5">Palmerini et al.* </text>
<text top="616" left="1326" width="27" height="15" font="13">(71)</text>
<text top="615" left="1354" width="4" height="16" font="0"> </text>
<text top="636" left="1230" width="79" height="15" font="5">Park et al.* </text>
<text top="636" left="1309" width="28" height="15" font="13">(72)</text>
<text top="635" left="1337" width="4" height="16" font="0"> </text>
<text top="654" left="1212" width="117" height="15" font="5">Sanmartín et al.* </text>
<text top="654" left="1328" width="27" height="15" font="13">(73)</text>
<text top="653" left="1355" width="4" height="16" font="0"> </text>
<text top="673" left="1223" width="94" height="15" font="5">Brener et al.* </text>
<text top="673" left="1317" width="27" height="15" font="13">(74)</text>
<text top="672" left="1344" width="4" height="16" font="0"> </text>
<text top="692" left="1209" width="121" height="15" font="5">Mäkikallio et al.* </text>
<text top="692" left="1330" width="27" height="15" font="13">(75)</text>
<text top="691" left="1358" width="4" height="16" font="0"> </text>
<text top="712" left="1284" width="4" height="16" font="0"> </text>
</page>
<page number="18" position="absolute" top="0" left="0" height="918" width="1512">
<text top="59" left="108" width="4" height="15" font="0"> </text>
<text top="59" left="459" width="4" height="15" font="0"> </text>
<text top="59" left="810" width="4" height="15" font="0"> </text>
<text top="59" left="864" width="4" height="15" font="0"> </text>
<text top="59" left="918" width="4" height="15" font="0"> </text>
<text top="59" left="972" width="4" height="15" font="0"> </text>
<text top="59" left="1026" width="4" height="15" font="0"> </text>
<text top="59" left="1080" width="4" height="15" font="0"> </text>
<text top="59" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="108" width="613" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="825" left="810" width="4" height="15" font="0"> </text>
<text top="825" left="864" width="4" height="15" font="0"> </text>
<text top="825" left="918" width="4" height="15" font="0"> </text>
<text top="825" left="972" width="4" height="15" font="0"> </text>
<text top="825" left="1026" width="4" height="15" font="0"> </text>
<text top="825" left="1080" width="4" height="15" font="0"> </text>
<text top="825" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="1188" width="4" height="15" font="0"> </text>
<text top="825" left="1242" width="22" height="15" font="0">18 </text>
<text top="847" left="108" width="4" height="15" font="0"> </text>
<text top="112" left="108" width="216" height="15" font="5">3-vessel disease with or without </text>
<text top="131" left="108" width="150" height="15" font="5">proximal LAD disease</text>
<text top="130" left="257" width="4" height="16" font="0"> </text>
<text top="151" left="242" width="4" height="16" font="0"> </text>
<text top="171" left="242" width="4" height="16" font="0"> </text>
<text top="112" left="497" width="30" height="15" font="14"><i>For:</i></text>
<text top="111" left="528" width="4" height="16" font="15"><i> </i></text>
<text top="131" left="451" width="102" height="15" font="5">Dzavik et al.* (</text>
<text top="131" left="552" width="17" height="15" font="13">59</text>
<text top="131" left="569" width="6" height="15" font="5">)</text>
<text top="130" left="574" width="4" height="16" font="0"> </text>
<text top="150" left="473" width="48" height="15" font="5">ECSS†</text>
<text top="150" left="521" width="32" height="15" font="13"> (76)</text>
<text top="149" left="552" width="4" height="16" font="0"> </text>
<text top="169" left="456" width="81" height="15" font="5">Jones et al.*</text>
<text top="169" left="537" width="31" height="15" font="13"> (77)</text>
<text top="168" left="569" width="4" height="16" font="0"> </text>
<text top="188" left="462" width="72" height="15" font="5">MASS II* </text>
<text top="188" left="535" width="28" height="15" font="13">(78)</text>
<text top="187" left="562" width="4" height="16" font="0"> </text>
<text top="207" left="453" width="91" height="15" font="5">Myers et al.† </text>
<text top="207" left="544" width="27" height="15" font="13">(79)</text>
<text top="206" left="571" width="4" height="16" font="0"> </text>
<text top="226" left="455" width="88" height="15" font="5">Smith et al.* </text>
<text top="226" left="543" width="28" height="15" font="13">(80)</text>
<text top="225" left="570" width="4" height="16" font="0"> </text>
<text top="245" left="461" width="75" height="15" font="5">SYNTAX†</text>
<text top="245" left="536" width="27" height="15" font="13">(61)</text>
<text top="244" left="564" width="4" height="16" font="0"> </text>
<text top="264" left="454" width="89" height="15" font="5">Yusuf et al.† </text>
<text top="264" left="543" width="28" height="15" font="13">(58)</text>
<text top="263" left="571" width="4" height="16" font="0"> </text>
<text top="112" left="754" width="30" height="15" font="14"><i>For:</i></text>
<text top="111" left="785" width="4" height="16" font="15"><i> </i></text>
<text top="131" left="708" width="92" height="15" font="5">Dzavik et al.*</text>
<text top="131" left="800" width="31" height="15" font="13"> (59)</text>
<text top="130" left="831" width="4" height="16" font="0"> </text>
<text top="150" left="712" width="88" height="15" font="5">Smith et al.* </text>
<text top="150" left="800" width="28" height="15" font="13">(80)</text>
<text top="149" left="827" width="4" height="16" font="0"> </text>
<text top="170" left="769" width="4" height="16" font="15"><i> </i></text>
<text top="190" left="741" width="56" height="15" font="14"><i>Against:</i></text>
<text top="189" left="797" width="4" height="16" font="15"><i> </i></text>
<text top="209" left="710" width="87" height="15" font="5">Boden et al.†</text>
<text top="209" left="798" width="32" height="15" font="13"> (81)</text>
<text top="208" left="829" width="4" height="16" font="0"> </text>
<text top="228" left="769" width="4" height="16" font="0"> </text>
<text top="249" left="769" width="4" height="16" font="2"><b> </b></text>
<text top="112" left="981" width="91" height="15" font="14"><i>CABG better:</i></text>
<text top="111" left="1072" width="4" height="16" font="15"><i> </i></text>
<text top="131" left="974" width="77" height="15" font="5">Bair et al.* </text>
<text top="131" left="1051" width="27" height="15" font="13">(82)</text>
<text top="130" left="1079" width="4" height="16" font="0"> </text>
<text top="150" left="968" width="89" height="15" font="5">Booth et al.† </text>
<text top="150" left="1057" width="28" height="15" font="13">(83)</text>
<text top="149" left="1085" width="4" height="16" font="0"> </text>
<text top="169" left="963" width="100" height="15" font="5">Hannan et al.* </text>
<text top="169" left="1063" width="28" height="15" font="13">(84)</text>
<text top="168" left="1090" width="4" height="16" font="0"> </text>
<text top="188" left="963" width="100" height="15" font="5">Hannan et al.* </text>
<text top="188" left="1063" width="28" height="15" font="13">(85)</text>
<text top="187" left="1090" width="4" height="16" font="0"> </text>
<text top="207" left="970" width="85" height="15" font="5">Jones et al.* </text>
<text top="207" left="1056" width="27" height="15" font="13">(77)</text>
<text top="206" left="1083" width="4" height="16" font="0"> </text>
<text top="226" left="976" width="72" height="15" font="5">MASS II* </text>
<text top="226" left="1049" width="28" height="15" font="13">(78)</text>
<text top="225" left="1076" width="4" height="16" font="0"> </text>
<text top="245" left="960" width="107" height="15" font="5">Malenka et al.* </text>
<text top="245" left="1066" width="27" height="15" font="13">(86)</text>
<text top="244" left="1093" width="4" height="16" font="0"> </text>
<text top="265" left="1027" width="4" height="16" font="2"><b> </b></text>
<text top="112" left="1220" width="96" height="15" font="5">Bravata et al.†</text>
<text top="112" left="1316" width="32" height="15" font="13"> (87)</text>
<text top="111" left="1347" width="4" height="16" font="0"> </text>
<text top="131" left="1218" width="104" height="15" font="5">Daemen et al.† </text>
<text top="131" left="1322" width="27" height="15" font="13">(88)</text>
<text top="130" left="1349" width="4" height="16" font="0"> </text>
<text top="150" left="1222" width="96" height="15" font="5">Dzavik et al.* </text>
<text top="150" left="1318" width="27" height="15" font="13">(59)</text>
<text top="149" left="1345" width="4" height="16" font="0"> </text>
<text top="169" left="1231" width="77" height="15" font="5">ERACI II† </text>
<text top="169" left="1308" width="28" height="15" font="13">(89)</text>
<text top="169" left="1336" width="4" height="15" font="5"> </text>
<text top="168" left="1340" width="4" height="16" font="0"> </text>
<text top="188" left="1216" width="107" height="15" font="5">Mercado et al.† </text>
<text top="188" left="1324" width="27" height="15" font="13">(90)</text>
<text top="187" left="1351" width="4" height="16" font="0"> </text>
<text top="207" left="1239" width="56" height="15" font="5">RITA I†</text>
<text top="207" left="1296" width="32" height="15" font="13"> (91)</text>
<text top="206" left="1327" width="4" height="16" font="0"> </text>
<text top="226" left="1198" width="139" height="15" font="5">Van Domburg et al.*</text>
<text top="226" left="1338" width="32" height="15" font="13"> (92)</text>
<text top="225" left="1369" width="4" height="16" font="0"> </text>
<text top="286" left="108" width="245" height="15" font="5">2-vessel disease with proximal LAD </text>
<text top="305" left="108" width="48" height="15" font="5">disease</text>
<text top="303" left="156" width="4" height="16" font="2"><b> </b></text>
<text top="324" left="242" width="4" height="16" font="2"><b> </b></text>
<text top="286" left="497" width="30" height="15" font="14"><i>For:</i></text>
<text top="285" left="528" width="4" height="16" font="15"><i> </i></text>
<text top="305" left="473" width="48" height="15" font="5">ECSS†</text>
<text top="305" left="521" width="32" height="15" font="13"> (76)</text>
<text top="304" left="552" width="4" height="16" font="0"> </text>
<text top="323" left="456" width="85" height="15" font="5">Jones et al.* </text>
<text top="323" left="541" width="27" height="15" font="13">(77)</text>
<text top="322" left="569" width="4" height="16" font="0"> </text>
<text top="342" left="455" width="88" height="15" font="5">Smith et al.* </text>
<text top="342" left="543" width="28" height="15" font="13">(80)</text>
<text top="341" left="570" width="4" height="16" font="0"> </text>
<text top="361" left="454" width="89" height="15" font="5">Yusuf et al.† </text>
<text top="361" left="543" width="28" height="15" font="13">(58)</text>
<text top="360" left="571" width="4" height="16" font="0"> </text>
<text top="286" left="754" width="30" height="15" font="14"><i>For:</i></text>
<text top="285" left="785" width="4" height="16" font="15"><i> </i></text>
<text top="305" left="708" width="92" height="15" font="5">Dzavik et al.*</text>
<text top="305" left="800" width="31" height="15" font="13"> (59)</text>
<text top="304" left="831" width="4" height="16" font="0"> </text>
<text top="323" left="713" width="85" height="15" font="5">Jones et al.* </text>
<text top="323" left="798" width="27" height="15" font="13">(77)</text>
<text top="322" left="826" width="4" height="16" font="0"> </text>
<text top="342" left="712" width="84" height="15" font="5">Smith et al.*</text>
<text top="342" left="796" width="32" height="15" font="13"> (80)</text>
<text top="341" left="827" width="4" height="16" font="0"> </text>
<text top="362" left="769" width="4" height="16" font="0"> </text>
<text top="382" left="741" width="56" height="15" font="14"><i>Against:</i></text>
<text top="381" left="797" width="4" height="16" font="15"><i> </i></text>
<text top="401" left="710" width="87" height="15" font="5">Boden et al.†</text>
<text top="401" left="798" width="32" height="15" font="13"> (81)</text>
<text top="400" left="829" width="4" height="16" font="15"><i> </i></text>
<text top="286" left="981" width="91" height="15" font="14"><i>CABG better:</i></text>
<text top="285" left="1072" width="4" height="16" font="15"><i> </i></text>
<text top="305" left="963" width="96" height="15" font="5">Hannan et al.*</text>
<text top="305" left="1059" width="32" height="15" font="13"> (84)</text>
<text top="304" left="1090" width="4" height="16" font="0"> </text>
<text top="323" left="963" width="96" height="15" font="5">Hannan et al.*</text>
<text top="323" left="1059" width="32" height="15" font="13"> (85)</text>
<text top="322" left="1090" width="4" height="16" font="0"> </text>
<text top="342" left="963" width="100" height="15" font="5">Hannan et al.* </text>
<text top="342" left="1063" width="28" height="15" font="13">(93)</text>
<text top="341" left="1090" width="4" height="16" font="0"> </text>
<text top="361" left="970" width="85" height="15" font="5">Jones et al.* </text>
<text top="361" left="1056" width="27" height="15" font="13">(77)</text>
<text top="360" left="1083" width="4" height="16" font="0"> </text>
<text top="381" left="1027" width="4" height="16" font="15"><i> </i></text>
<text top="286" left="1223" width="94" height="15" font="5">Berger et al.† </text>
<text top="286" left="1317" width="27" height="15" font="13">(94)</text>
<text top="285" left="1344" width="4" height="16" font="0"> </text>
<text top="305" left="1231" width="77" height="15" font="5">ERACI II† </text>
<text top="305" left="1308" width="28" height="15" font="13">(89)</text>
<text top="305" left="1336" width="4" height="15" font="5"> </text>
<text top="304" left="1340" width="4" height="16" font="0"> </text>
<text top="323" left="1217" width="107" height="15" font="5">Malenka et al.* </text>
<text top="323" left="1323" width="27" height="15" font="13">(86)</text>
<text top="322" left="1350" width="4" height="16" font="0"> </text>
<text top="343" left="1284" width="4" height="16" font="0"> </text>
<text top="421" left="108" width="266" height="15" font="5">2-vessel disease without proximal LAD </text>
<text top="440" left="108" width="48" height="15" font="5">disease</text>
<text top="439" left="156" width="4" height="16" font="0"> </text>
<text top="421" left="497" width="30" height="15" font="14"><i>For:</i></text>
<text top="420" left="528" width="4" height="16" font="15"><i> </i></text>
<text top="440" left="455" width="84" height="15" font="5">Smith et al.*</text>
<text top="440" left="539" width="32" height="15" font="13"> (80)</text>
<text top="439" left="570" width="4" height="16" font="0"> </text>
<text top="459" left="512" width="4" height="16" font="0"> </text>
<text top="421" left="754" width="30" height="15" font="14"><i>For:</i></text>
<text top="420" left="785" width="4" height="16" font="15"><i> </i></text>
<text top="440" left="713" width="81" height="15" font="5">Jones et al.*</text>
<text top="440" left="795" width="31" height="15" font="13"> (77)</text>
<text top="439" left="826" width="4" height="16" font="0"> </text>
<text top="459" left="712" width="88" height="15" font="5">Smith et al.* </text>
<text top="459" left="800" width="28" height="15" font="13">(80)</text>
<text top="458" left="827" width="4" height="16" font="0"> </text>
<text top="478" left="769" width="4" height="16" font="0"> </text>
<text top="498" left="741" width="56" height="15" font="14"><i>Against:</i></text>
<text top="497" left="797" width="4" height="16" font="15"><i> </i></text>
<text top="517" left="710" width="92" height="15" font="5">Boden et al.† </text>
<text top="517" left="802" width="27" height="15" font="13">(81)</text>
<text top="516" left="829" width="4" height="16" font="0"> </text>
<text top="536" left="714" width="84" height="15" font="5">Cecil et al.† </text>
<text top="536" left="798" width="27" height="15" font="13">(95)</text>
<text top="535" left="825" width="4" height="16" font="0"> </text>
<text top="555" left="720" width="72" height="15" font="5">Pitt et al.† </text>
<text top="555" left="792" width="27" height="15" font="13">(96)</text>
<text top="554" left="819" width="4" height="16" font="0"> </text>
<text top="421" left="981" width="91" height="15" font="14"><i>CABG better:</i></text>
<text top="420" left="1072" width="4" height="16" font="15"><i> </i></text>
<text top="440" left="974" width="77" height="15" font="5">Bair et al.* </text>
<text top="440" left="1051" width="27" height="15" font="13">(82)</text>
<text top="439" left="1079" width="4" height="16" font="0"> </text>
<text top="459" left="968" width="85" height="15" font="5">Booth et al.†</text>
<text top="459" left="1053" width="32" height="15" font="13"> (83)</text>
<text top="458" left="1085" width="4" height="16" font="0"> </text>
<text top="478" left="965" width="96" height="15" font="5">Dzavik et al.* </text>
<text top="478" left="1061" width="27" height="15" font="13">(59)</text>
<text top="477" left="1088" width="4" height="16" font="0"> </text>
<text top="497" left="963" width="100" height="15" font="5">Hannan et al.* </text>
<text top="497" left="1063" width="28" height="15" font="13">(93)</text>
<text top="496" left="1090" width="4" height="16" font="0"> </text>
<text top="516" left="963" width="100" height="15" font="5">Hannan et al.* </text>
<text top="516" left="1063" width="28" height="15" font="13">(85)</text>
<text top="515" left="1090" width="4" height="16" font="0"> </text>
<text top="535" left="970" width="85" height="15" font="5">Jones et al.* </text>
<text top="535" left="1056" width="27" height="15" font="13">(77)</text>
<text top="534" left="1083" width="4" height="16" font="0"> </text>
<text top="554" left="1027" width="4" height="16" font="0"> </text>
<text top="421" left="1220" width="96" height="15" font="5">Bravata et al.†</text>
<text top="421" left="1316" width="32" height="15" font="13"> (87)</text>
<text top="420" left="1347" width="4" height="16" font="0"> </text>
<text top="440" left="1218" width="99" height="15" font="5">Daemen et al.†</text>
<text top="440" left="1318" width="32" height="15" font="13"> (88)</text>
<text top="439" left="1349" width="4" height="16" font="0"> </text>
<text top="459" left="1222" width="96" height="15" font="5">Dzavik et al.* </text>
<text top="459" left="1318" width="27" height="15" font="13">(59)</text>
<text top="458" left="1345" width="4" height="16" font="0"> </text>
<text top="478" left="1227" width="81" height="15" font="5">Jones et al.*</text>
<text top="478" left="1309" width="31" height="15" font="13"> (77)</text>
<text top="477" left="1340" width="4" height="16" font="0"> </text>
<text top="497" left="1216" width="107" height="15" font="5">Mercado et al.† </text>
<text top="497" left="1324" width="27" height="15" font="13">(90)</text>
<text top="496" left="1351" width="4" height="16" font="0"> </text>
<text top="516" left="1200" width="140" height="15" font="5">van Domburg et al.* </text>
<text top="516" left="1340" width="27" height="15" font="13">(92)</text>
<text top="515" left="1367" width="4" height="16" font="0"> </text>
<text top="535" left="1163" width="4" height="16" font="0"> </text>
</page>
<page number="19" position="absolute" top="0" left="0" height="918" width="1512">
	<fontspec id="17" size="11" family="Times" color="#000000"/>
<text top="59" left="108" width="4" height="15" font="0"> </text>
<text top="59" left="459" width="4" height="15" font="0"> </text>
<text top="59" left="810" width="4" height="15" font="0"> </text>
<text top="59" left="864" width="4" height="15" font="0"> </text>
<text top="59" left="918" width="4" height="15" font="0"> </text>
<text top="59" left="972" width="4" height="15" font="0"> </text>
<text top="59" left="1026" width="4" height="15" font="0"> </text>
<text top="59" left="1080" width="4" height="15" font="0"> </text>
<text top="59" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="108" width="613" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="825" left="810" width="4" height="15" font="0"> </text>
<text top="825" left="864" width="4" height="15" font="0"> </text>
<text top="825" left="918" width="4" height="15" font="0"> </text>
<text top="825" left="972" width="4" height="15" font="0"> </text>
<text top="825" left="1026" width="4" height="15" font="0"> </text>
<text top="825" left="1080" width="4" height="15" font="0"> </text>
<text top="825" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="1188" width="4" height="15" font="0"> </text>
<text top="825" left="1242" width="22" height="15" font="0">19 </text>
<text top="847" left="108" width="4" height="15" font="0"> </text>
<text top="112" left="108" width="208" height="15" font="5">1-vessel proximal LAD disease</text>
<text top="111" left="316" width="4" height="16" font="0"> </text>
<text top="132" left="242" width="4" height="16" font="2"><b> </b></text>
<text top="112" left="497" width="30" height="15" font="14"><i>For:</i></text>
<text top="111" left="528" width="4" height="16" font="15"><i> </i></text>
<text top="131" left="455" width="88" height="15" font="5">Smith et al.* </text>
<text top="131" left="543" width="28" height="15" font="13">(80)</text>
<text top="130" left="570" width="4" height="16" font="0"> </text>
<text top="151" left="512" width="4" height="16" font="0"> </text>
<text top="171" left="484" width="56" height="15" font="14"><i>Against:</i></text>
<text top="170" left="540" width="4" height="16" font="15"><i> </i></text>
<text top="190" left="436" width="122" height="15" font="5">Greenbaum et al.*</text>
<text top="190" left="557" width="32" height="15" font="13"> (97)</text>
<text top="189" left="589" width="4" height="16" font="0"> </text>
<text top="209" left="512" width="4" height="16" font="0"> </text>
<text top="112" left="754" width="30" height="15" font="14"><i>For:</i></text>
<text top="111" left="785" width="4" height="16" font="15"><i> </i></text>
<text top="131" left="713" width="85" height="15" font="5">Jones et al.* </text>
<text top="131" left="798" width="27" height="15" font="13">(77)</text>
<text top="130" left="826" width="4" height="16" font="0"> </text>
<text top="150" left="712" width="88" height="15" font="5">Smith et al.* </text>
<text top="150" left="800" width="28" height="15" font="13">(80)</text>
<text top="149" left="827" width="4" height="16" font="0"> </text>
<text top="169" left="769" width="4" height="16" font="0"> </text>
<text top="190" left="741" width="56" height="15" font="14"><i>Against:</i></text>
<text top="189" left="797" width="4" height="16" font="15"><i> </i></text>
<text top="209" left="693" width="126" height="15" font="5">Greenbaum et al.* </text>
<text top="209" left="819" width="27" height="15" font="13">(97)</text>
<text top="208" left="846" width="4" height="16" font="0"> </text>
<text top="228" left="769" width="4" height="16" font="0"> </text>
<text top="112" left="981" width="91" height="15" font="14"><i>CABG better:</i></text>
<text top="111" left="1072" width="4" height="16" font="15"><i> </i></text>
<text top="131" left="967" width="88" height="15" font="5">Hannan et al.</text>
<text top="131" left="1055" width="32" height="15" font="13"> (84)</text>
<text top="130" left="1086" width="4" height="16" font="0"> </text>
<text top="112" left="1230" width="80" height="15" font="5">Aziz et al.† </text>
<text top="112" left="1310" width="28" height="15" font="13">(98)</text>
<text top="111" left="1337" width="4" height="16" font="0"> </text>
<text top="131" left="1218" width="100" height="15" font="5">Ben-Gal et al.*</text>
<text top="131" left="1318" width="32" height="15" font="13"> (99)</text>
<text top="130" left="1349" width="4" height="16" font="0"> </text>
<text top="150" left="1220" width="96" height="15" font="5">Bravata et al.†</text>
<text top="150" left="1316" width="32" height="15" font="13"> (87)</text>
<text top="149" left="1347" width="4" height="16" font="0"> </text>
<text top="169" left="1211" width="106" height="15" font="5">Cisowski et al.§</text>
<text top="169" left="1317" width="40" height="15" font="13"> (100)</text>
<text top="168" left="1356" width="4" height="16" font="0"> </text>
<text top="188" left="1213" width="101" height="15" font="5">Diegeler et al.†</text>
<text top="188" left="1314" width="40" height="15" font="13"> (101)</text>
<text top="187" left="1354" width="4" height="16" font="0"> </text>
<text top="207" left="1218" width="94" height="15" font="5">Drenth et al.† </text>
<text top="207" left="1313" width="36" height="15" font="13">(102)</text>
<text top="206" left="1349" width="4" height="16" font="0"> </text>
<text top="226" left="1218" width="96" height="15" font="5">Fraund et al.* </text>
<text top="226" left="1313" width="36" height="15" font="13">(103)</text>
<text top="225" left="1349" width="4" height="16" font="0"> </text>
<text top="245" left="1211" width="146" height="15" font="5">Goy et al.† (104, 105)</text>
<text top="244" left="1356" width="4" height="16" font="0"> </text>
<text top="264" left="1207" width="126" height="15" font="5">Greenbaum et al.* </text>
<text top="264" left="1333" width="27" height="15" font="13">(97)</text>
<text top="263" left="1360" width="4" height="16" font="0"> </text>
<text top="283" left="1223" width="85" height="15" font="5">Hong et al.† </text>
<text top="283" left="1308" width="36" height="15" font="13">(106)</text>
<text top="282" left="1344" width="4" height="16" font="0"> </text>
<text top="302" left="1218" width="94" height="15" font="5">Jaffery et al.† </text>
<text top="302" left="1313" width="36" height="15" font="13">(107)</text>
<text top="301" left="1349" width="4" height="16" font="0"> </text>
<text top="321" left="1227" width="85" height="15" font="5">Jones et al.* </text>
<text top="321" left="1313" width="27" height="15" font="13">(77)</text>
<text top="320" left="1340" width="4" height="16" font="0"> </text>
<text top="340" left="1217" width="94" height="15" font="5">Kapoor et al.†</text>
<text top="340" left="1311" width="40" height="15" font="13"> (108)</text>
<text top="339" left="1350" width="4" height="16" font="0"> </text>
<text top="359" left="1232" width="63" height="15" font="5">MASS I†</text>
<text top="359" left="1295" width="40" height="15" font="13"> (109)</text>
<text top="358" left="1335" width="4" height="16" font="0"> </text>
<text top="379" left="108" width="266" height="15" font="5">1-vessel disease without proximal LAD </text>
<text top="398" left="108" width="82" height="15" font="5">involvement</text>
<text top="397" left="190" width="4" height="16" font="0"> </text>
<text top="417" left="242" width="4" height="16" font="2"><b> </b></text>
<text top="379" left="484" width="56" height="15" font="14"><i>Against:</i></text>
<text top="378" left="540" width="4" height="16" font="0"> </text>
<text top="398" left="456" width="81" height="15" font="5">Jones et al.*</text>
<text top="398" left="537" width="31" height="15" font="13"> (77)</text>
<text top="397" left="569" width="4" height="16" font="0"> </text>
<text top="417" left="455" width="84" height="15" font="5">Smith et al.*</text>
<text top="417" left="539" width="32" height="15" font="13"> (80)</text>
<text top="416" left="570" width="4" height="16" font="0"> </text>
<text top="436" left="454" width="85" height="15" font="5">Yusuf et al.†</text>
<text top="436" left="539" width="32" height="15" font="13"> (58)</text>
<text top="435" left="571" width="4" height="16" font="15"><i> </i></text>
<text top="379" left="741" width="56" height="15" font="14"><i>Against:</i></text>
<text top="378" left="797" width="4" height="16" font="15"><i> </i></text>
<text top="398" left="713" width="85" height="15" font="5">Jones et al.* </text>
<text top="398" left="798" width="27" height="15" font="13">(77)</text>
<text top="397" left="826" width="4" height="16" font="15"><i> </i></text>
<text top="379" left="989" width="75" height="15" font="14"><i>PCI better:</i></text>
<text top="378" left="1064" width="4" height="16" font="0"> </text>
<text top="398" left="963" width="100" height="15" font="5">Hannan et al.* </text>
<text top="398" left="1063" width="28" height="15" font="13">(84)</text>
<text top="397" left="1090" width="4" height="16" font="0"> </text>
<text top="417" left="970" width="85" height="15" font="5">Jones et al * </text>
<text top="417" left="1056" width="27" height="15" font="13">(77)</text>
<text top="416" left="1083" width="4" height="16" font="15"><i> </i></text>
<text top="379" left="1227" width="81" height="15" font="5">Jones et al.*</text>
<text top="379" left="1309" width="31" height="15" font="13"> (77)</text>
<text top="378" left="1340" width="4" height="16" font="0"> </text>
<text top="398" left="1284" width="4" height="16" font="0"> </text>
<text top="455" left="108" width="203" height="15" font="5">Multivessel CAD, DM present</text>
<text top="454" left="310" width="4" height="16" font="15"><i> </i></text>
<text top="455" left="497" width="30" height="15" font="14"><i>For:</i></text>
<text top="454" left="528" width="4" height="16" font="15"><i> </i></text>
<text top="474" left="458" width="72" height="15" font="5">MASS II† </text>
<text top="474" left="531" width="36" height="15" font="13">(110)</text>
<text top="473" left="566" width="4" height="16" font="0"> </text>
<text top="493" left="447" width="91" height="15" font="5">Sorajja et al.*</text>
<text top="493" left="538" width="40" height="15" font="13"> (111)</text>
<text top="492" left="578" width="4" height="16" font="0"> </text>
<text top="512" left="512" width="4" height="16" font="0"> </text>
<text top="533" left="476" width="74" height="15" font="14"><i>No benefit:</i></text>
<text top="532" left="549" width="4" height="16" font="15"><i> </i></text>
<text top="552" left="456" width="76" height="15" font="5">BARI 2D† </text>
<text top="552" left="533" width="36" height="15" font="13">(112)</text>
<text top="551" left="568" width="4" height="16" font="0"> </text>
<text top="455" left="754" width="30" height="15" font="14"><i>For:</i></text>
<text top="454" left="785" width="4" height="16" font="15"><i> </i></text>
<text top="474" left="715" width="68" height="15" font="5">MASS II†</text>
<text top="474" left="784" width="40" height="15" font="13"> (110)</text>
<text top="473" left="823" width="4" height="16" font="0"> </text>
<text top="494" left="769" width="4" height="16" font="15"><i> </i></text>
<text top="514" left="737" width="65" height="15" font="14"><i>No effect:</i></text>
<text top="513" left="802" width="4" height="16" font="15"><i> </i></text>
<text top="533" left="714" width="72" height="15" font="5">BARI 2D†</text>
<text top="533" left="786" width="40" height="15" font="13"> (112)</text>
<text top="532" left="825" width="4" height="16" font="15"><i> </i></text>
<text top="552" left="704" width="95" height="15" font="5">Sorajja et al.* </text>
<text top="552" left="799" width="36" height="15" font="13">(111)</text>
<text top="551" left="835" width="4" height="16" font="0"> </text>
<text top="571" left="769" width="4" height="16" font="0"> </text>
<text top="455" left="981" width="91" height="15" font="14"><i>CABG better:</i></text>
<text top="454" left="1072" width="4" height="16" font="15"><i> </i></text>
<text top="474" left="961" width="67" height="15" font="5">BARI I† (</text>
<text top="474" left="1028" width="25" height="15" font="13">113</text>
<text top="474" left="1053" width="8" height="15" font="5">, </text>
<text top="474" left="1061" width="25" height="15" font="13">114</text>
<text top="474" left="1086" width="6" height="15" font="5">)</text>
<text top="473" left="1092" width="4" height="16" font="0"> </text>
<text top="493" left="962" width="89" height="15" font="5">Brener et al.*</text>
<text top="493" left="1051" width="40" height="15" font="13"> (115)</text>
<text top="492" left="1091" width="4" height="16" font="0"> </text>
<text top="512" left="962" width="94" height="15" font="5">Hlatky et al.† </text>
<text top="512" left="1056" width="36" height="15" font="13">(116)</text>
<text top="511" left="1091" width="4" height="16" font="0"> </text>
<text top="531" left="963" width="91" height="15" font="5">Javaid et al.* </text>
<text top="531" left="1054" width="36" height="15" font="13">(117)</text>
<text top="530" left="1090" width="4" height="16" font="0"> </text>
<text top="550" left="960" width="102" height="15" font="5">Malenka et al.*</text>
<text top="550" left="1062" width="31" height="15" font="13"> (86)</text>
<text top="549" left="1093" width="4" height="16" font="0"> </text>
<text top="569" left="967" width="84" height="15" font="5">Niles et al.* </text>
<text top="569" left="1050" width="36" height="15" font="13">(118)</text>
<text top="568" left="1086" width="4" height="16" font="0"> </text>
<text top="588" left="925" width="166" height="15" font="5">Pell et al.* for 3-V CAD </text>
<text top="588" left="1092" width="36" height="15" font="13">(119)</text>
<text top="587" left="1128" width="4" height="16" font="0"> </text>
<text top="607" left="949" width="114" height="15" font="5">Weintraub et al.†</text>
<text top="607" left="1064" width="40" height="15" font="13"> (120)</text>
<text top="606" left="1103" width="4" height="16" font="0"> </text>
<text top="455" left="1234" width="64" height="15" font="5">ARTS I* </text>
<text top="455" left="1298" width="36" height="15" font="13">(121)</text>
<text top="454" left="1333" width="4" height="16" font="0"> </text>
<text top="474" left="1231" width="73" height="15" font="5">Bair et al.*</text>
<text top="474" left="1304" width="31" height="15" font="13"> (82)</text>
<text top="473" left="1336" width="4" height="16" font="0"> </text>
<text top="493" left="1212" width="103" height="15" font="5">Barsness et al.*</text>
<text top="493" left="1315" width="40" height="15" font="13"> (122)</text>
<text top="492" left="1355" width="4" height="16" font="0"> </text>
<text top="512" left="1220" width="100" height="15" font="5">Bravata et al.† </text>
<text top="512" left="1320" width="28" height="15" font="13">(87)</text>
<text top="511" left="1347" width="4" height="16" font="0"> </text>
<text top="531" left="1231" width="66" height="15" font="5">CARDia†</text>
<text top="531" left="1297" width="40" height="15" font="13"> (123)</text>
<text top="530" left="1336" width="4" height="16" font="0"> </text>
<text top="550" left="1222" width="96" height="15" font="5">Dzavik et al.* </text>
<text top="550" left="1318" width="27" height="15" font="13">(59)</text>
<text top="549" left="1345" width="4" height="16" font="0"> </text>
<text top="569" left="1229" width="72" height="15" font="5">MASS II† </text>
<text top="569" left="1302" width="36" height="15" font="13">(110)</text>
<text top="568" left="1338" width="4" height="16" font="0"> </text>
<text top="588" left="1202" width="166" height="15" font="5">Pell et al.* for 2-V CAD </text>
<text top="587" left="1369" width="4" height="16" font="0"> </text>
<text top="607" left="1266" width="36" height="15" font="13">(119)</text>
<text top="606" left="1301" width="4" height="16" font="2"><b> </b></text>
<text top="646" left="108" width="1256" height="12" font="17">*Observational study, including articles on long-term follow-up, clinical trials not specified as randomized, comparative registry studies, comparative studies, prospective cohort studies, prospective observational studies, prospective </text>
<text top="661" left="108" width="803" height="12" font="17">registries, and prospective studies. †Randomized controlled trials, including meta-analyses. ‡Reviews (systematic or not). §Unknown study design.  </text>
<text top="677" left="108" width="3" height="12" font="17"> </text>
<text top="692" left="108" width="1232" height="12" font="17">ARTS indicates Arterial Revascularization Therapies Study Part; AWESOME, Angina With Extremely Serious Operative Mortality Evaluation; BARI I,  Bypass Angioplasty Revascularization Investigation I; BARI 2D, Bypass </text>
<text top="708" left="108" width="1272" height="12" font="17">Angioplasty Revascularization Investigation 2 Diabetes; CAD, coronary artery disease; CARDIA, Coronary Artery Revascularization in Diabetes; DM, diabetes mellitus; ECSS, European Coronary Surgery Study; ERACI II, Argentine </text>
<text top="723" left="108" width="1124" height="12" font="17">Randomized Trial of Percutaneous Transluminal Coronary Angioplasty versus Coronary Artery Bypass Surgery in Multivessel Disease II; LAD,  left anterior descending; LIMA, left internal mammary artery;</text>
<text top="720" left="1232" width="4" height="16" font="2"><b> </b></text>
<text top="723" left="1237" width="105" height="12" font="17">MASS,  Medicine, </text>
<text top="739" left="108" width="1285" height="12" font="17">Angioplasty, or Surgery Study;  RITA, Randomised Intervention Treatment of Angina; SIHD, stable ischemic heart disease; SYNTAX, Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery; V, vessel; </text>
<text top="754" left="108" width="189" height="12" font="17">and VA, Veterans Administration. </text>
<text top="771" left="108" width="4" height="15" font="4"><b> </b></text>
<text top="790" left="108" width="4" height="15" font="4"><b> </b></text>
</page>
<page number="20" position="absolute" top="0" left="0" height="918" width="1512">
<text top="59" left="108" width="4" height="15" font="0"> </text>
<text top="59" left="459" width="4" height="15" font="0"> </text>
<text top="59" left="810" width="4" height="15" font="0"> </text>
<text top="59" left="864" width="4" height="15" font="0"> </text>
<text top="59" left="918" width="4" height="15" font="0"> </text>
<text top="59" left="972" width="4" height="15" font="0"> </text>
<text top="59" left="1026" width="4" height="15" font="0"> </text>
<text top="59" left="1080" width="4" height="15" font="0"> </text>
<text top="59" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="108" width="613" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="825" left="810" width="4" height="15" font="0"> </text>
<text top="825" left="864" width="4" height="15" font="0"> </text>
<text top="825" left="918" width="4" height="15" font="0"> </text>
<text top="825" left="972" width="4" height="15" font="0"> </text>
<text top="825" left="1026" width="4" height="15" font="0"> </text>
<text top="825" left="1080" width="4" height="15" font="0"> </text>
<text top="825" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="1188" width="4" height="15" font="0"> </text>
<text top="825" left="1242" width="22" height="15" font="0">20 </text>
<text top="847" left="108" width="4" height="15" font="0"> </text>
<text top="112" left="108" width="4" height="15" font="6"><i><b> </b></i></text>
<text top="131" left="108" width="1216" height="16" font="2"><b>Data Supplement 4. Evidence for Relief of Unacceptable Angina in Subsets of Patients With SIHD Who are Receiving GDMT and Have Anatomy Suitable for </b></text>
<text top="152" left="108" width="143" height="16" font="2"><b>Revascularization </b></text>
<text top="173" left="174" width="149" height="15" font="4"><b>Anatomic Subgroups</b></text>
<text top="172" left="323" width="4" height="16" font="2"><b> </b></text>
<text top="173" left="399" width="218" height="15" font="4"><b>Evidence Supporting CABG + </b></text>
<text top="192" left="439" width="132" height="15" font="4"><b>GDMT for Angina</b></text>
<text top="191" left="571" width="4" height="16" font="2"><b> </b></text>
<text top="173" left="631" width="254" height="15" font="4"><b>Evidence Supporting PCI + GDMT </b></text>
<text top="192" left="718" width="77" height="15" font="4"><b>for Angina</b></text>
<text top="191" left="794" width="4" height="16" font="2"><b> </b></text>
<text top="173" left="896" width="237" height="15" font="4"><b>Evidence Supporting Superiority </b></text>
<text top="192" left="891" width="244" height="15" font="4"><b>of either CABG or PCI for Angina</b></text>
<text top="173" left="1142" width="261" height="15" font="4"><b>Evidence Supporting Equivalence of </b></text>
<text top="192" left="1174" width="192" height="15" font="4"><b>CABG and PCI for Angina</b></text>
<text top="191" left="1366" width="4" height="16" font="2"><b> </b></text>
<text top="216" left="108" width="116" height="15" font="5">Multivessel CAD</text>
<text top="215" left="224" width="4" height="16" font="0"> </text>
<text top="216" left="479" width="52" height="15" font="14"><i>Benefit:</i></text>
<text top="215" left="531" width="4" height="16" font="15"><i> </i></text>
<text top="235" left="440" width="91" height="15" font="5">Benzer et al.*</text>
<text top="235" left="531" width="40" height="15" font="13"> (124)</text>
<text top="234" left="571" width="4" height="16" font="0"> </text>
<text top="254" left="436" width="100" height="15" font="5">Bonaros et al.*</text>
<text top="254" left="535" width="40" height="15" font="13"> (125)</text>
<text top="253" left="575" width="4" height="16" font="0"> </text>
<text top="273" left="434" width="103" height="15" font="5">Favaroto et al.†</text>
<text top="273" left="537" width="40" height="15" font="13"> (126)</text>
<text top="272" left="577" width="4" height="16" font="0"> </text>
<text top="292" left="444" width="87" height="15" font="5">Hofer et al.* </text>
<text top="292" left="531" width="36" height="15" font="13">(127)</text>
<text top="291" left="567" width="4" height="16" font="0"> </text>
<text top="311" left="425" width="125" height="15" font="5">Lukkarinen et al.* </text>
<text top="311" left="550" width="36" height="15" font="13">(128)</text>
<text top="310" left="586" width="4" height="16" font="0"> </text>
<text top="330" left="455" width="68" height="15" font="5">MASS II†</text>
<text top="330" left="524" width="32" height="15" font="13"> (78)</text>
<text top="329" left="555" width="4" height="16" font="0"> </text>
<text top="349" left="457" width="60" height="15" font="5">RITA I† </text>
<text top="349" left="518" width="36" height="15" font="13">(129)</text>
<text top="348" left="553" width="4" height="16" font="0"> </text>
<text top="368" left="505" width="4" height="16" font="0"> </text>
<text top="216" left="719" width="74" height="15" font="14"><i>No benefit:</i></text>
<text top="215" left="793" width="4" height="16" font="15"><i> </i></text>
<text top="235" left="676" width="121" height="15" font="5">Lukkarinen et al.*</text>
<text top="235" left="796" width="40" height="15" font="13"> (128)</text>
<text top="234" left="836" width="4" height="16" font="0"> </text>
<text top="254" left="756" width="4" height="16" font="0"> </text>
<text top="275" left="730" width="52" height="15" font="14"><i>Benefit:</i></text>
<text top="273" left="782" width="4" height="16" font="0"> </text>
<text top="294" left="690" width="95" height="15" font="5">Benzer et al.* </text>
<text top="294" left="786" width="36" height="15" font="13">(124)</text>
<text top="293" left="822" width="4" height="16" font="0"> </text>
<text top="312" left="680" width="98" height="15" font="5">COURAGE† (</text>
<text top="312" left="777" width="17" height="15" font="13">81</text>
<text top="312" left="794" width="8" height="15" font="5">, </text>
<text top="312" left="802" width="25" height="15" font="13">130</text>
<text top="312" left="827" width="6" height="15" font="5">)</text>
<text top="311" left="832" width="4" height="16" font="0"> </text>
<text top="332" left="677" width="118" height="15" font="5">Hambrecht et al.‡</text>
<text top="332" left="795" width="40" height="15" font="13"> (131)</text>
<text top="331" left="835" width="4" height="16" font="0"> </text>
<text top="350" left="695" width="83" height="15" font="5">Hofer et al.*</text>
<text top="350" left="778" width="40" height="15" font="13"> (127)</text>
<text top="349" left="817" width="4" height="16" font="0"> </text>
<text top="369" left="706" width="68" height="15" font="5">MASS II†</text>
<text top="369" left="774" width="32" height="15" font="13"> (78)</text>
<text top="368" left="806" width="4" height="16" font="0"> </text>
<text top="388" left="708" width="60" height="15" font="5">RITA I† </text>
<text top="388" left="768" width="36" height="15" font="13">(129)</text>
<text top="387" left="804" width="4" height="16" font="0"> </text>
<text top="407" left="705" width="66" height="15" font="5">RITA II† </text>
<text top="407" left="771" width="36" height="15" font="13">(132)</text>
<text top="406" left="807" width="4" height="16" font="0"> </text>
<text top="426" left="668" width="140" height="15" font="5">Wijeysundera et al.‡ </text>
<text top="426" left="808" width="36" height="15" font="13">(133)</text>
<text top="425" left="844" width="4" height="16" font="0"> </text>
<text top="216" left="967" width="91" height="15" font="14"><i>CABG better:</i></text>
<text top="216" left="1059" width="12" height="15" font="5">   </text>
<text top="215" left="1071" width="4" height="16" font="0"> </text>
<text top="235" left="947" width="91" height="15" font="5">Benzer et al.*</text>
<text top="235" left="1039" width="40" height="15" font="13"> (124)</text>
<text top="234" left="1078" width="4" height="16" font="0"> </text>
<text top="254" left="943" width="104" height="15" font="5">Bonaros et al.* </text>
<text top="254" left="1047" width="36" height="15" font="13">(125)</text>
<text top="253" left="1083" width="4" height="16" font="0"> </text>
<text top="276" left="933" width="121" height="15" font="5">Lukkarinen et al.*</text>
<text top="276" left="1053" width="40" height="15" font="13"> (128)</text>
<text top="275" left="1093" width="4" height="16" font="0"> </text>
<text top="295" left="965" width="66" height="15" font="5">RITA I† (</text>
<text top="295" left="1031" width="30" height="15" font="13">129)</text>
<text top="294" left="1061" width="4" height="16" font="0"> </text>
<text top="314" left="1013" width="4" height="16" font="0"> </text>
<text top="334" left="975" width="75" height="15" font="14"><i>PCI better:</i></text>
<text top="334" left="1050" width="8" height="15" font="5">  </text>
<text top="333" left="1058" width="4" height="16" font="0"> </text>
<text top="353" left="974" width="78" height="15" font="5">None found</text>
<text top="352" left="1052" width="4" height="16" font="0"> </text>
<text top="372" left="1013" width="4" height="16" font="0"> </text>
<text top="393" left="891" width="4" height="16" font="0"> </text>
<text top="216" left="1208" width="83" height="15" font="5">Hofer et al.*</text>
<text top="216" left="1291" width="40" height="15" font="13"> (127)</text>
<text top="215" left="1331" width="4" height="16" font="0"> </text>
<text top="235" left="1202" width="109" height="15" font="5">MASS II et al.† </text>
<text top="235" left="1310" width="27" height="15" font="13">(78)</text>
<text top="234" left="1338" width="4" height="16" font="0"> </text>
<text top="254" left="1205" width="90" height="15" font="5">Takagi et al.‡</text>
<text top="254" left="1295" width="40" height="15" font="13"> (134)</text>
<text top="253" left="1335" width="4" height="16" font="0"> </text>
<text top="446" left="108" width="255" height="15" font="5">1-vessel CAD excluding the proximal </text>
<text top="465" left="108" width="34" height="15" font="5">LAD</text>
<text top="464" left="142" width="4" height="16" font="0"> </text>
<text top="446" left="458" width="94" height="15" font="5">No data found</text>
<text top="445" left="552" width="4" height="16" font="0"> </text>
<text top="446" left="677" width="118" height="15" font="5">Hambrecht et al.†</text>
<text top="446" left="795" width="40" height="15" font="13"> (131)</text>
<text top="445" left="835" width="4" height="16" font="0"> </text>
<text top="465" left="695" width="82" height="15" font="5">Parisi et al.†</text>
<text top="465" left="777" width="40" height="15" font="13"> (135)</text>
<text top="464" left="817" width="4" height="16" font="0"> </text>
<text top="484" left="706" width="72" height="15" font="5">Pitt et al.† </text>
<text top="484" left="778" width="27" height="15" font="13">(96)</text>
<text top="483" left="805" width="4" height="16" font="0"> </text>
<text top="503" left="690" width="93" height="15" font="5">Pocock et al.†</text>
<text top="503" left="783" width="40" height="15" font="13"> (132)</text>
<text top="502" left="822" width="4" height="16" font="15"><i> </i></text>
<text top="446" left="966" width="94" height="15" font="5">No data found</text>
<text top="445" left="1060" width="4" height="16" font="0"> </text>
<text top="446" left="1223" width="94" height="15" font="5">No data found</text>
<text top="445" left="1317" width="4" height="16" font="0"> </text>
<text top="523" left="108" width="253" height="15" font="5">1-vessel CAD involving the proximal </text>
<text top="542" left="108" width="34" height="15" font="5">LAD</text>
<text top="541" left="142" width="4" height="16" font="0"> </text>
<text top="523" left="454" width="103" height="15" font="5">MASS I† (109)</text>
<text top="522" left="557" width="4" height="16" font="0"> </text>
<text top="542" left="505" width="4" height="16" font="0"> </text>
<text top="523" left="677" width="118" height="15" font="5">Hambrecht et al.†</text>
<text top="523" left="795" width="40" height="15" font="13"> (131)</text>
<text top="522" left="835" width="4" height="16" font="0"> </text>
<text top="542" left="695" width="82" height="15" font="5">Parisi et al.†</text>
<text top="542" left="777" width="40" height="15" font="13"> (135)</text>
<text top="541" left="817" width="4" height="16" font="0"> </text>
<text top="561" left="706" width="67" height="15" font="5">Pitt et al.†</text>
<text top="561" left="774" width="32" height="15" font="13"> (96)</text>
<text top="560" left="805" width="4" height="16" font="0"> </text>
<text top="580" left="690" width="97" height="15" font="5">Pocock et al.† </text>
<text top="580" left="787" width="36" height="15" font="13">(132)</text>
<text top="579" left="822" width="4" height="16" font="0"> </text>
<text top="599" left="756" width="4" height="16" font="0"> </text>
<text top="523" left="967" width="91" height="15" font="14"><i>CABG better:</i></text>
<text top="522" left="1059" width="4" height="16" font="0"> </text>
<text top="544" left="947" width="105" height="15" font="5">Ben-Gal et al.* </text>
<text top="544" left="1052" width="27" height="15" font="13">(99)</text>
<text top="543" left="1079" width="4" height="16" font="0"> </text>
<text top="566" left="940" width="106" height="15" font="5">Cisowski et al.†</text>
<text top="566" left="1046" width="40" height="15" font="13"> (100)</text>
<text top="565" left="1086" width="4" height="16" font="0"> </text>
<text top="588" left="942" width="105" height="15" font="5">Diegeler et al.‡ </text>
<text top="588" left="1048" width="36" height="15" font="13">(101)</text>
<text top="587" left="1083" width="4" height="16" font="0"> </text>
<text top="610" left="957" width="73" height="15" font="5">Goy et al.†</text>
<text top="610" left="1030" width="40" height="15" font="13"> (104)</text>
<text top="609" left="1069" width="4" height="16" font="0"> </text>
<text top="629" left="936" width="123" height="15" font="5">Toutouzas et al.* (</text>
<text top="629" left="1059" width="25" height="15" font="13">130</text>
<text top="629" left="1084" width="6" height="15" font="5">)</text>
<text top="628" left="1089" width="4" height="16" font="0"> </text>
<text top="648" left="962" width="67" height="15" font="5">MASS I† </text>
<text top="648" left="1029" width="36" height="15" font="13">(109)</text>
<text top="647" left="1064" width="4" height="16" font="0"> </text>
<text top="523" left="1197" width="110" height="15" font="5">Cisowski et al.† </text>
<text top="523" left="1307" width="36" height="15" font="13">(136)</text>
<text top="522" left="1343" width="4" height="16" font="0"> </text>
<text top="542" left="1205" width="94" height="15" font="5">Drenth et al.§ </text>
<text top="542" left="1299" width="36" height="15" font="13">(137)</text>
<text top="541" left="1335" width="4" height="16" font="0"> </text>
<text top="561" left="1207" width="91" height="15" font="5">Thiele et al.† </text>
<text top="561" left="1297" width="36" height="15" font="13">(138)</text>
<text top="560" left="1333" width="4" height="16" font="0"> </text>
<text top="668" left="108" width="150" height="15" font="5">Special Circumstances</text>
<text top="667" left="258" width="4" height="16" font="0"> </text>
<text top="668" left="897" width="4" height="16" font="0"> </text>
<text top="695" left="108" width="262" height="15" font="5">Patients with prior CABG and small or </text>
<text top="714" left="108" width="212" height="15" font="5">moderate sized area of ischemia</text>
<text top="713" left="320" width="4" height="16" font="0"> </text>
<text top="695" left="458" width="94" height="15" font="5">No data found</text>
<text top="694" left="552" width="4" height="16" font="0"> </text>
<text top="695" left="682" width="113" height="15" font="5">Gurfinkel et al.§ </text>
<text top="695" left="795" width="36" height="15" font="13">(139)</text>
<text top="694" left="830" width="4" height="16" font="0"> </text>
<text top="714" left="685" width="106" height="15" font="5">Pfautsch et al.* </text>
<text top="714" left="791" width="36" height="15" font="13">(140)</text>
<text top="713" left="827" width="4" height="16" font="0"> </text>
<text top="733" left="670" width="136" height="15" font="5">Subramanian et al.* </text>
<text top="733" left="806" width="36" height="15" font="13">(141)</text>
<text top="732" left="842" width="4" height="16" font="0"> </text>
<text top="695" left="967" width="91" height="15" font="14"><i>CABG better:</i></text>
<text top="694" left="1059" width="4" height="16" font="15"><i> </i></text>
<text top="714" left="936" width="118" height="15" font="5">Weintraub et al.† </text>
<text top="714" left="1054" width="36" height="15" font="13">(142)</text>
<text top="713" left="1090" width="4" height="16" font="0"> </text>
<text top="695" left="1201" width="102" height="15" font="5">Stephan et al.* </text>
<text top="695" left="1303" width="36" height="15" font="13">(143)</text>
<text top="694" left="1338" width="4" height="16" font="0"> </text>
<text top="772" left="108" width="1256" height="12" font="17">*Observational study, including articles on long-term follow-up, clinical trials not specified as randomized, comparative registry studies, comparative studies, prospective cohort studies, prospective observational studies, prospective </text>
<text top="788" left="108" width="803" height="12" font="17">registries, and prospective studies. †Randomized controlled trials, including meta-analyses. ‡Reviews (systematic or not). §Unknown study design.  </text>
</page>
<page number="21" position="absolute" top="0" left="0" height="918" width="1512">
	<fontspec id="18" size="12" family="Times" color="#000000"/>
	<fontspec id="19" size="8" family="Times" color="#000000"/>
	<fontspec id="20" size="10" family="Times" color="#000000"/>
<text top="59" left="108" width="4" height="15" font="0"> </text>
<text top="59" left="459" width="4" height="15" font="0"> </text>
<text top="59" left="810" width="4" height="15" font="0"> </text>
<text top="59" left="864" width="4" height="15" font="0"> </text>
<text top="59" left="918" width="4" height="15" font="0"> </text>
<text top="59" left="972" width="4" height="15" font="0"> </text>
<text top="59" left="1026" width="4" height="15" font="0"> </text>
<text top="59" left="1080" width="4" height="15" font="0"> </text>
<text top="59" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="108" width="613" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="825" left="810" width="4" height="15" font="0"> </text>
<text top="825" left="864" width="4" height="15" font="0"> </text>
<text top="825" left="918" width="4" height="15" font="0"> </text>
<text top="825" left="972" width="4" height="15" font="0"> </text>
<text top="825" left="1026" width="4" height="15" font="0"> </text>
<text top="825" left="1080" width="4" height="15" font="0"> </text>
<text top="825" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="1188" width="4" height="15" font="0"> </text>
<text top="825" left="1242" width="22" height="15" font="0">21 </text>
<text top="847" left="108" width="4" height="15" font="0"> </text>
<text top="111" left="108" width="3" height="12" font="17"> </text>
<text top="126" left="108" width="1292" height="12" font="17">ARTS indicates Arterial Revascularization Therapies Study Part; AWESOME, Angina With Extremely Serious Operative Mortality Evaluation; BARI 2D,  Bypass Angioplasty Revascularization Investigation 2 Diabetes; CABG, coronary </text>
<text top="142" left="108" width="1296" height="12" font="17">artery bypass graft; CAD, coronary artery disease; CARDia, Coronary Artery Revascularization in Diabetes; COURAGE, Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation; GDMT, guideline-directed medical </text>
<text top="158" left="108" width="1252" height="12" font="17">therapy; LAD, left anterior descending artery; LOE, level of evidence; MASS, Medicine, Angioplasty or Surgery Study; PCI, percutaneous coronary intervention; RITA, Randomised Intervention Treatment of Angina; SIHD, stable </text>
<text top="173" left="108" width="515" height="12" font="17">ischemic heart disease; and TIME, Trial of invasive versus medical therapy in elderly patients. </text>
<text top="189" left="108" width="4" height="13" font="18"><b> </b></text>
<text top="207" left="108" width="4" height="16" font="2"><b> </b></text>
<text top="228" left="108" width="4" height="16" font="2"><b> </b></text>
<text top="248" left="108" width="499" height="16" font="2"><b>Data Supplement 5. RCTs of CABG Versus Balloon Angioplasty </b></text>
<text top="277" left="291" width="4" height="16" font="2"><b> </b></text>
<text top="277" left="523" width="110" height="15" font="4"><b>Acute Outcome</b></text>
<text top="276" left="632" width="4" height="16" font="2"><b> </b></text>
<text top="277" left="801" width="101" height="15" font="4"><b>Late Outcome</b></text>
<text top="276" left="901" width="4" height="16" font="2"><b> </b></text>
<text top="277" left="1276" width="4" height="16" font="0"> </text>
<text top="308" left="291" width="4" height="16" font="2"><b> </b></text>
<text top="307" left="495" width="63" height="15" font="4"><b>Death %</b></text>
<text top="306" left="558" width="4" height="16" font="2"><b> </b></text>
<text top="307" left="590" width="88" height="15" font="4"><b>Q Wave MI </b></text>
<text top="326" left="623" width="17" height="15" font="4"><b>%</b></text>
<text top="325" left="640" width="4" height="16" font="2"><b> </b></text>
<text top="307" left="701" width="63" height="15" font="4"><b>Death %</b></text>
<text top="306" left="764" width="4" height="16" font="2"><b> </b></text>
<text top="307" left="785" width="104" height="15" font="4"><b>Q Wave MI %</b></text>
<text top="306" left="889" width="4" height="16" font="2"><b> </b></text>
<text top="307" left="919" width="72" height="15" font="4"><b>Angina %</b></text>
<text top="306" left="991" width="4" height="16" font="2"><b> </b></text>
<text top="307" left="1072" width="54" height="15" font="4"><b>Repeat </b></text>
<text top="326" left="1024" width="147" height="15" font="4"><b>Revascularization %</b></text>
<text top="325" left="1171" width="4" height="16" font="2"><b> </b></text>
<text top="307" left="1209" width="64" height="15" font="4"><b>Primary </b></text>
<text top="326" left="1206" width="66" height="15" font="4"><b>Endpoint</b></text>
<text top="325" left="1272" width="4" height="16" font="2"><b> </b></text>
<text top="307" left="1334" width="64" height="15" font="4"><b>Primary </b></text>
<text top="326" left="1331" width="66" height="15" font="4"><b>Endpoint</b></text>
<text top="325" left="1397" width="4" height="16" font="2"><b> </b></text>
<text top="307" left="1432" width="83" height="15" font="4"><b>Follow-Up i</b></text>
<text top="326" left="1458" width="41" height="15" font="4"><b>Years</b></text>
<text top="325" left="1499" width="4" height="16" font="2"><b> </b></text>
<text top="346" left="148" width="36" height="15" font="4"><b>Trial</b></text>
<text top="345" left="184" width="4" height="16" font="2"><b> </b></text>
<text top="346" left="235" width="24" height="15" font="4"><b>No.</b></text>
<text top="345" left="259" width="4" height="16" font="2"><b> </b></text>
<text top="346" left="275" width="51" height="15" font="4"><b>Age (y)</b></text>
<text top="345" left="326" width="4" height="16" font="2"><b> </b></text>
<text top="346" left="336" width="51" height="15" font="4"><b>Female</b></text>
<text top="345" left="387" width="4" height="16" font="2"><b> </b></text>
<text top="346" left="414" width="36" height="15" font="4"><b>CAD</b></text>
<text top="345" left="450" width="4" height="16" font="2"><b> </b></text>
<text top="346" left="501" width="52" height="15" font="4"><b>CABG/</b></text>
<text top="345" left="553" width="4" height="16" font="2"><b> </b></text>
<text top="365" left="513" width="29" height="15" font="4"><b>PCI</b></text>
<text top="364" left="541" width="4" height="16" font="2"><b> </b></text>
<text top="346" left="605" width="52" height="15" font="4"><b>CABG/</b></text>
<text top="345" left="658" width="4" height="16" font="2"><b> </b></text>
<text top="365" left="617" width="29" height="15" font="4"><b>PCI</b></text>
<text top="364" left="646" width="4" height="16" font="2"><b> </b></text>
<text top="346" left="707" width="52" height="15" font="4"><b>CABG/</b></text>
<text top="345" left="759" width="4" height="16" font="2"><b> </b></text>
<text top="365" left="719" width="29" height="15" font="4"><b>PCI</b></text>
<text top="364" left="747" width="4" height="16" font="2"><b> </b></text>
<text top="346" left="811" width="52" height="15" font="4"><b>CABG/</b></text>
<text top="345" left="863" width="4" height="16" font="2"><b> </b></text>
<text top="365" left="823" width="29" height="15" font="4"><b>PCI</b></text>
<text top="364" left="852" width="4" height="16" font="2"><b> </b></text>
<text top="346" left="929" width="52" height="15" font="4"><b>CABG/</b></text>
<text top="345" left="982" width="4" height="16" font="2"><b> </b></text>
<text top="365" left="941" width="29" height="15" font="4"><b>PCI</b></text>
<text top="364" left="970" width="4" height="16" font="2"><b> </b></text>
<text top="346" left="1071" width="52" height="15" font="4"><b>CABG/</b></text>
<text top="345" left="1123" width="4" height="16" font="2"><b> </b></text>
<text top="365" left="1083" width="29" height="15" font="4"><b>PCI</b></text>
<text top="364" left="1111" width="4" height="16" font="2"><b> </b></text>
<text top="346" left="1239" width="4" height="16" font="2"><b> </b></text>
<text top="346" left="1338" width="52" height="15" font="4"><b>CABG/</b></text>
<text top="345" left="1390" width="4" height="16" font="2"><b> </b></text>
<text top="365" left="1350" width="29" height="15" font="4"><b>PCI</b></text>
<text top="364" left="1378" width="4" height="16" font="2"><b> </b></text>
<text top="346" left="1479" width="4" height="16" font="2"><b> </b></text>
<text top="385" left="109" width="49" height="15" font="5">BARI (</text>
<text top="385" left="158" width="25" height="15" font="13">114</text>
<text top="385" left="183" width="8" height="15" font="5">, </text>
<text top="385" left="191" width="25" height="15" font="13">144</text>
<text top="385" left="216" width="8" height="15" font="5">, </text>
<text top="404" left="109" width="25" height="15" font="13">145</text>
<text top="404" left="134" width="8" height="15" font="5">, </text>
<text top="404" left="142" width="25" height="15" font="13">146</text>
<text top="404" left="166" width="6" height="15" font="5">)</text>
<text top="403" left="172" width="4" height="16" font="0"> </text>
<text top="385" left="228" width="37" height="15" font="5">1,829</text>
<text top="384" left="265" width="4" height="16" font="0"> </text>
<text top="385" left="292" width="17" height="15" font="5">61</text>
<text top="384" left="309" width="4" height="16" font="0"> </text>
<text top="385" left="346" width="30" height="15" font="5">26%</text>
<text top="384" left="377" width="4" height="16" font="0"> </text>
<text top="385" left="419" width="27" height="15" font="5">MV</text>
<text top="384" left="446" width="4" height="16" font="0"> </text>
<text top="385" left="504" width="46" height="15" font="5">1.3/1.1</text>
<text top="384" left="550" width="4" height="16" font="0"> </text>
<text top="385" left="608" width="46" height="15" font="5">4.6/2.1</text>
<text top="384" left="654" width="4" height="16" font="0"> </text>
<text top="385" left="708" width="50" height="15" font="5">26.5/29</text>
<text top="384" left="758" width="4" height="16" font="0"> </text>
<text top="385" left="818" width="38" height="15" font="5">36/36</text>
<text top="384" left="856" width="4" height="16" font="0"> </text>
<text top="385" left="929" width="52" height="15" font="5">NA/NA</text>
<text top="384" left="982" width="4" height="16" font="0"> </text>
<text top="385" left="1074" width="46" height="15" font="5">20/77*</text>
<text top="384" left="1120" width="4" height="16" font="0"> </text>
<text top="385" left="1233" width="12" height="15" font="5">D</text>
<text top="384" left="1245" width="4" height="16" font="0"> </text>
<text top="385" left="1339" width="50" height="15" font="5">26.5/29</text>
<text top="384" left="1389" width="4" height="16" font="0"> </text>
<text top="385" left="1470" width="17" height="15" font="5">10</text>
<text top="384" left="1487" width="4" height="16" font="0"> </text>
<text top="424" left="109" width="51" height="15" font="5">EAST (</text>
<text top="424" left="160" width="25" height="15" font="13">147</text>
<text top="424" left="184" width="8" height="15" font="5">, </text>
<text top="443" left="109" width="25" height="15" font="13">148</text>
<text top="443" left="134" width="6" height="15" font="5">)</text>
<text top="442" left="139" width="4" height="16" font="0"> </text>
<text top="424" left="234" width="25" height="15" font="5">392</text>
<text top="423" left="259" width="4" height="16" font="0"> </text>
<text top="424" left="292" width="17" height="15" font="5">61</text>
<text top="423" left="309" width="4" height="16" font="0"> </text>
<text top="424" left="346" width="30" height="15" font="5">26%</text>
<text top="423" left="377" width="4" height="16" font="0"> </text>
<text top="424" left="419" width="27" height="15" font="5">MV</text>
<text top="423" left="446" width="4" height="16" font="0"> </text>
<text top="424" left="504" width="46" height="15" font="5">1.0/1.0</text>
<text top="423" left="550" width="4" height="16" font="0"> </text>
<text top="424" left="600" width="62" height="15" font="5">10.3/3.0*</text>
<text top="423" left="663" width="4" height="16" font="0"> </text>
<text top="424" left="714" width="38" height="15" font="5">17/21</text>
<text top="423" left="751" width="4" height="16" font="0"> </text>
<text top="424" left="806" width="62" height="15" font="5">19.6/16.6</text>
<text top="423" left="868" width="4" height="16" font="0"> </text>
<text top="424" left="932" width="46" height="15" font="5">12/20*</text>
<text top="423" left="978" width="4" height="16" font="0"> </text>
<text top="424" left="1074" width="46" height="15" font="5">27/65*</text>
<text top="423" left="1120" width="4" height="16" font="0"> </text>
<text top="424" left="1209" width="61" height="15" font="5">D+MI+T</text>
<text top="423" left="1269" width="4" height="16" font="0"> </text>
<text top="424" left="1333" width="62" height="15" font="5">27.3/28.8</text>
<text top="423" left="1395" width="4" height="16" font="0"> </text>
<text top="424" left="1472" width="8" height="15" font="5">8</text>
<text top="420" left="1480" width="5" height="9" font="19">a</text>
<text top="418" left="1485" width="3" height="11" font="20"> </text>
<text top="469" left="109" width="44" height="15" font="5">GABI </text>
<text top="469" left="153" width="36" height="15" font="13">(149)</text>
<text top="468" left="189" width="4" height="16" font="0"> </text>
<text top="462" left="234" width="25" height="15" font="5">359</text>
<text top="461" left="259" width="4" height="16" font="0"> </text>
<text top="462" left="289" width="24" height="15" font="5">NA</text>
<text top="461" left="312" width="4" height="16" font="0"> </text>
<text top="462" left="346" width="30" height="15" font="5">20%</text>
<text top="461" left="377" width="4" height="16" font="0"> </text>
<text top="462" left="419" width="27" height="15" font="5">MV</text>
<text top="461" left="446" width="4" height="16" font="0"> </text>
<text top="462" left="504" width="46" height="15" font="5">2.5/1.1</text>
<text top="461" left="550" width="4" height="16" font="0"> </text>
<text top="462" left="611" width="42" height="15" font="5">8/2.3*</text>
<text top="461" left="652" width="4" height="16" font="0"> </text>
<text top="462" left="714" width="38" height="15" font="5">22/25</text>
<text top="461" left="751" width="4" height="16" font="0"> </text>
<text top="462" left="814" width="46" height="15" font="5">9.4/4.5</text>
<text top="461" left="860" width="4" height="16" font="0"> </text>
<text top="462" left="937" width="38" height="15" font="5">26/29</text>
<text top="461" left="974" width="4" height="16" font="0"> </text>
<text top="462" left="1074" width="46" height="15" font="5">59/83*</text>
<text top="461" left="1120" width="4" height="16" font="0"> </text>
<text top="462" left="1233" width="12" height="15" font="5">A</text>
<text top="461" left="1245" width="4" height="16" font="0"> </text>
<text top="462" left="1345" width="38" height="15" font="5">26/29</text>
<text top="461" left="1383" width="4" height="16" font="0"> </text>
<text top="462" left="1468" width="17" height="15" font="5">13</text>
<text top="459" left="1484" width="5" height="9" font="19">b</text>
<text top="457" left="1489" width="3" height="11" font="20"> </text>
<text top="496" left="109" width="102" height="15" font="5">Toulouse et al. </text>
<text top="515" left="109" width="36" height="15" font="13">(150)</text>
<text top="514" left="145" width="4" height="16" font="0"> </text>
<text top="496" left="234" width="25" height="15" font="5">152</text>
<text top="495" left="259" width="4" height="16" font="0"> </text>
<text top="496" left="292" width="17" height="15" font="5">67</text>
<text top="495" left="309" width="4" height="16" font="0"> </text>
<text top="496" left="346" width="30" height="15" font="5">23%</text>
<text top="495" left="377" width="4" height="16" font="0"> </text>
<text top="496" left="419" width="27" height="15" font="5">MV</text>
<text top="495" left="446" width="4" height="16" font="0"> </text>
<text top="496" left="504" width="46" height="15" font="5">1.3/1.3</text>
<text top="495" left="550" width="4" height="16" font="0"> </text>
<text top="496" left="608" width="46" height="15" font="5">6.6/3.9</text>
<text top="495" left="654" width="4" height="16" font="0"> </text>
<text top="496" left="702" width="62" height="15" font="5">10.5/13.2</text>
<text top="495" left="764" width="4" height="16" font="0"> </text>
<text top="496" left="814" width="46" height="15" font="5">1.3/5.3</text>
<text top="495" left="860" width="4" height="16" font="0"> </text>
<text top="496" left="924" width="62" height="15" font="5">5.3/21.1*</text>
<text top="495" left="987" width="4" height="16" font="0"> </text>
<text top="496" left="1078" width="38" height="15" font="5">9/29*</text>
<text top="495" left="1116" width="4" height="16" font="0"> </text>
<text top="496" left="1233" width="12" height="15" font="5">A</text>
<text top="495" left="1245" width="4" height="16" font="0"> </text>
<text top="496" left="1333" width="62" height="15" font="5">5.2/21.1*</text>
<text top="495" left="1395" width="4" height="16" font="0"> </text>
<text top="496" left="1475" width="8" height="15" font="5">5</text>
<text top="495" left="1483" width="4" height="16" font="0"> </text>
<text top="554" left="109" width="52" height="15" font="5">RITA I </text>
<text top="554" left="161" width="22" height="15" font="13">(91</text>
<text top="554" left="183" width="8" height="15" font="5">, </text>
<text top="554" left="191" width="25" height="15" font="13">129</text>
<text top="554" left="216" width="8" height="15" font="5">, </text>
<text top="573" left="109" width="30" height="15" font="13">151)</text>
<text top="572" left="139" width="4" height="16" font="0"> </text>
<text top="535" left="228" width="37" height="15" font="5">1,011</text>
<text top="534" left="265" width="4" height="16" font="0"> </text>
<text top="535" left="292" width="17" height="15" font="5">57</text>
<text top="534" left="309" width="4" height="16" font="0"> </text>
<text top="535" left="346" width="30" height="15" font="5">19%</text>
<text top="534" left="377" width="4" height="16" font="0"> </text>
<text top="535" left="406" width="52" height="15" font="5">SV/MV</text>
<text top="534" left="458" width="4" height="16" font="0"> </text>
<text top="535" left="504" width="46" height="15" font="5">1.2/0.8</text>
<text top="534" left="550" width="4" height="16" font="0"> </text>
<text top="554" left="477" width="104" height="15" font="5">RR: 0.88 (95% </text>
<text top="573" left="491" width="75" height="15" font="5">CI: 0.59 to </text>
<text top="592" left="510" width="34" height="15" font="5">1.29)</text>
<text top="591" left="544" width="4" height="16" font="0"> </text>
<text top="535" left="608" width="46" height="15" font="5">2.4/3.5</text>
<text top="534" left="654" width="4" height="16" font="0"> </text>
<text top="535" left="710" width="46" height="15" font="5">9.0/7.7</text>
<text top="534" left="756" width="4" height="16" font="0"> </text>
<text top="535" left="810" width="54" height="15" font="5">7.4/10.8</text>
<text top="534" left="864" width="4" height="16" font="0"> </text>
<text top="535" left="932" width="46" height="15" font="5">52/78*</text>
<text top="534" left="978" width="4" height="16" font="0"> </text>
<text top="535" left="1074" width="46" height="15" font="5">11/44*</text>
<text top="534" left="1120" width="4" height="16" font="0"> </text>
<text top="535" left="1209" width="61" height="15" font="5">D+MI+T</text>
<text top="534" left="1269" width="4" height="16" font="0"> </text>
<text top="535" left="1341" width="46" height="15" font="5">8.6/9.8</text>
<text top="534" left="1387" width="4" height="16" font="0"> </text>
<text top="535" left="1475" width="8" height="15" font="5">5</text>
<text top="534" left="1483" width="4" height="16" font="0"> </text>
<text top="612" left="109" width="59" height="15" font="5">ERACI (</text>
<text top="612" left="168" width="25" height="15" font="13">152</text>
<text top="612" left="193" width="8" height="15" font="5">, </text>
<text top="631" left="109" width="30" height="15" font="13">153)</text>
<text top="630" left="139" width="4" height="16" font="0"> </text>
<text top="612" left="234" width="25" height="15" font="5">127</text>
<text top="611" left="259" width="4" height="16" font="0"> </text>
<text top="612" left="292" width="17" height="15" font="5">58</text>
<text top="611" left="309" width="4" height="16" font="0"> </text>
<text top="612" left="346" width="30" height="15" font="5">13%</text>
<text top="611" left="377" width="4" height="16" font="0"> </text>
<text top="612" left="419" width="27" height="15" font="5">MV</text>
<text top="611" left="446" width="4" height="16" font="0"> </text>
<text top="612" left="504" width="46" height="15" font="5">4.6/1.5</text>
<text top="611" left="550" width="4" height="16" font="0"> </text>
<text top="612" left="608" width="46" height="15" font="5">6.2/6.3</text>
<text top="611" left="654" width="4" height="16" font="0"> </text>
<text top="612" left="710" width="46" height="15" font="5">4.7/9.5</text>
<text top="611" left="756" width="4" height="16" font="0"> </text>
<text top="612" left="814" width="46" height="15" font="5">7.8/7.8</text>
<text top="611" left="860" width="4" height="16" font="0"> </text>
<text top="612" left="932" width="46" height="15" font="5">3.2/4.8</text>
<text top="611" left="978" width="4" height="16" font="0"> </text>
<text top="612" left="1078" width="38" height="15" font="5">6/37*</text>
<text top="611" left="1116" width="4" height="16" font="0"> </text>
<text top="612" left="1179" width="119" height="15" font="5">D+MI+A+Revasc</text>
<text top="611" left="1299" width="4" height="16" font="0"> </text>
<text top="612" left="1341" width="46" height="15" font="5">23/53*</text>
<text top="611" left="1387" width="4" height="16" font="0"> </text>
<text top="612" left="1475" width="8" height="15" font="5">3</text>
<text top="611" left="1483" width="4" height="16" font="0"> </text>
<text top="656" left="109" width="49" height="15" font="5">MASS </text>
<text top="656" left="158" width="35" height="15" font="13">(109,</text>
<text top="656" left="192" width="4" height="15" font="5"> </text>
<text top="675" left="109" width="30" height="15" font="13">154)</text>
<text top="674" left="139" width="4" height="16" font="0"> </text>
<text top="650" left="234" width="25" height="15" font="5">142</text>
<text top="649" left="259" width="4" height="16" font="0"> </text>
<text top="650" left="292" width="17" height="15" font="5">56</text>
<text top="649" left="309" width="4" height="16" font="0"> </text>
<text top="650" left="346" width="30" height="15" font="5">42%</text>
<text top="649" left="377" width="4" height="16" font="0"> </text>
<text top="650" left="397" width="70" height="15" font="5">SV (LAD)</text>
<text top="649" left="467" width="4" height="16" font="0"> </text>
<text top="650" left="504" width="46" height="15" font="5">1.4/1.4</text>
<text top="649" left="550" width="4" height="16" font="0"> </text>
<text top="650" left="615" width="34" height="15" font="5">1.4/0</text>
<text top="649" left="648" width="4" height="16" font="0"> </text>
<text top="650" left="710" width="46" height="15" font="5">2.9/5.7</text>
<text top="649" left="756" width="4" height="16" font="0"> </text>
<text top="650" left="823" width="30" height="15" font="5">7/11</text>
<text top="649" left="852" width="4" height="16" font="0"> </text>
<text top="650" left="937" width="38" height="15" font="5">23/25</text>
<text top="649" left="974" width="4" height="16" font="0"> </text>
<text top="650" left="1078" width="38" height="15" font="5">0/30*</text>
<text top="649" left="1116" width="4" height="16" font="0"> </text>
<text top="650" left="1190" width="98" height="15" font="5">D+MI+Revasc</text>
<text top="649" left="1288" width="4" height="16" font="0"> </text>
<text top="650" left="1345" width="38" height="15" font="5">3/24*</text>
<text top="649" left="1383" width="4" height="16" font="0"> </text>
<text top="650" left="1475" width="8" height="15" font="5">3</text>
<text top="649" left="1483" width="4" height="16" font="0"> </text>
<text top="729" left="109" width="74" height="15" font="5">Goy et al. (</text>
<text top="729" left="183" width="25" height="15" font="13">104</text>
<text top="729" left="208" width="6" height="15" font="5">)</text>
<text top="728" left="213" width="4" height="16" font="0"> </text>
<text top="701" left="234" width="25" height="15" font="5">134</text>
<text top="700" left="259" width="4" height="16" font="0"> </text>
<text top="701" left="292" width="17" height="15" font="5">56</text>
<text top="700" left="309" width="4" height="16" font="0"> </text>
<text top="701" left="346" width="30" height="15" font="5">20%</text>
<text top="700" left="377" width="4" height="16" font="0"> </text>
<text top="701" left="397" width="70" height="15" font="5">SV (LAD)</text>
<text top="700" left="467" width="4" height="16" font="0"> </text>
<text top="701" left="516" width="21" height="15" font="5">0/0</text>
<text top="700" left="537" width="4" height="16" font="0"> </text>
<text top="701" left="621" width="21" height="15" font="5">0/0</text>
<text top="700" left="642" width="4" height="16" font="0"> </text>
<text top="701" left="722" width="21" height="15" font="5">2/9</text>
<text top="700" left="743" width="4" height="16" font="0"> </text>
<text top="701" left="818" width="38" height="15" font="5">4/15*</text>
<text top="700" left="856" width="4" height="16" font="0"> </text>
<text top="720" left="792" width="96" height="15" font="5">RR: 2.6 (95% </text>
<text top="739" left="791" width="96" height="15" font="5">CI: 1.1 to 5.4; </text>
<text top="758" left="797" width="77" height="15" font="5">p=0.00004)</text>
<text top="755" left="874" width="5" height="9" font="19">c</text>
<text top="757" left="878" width="4" height="16" font="0"> </text>
<text top="701" left="937" width="38" height="15" font="5">29/26</text>
<text top="700" left="974" width="4" height="16" font="0"> </text>
<text top="701" left="1078" width="38" height="15" font="5">9/38*</text>
<text top="700" left="1116" width="4" height="16" font="0"> </text>
<text top="701" left="1190" width="98" height="15" font="5">D+MI+Revasc</text>
<text top="700" left="1288" width="4" height="16" font="0"> </text>
<text top="701" left="1333" width="62" height="15" font="5">7.6/36.8*</text>
<text top="700" left="1395" width="4" height="16" font="0"> </text>
<text top="701" left="1475" width="8" height="15" font="5">5</text>
<text top="700" left="1483" width="4" height="16" font="0"> </text>
</page>
<page number="22" position="absolute" top="0" left="0" height="918" width="1512">
	<fontspec id="21" size="6" family="Times" color="#000000"/>
<text top="59" left="108" width="4" height="15" font="0"> </text>
<text top="59" left="459" width="4" height="15" font="0"> </text>
<text top="59" left="810" width="4" height="15" font="0"> </text>
<text top="59" left="864" width="4" height="15" font="0"> </text>
<text top="59" left="918" width="4" height="15" font="0"> </text>
<text top="59" left="972" width="4" height="15" font="0"> </text>
<text top="59" left="1026" width="4" height="15" font="0"> </text>
<text top="59" left="1080" width="4" height="15" font="0"> </text>
<text top="59" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="108" width="613" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="825" left="810" width="4" height="15" font="0"> </text>
<text top="825" left="864" width="4" height="15" font="0"> </text>
<text top="825" left="918" width="4" height="15" font="0"> </text>
<text top="825" left="972" width="4" height="15" font="0"> </text>
<text top="825" left="1026" width="4" height="15" font="0"> </text>
<text top="825" left="1080" width="4" height="15" font="0"> </text>
<text top="825" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="1188" width="4" height="15" font="0"> </text>
<text top="825" left="1242" width="22" height="15" font="0">22 </text>
<text top="847" left="108" width="4" height="15" font="0"> </text>
<text top="142" left="109" width="60" height="15" font="5">CABRI (</text>
<text top="142" left="169" width="29" height="15" font="13">155,</text>
<text top="142" left="198" width="4" height="15" font="5"> </text>
<text top="161" left="109" width="25" height="15" font="13">156</text>
<text top="161" left="134" width="6" height="15" font="5">)</text>
<text top="160" left="139" width="4" height="16" font="0"> </text>
<text top="112" left="228" width="37" height="15" font="5">1,054</text>
<text top="111" left="265" width="4" height="16" font="0"> </text>
<text top="112" left="292" width="17" height="15" font="5">60</text>
<text top="111" left="309" width="4" height="16" font="0"> </text>
<text top="112" left="346" width="30" height="15" font="5">22%</text>
<text top="111" left="377" width="4" height="16" font="0"> </text>
<text top="112" left="419" width="27" height="15" font="5">MV</text>
<text top="111" left="446" width="4" height="16" font="0"> </text>
<text top="112" left="504" width="46" height="15" font="5">1.3/1.3</text>
<text top="111" left="550" width="4" height="16" font="0"> </text>
<text top="112" left="601" width="62" height="15" font="5">N/A/N/A</text>
<text top="111" left="662" width="4" height="16" font="0"> </text>
<text top="112" left="710" width="46" height="15" font="5">2.7/3.9</text>
<text top="111" left="756" width="4" height="16" font="0"> </text>
<text top="131" left="683" width="104" height="15" font="5">RR: 1.42 (95% </text>
<text top="150" left="693" width="84" height="15" font="5">CI: 0.731 to </text>
<text top="169" left="684" width="98" height="15" font="5">2.76; p=0.297)</text>
<text top="168" left="782" width="4" height="16" font="0"> </text>
<text top="112" left="814" width="46" height="15" font="5">3.5/4.9</text>
<text top="111" left="860" width="4" height="16" font="0"> </text>
<text top="131" left="787" width="104" height="15" font="5">RR: 1.42 (95% </text>
<text top="150" left="802" width="75" height="15" font="5">CI: 0.80 to </text>
<text top="169" left="788" width="98" height="15" font="5">2.54; p=0.234)</text>
<text top="168" left="886" width="4" height="16" font="0"> </text>
<text top="112" left="920" width="71" height="15" font="5">10.1/13.9*</text>
<text top="111" left="991" width="4" height="16" font="0"> </text>
<text top="131" left="893" width="129" height="15" font="5">RR: 1.54 (95% CI: </text>
<text top="150" left="914" width="88" height="15" font="5">1.09 to 2.16; </text>
<text top="169" left="925" width="60" height="15" font="5">p=0.012)</text>
<text top="168" left="985" width="4" height="16" font="0"> </text>
<text top="188" left="955" width="4" height="16" font="0"> </text>
<text top="112" left="1078" width="38" height="15" font="5">9/36*</text>
<text top="111" left="1116" width="4" height="16" font="0"> </text>
<text top="131" left="1035" width="129" height="15" font="5">RR: 5.23 (95% CI: </text>
<text top="150" left="1023" width="148" height="15" font="5">3.90 to 7.03; p&lt;0.001)</text>
<text top="149" left="1171" width="4" height="16" font="0"> </text>
<text top="112" left="1233" width="12" height="15" font="5">D</text>
<text top="111" left="1245" width="4" height="16" font="0"> </text>
<text top="112" left="1341" width="46" height="15" font="5">2.7/3.9</text>
<text top="111" left="1387" width="4" height="16" font="0"> </text>
<text top="112" left="1475" width="8" height="15" font="5">1</text>
<text top="111" left="1483" width="4" height="16" font="0"> </text>
<text top="209" left="108" width="138" height="12" font="17">*Statistically significant; </text>
<text top="206" left="246" width="4" height="8" font="21">a</text>
<text top="209" left="250" width="370" height="12" font="17">Mortality and repeat revascularization at 8 y, other endpoints at 3 y; </text>
<text top="206" left="620" width="4" height="8" font="21">b</text>
<text top="209" left="624" width="377" height="12" font="17">Mortality and repeat revascularization at 13 y, other endpoints at 1 y; </text>
<text top="206" left="1001" width="6" height="8" font="21">c </text>
<text top="209" left="1008" width="323" height="12" font="17">Relative risk for combined endpoint cardiac death and MI.  </text>
<text top="225" left="108" width="3" height="12" font="17"> </text>
<text top="240" left="108" width="1257" height="12" font="17">A indicates angina; BARI, Bypass Angioplasty Revascularization Investigation; CAD, coronary artery disease; CABG, coronary artery bypass graft; CABRI, Coronary Angioplasty versus Bypass Revascularization Investigation; CI, </text>
<text top="256" left="108" width="1275" height="12" font="17">confidence interval; D, death; EAST, Emory Angioplasty versus Surgery Trial; ERACI, Argentine Randomized Trial of Percutaneous Transluminal Coronary Angioplasty versus Coronary Artery Bypass Surgery in Multivessel Disease; </text>
<text top="271" left="108" width="1289" height="12" font="17">GABI, German Angioplasty Bypass Surgery Investigation; LAD, left anterior descending; MASS, Medicine, Angioplasty, or Surgery Study; MI, myocardial infarction; MV, multivessel; NA, not available; No., number; PCI, percutaneous </text>
<text top="287" left="108" width="927" height="12" font="17">coronary intervention; RITA, Randomized Intervention Treatment of Angina; Revasc, repeat revascularization; RR, relative risk; SV, single-vessel; and T, thallium defect. </text>
<text top="303" left="108" width="4" height="15" font="5"> </text>
<text top="322" left="108" width="4" height="15" font="5"> </text>
<text top="341" left="108" width="4" height="16" font="2"><b> </b></text>
<text top="362" left="108" width="382" height="16" font="2"><b>Data Supplement 6. RCTs of CABG Versus BMS<i> </i></b></text>
<text top="383" left="162" width="4" height="16" font="2"><b> </b></text>
<text top="383" left="248" width="4" height="16" font="2"><b> </b></text>
<text top="383" left="308" width="4" height="16" font="2"><b> </b></text>
<text top="383" left="372" width="4" height="16" font="2"><b> </b></text>
<text top="383" left="440" width="4" height="16" font="2"><b> </b></text>
<text top="383" left="522" width="4" height="16" font="2"><b> </b></text>
<text top="383" left="595" width="63" height="15" font="4"><b>Death %</b></text>
<text top="382" left="658" width="4" height="16" font="2"><b> </b></text>
<text top="383" left="690" width="88" height="15" font="4"><b>Q Wave MI </b></text>
<text top="402" left="724" width="17" height="15" font="4"><b>%</b></text>
<text top="401" left="740" width="4" height="16" font="2"><b> </b></text>
<text top="383" left="789" width="56" height="15" font="4"><b>Angina </b></text>
<text top="402" left="807" width="17" height="15" font="4"><b>%</b></text>
<text top="401" left="823" width="4" height="16" font="2"><b> </b></text>
<text top="383" left="908" width="54" height="15" font="4"><b>Repeat </b></text>
<text top="402" left="859" width="147" height="15" font="4"><b>Revascularization %</b></text>
<text top="401" left="1007" width="4" height="16" font="2"><b> </b></text>
<text top="383" left="1043" width="64" height="15" font="4"><b>Primary </b></text>
<text top="402" left="1040" width="66" height="15" font="4"><b>Endpoint</b></text>
<text top="401" left="1106" width="4" height="16" font="2"><b> </b></text>
<text top="383" left="1131" width="151" height="15" font="4"><b>Primary Endpoint %</b></text>
<text top="382" left="1281" width="4" height="16" font="2"><b> </b></text>
<text top="383" left="1297" width="96" height="15" font="4"><b>Follow-Up in </b></text>
<text top="402" left="1323" width="41" height="15" font="4"><b>Years</b></text>
<text top="401" left="1364" width="4" height="16" font="2"><b> </b></text>
<text top="423" left="144" width="36" height="15" font="4"><b>Trial</b></text>
<text top="422" left="180" width="4" height="16" font="2"><b> </b></text>
<text top="423" left="236" width="24" height="15" font="4"><b>No.</b></text>
<text top="422" left="260" width="4" height="16" font="2"><b> </b></text>
<text top="423" left="282" width="51" height="15" font="4"><b>Age (y)</b></text>
<text top="422" left="333" width="4" height="16" font="2"><b> </b></text>
<text top="423" left="346" width="51" height="15" font="4"><b>Female</b></text>
<text top="422" left="397" width="4" height="16" font="2"><b> </b></text>
<text top="423" left="422" width="36" height="15" font="4"><b>CAD</b></text>
<text top="422" left="458" width="4" height="16" font="2"><b> </b></text>
<text top="423" left="481" width="85" height="15" font="4"><b>Enrollment </b></text>
<text top="442" left="498" width="47" height="15" font="4"><b>Period</b></text>
<text top="441" left="545" width="4" height="16" font="2"><b> </b></text>
<text top="423" left="601" width="52" height="15" font="4"><b>CABG/</b></text>
<text top="422" left="653" width="4" height="16" font="2"><b> </b></text>
<text top="442" left="613" width="29" height="15" font="4"><b>PCI</b></text>
<text top="441" left="641" width="4" height="16" font="2"><b> </b></text>
<text top="423" left="706" width="52" height="15" font="4"><b>CABG/</b></text>
<text top="422" left="758" width="4" height="16" font="2"><b> </b></text>
<text top="442" left="718" width="29" height="15" font="4"><b>PCI</b></text>
<text top="441" left="746" width="4" height="16" font="2"><b> </b></text>
<text top="423" left="789" width="52" height="15" font="4"><b>CABG/</b></text>
<text top="422" left="841" width="4" height="16" font="2"><b> </b></text>
<text top="442" left="801" width="29" height="15" font="4"><b>PCI</b></text>
<text top="441" left="829" width="4" height="16" font="2"><b> </b></text>
<text top="423" left="893" width="81" height="15" font="4"><b>CABG/PCI</b></text>
<text top="422" left="973" width="4" height="16" font="2"><b> </b></text>
<text top="423" left="1073" width="4" height="16" font="2"><b> </b></text>
<text top="423" left="1180" width="52" height="15" font="4"><b>CABG/</b></text>
<text top="422" left="1232" width="4" height="16" font="2"><b> </b></text>
<text top="442" left="1192" width="29" height="15" font="4"><b>PCI</b></text>
<text top="441" left="1220" width="4" height="16" font="2"><b> </b></text>
<text top="423" left="1343" width="4" height="16" font="2"><b> </b></text>
<text top="471" left="108" width="41" height="14" font="7">SIMA </text>
<text top="471" left="149" width="33" height="14" font="8">(157)</text>
<text top="471" left="182" width="4" height="14" font="7"> </text>
<text top="462" left="237" width="26" height="14" font="7">121 </text>
<text top="462" left="300" width="19" height="14" font="7">59 </text>
<text top="462" left="358" width="31" height="14" font="7">21% </text>
<text top="462" left="430" width="23" height="14" font="7">SV </text>
<text top="462" left="489" width="69" height="14" font="7">1994-1998 </text>
<text top="462" left="617" width="23" height="14" font="7">4/2 </text>
<text top="462" left="723" width="23" height="14" font="7">4/5 </text>
<text top="462" left="806" width="23" height="14" font="7">5/9 </text>
<text top="462" left="920" width="30" height="14" font="7">8/24 </text>
<text top="462" left="1038" width="74" height="14" font="7">D+MI+Rep </text>
<text top="479" left="1052" width="47" height="14" font="7">Revasc </text>
<text top="462" left="1189" width="38" height="14" font="7">7/31* </text>
<text top="462" left="1334" width="22" height="14" font="7">2.4 </text>
<text top="497" left="108" width="79" height="14" font="7">AWESOME </text>
<text top="515" left="108" width="5" height="14" font="7">(</text>
<text top="515" left="113" width="23" height="14" font="8">158</text>
<text top="515" left="136" width="7" height="14" font="7">, </text>
<text top="515" left="143" width="27" height="14" font="8">159)</text>
<text top="515" left="170" width="4" height="14" font="7"> </text>
<text top="497" left="237" width="26" height="14" font="7">454 </text>
<text top="497" left="300" width="19" height="14" font="7">67 </text>
<text top="497" left="361" width="25" height="14" font="7">NA </text>
<text top="497" left="428" width="28" height="14" font="7">MV </text>
<text top="497" left="489" width="69" height="14" font="7">1995-2000 </text>
<text top="497" left="610" width="38" height="14" font="7">21/18 </text>
<text top="497" left="721" width="25" height="14" font="7">NA </text>
<text top="497" left="804" width="25" height="14" font="7">NA </text>
<text top="497" left="912" width="45" height="14" font="7">22/43* </text>
<text top="497" left="1068" width="15" height="14" font="7">D </text>
<text top="497" left="1189" width="38" height="14" font="7">21/20 </text>
<text top="497" left="1340" width="11" height="14" font="7">5 </text>
<text top="558" left="108" width="58" height="14" font="7">MASS II </text>
<text top="558" left="166" width="25" height="14" font="8">(78)</text>
<text top="558" left="191" width="4" height="14" font="7"> </text>
<text top="533" left="237" width="26" height="14" font="7">408 </text>
<text top="533" left="300" width="19" height="14" font="7">60 </text>
<text top="533" left="358" width="31" height="14" font="7">32% </text>
<text top="533" left="428" width="28" height="14" font="7">MV </text>
<text top="533" left="489" width="69" height="14" font="7">1995-2000 </text>
<text top="533" left="610" width="38" height="14" font="7">25/24 </text>
<text top="533" left="715" width="38" height="14" font="7">10/13 </text>
<text top="533" left="804" width="25" height="14" font="7">NA </text>
<text top="533" left="908" width="53" height="14" font="7">7.5/41.9 </text>
<text top="533" left="1038" width="74" height="14" font="7">D+MI+Rep </text>
<text top="550" left="1052" width="47" height="14" font="7">Revasc </text>
<text top="567" left="1028" width="95" height="14" font="7">HR: 1.85 (95% </text>
<text top="584" left="1024" width="103" height="14" font="7">CI: 1.39 to 2.47) </text>
<text top="533" left="1185" width="45" height="14" font="7">33/42* </text>
<text top="533" left="1336" width="19" height="14" font="7">10 </text>
<text top="602" left="108" width="67" height="14" font="7">ERACI II (</text>
<text top="602" left="175" width="26" height="14" font="8">153,</text>
<text top="602" left="202" width="4" height="14" font="7"> </text>
<text top="620" left="108" width="28" height="14" font="8">160)</text>
<text top="620" left="136" width="4" height="14" font="7"> </text>
<text top="602" left="237" width="26" height="14" font="7">450 </text>
<text top="602" left="300" width="19" height="14" font="7">62 </text>
<text top="602" left="358" width="31" height="14" font="7">21% </text>
<text top="602" left="428" width="28" height="14" font="7">MV </text>
<text top="602" left="489" width="69" height="14" font="7">1996-1998 </text>
<text top="602" left="602" width="53" height="14" font="7">11.6/7.2 </text>
<text top="602" left="711" width="45" height="14" font="7">6.2/2.8 </text>
<text top="602" left="798" width="38" height="14" font="7">18/14 </text>
<text top="602" left="905" width="60" height="14" font="7">7.2/28.4* </text>
<text top="602" left="1018" width="114" height="14" font="7">D+MI+CVA+Rep </text>
<text top="620" left="1052" width="47" height="14" font="7">Revasc </text>
<text top="602" left="1174" width="68" height="14" font="7">23.6/34.7* </text>
<text top="602" left="1340" width="11" height="14" font="7">5 </text>
<text top="663" left="108" width="28" height="14" font="7">SoS </text>
<text top="663" left="136" width="33" height="14" font="8">(161)</text>
<text top="663" left="168" width="4" height="14" font="7"> </text>
<text top="638" left="237" width="26" height="14" font="7">988 </text>
<text top="638" left="300" width="19" height="14" font="7">61 </text>
<text top="638" left="358" width="31" height="14" font="7">21% </text>
<text top="638" left="428" width="28" height="14" font="7">MV </text>
<text top="638" left="489" width="69" height="14" font="7">1996-1999 </text>
<text top="638" left="598" width="60" height="14" font="7">6.8/10.9* </text>
<text top="655" left="581" width="95" height="14" font="7">HR: 2.91 (95% </text>
<text top="672" left="577" width="103" height="14" font="7">CI: 1.29 to 6.53; </text>
<text top="689" left="603" width="51" height="14" font="7">p=0.01) </text>
<text top="638" left="711" width="45" height="14" font="7">8.2/4.9 </text>
<text top="638" left="804" width="25" height="14" font="7">NA </text>
<text top="638" left="916" width="38" height="14" font="7">6/21* </text>
<text top="655" left="853" width="163" height="14" font="7">HR: 3.85 (95% CI: 2.56 to </text>
<text top="672" left="885" width="100" height="14" font="7">5.79; p&lt;0.0001) </text>
<text top="638" left="1038" width="75" height="14" font="7">Rep Revasc </text>
<text top="638" left="1189" width="38" height="14" font="7">6/21* </text>
<text top="638" left="1340" width="11" height="14" font="7">6 </text>
<text top="733" left="108" width="60" height="14" font="7">ARTS I  (</text>
<text top="733" left="168" width="27" height="14" font="8">162)</text>
<text top="733" left="195" width="4" height="14" font="7"> </text>
<text top="707" left="233" width="34" height="14" font="7">1205 </text>
<text top="707" left="300" width="19" height="14" font="7">61 </text>
<text top="707" left="358" width="31" height="14" font="7">24% </text>
<text top="707" left="428" width="28" height="14" font="7">MV </text>
<text top="707" left="489" width="69" height="14" font="7">1997-1998 </text>
<text top="707" left="606" width="45" height="14" font="7">7.6/8.0 </text>
<text top="724" left="582" width="94" height="14" font="7">RR: 1.05 (95% </text>
<text top="742" left="577" width="103" height="14" font="7">CI: 0.71 to 1.55; </text>
<text top="759" left="603" width="51" height="14" font="7">p=0.83) </text>
<text top="707" left="711" width="45" height="14" font="7">5.6/6.7 </text>
<text top="724" left="687" width="94" height="14" font="7">RR: 1.19 (95% </text>
<text top="742" left="683" width="103" height="14" font="7">CI: 0.76 to 1.85; </text>
<text top="759" left="708" width="51" height="14" font="7">p=0.47) </text>
<text top="707" left="804" width="25" height="14" font="7">NA </text>
<text top="707" left="905" width="60" height="14" font="7">8.8/30.3* </text>
<text top="724" left="854" width="163" height="14" font="7">RR: 3.46 (95% CI: 2.61 to </text>
<text top="742" left="889" width="93" height="14" font="7">4.60; p&lt;0.001) </text>
<text top="707" left="1018" width="114" height="14" font="7">D+MI+CVA+Rep </text>
<text top="724" left="1052" width="47" height="14" font="7">Revasc </text>
<text top="707" left="1174" width="68" height="14" font="7">21.8/41.7* </text>
<text top="724" left="1134" width="147" height="14" font="7">RR: 1.91 (95% CI: 1.60 </text>
<text top="742" left="1154" width="108" height="14" font="7">to 2.28; p&lt;0.001) </text>
<text top="707" left="1340" width="11" height="14" font="7">5 </text>
<text top="777" left="108" width="78" height="14" font="7">Drenth et al. </text>
<text top="794" left="108" width="5" height="14" font="7">(</text>
<text top="794" left="113" width="23" height="14" font="8">102</text>
<text top="794" left="136" width="7" height="14" font="7">, </text>
<text top="794" left="143" width="27" height="14" font="8">137)</text>
<text top="794" left="170" width="4" height="14" font="7"> </text>
<text top="777" left="237" width="26" height="14" font="7">102 </text>
<text top="777" left="300" width="19" height="14" font="7">61 </text>
<text top="777" left="358" width="31" height="14" font="7">24% </text>
<text top="777" left="430" width="23" height="14" font="7">SV </text>
<text top="777" left="489" width="69" height="14" font="7">1997-1999 </text>
<text top="777" left="617" width="23" height="14" font="7">2/0 </text>
<text top="777" left="719" width="30" height="14" font="7">2/10 </text>
<text top="777" left="798" width="38" height="14" font="7">15/33 </text>
<text top="777" left="920" width="30" height="14" font="7">4/16 </text>
<text top="777" left="1018" width="114" height="14" font="7">D+MI+CVA+Rep </text>
<text top="794" left="1052" width="47" height="14" font="7">Revasc </text>
<text top="777" left="1189" width="38" height="14" font="7">14/29 </text>
<text top="777" left="1340" width="11" height="14" font="7">4 </text>
</page>
<page number="23" position="absolute" top="0" left="0" height="918" width="1512">
<text top="59" left="108" width="4" height="15" font="0"> </text>
<text top="59" left="459" width="4" height="15" font="0"> </text>
<text top="59" left="810" width="4" height="15" font="0"> </text>
<text top="59" left="864" width="4" height="15" font="0"> </text>
<text top="59" left="918" width="4" height="15" font="0"> </text>
<text top="59" left="972" width="4" height="15" font="0"> </text>
<text top="59" left="1026" width="4" height="15" font="0"> </text>
<text top="59" left="1080" width="4" height="15" font="0"> </text>
<text top="59" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="108" width="613" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="825" left="810" width="4" height="15" font="0"> </text>
<text top="825" left="864" width="4" height="15" font="0"> </text>
<text top="825" left="918" width="4" height="15" font="0"> </text>
<text top="825" left="972" width="4" height="15" font="0"> </text>
<text top="825" left="1026" width="4" height="15" font="0"> </text>
<text top="825" left="1080" width="4" height="15" font="0"> </text>
<text top="825" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="1188" width="4" height="15" font="0"> </text>
<text top="825" left="1242" width="22" height="15" font="0">23 </text>
<text top="847" left="108" width="4" height="15" font="0"> </text>
<text top="129" left="108" width="54" height="14" font="7">Leipzig (</text>
<text top="129" left="163" width="23" height="14" font="8">101</text>
<text top="129" left="185" width="8" height="14" font="7">, </text>
<text top="147" left="108" width="28" height="14" font="8">163)</text>
<text top="147" left="136" width="4" height="14" font="7"> </text>
<text top="112" left="237" width="26" height="14" font="7">220 </text>
<text top="112" left="300" width="19" height="14" font="7">62 </text>
<text top="112" left="358" width="31" height="14" font="7">25% </text>
<text top="112" left="430" width="23" height="14" font="7">SV </text>
<text top="112" left="489" width="69" height="14" font="7">1997-2001 </text>
<text top="112" left="610" width="38" height="14" font="7">12/10 </text>
<text top="129" left="582" width="94" height="14" font="7">RR: 0.85 (95% </text>
<text top="147" left="577" width="103" height="14" font="7">CI: 0.37 to 1.93; </text>
<text top="164" left="603" width="51" height="14" font="7">p=0.54) </text>
<text top="112" left="723" width="23" height="14" font="7">7/5 </text>
<text top="129" left="687" width="94" height="14" font="7">RR: 0.71 (95% </text>
<text top="147" left="683" width="103" height="14" font="7">CI: 0.20 to 2.43; </text>
<text top="164" left="708" width="51" height="14" font="7">p=0.46) </text>
<text top="112" left="804" width="25" height="14" font="7">NA </text>
<text top="112" left="912" width="45" height="14" font="7">10/32* </text>
<text top="129" left="854" width="163" height="14" font="7">RR: 3.18 (95% CI: 1.67 to </text>
<text top="147" left="889" width="93" height="14" font="7">6.39; p&lt;0.001) </text>
<text top="164" left="933" width="4" height="14" font="7"> </text>
<text top="112" left="1038" width="74" height="14" font="7">D+MI+Rep </text>
<text top="129" left="1052" width="47" height="14" font="7">Revasc </text>
<text top="112" left="1185" width="45" height="14" font="7">29/47* </text>
<text top="129" left="1134" width="147" height="14" font="7">RR: 1.64 (95% CI: 1.13 </text>
<text top="147" left="1157" width="101" height="14" font="7">to 2.42; p=0.02) </text>
<text top="112" left="1340" width="11" height="14" font="7">5 </text>
<text top="190" left="108" width="74" height="14" font="7">Myoprotect </text>
<text top="190" left="182" width="33" height="14" font="8">(164)</text>
<text top="190" left="214" width="4" height="14" font="7"> </text>
<text top="182" left="241" width="19" height="14" font="7">44 </text>
<text top="182" left="300" width="19" height="14" font="7">70 </text>
<text top="182" left="358" width="31" height="14" font="7">30% </text>
<text top="182" left="428" width="28" height="14" font="7">MV </text>
<text top="182" left="489" width="69" height="14" font="7">1998-2001 </text>
<text top="182" left="610" width="38" height="14" font="7">24/22 </text>
<text top="182" left="723" width="23" height="14" font="7">0/4 </text>
<text top="182" left="804" width="25" height="14" font="7">NA </text>
<text top="182" left="920" width="30" height="14" font="7">5/30 </text>
<text top="182" left="1038" width="74" height="14" font="7">D+MI+Rep </text>
<text top="199" left="1052" width="47" height="14" font="7">Revasc </text>
<text top="182" left="1185" width="45" height="14" font="7">29/48* </text>
<text top="182" left="1340" width="11" height="14" font="7">1 </text>
<text top="234" left="108" width="61" height="14" font="7">Octostent </text>
<text top="234" left="169" width="33" height="14" font="8">(165)</text>
<text top="234" left="202" width="4" height="14" font="7"> </text>
<text top="217" left="237" width="26" height="14" font="7">280 </text>
<text top="217" left="300" width="19" height="14" font="7">60 </text>
<text top="217" left="358" width="31" height="14" font="7">29% </text>
<text top="217" left="428" width="28" height="14" font="7">MV </text>
<text top="217" left="489" width="69" height="14" font="7">1998-2000 </text>
<text top="217" left="612" width="34" height="14" font="7">2.8/0 </text>
<text top="217" left="711" width="45" height="14" font="7">4.9/4.4 </text>
<text top="217" left="798" width="38" height="14" font="7">13/22 </text>
<text top="217" left="908" width="53" height="14" font="7">4.2/15.2 </text>
<text top="217" left="1018" width="114" height="14" font="7">D+MI+CVA+Rep </text>
<text top="234" left="1052" width="47" height="14" font="7">Revasc </text>
<text top="217" left="1181" width="53" height="14" font="7">9.5/14.5 </text>
<text top="234" left="1134" width="147" height="14" font="7">RR: 0.93 (95% CI: 0.86 </text>
<text top="251" left="1182" width="50" height="14" font="7">to 1.02) </text>
<text top="217" left="1340" width="11" height="14" font="7">1 </text>
<text top="278" left="108" width="55" height="14" font="7">AMIST (</text>
<text top="278" left="163" width="28" height="14" font="8">166)</text>
<text top="278" left="191" width="4" height="14" font="7"> </text>
<text top="269" left="237" width="26" height="14" font="7">100 </text>
<text top="269" left="300" width="19" height="14" font="7">57 </text>
<text top="269" left="358" width="31" height="14" font="7">22% </text>
<text top="269" left="430" width="23" height="14" font="7">SV </text>
<text top="269" left="489" width="69" height="14" font="7">1999-2001 </text>
<text top="269" left="610" width="38" height="14" font="7">25/30 </text>
<text top="269" left="723" width="23" height="14" font="7">0/4 </text>
<text top="269" left="802" width="30" height="14" font="7">8/10 </text>
<text top="269" left="924" width="23" height="14" font="7">0/4 </text>
<text top="269" left="1038" width="74" height="14" font="7">D+MI+Rep </text>
<text top="287" left="1043" width="65" height="14" font="7">Revasc+T </text>
<text top="269" left="1189" width="38" height="14" font="7">28/34 </text>
<text top="269" left="1340" width="11" height="14" font="7">1 </text>
<text top="305" left="108" width="96" height="14" font="7">Cisowski et  al. </text>
<text top="322" left="108" width="5" height="14" font="7">(</text>
<text top="322" left="113" width="23" height="14" font="8">100</text>
<text top="322" left="136" width="4" height="14" font="7">,</text>
<text top="322" left="139" width="31" height="14" font="8"> 136)</text>
<text top="322" left="171" width="7" height="14" font="7">  </text>
<text top="305" left="237" width="26" height="14" font="7">100 </text>
<text top="305" left="300" width="19" height="14" font="7">54 </text>
<text top="305" left="358" width="31" height="14" font="7">17% </text>
<text top="305" left="430" width="23" height="14" font="7">SV </text>
<text top="305" left="489" width="69" height="14" font="7">2000-2001 </text>
<text top="305" left="612" width="34" height="14" font="7">0/3.6 </text>
<text top="305" left="723" width="23" height="14" font="7">0/0 </text>
<text top="305" left="802" width="30" height="14" font="7">0/20 </text>
<text top="305" left="920" width="30" height="14" font="7">0/20 </text>
<text top="305" left="1055" width="41" height="14" font="7">D+MI </text>
<text top="305" left="1196" width="23" height="14" font="7">0/4 </text>
<text top="305" left="1340" width="11" height="14" font="7">1 </text>
<text top="348" left="108" width="63" height="14" font="7">Kim et al. </text>
<text top="348" left="171" width="33" height="14" font="8">(167)</text>
<text top="348" left="204" width="4" height="14" font="7"> </text>
<text top="340" left="237" width="26" height="14" font="7">100 </text>
<text top="340" left="300" width="19" height="14" font="7">62 </text>
<text top="340" left="358" width="31" height="14" font="7">35% </text>
<text top="340" left="430" width="23" height="14" font="7">SV </text>
<text top="340" left="489" width="69" height="14" font="7">2000-2001 </text>
<text top="340" left="606" width="45" height="14" font="7">4.0/4.0 </text>
<text top="340" left="721" width="25" height="14" font="7">NA </text>
<text top="340" left="802" width="30" height="14" font="7">6/19 </text>
<text top="340" left="920" width="30" height="14" font="7">2/14 </text>
<text top="340" left="1063" width="25" height="14" font="7">NA </text>
<text top="340" left="1195" width="25" height="14" font="7">NA </text>
<text top="340" left="1340" width="11" height="14" font="7">1 </text>
<text top="373" left="108" width="1238" height="12" font="17">*Statistically significant. AMIST indicates Angioplasty versus Minimally Invasive Surgery Trial; ARTS, Arterial Revascularization Therapies Study; AWESOME, Angina with Extremely Serious Operative Mortality Evaluation; </text>
<text top="389" left="108" width="1248" height="12" font="17">BMS, bare-metal stent; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CI, confidence interval; CVA, cerebrovascular accident; D, death; ERACI, Argentine Randomized Trial of Percutaneous Transluminal </text>
<text top="405" left="108" width="1257" height="12" font="17">Coronary Angioplasty Versus Coronary Artery Bypass Surgery in Multivessel Disease; MASS, Medicine, Angioplasty, or Surgery Study; MI, myocardial infarction; MIDCAB, minimally invasive direct coronary artery bypass; MV, </text>
<text top="420" left="108" width="1242" height="12" font="17">multivessel; NA, not available; Octostent, Long-term comparison of stenting versus off-pump; PCI, percutaneous coronary intervention; RITA, Randomized Intervention Treatment of Angina; RR, relative risk; Rep Revasc, repeat </text>
<text top="435" left="108" width="759" height="12" font="17">revascularization; SIMA, Stenting versus Internal Mammary Artery Study; SoS, Stent or Surgery; SV, single-vessel; and T, thallium defect. </text>
<text top="452" left="108" width="4" height="15" font="4"><b> </b></text>
<text top="480" left="108" width="4" height="15" font="4"><b> </b></text>
<text top="509" left="108" width="388" height="16" font="2"><b> Data Supplement 7.  RCTs of CABG Versus DES </b></text>
<text top="531" left="310" width="4" height="16" font="2"><b> </b></text>
<text top="530" left="529" width="63" height="15" font="4"><b>Death %</b></text>
<text top="529" left="592" width="4" height="16" font="2"><b> </b></text>
<text top="530" left="640" width="43" height="15" font="4"><b>MI %</b></text>
<text top="529" left="682" width="4" height="16" font="2"><b> </b></text>
<text top="530" left="772" width="54" height="15" font="4"><b>Repeat </b></text>
<text top="549" left="723" width="147" height="15" font="4"><b>Revascularization %</b></text>
<text top="548" left="870" width="4" height="16" font="2"><b> </b></text>
<text top="530" left="928" width="130" height="15" font="4"><b>Primary Endpoint</b></text>
<text top="529" left="1058" width="4" height="16" font="2"><b> </b></text>
<text top="530" left="1124" width="114" height="15" font="4"><b>RR and 95% CI</b></text>
<text top="529" left="1238" width="4" height="16" font="2"><b> </b></text>
<text top="530" left="1284" width="96" height="15" font="4"><b>Follow-Up in </b></text>
<text top="549" left="1303" width="54" height="15" font="4"><b>Months</b></text>
<text top="548" left="1357" width="4" height="16" font="2"><b> </b></text>
<text top="569" left="137" width="36" height="15" font="4"><b>Trial</b></text>
<text top="568" left="173" width="4" height="16" font="2"><b> </b></text>
<text top="569" left="216" width="24" height="15" font="4"><b>No.</b></text>
<text top="568" left="240" width="4" height="16" font="2"><b> </b></text>
<text top="569" left="266" width="32" height="15" font="4"><b>Age </b></text>
<text top="588" left="270" width="19" height="15" font="4"><b>(y)</b></text>
<text top="587" left="289" width="4" height="16" font="2"><b> </b></text>
<text top="569" left="310" width="51" height="15" font="4"><b>Female</b></text>
<text top="568" left="361" width="4" height="16" font="2"><b> </b></text>
<text top="569" left="373" width="36" height="15" font="4"><b>CAD</b></text>
<text top="568" left="409" width="4" height="16" font="2"><b> </b></text>
<text top="569" left="424" width="85" height="15" font="4"><b>Enrollment </b></text>
<text top="588" left="441" width="47" height="15" font="4"><b>Period</b></text>
<text top="587" left="488" width="4" height="16" font="2"><b> </b></text>
<text top="569" left="521" width="81" height="15" font="4"><b>CABG/PCI</b></text>
<text top="568" left="601" width="4" height="16" font="2"><b> </b></text>
<text top="569" left="621" width="81" height="15" font="4"><b>CABG/PCI</b></text>
<text top="568" left="701" width="4" height="16" font="2"><b> </b></text>
<text top="569" left="756" width="81" height="15" font="4"><b>CABG/PCI</b></text>
<text top="568" left="837" width="4" height="16" font="2"><b> </b></text>
<text top="569" left="941" width="4" height="16" font="2"><b> </b></text>
<text top="569" left="1014" width="81" height="15" font="4"><b>CABG/PCI</b></text>
<text top="568" left="1095" width="4" height="16" font="2"><b> </b></text>
<text top="569" left="1181" width="4" height="16" font="2"><b> </b></text>
<text top="569" left="1330" width="4" height="16" font="2"><b> </b></text>
<text top="609" left="108" width="77" height="15" font="5">Hong et al. </text>
<text top="628" left="108" width="36" height="15" font="13">(106)</text>
<text top="627" left="144" width="4" height="16" font="0"> </text>
<text top="619" left="216" width="25" height="15" font="5">189</text>
<text top="618" left="241" width="4" height="16" font="0"> </text>
<text top="619" left="272" width="17" height="15" font="5">61</text>
<text top="618" left="288" width="4" height="16" font="0"> </text>
<text top="619" left="321" width="30" height="15" font="5">36%</text>
<text top="618" left="351" width="4" height="16" font="0"> </text>
<text top="619" left="381" width="21" height="15" font="5">SV</text>
<text top="618" left="402" width="4" height="16" font="0"> </text>
<text top="619" left="448" width="33" height="15" font="5">2003</text>
<text top="618" left="481" width="4" height="16" font="0"> </text>
<text top="619" left="544" width="34" height="15" font="5">2.9/0</text>
<text top="618" left="578" width="4" height="16" font="0"> </text>
<text top="619" left="638" width="46" height="15" font="5">2.9/1.7</text>
<text top="618" left="684" width="4" height="16" font="0"> </text>
<text top="619" left="774" width="46" height="15" font="5">5.9/1.7</text>
<text top="618" left="820" width="4" height="16" font="0"> </text>
<text top="609" left="904" width="79" height="15" font="5">D, MI, Rep </text>
<text top="628" left="917" width="48" height="15" font="5">Revasc</text>
<text top="627" left="965" width="4" height="16" font="0"> </text>
<text top="619" left="1027" width="54" height="15" font="5">11.7/4.3</text>
<text top="618" left="1081" width="4" height="16" font="0"> </text>
<text top="619" left="1167" width="29" height="15" font="5">N/A</text>
<text top="618" left="1196" width="4" height="16" font="0"> </text>
<text top="619" left="1326" width="8" height="15" font="5">6</text>
<text top="618" left="1334" width="4" height="16" font="0"> </text>
<text top="657" left="108" width="55" height="15" font="5">Leipzig </text>
<text top="657" left="163" width="36" height="15" font="13">(138)</text>
<text top="656" left="198" width="4" height="16" font="0"> </text>
<text top="657" left="216" width="25" height="15" font="5">130</text>
<text top="656" left="241" width="4" height="16" font="0"> </text>
<text top="657" left="272" width="17" height="15" font="5">66</text>
<text top="656" left="288" width="4" height="16" font="0"> </text>
<text top="657" left="321" width="30" height="15" font="5">30%</text>
<text top="656" left="351" width="4" height="16" font="0"> </text>
<text top="657" left="381" width="21" height="15" font="5">SV</text>
<text top="656" left="402" width="4" height="16" font="0"> </text>
<text top="657" left="429" width="71" height="15" font="5">2003-2007</text>
<text top="656" left="501" width="4" height="16" font="0"> </text>
<text top="657" left="550" width="21" height="15" font="5">0/0</text>
<text top="656" left="571" width="4" height="16" font="0"> </text>
<text top="657" left="634" width="54" height="15" font="5">7.7/1.5*</text>
<text top="656" left="688" width="4" height="16" font="0"> </text>
<text top="657" left="780" width="34" height="15" font="5">0/6.2</text>
<text top="656" left="813" width="4" height="16" font="0"> </text>
<text top="648" left="903" width="81" height="15" font="5">D+MI+Rep </text>
<text top="667" left="917" width="48" height="15" font="5">Revasc</text>
<text top="666" left="965" width="4" height="16" font="0"> </text>
<text top="657" left="1032" width="46" height="15" font="5">7.7/7.7</text>
<text top="656" left="1077" width="4" height="16" font="0"> </text>
<text top="657" left="1167" width="29" height="15" font="5">N/A</text>
<text top="656" left="1196" width="4" height="16" font="0"> </text>
<text top="657" left="1322" width="17" height="15" font="5">12</text>
<text top="656" left="1338" width="4" height="16" font="0"> </text>
<text top="706" left="108" width="71" height="15" font="5">SYNTAX </text>
<text top="724" left="108" width="6" height="15" font="5">(</text>
<text top="724" left="114" width="25" height="15" font="13">168</text>
<text top="724" left="138" width="8" height="15" font="5">, </text>
<text top="724" left="147" width="30" height="15" font="13">169)</text>
<text top="723" left="177" width="4" height="16" font="0"> </text>
<text top="715" left="212" width="33" height="15" font="5">1800</text>
<text top="714" left="245" width="4" height="16" font="0"> </text>
<text top="715" left="272" width="17" height="15" font="5">65</text>
<text top="714" left="288" width="4" height="16" font="0"> </text>
<text top="715" left="321" width="30" height="15" font="5">22%</text>
<text top="714" left="351" width="4" height="16" font="0"> </text>
<text top="715" left="378" width="27" height="15" font="5">MV</text>
<text top="714" left="405" width="4" height="16" font="0"> </text>
<text top="715" left="429" width="71" height="15" font="5">2005-2007</text>
<text top="714" left="501" width="4" height="16" font="0"> </text>
<text top="715" left="538" width="46" height="15" font="5">6.7/8.6</text>
<text top="714" left="584" width="4" height="16" font="0"> </text>
<text top="715" left="638" width="46" height="15" font="5">3.6/7.1</text>
<text top="714" left="684" width="4" height="16" font="0"> </text>
<text top="715" left="766" width="62" height="15" font="5">10.7/19.7</text>
<text top="714" left="828" width="4" height="16" font="0"> </text>
<text top="706" left="880" width="126" height="15" font="5">D+MI+CVA+Rep </text>
<text top="724" left="917" width="48" height="15" font="5">Revasc</text>
<text top="723" left="965" width="4" height="16" font="0"> </text>
<text top="715" left="1023" width="62" height="15" font="5">20.2/28.0</text>
<text top="714" left="1086" width="4" height="16" font="0"> </text>
<text top="686" left="1129" width="109" height="15" font="5">MACCE 12 mo </text>
<text top="706" left="1131" width="105" height="15" font="5">follow-up; RR: </text>
<text top="724" left="1120" width="126" height="15" font="5">1.44 95% CI: 1.15 </text>
<text top="744" left="1158" width="46" height="15" font="5">to 1.81</text>
<text top="743" left="1204" width="4" height="16" font="0"> </text>
<text top="715" left="1322" width="17" height="15" font="5">36</text>
<text top="714" left="1338" width="4" height="16" font="0"> </text>
<text top="763" left="108" width="1262" height="12" font="17">*Statistically significant. CABG indicates coronary artery bypass surgery; CAD, coronary artery disease; CI, confidence interval; CVA, cerebrovascular accident; D, death; MACCE, major adverse cardiac and cerebrovascular events; </text>
<text top="778" left="108" width="1257" height="12" font="17">MI, myocardial infarction; N/A, not applicable; No., number of patients; MV, multivessel; PCI, percutaneous coronary intervention; RR, relative risk; Rep Revasc, repeat revascularization; SV, single vessel; and SYNTAX,  Synergy </text>
<text top="794" left="108" width="443" height="12" font="17">Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery. </text>
</page>
<page number="24" position="absolute" top="0" left="0" height="918" width="1512">
	<fontspec id="22" size="11" family="Times" color="#000000"/>
<text top="59" left="108" width="4" height="15" font="0"> </text>
<text top="59" left="459" width="4" height="15" font="0"> </text>
<text top="59" left="810" width="4" height="15" font="0"> </text>
<text top="59" left="864" width="4" height="15" font="0"> </text>
<text top="59" left="918" width="4" height="15" font="0"> </text>
<text top="59" left="972" width="4" height="15" font="0"> </text>
<text top="59" left="1026" width="4" height="15" font="0"> </text>
<text top="59" left="1080" width="4" height="15" font="0"> </text>
<text top="59" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="108" width="613" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="825" left="810" width="4" height="15" font="0"> </text>
<text top="825" left="864" width="4" height="15" font="0"> </text>
<text top="825" left="918" width="4" height="15" font="0"> </text>
<text top="825" left="972" width="4" height="15" font="0"> </text>
<text top="825" left="1026" width="4" height="15" font="0"> </text>
<text top="825" left="1080" width="4" height="15" font="0"> </text>
<text top="825" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="1188" width="4" height="15" font="0"> </text>
<text top="825" left="1242" width="22" height="15" font="0">24 </text>
<text top="847" left="108" width="4" height="15" font="0"> </text>
<text top="112" left="108" width="4" height="15" font="5"> </text>
<text top="141" left="108" width="715" height="16" font="2"><b>Data Supplement 8. Hazard Ratios in Observational Studies Comparing PCI-DES to CABG  </b></text>
<text top="162" left="174" width="41" height="15" font="4"><b>Study</b></text>
<text top="161" left="215" width="4" height="16" font="2"><b> </b></text>
<text top="162" left="296" width="62" height="15" font="4"><b>Location</b></text>
<text top="161" left="358" width="4" height="16" font="2"><b> </b></text>
<text top="162" left="398" width="90" height="15" font="4"><b>No. Patients </b></text>
<text top="181" left="395" width="92" height="15" font="4"><b>(CABG/PCI)</b></text>
<text top="180" left="487" width="4" height="16" font="2"><b> </b></text>
<text top="162" left="521" width="63" height="15" font="4"><b>Average </b></text>
<text top="181" left="525" width="51" height="15" font="4"><b>Age (y)</b></text>
<text top="180" left="576" width="4" height="16" font="2"><b> </b></text>
<text top="162" left="606" width="56" height="15" font="4"><b>Female </b></text>
<text top="181" left="593" width="78" height="15" font="4"><b>Patients %</b></text>
<text top="180" left="670" width="4" height="16" font="2"><b> </b></text>
<text top="162" left="699" width="36" height="15" font="4"><b>CAD</b></text>
<text top="161" left="735" width="4" height="16" font="2"><b> </b></text>
<text top="162" left="778" width="85" height="15" font="4"><b>Enrollment </b></text>
<text top="181" left="795" width="47" height="15" font="4"><b>Period</b></text>
<text top="180" left="841" width="4" height="16" font="2"><b> </b></text>
<text top="162" left="903" width="78" height="15" font="4"><b>Combined </b></text>
<text top="181" left="885" width="113" height="15" font="4"><b>Death/MI/CVA </b></text>
<text top="180" left="998" width="4" height="16" font="2"><b> </b></text>
<text top="200" left="882" width="115" height="15" font="4"><b>HR and 95% CI</b></text>
<text top="199" left="997" width="4" height="16" font="2"><b> </b></text>
<text top="162" left="1066" width="54" height="15" font="4"><b>Repeat </b></text>
<text top="181" left="1027" width="131" height="15" font="4"><b>Revascularization </b></text>
<text top="180" left="1158" width="4" height="16" font="2"><b> </b></text>
<text top="200" left="1033" width="115" height="15" font="4"><b>HR and 95% CI</b></text>
<text top="199" left="1148" width="4" height="16" font="2"><b> </b></text>
<text top="162" left="1207" width="66" height="15" font="4"><b>MACCE </b></text>
<text top="161" left="1273" width="4" height="16" font="2"><b> </b></text>
<text top="181" left="1180" width="115" height="15" font="4"><b>HR and 95% CI</b></text>
<text top="180" left="1295" width="4" height="16" font="2"><b> </b></text>
<text top="162" left="1305" width="96" height="15" font="4"><b>Follow-Up in </b></text>
<text top="181" left="1324" width="54" height="15" font="4"><b>Months</b></text>
<text top="180" left="1378" width="4" height="16" font="2"><b> </b></text>
<text top="238" left="108" width="71" height="15" font="5">Park et al. </text>
<text top="238" left="179" width="36" height="15" font="13">(170)</text>
<text top="237" left="214" width="4" height="16" font="0"> </text>
<text top="238" left="282" width="40" height="15" font="5">Korea</text>
<text top="237" left="322" width="4" height="16" font="0"> </text>
<text top="238" left="402" width="79" height="15" font="5">1,495/1,547</text>
<text top="237" left="481" width="4" height="16" font="0"> </text>
<text top="238" left="542" width="17" height="15" font="5">62</text>
<text top="237" left="558" width="4" height="16" font="0"> </text>
<text top="238" left="617" width="30" height="15" font="5">29%</text>
<text top="237" left="647" width="4" height="16" font="0"> </text>
<text top="238" left="698" width="39" height="15" font="5">MVD</text>
<text top="237" left="736" width="4" height="16" font="0"> </text>
<text top="238" left="782" width="71" height="15" font="5">2003-2005</text>
<text top="237" left="854" width="4" height="16" font="0"> </text>
<text top="219" left="925" width="29" height="15" font="5">0.7*</text>
<text top="218" left="954" width="4" height="16" font="0"> </text>
<text top="238" left="900" width="79" height="15" font="5">0.53 to 0.91</text>
<text top="237" left="979" width="4" height="16" font="0"> </text>
<text top="219" left="1072" width="37" height="15" font="5">2.56*</text>
<text top="218" left="1109" width="4" height="16" font="0"> </text>
<text top="238" left="1055" width="71" height="15" font="5">1.96 to 3.4</text>
<text top="237" left="1126" width="4" height="16" font="0"> </text>
<text top="219" left="1219" width="37" height="15" font="5">1.37*</text>
<text top="218" left="1256" width="4" height="16" font="0"> </text>
<text top="238" left="1198" width="79" height="15" font="5">1.16 to 1.63</text>
<text top="237" left="1277" width="4" height="16" font="0"> </text>
<text top="238" left="1343" width="17" height="15" font="5">31</text>
<text top="237" left="1359" width="4" height="16" font="0"> </text>
<text top="277" left="108" width="92" height="15" font="5">Hannan et al. </text>
<text top="277" left="200" width="27" height="15" font="13">(85)</text>
<text top="276" left="227" width="4" height="16" font="0"> </text>
<text top="277" left="282" width="33" height="15" font="5">USA</text>
<text top="276" left="315" width="4" height="16" font="0"> </text>
<text top="277" left="402" width="79" height="15" font="5">7,437/9,964</text>
<text top="276" left="481" width="4" height="16" font="0"> </text>
<text top="277" left="542" width="17" height="15" font="5">66</text>
<text top="276" left="558" width="4" height="16" font="0"> </text>
<text top="277" left="617" width="30" height="15" font="5">30%</text>
<text top="276" left="647" width="4" height="16" font="0"> </text>
<text top="277" left="698" width="39" height="15" font="5">MVD</text>
<text top="276" left="736" width="4" height="16" font="0"> </text>
<text top="277" left="782" width="71" height="15" font="5">2003-2004</text>
<text top="276" left="854" width="4" height="16" font="0"> </text>
<text top="258" left="925" width="29" height="15" font="5">0.99</text>
<text top="257" left="954" width="4" height="16" font="0"> </text>
<text top="277" left="896" width="87" height="15" font="5">0.89 to 1.098</text>
<text top="276" left="983" width="4" height="16" font="0"> </text>
<text top="258" left="1072" width="37" height="15" font="5">5.88*</text>
<text top="257" left="1109" width="4" height="16" font="0"> </text>
<text top="277" left="1051" width="79" height="15" font="5">5.31 to 6.51</text>
<text top="276" left="1130" width="4" height="16" font="0"> </text>
<text top="258" left="1219" width="37" height="15" font="5">2.89*</text>
<text top="257" left="1256" width="4" height="16" font="0"> </text>
<text top="277" left="1198" width="79" height="15" font="5">2.72 to 3.08</text>
<text top="276" left="1277" width="4" height="16" font="0"> </text>
<text top="277" left="1343" width="17" height="15" font="5">19</text>
<text top="276" left="1359" width="4" height="16" font="0"> </text>
<text top="315" left="108" width="96" height="15" font="5">Briguori et al. </text>
<text top="315" left="204" width="36" height="15" font="13">(171)</text>
<text top="314" left="240" width="4" height="16" font="0"> </text>
<text top="315" left="282" width="30" height="15" font="5">Italy</text>
<text top="314" left="312" width="4" height="16" font="0"> </text>
<text top="315" left="418" width="46" height="15" font="5">149/69</text>
<text top="314" left="464" width="4" height="16" font="0"> </text>
<text top="315" left="542" width="17" height="15" font="5">65</text>
<text top="314" left="558" width="4" height="16" font="0"> </text>
<text top="315" left="617" width="30" height="15" font="5">29%</text>
<text top="314" left="647" width="4" height="16" font="0"> </text>
<text top="315" left="698" width="39" height="15" font="5">MVD</text>
<text top="314" left="736" width="4" height="16" font="0"> </text>
<text top="315" left="782" width="71" height="15" font="5">2002-2004</text>
<text top="314" left="854" width="4" height="16" font="0"> </text>
<text top="297" left="925" width="29" height="15" font="5">1.03</text>
<text top="296" left="954" width="4" height="16" font="0"> </text>
<text top="315" left="900" width="79" height="15" font="5">0.53 to 1.99</text>
<text top="314" left="979" width="4" height="16" font="0"> </text>
<text top="297" left="1072" width="37" height="15" font="5">4.01*</text>
<text top="296" left="1109" width="4" height="16" font="0"> </text>
<text top="315" left="1051" width="79" height="15" font="5">1.67 to 9.60</text>
<text top="314" left="1130" width="4" height="16" font="0"> </text>
<text top="297" left="1219" width="37" height="15" font="5">1.48*</text>
<text top="296" left="1256" width="4" height="16" font="0"> </text>
<text top="315" left="1198" width="79" height="15" font="5">0.91 to 2.43</text>
<text top="314" left="1277" width="4" height="16" font="0"> </text>
<text top="315" left="1343" width="17" height="15" font="5">12</text>
<text top="314" left="1359" width="4" height="16" font="0"> </text>
<text top="354" left="108" width="76" height="15" font="5">Yang et al. </text>
<text top="354" left="184" width="36" height="15" font="13">(172)</text>
<text top="353" left="220" width="4" height="16" font="0"> </text>
<text top="354" left="282" width="40" height="15" font="5">China</text>
<text top="353" left="321" width="4" height="16" font="0"> </text>
<text top="354" left="414" width="54" height="15" font="5">231/235</text>
<text top="353" left="468" width="4" height="16" font="0"> </text>
<text top="354" left="542" width="17" height="15" font="5">65</text>
<text top="353" left="558" width="4" height="16" font="0"> </text>
<text top="354" left="617" width="30" height="15" font="5">22%</text>
<text top="353" left="647" width="4" height="16" font="0"> </text>
<text top="354" left="698" width="39" height="15" font="5">MVD</text>
<text top="353" left="736" width="4" height="16" font="0"> </text>
<text top="354" left="782" width="71" height="15" font="5">2003-2004</text>
<text top="353" left="854" width="4" height="16" font="0"> </text>
<text top="335" left="929" width="21" height="15" font="5">0.7</text>
<text top="334" left="950" width="4" height="16" font="0"> </text>
<text top="354" left="900" width="79" height="15" font="5">0.33 to 1.49</text>
<text top="353" left="979" width="4" height="16" font="0"> </text>
<text top="335" left="1068" width="46" height="15" font="5">13.26*</text>
<text top="334" left="1113" width="4" height="16" font="0"> </text>
<text top="354" left="1047" width="87" height="15" font="5">4.15 to 42.34</text>
<text top="353" left="1134" width="4" height="16" font="0"> </text>
<text top="335" left="1219" width="37" height="15" font="5">3.09*</text>
<text top="334" left="1256" width="4" height="16" font="0"> </text>
<text top="354" left="1198" width="79" height="15" font="5">1.80 to 5.30</text>
<text top="353" left="1277" width="4" height="16" font="0"> </text>
<text top="354" left="1343" width="17" height="15" font="5">25</text>
<text top="353" left="1359" width="4" height="16" font="0"> </text>
<text top="393" left="108" width="61" height="15" font="5">Lee et al.</text>
<text top="393" left="169" width="40" height="15" font="13"> (173)</text>
<text top="392" left="209" width="4" height="16" font="0"> </text>
<text top="393" left="282" width="33" height="15" font="5">USA</text>
<text top="392" left="315" width="4" height="16" font="0"> </text>
<text top="393" left="414" width="54" height="15" font="5">103/102</text>
<text top="392" left="468" width="4" height="16" font="0"> </text>
<text top="393" left="542" width="17" height="15" font="5">68</text>
<text top="392" left="558" width="4" height="16" font="0"> </text>
<text top="393" left="617" width="30" height="15" font="5">35%</text>
<text top="392" left="647" width="4" height="16" font="0"> </text>
<text top="393" left="698" width="39" height="15" font="5">MVD</text>
<text top="392" left="736" width="4" height="16" font="0"> </text>
<text top="393" left="785" width="67" height="15" font="5">2003-N/A</text>
<text top="392" left="852" width="4" height="16" font="0"> </text>
<text top="374" left="925" width="29" height="15" font="5">1.29</text>
<text top="373" left="954" width="4" height="16" font="0"> </text>
<text top="393" left="900" width="79" height="15" font="5">0.68 to 2.46</text>
<text top="392" left="979" width="4" height="16" font="0"> </text>
<text top="374" left="1072" width="37" height="15" font="5">6.73*</text>
<text top="373" left="1109" width="4" height="16" font="0"> </text>
<text top="393" left="1047" width="87" height="15" font="5">2.06 to 21.95</text>
<text top="392" left="1134" width="4" height="16" font="0"> </text>
<text top="374" left="1219" width="37" height="15" font="5">2.25*</text>
<text top="373" left="1256" width="4" height="16" font="0"> </text>
<text top="393" left="1206" width="63" height="15" font="5">1.36-3.72</text>
<text top="392" left="1270" width="4" height="16" font="0"> </text>
<text top="393" left="1343" width="17" height="15" font="5">12</text>
<text top="392" left="1359" width="4" height="16" font="0"> </text>
<text top="432" left="108" width="82" height="15" font="5">Yang et al. (</text>
<text top="432" left="190" width="30" height="15" font="13">174)</text>
<text top="431" left="220" width="4" height="16" font="0"> </text>
<text top="432" left="282" width="40" height="15" font="5">Korea</text>
<text top="431" left="322" width="4" height="16" font="0"> </text>
<text top="432" left="414" width="54" height="15" font="5">390/441</text>
<text top="431" left="468" width="4" height="16" font="0"> </text>
<text top="432" left="542" width="17" height="15" font="5">63</text>
<text top="431" left="558" width="4" height="16" font="0"> </text>
<text top="432" left="617" width="30" height="15" font="5">29%</text>
<text top="431" left="647" width="4" height="16" font="0"> </text>
<text top="432" left="698" width="39" height="15" font="5">MVD</text>
<text top="431" left="736" width="4" height="16" font="0"> </text>
<text top="432" left="782" width="71" height="15" font="5">2003-2004</text>
<text top="431" left="854" width="4" height="16" font="0"> </text>
<text top="413" left="925" width="29" height="15" font="5">0.75</text>
<text top="412" left="954" width="4" height="16" font="0"> </text>
<text top="432" left="900" width="79" height="15" font="5">0.43 to 1.31</text>
<text top="431" left="979" width="4" height="16" font="0"> </text>
<text top="413" left="1072" width="37" height="15" font="5">4.26*</text>
<text top="412" left="1109" width="4" height="16" font="0"> </text>
<text top="432" left="1047" width="87" height="15" font="5">1.78 to 10.15</text>
<text top="431" left="1134" width="4" height="16" font="0"> </text>
<text top="413" left="1219" width="37" height="15" font="5">1.41*</text>
<text top="412" left="1256" width="4" height="16" font="0"> </text>
<text top="432" left="1198" width="79" height="15" font="5">0.93 to 2.13</text>
<text top="431" left="1277" width="4" height="16" font="0"> </text>
<text top="432" left="1343" width="17" height="15" font="5">12</text>
<text top="431" left="1359" width="4" height="16" font="0"> </text>
<text top="470" left="108" width="83" height="15" font="5">Javaid et al. </text>
<text top="470" left="191" width="36" height="15" font="13">(117)</text>
<text top="469" left="226" width="4" height="16" font="0"> </text>
<text top="470" left="282" width="33" height="15" font="5">USA</text>
<text top="469" left="315" width="4" height="16" font="0"> </text>
<text top="470" left="414" width="54" height="15" font="5">701/979</text>
<text top="469" left="468" width="4" height="16" font="0"> </text>
<text top="470" left="542" width="17" height="15" font="5">65</text>
<text top="469" left="558" width="4" height="16" font="0"> </text>
<text top="470" left="617" width="30" height="15" font="5">33%</text>
<text top="469" left="647" width="4" height="16" font="0"> </text>
<text top="470" left="698" width="39" height="15" font="5">MVD</text>
<text top="469" left="736" width="4" height="16" font="0"> </text>
<text top="470" left="804" width="29" height="15" font="5">N/A</text>
<text top="469" left="832" width="4" height="16" font="0"> </text>
<text top="451" left="925" width="29" height="15" font="5">1.93</text>
<text top="450" left="954" width="4" height="16" font="0"> </text>
<text top="470" left="900" width="79" height="15" font="5">1.37 to 2.73</text>
<text top="469" left="979" width="4" height="16" font="0"> </text>
<text top="451" left="1072" width="37" height="15" font="5">2.43*</text>
<text top="450" left="1109" width="4" height="16" font="0"> </text>
<text top="470" left="1051" width="79" height="15" font="5">1.73 to 3.41</text>
<text top="469" left="1130" width="4" height="16" font="0"> </text>
<text top="451" left="1219" width="37" height="15" font="5">2.44*</text>
<text top="450" left="1256" width="4" height="16" font="0"> </text>
<text top="470" left="1198" width="79" height="15" font="5">1.87 to 3.19</text>
<text top="469" left="1277" width="4" height="16" font="0"> </text>
<text top="470" left="1343" width="17" height="15" font="5">12</text>
<text top="469" left="1359" width="4" height="16" font="0"> </text>
<text top="509" left="108" width="81" height="15" font="5">Varani et al.</text>
<text top="509" left="189" width="40" height="15" font="13"> (175)</text>
<text top="508" left="229" width="4" height="16" font="0"> </text>
<text top="509" left="282" width="30" height="15" font="5">Italy</text>
<text top="508" left="312" width="4" height="16" font="0"> </text>
<text top="509" left="418" width="46" height="15" font="5">95/111</text>
<text top="508" left="464" width="4" height="16" font="0"> </text>
<text top="509" left="542" width="17" height="15" font="5">65</text>
<text top="508" left="558" width="4" height="16" font="0"> </text>
<text top="509" left="617" width="30" height="15" font="5">31%</text>
<text top="508" left="647" width="4" height="16" font="0"> </text>
<text top="509" left="698" width="39" height="15" font="5">MVD</text>
<text top="508" left="736" width="4" height="16" font="0"> </text>
<text top="509" left="782" width="71" height="15" font="5">2003-2005</text>
<text top="508" left="854" width="4" height="16" font="0"> </text>
<text top="490" left="921" width="37" height="15" font="5">0.47*</text>
<text top="489" left="958" width="4" height="16" font="0"> </text>
<text top="509" left="900" width="79" height="15" font="5">0.16 to 1.37</text>
<text top="508" left="979" width="4" height="16" font="0"> </text>
<text top="490" left="1072" width="37" height="15" font="5">5.91*</text>
<text top="489" left="1109" width="4" height="16" font="0"> </text>
<text top="509" left="1051" width="79" height="15" font="5">1.39 to 25.6</text>
<text top="508" left="1130" width="4" height="16" font="0"> </text>
<text top="490" left="1219" width="37" height="15" font="5">1.52*</text>
<text top="489" left="1256" width="4" height="16" font="0"> </text>
<text top="509" left="1198" width="79" height="15" font="5">0.70 to 3.28</text>
<text top="508" left="1277" width="4" height="16" font="0"> </text>
<text top="509" left="1343" width="17" height="15" font="5">12</text>
<text top="508" left="1359" width="4" height="16" font="0"> </text>
<text top="548" left="108" width="106" height="15" font="5">Tarantini et al. (</text>
<text top="548" left="214" width="30" height="15" font="13">176)</text>
<text top="547" left="245" width="4" height="16" font="0"> </text>
<text top="548" left="282" width="30" height="15" font="5">Italy</text>
<text top="547" left="312" width="4" height="16" font="0"> </text>
<text top="548" left="418" width="46" height="15" font="5">127/93</text>
<text top="547" left="464" width="4" height="16" font="0"> </text>
<text top="548" left="542" width="17" height="15" font="5">66</text>
<text top="547" left="558" width="4" height="16" font="0"> </text>
<text top="548" left="617" width="30" height="15" font="5">18%</text>
<text top="547" left="647" width="4" height="16" font="0"> </text>
<text top="548" left="698" width="39" height="15" font="5">MVD</text>
<text top="547" left="736" width="4" height="16" font="0"> </text>
<text top="548" left="782" width="71" height="15" font="5">2005-2005</text>
<text top="547" left="854" width="4" height="16" font="0"> </text>
<text top="529" left="925" width="29" height="15" font="5">0.56</text>
<text top="528" left="954" width="4" height="16" font="0"> </text>
<text top="548" left="900" width="79" height="15" font="5">0.20 to 1.56</text>
<text top="547" left="979" width="4" height="16" font="0"> </text>
<text top="529" left="1072" width="37" height="15" font="5">1.91*</text>
<text top="528" left="1109" width="4" height="16" font="0"> </text>
<text top="548" left="1051" width="79" height="15" font="5">0.62 to 5.83</text>
<text top="547" left="1130" width="4" height="16" font="0"> </text>
<text top="529" left="1219" width="37" height="15" font="5">0.96*</text>
<text top="528" left="1256" width="4" height="16" font="0"> </text>
<text top="548" left="1198" width="79" height="15" font="5">0.48 to 1.92</text>
<text top="547" left="1277" width="4" height="16" font="0"> </text>
<text top="548" left="1343" width="17" height="15" font="5">24</text>
<text top="547" left="1359" width="4" height="16" font="0"> </text>
<text top="569" left="108" width="4" height="15" font="5"> </text>
<text top="568" left="112" width="4" height="16" font="0"> </text>
<text top="568" left="282" width="4" height="16" font="0"> </text>
<text top="568" left="441" width="4" height="16" font="0"> </text>
<text top="568" left="550" width="4" height="16" font="0"> </text>
<text top="568" left="632" width="4" height="16" font="0"> </text>
<text top="568" left="673" width="4" height="16" font="0"> </text>
<text top="568" left="818" width="4" height="16" font="0"> </text>
<text top="568" left="939" width="4" height="16" font="0"> </text>
<text top="568" left="1091" width="4" height="16" font="0"> </text>
<text top="568" left="1238" width="4" height="16" font="0"> </text>
<text top="569" left="1349" width="4" height="15" font="5"> </text>
<text top="568" left="1353" width="4" height="16" font="0"> </text>
<text top="591" left="108" width="73" height="15" font="5">Pooled HR</text>
<text top="590" left="181" width="4" height="16" font="0"> </text>
<text top="589" left="441" width="4" height="16" font="0"> </text>
<text top="589" left="550" width="4" height="16" font="0"> </text>
<text top="589" left="632" width="4" height="16" font="0"> </text>
<text top="589" left="673" width="4" height="16" font="0"> </text>
<text top="589" left="818" width="4" height="16" font="0"> </text>
<text top="591" left="925" width="29" height="15" font="5">0.94</text>
<text top="590" left="954" width="4" height="16" font="0"> </text>
<text top="591" left="1076" width="29" height="15" font="5">4.06</text>
<text top="590" left="1105" width="4" height="16" font="0"> </text>
<text top="591" left="1223" width="29" height="15" font="5">1.86</text>
<text top="590" left="1252" width="4" height="16" font="0"> </text>
<text top="591" left="1349" width="4" height="15" font="5"> </text>
<text top="590" left="1353" width="4" height="16" font="0"> </text>
<text top="610" left="108" width="4" height="15" font="5"> </text>
<text top="609" left="112" width="4" height="16" font="0"> </text>
<text top="610" left="309" width="4" height="15" font="5"> </text>
<text top="609" left="313" width="4" height="16" font="0"> </text>
<text top="610" left="439" width="4" height="15" font="5"> </text>
<text top="609" left="443" width="4" height="16" font="0"> </text>
<text top="610" left="548" width="4" height="15" font="5"> </text>
<text top="609" left="552" width="4" height="16" font="0"> </text>
<text top="610" left="630" width="4" height="15" font="5"> </text>
<text top="609" left="634" width="4" height="16" font="0"> </text>
<text top="610" left="673" width="4" height="15" font="5"> </text>
<text top="609" left="677" width="4" height="16" font="0"> </text>
<text top="610" left="816" width="4" height="15" font="5"> </text>
<text top="609" left="820" width="4" height="16" font="0"> </text>
<text top="610" left="915" width="48" height="15" font="14"><i>p=0.66</i></text>
<text top="609" left="964" width="4" height="16" font="15"><i> </i></text>
<text top="610" left="1062" width="57" height="15" font="14"><i>p&lt;0.001</i></text>
<text top="609" left="1119" width="4" height="16" font="15"><i> </i></text>
<text top="610" left="1210" width="57" height="15" font="14"><i>p&lt;0.001</i></text>
<text top="609" left="1266" width="4" height="16" font="15"><i> </i></text>
<text top="610" left="1349" width="4" height="15" font="5"> </text>
<text top="609" left="1353" width="4" height="16" font="0"> </text>
<text top="629" left="108" width="1239" height="12" font="17">*Statistically significant.<i><b> </b></i>CABG, coronary artery bypass surgery; CAD, coronary artery disease; CI, confidence interval; CVA, cerebrovascular accident; DES, drug-eluting stent; HR, hazard ratio; MACCE, major adverse cardiac </text>
<text top="645" left="108" width="996" height="12" font="17">and cerebrovascular events; MI, myocardial infarction; Mo, months; MVD, multivessel disease; N/A, not available; No, number; PCI, percutaneous coronary intervention, and y, year.  </text>
<text top="660" left="108" width="3" height="12" font="17"> </text>
<text top="677" left="108" width="4" height="15" font="4"><b> </b></text>
<text top="696" left="108" width="4" height="15" font="4"><b> </b></text>
<text top="715" left="108" width="4" height="16" font="2"><b> </b></text>
<text top="736" left="108" width="4" height="16" font="2"><b> </b></text>
<text top="736" left="324" width="4" height="16" font="2"><b> </b></text>
</page>
<page number="25" position="absolute" top="0" left="0" height="918" width="1512">
<text top="59" left="108" width="4" height="15" font="0"> </text>
<text top="59" left="459" width="4" height="15" font="0"> </text>
<text top="59" left="810" width="4" height="15" font="0"> </text>
<text top="59" left="864" width="4" height="15" font="0"> </text>
<text top="59" left="918" width="4" height="15" font="0"> </text>
<text top="59" left="972" width="4" height="15" font="0"> </text>
<text top="59" left="1026" width="4" height="15" font="0"> </text>
<text top="59" left="1080" width="4" height="15" font="0"> </text>
<text top="59" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="108" width="613" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="825" left="810" width="4" height="15" font="0"> </text>
<text top="825" left="864" width="4" height="15" font="0"> </text>
<text top="825" left="918" width="4" height="15" font="0"> </text>
<text top="825" left="972" width="4" height="15" font="0"> </text>
<text top="825" left="1026" width="4" height="15" font="0"> </text>
<text top="825" left="1080" width="4" height="15" font="0"> </text>
<text top="825" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="1188" width="4" height="15" font="0"> </text>
<text top="825" left="1242" width="22" height="15" font="0">25 </text>
<text top="847" left="108" width="4" height="15" font="0"> </text>
<text top="112" left="108" width="953" height="16" font="2"><b>Data Supplement 9. Evidence from RCTs and Cohort Studies Comparing PCI with CABG for Unprotected Left Main CAD </b></text>
<text top="133" left="211" width="41" height="15" font="4"><b>Study</b></text>
<text top="132" left="252" width="4" height="16" font="2"><b> </b></text>
<text top="133" left="439" width="104" height="15" font="4"><b>Type of Study/</b></text>
<text top="132" left="543" width="4" height="16" font="2"><b> </b></text>
<text top="152" left="415" width="152" height="15" font="4"><b>Years of Recruitment</b></text>
<text top="151" left="567" width="4" height="16" font="2"><b> </b></text>
<text top="133" left="654" width="85" height="15" font="4"><b>PCI/CABG </b></text>
<text top="132" left="738" width="4" height="16" font="2"><b> </b></text>
<text top="152" left="642" width="103" height="15" font="4"><b>No. of Patients</b></text>
<text top="151" left="746" width="4" height="16" font="2"><b> </b></text>
<text top="133" left="813" width="257" height="15" font="4"><b>Early Results for PCI Versus CABG</b></text>
<text top="132" left="1070" width="4" height="16" font="2"><b> </b></text>
<text top="133" left="1126" width="274" height="15" font="4"><b>1 to 5-Y Results for PCI Versus CABG</b></text>
<text top="132" left="1399" width="4" height="16" font="2"><b> </b></text>
<text top="172" left="108" width="71" height="15" font="5">SYNTAX </text>
<text top="172" left="179" width="27" height="15" font="13">(62)</text>
<text top="171" left="206" width="4" height="16" font="0"> </text>
<text top="172" left="356" width="159" height="15" font="5">Randomized/2005-2007</text>
<text top="171" left="516" width="4" height="16" font="0"> </text>
<text top="191" left="356" width="252" height="15" font="5">45% of screened pts with LM disease </text>
<text top="210" left="356" width="230" height="15" font="5">not randomized, 89% of these had </text>
<text top="229" left="356" width="46" height="15" font="5">CABG</text>
<text top="228" left="402" width="4" height="16" font="0"> </text>
<text top="172" left="627" width="54" height="15" font="5">357/348</text>
<text top="171" left="681" width="4" height="16" font="0"> </text>
<text top="172" left="762" width="182" height="15" font="5">30-d outcomes not reported</text>
<text top="171" left="944" width="4" height="16" font="0"> </text>
<text top="172" left="1121" width="279" height="15" font="5">3-y follow-up: MACCE 13.0% vs. 14.3% </text>
<text top="191" left="1121" width="274" height="15" font="5">(p=0.60); repeat revascularization 20.0% </text>
<text top="210" left="1121" width="285" height="15" font="5">vs. 11.7% (p=0.004); all-cause death 7.3% </text>
<text top="229" left="1121" width="222" height="15" font="5">vs. 8.4% (change -0.2%, p=0.64).</text>
<text top="228" left="1343" width="4" height="16" font="0"> </text>
<text top="251" left="108" width="72" height="15" font="5">LE MANS</text>
<text top="251" left="180" width="32" height="15" font="13"> (63)</text>
<text top="250" left="211" width="4" height="16" font="0"> </text>
<text top="251" left="356" width="159" height="15" font="5">Randomized/2001-2004</text>
<text top="250" left="516" width="4" height="16" font="0"> </text>
<text top="270" left="356" width="244" height="15" font="5">65% of screened pts excluded as not </text>
<text top="289" left="356" width="185" height="15" font="5">suitable for both procedures</text>
<text top="288" left="541" width="4" height="16" font="0"> </text>
<text top="251" left="627" width="38" height="15" font="5">52/53</text>
<text top="250" left="664" width="4" height="16" font="0"> </text>
<text top="251" left="762" width="330" height="15" font="5">30-d outcomes: death  0% vs. 0%; MI 2% vs. 4% </text>
<text top="270" left="762" width="418" height="15" font="5">(p=NS)  MACCE 2% vs. 14% (p=0.01)                                      </text>
<text top="289" left="762" width="349" height="15" font="5">MAE RR: 0.78, p=0.006; MACCE RR: 0.88, p=0.03</text>
<text top="288" left="1111" width="4" height="16" font="0"> </text>
<text top="251" left="1121" width="272" height="15" font="5">1 y follow-up: death 2% vs. 8% (p=NS); </text>
<text top="270" left="1121" width="275" height="15" font="5">MI 2% vs. 6% (p=NS); revascularization </text>
<text top="289" left="1121" width="278" height="15" font="5">30% vs. 10% (p=0.01); MACCE 32% vs. </text>
<text top="308" left="1121" width="284" height="15" font="5">26% (p=NS); MACCE RR: 1.09 (95% CI: </text>
<text top="327" left="1121" width="263" height="15" font="5">0.85 to 1.38); MAE RR: 0.89 (95% CI: </text>
<text top="346" left="1121" width="85" height="15" font="5">0.64 to 1.23)</text>
<text top="345" left="1206" width="4" height="16" font="0"> </text>
<text top="366" left="108" width="99" height="15" font="5">Boudriot et al. </text>
<text top="366" left="207" width="28" height="15" font="13">(64)</text>
<text top="365" left="235" width="4" height="16" font="0"> </text>
<text top="366" left="356" width="159" height="15" font="5">Randomized/2003-2009</text>
<text top="365" left="516" width="4" height="16" font="0"> </text>
<text top="385" left="356" width="197" height="15" font="5">53% of screened pts excluded</text>
<text top="384" left="553" width="4" height="16" font="0"> </text>
<text top="366" left="627" width="54" height="15" font="5">100/201</text>
<text top="365" left="681" width="4" height="16" font="0"> </text>
<text top="366" left="762" width="187" height="15" font="5">Early outcomes not reported</text>
<text top="365" left="949" width="4" height="16" font="0"> </text>
<text top="366" left="1121" width="258" height="15" font="5">12 mo outcomes: death 2.0% vs. 5.0% </text>
<text top="385" left="1121" width="280" height="15" font="5">(p&lt;0.001 for noninferiority); death, MI or </text>
<text top="404" left="1121" width="233" height="15" font="5">revascularization 19.0% vs. 13.9% </text>
<text top="423" left="1121" width="177" height="15" font="5">(p=0.19 for noninferiority)</text>
<text top="422" left="1298" width="4" height="16" font="0"> </text>
<text top="445" left="108" width="81" height="15" font="5">Brener et al.</text>
<text top="445" left="189" width="32" height="15" font="13"> (74)</text>
<text top="444" left="221" width="4" height="16" font="0"> </text>
<text top="445" left="356" width="122" height="15" font="5">Cohort/1997-2006</text>
<text top="444" left="478" width="4" height="16" font="0"> </text>
<text top="445" left="627" width="46" height="15" font="5">97/190</text>
<text top="444" left="673" width="4" height="16" font="0"> </text>
<text top="445" left="762" width="312" height="15" font="5">In-hospital outcomes: death 3% vs. 4% (p=NS)</text>
<text top="444" left="1074" width="4" height="16" font="0"> </text>
<text top="445" left="1121" width="289" height="15" font="5">3 y follow-up: survival 80% vs. 85%;          </text>
<text top="464" left="1121" width="269" height="15" font="5">OR: 1.42 (95% CI: 0.56 to 3.63; p=0.14)</text>
<text top="463" left="1390" width="4" height="16" font="0"> </text>
<text top="493" left="108" width="95" height="15" font="5">Cedars-Sinai (</text>
<text top="493" left="203" width="17" height="15" font="13">67</text>
<text top="493" left="220" width="8" height="15" font="5">, </text>
<text top="493" left="228" width="17" height="15" font="13">69</text>
<text top="493" left="244" width="8" height="15" font="5">, </text>
<text top="493" left="253" width="17" height="15" font="13">70</text>
<text top="493" left="269" width="6" height="15" font="5">)</text>
<text top="492" left="274" width="4" height="16" font="0"> </text>
<text top="493" left="356" width="122" height="15" font="5">Cohort/2003-2005</text>
<text top="492" left="478" width="4" height="16" font="0"> </text>
<text top="493" left="627" width="38" height="15" font="5">67/67</text>
<text top="492" left="664" width="4" height="16" font="0"> </text>
<text top="493" left="762" width="353" height="15" font="5">30-d outcomes: death 2% vs. 5% (p=NS); MI 0% vs. </text>
<text top="512" left="762" width="333" height="15" font="5">2% (p=NS); stroke 0% vs. 8% (p=0.03); MACCE </text>
<text top="531" left="762" width="146" height="15" font="5">17% vs. 2%; (p&lt;0.01)</text>
<text top="530" left="908" width="4" height="16" font="0"> </text>
<text top="493" left="1121" width="274" height="15" font="5">1-2 y follow-up: propensity-adjusted HR </text>
<text top="512" left="1121" width="281" height="15" font="5">for death HR: 1.93 (95% CI: 0.89 to 4.19; </text>
<text top="531" left="1121" width="286" height="15" font="5">p=0.10), MACCE HR: 1.83 (95% CI: 1.01 </text>
<text top="550" left="1121" width="107" height="15" font="5">to 3.32; p=0.05)</text>
<text top="549" left="1228" width="4" height="16" font="0"> </text>
<text top="573" left="108" width="96" height="15" font="5">Chieffo et al. (</text>
<text top="573" left="204" width="17" height="15" font="13">65</text>
<text top="573" left="221" width="8" height="15" font="5">, </text>
<text top="573" left="229" width="17" height="15" font="13">66</text>
<text top="573" left="246" width="6" height="15" font="5">)</text>
<text top="572" left="251" width="4" height="16" font="0"> </text>
<text top="573" left="356" width="122" height="15" font="5">Cohort/2002-2004</text>
<text top="572" left="478" width="4" height="16" font="0"> </text>
<text top="573" left="627" width="54" height="15" font="5">107/142</text>
<text top="572" left="681" width="4" height="16" font="0"> </text>
<text top="573" left="762" width="375" height="15" font="5">In-hospital outcomes: death 0% vs. 2.1% (p=NS);           </text>
<text top="592" left="762" width="335" height="15" font="5">MI 9.3% vs. 26.1% (p=0.0009); stroke 0% vs. 2% </text>
<text top="611" left="762" width="50" height="15" font="5">(p=NS)</text>
<text top="610" left="812" width="4" height="16" font="0"> </text>
<text top="573" left="1121" width="280" height="15" font="5">5 y adjusted cardiac death OR: 0.50 (95% </text>
<text top="592" left="1121" width="283" height="15" font="5">CI: 0.16 to 1.46; p=0.24), cardiac death or </text>
<text top="611" left="1121" width="250" height="15" font="5">MI   OR: 0.41 (95% CI: 0.15 to 1.06; </text>
<text top="630" left="1121" width="260" height="15" font="5">p=0.06); death, MI, or stroke OR: 0.40 </text>
<text top="649" left="1121" width="282" height="15" font="5">(95% CI: 0.15 to 0.99; p=0.04); TVR OR: </text>
<text top="668" left="1121" width="267" height="15" font="5">4.41(95% CI: 1.83 to 11.37; p=0.0004), </text>
<text top="687" left="1121" width="280" height="15" font="5">MACCE OR: 1.58 (95% CI: 0.83 to 3.05; </text>
<text top="706" left="1121" width="52" height="15" font="5">p=0.18)</text>
<text top="705" left="1173" width="4" height="16" font="0"> </text>
</page>
<page number="26" position="absolute" top="0" left="0" height="918" width="1512">
<text top="59" left="108" width="4" height="15" font="0"> </text>
<text top="59" left="459" width="4" height="15" font="0"> </text>
<text top="59" left="810" width="4" height="15" font="0"> </text>
<text top="59" left="864" width="4" height="15" font="0"> </text>
<text top="59" left="918" width="4" height="15" font="0"> </text>
<text top="59" left="972" width="4" height="15" font="0"> </text>
<text top="59" left="1026" width="4" height="15" font="0"> </text>
<text top="59" left="1080" width="4" height="15" font="0"> </text>
<text top="59" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="108" width="613" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="825" left="810" width="4" height="15" font="0"> </text>
<text top="825" left="864" width="4" height="15" font="0"> </text>
<text top="825" left="918" width="4" height="15" font="0"> </text>
<text top="825" left="972" width="4" height="15" font="0"> </text>
<text top="825" left="1026" width="4" height="15" font="0"> </text>
<text top="825" left="1080" width="4" height="15" font="0"> </text>
<text top="825" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="1188" width="4" height="15" font="0"> </text>
<text top="825" left="1242" width="22" height="15" font="0">26 </text>
<text top="847" left="108" width="4" height="15" font="0"> </text>
<text top="112" left="108" width="139" height="15" font="5">MAIN-COMPARE (</text>
<text top="112" left="247" width="17" height="15" font="13">72</text>
<text top="112" left="263" width="8" height="15" font="5">, </text>
<text top="112" left="272" width="25" height="15" font="13">177</text>
<text top="112" left="296" width="6" height="15" font="5">)</text>
<text top="111" left="302" width="4" height="16" font="0"> </text>
<text top="112" left="356" width="122" height="15" font="5">Cohort/2000-2006</text>
<text top="111" left="478" width="4" height="16" font="0"> </text>
<text top="112" left="627" width="71" height="15" font="5">1102/1138</text>
<text top="111" left="697" width="4" height="16" font="0"> </text>
<text top="112" left="762" width="182" height="15" font="5">30-d outcomes not reported</text>
<text top="111" left="944" width="4" height="16" font="0"> </text>
<text top="112" left="1121" width="110" height="15" font="5">5-y adjusted risk</text>
<text top="109" left="1231" width="3" height="9" font="19"> </text>
<text top="112" left="1234" width="162" height="15" font="5">of death HR: 1.13 (95% </text>
<text top="131" left="1121" width="242" height="15" font="5">CI: 0.88 to 1.44, p=0.35), combined </text>
<text top="150" left="1121" width="202" height="15" font="5">adjusted risk of death, Q-wave</text>
<text top="147" left="1323" width="3" height="9" font="19"> </text>
<text top="150" left="1326" width="46" height="15" font="5">MI, or </text>
<text top="169" left="1121" width="265" height="15" font="5">stroke HR: 1.07          ( 95% CI: 0.84 to </text>
<text top="188" left="1121" width="265" height="15" font="5">1.37,p=0.59); TVR HR: 5.11  (95% CI: </text>
<text top="207" left="1121" width="143" height="15" font="5">3.52 to 7.42,p&lt;0.001)</text>
<text top="206" left="1264" width="4" height="16" font="0"> </text>
<text top="228" left="108" width="113" height="15" font="5">Mäkikallio et al. </text>
<text top="228" left="221" width="27" height="15" font="13">(75)</text>
<text top="227" left="248" width="4" height="16" font="0"> </text>
<text top="228" left="356" width="122" height="15" font="5">Cohort/2005-2207</text>
<text top="227" left="478" width="4" height="16" font="0"> </text>
<text top="228" left="627" width="46" height="15" font="5">49/238</text>
<text top="227" left="673" width="4" height="16" font="0"> </text>
<text top="228" left="762" width="477" height="15" font="5">30-d outcomes: death 2% vs. 7% (p=0.13)                                                </text>
<text top="228" left="1121" width="223" height="15" font="5">1-y follow-up: death 4% vs. 11% </text>
<text top="247" left="1121" width="284" height="15" font="5">(p=0.14);                             PCI vs. CABG </text>
<text top="266" left="1121" width="54" height="15" font="5">(using 1</text>
<text top="262" left="1175" width="5" height="9" font="19">o</text>
<text top="266" left="1180" width="40" height="15" font="5"> and 2</text>
<text top="262" left="1221" width="8" height="9" font="19">o </text>
<text top="266" left="1228" width="164" height="15" font="5">endpoint) HR: 2.1 (95% </text>
<text top="285" left="1121" width="160" height="15" font="5">CI: 0.7 to 5.8, p= 0.180)</text>
<text top="284" left="1281" width="4" height="16" font="0"> </text>
<text top="304" left="108" width="105" height="15" font="5">Palmerini et al. </text>
<text top="304" left="213" width="27" height="15" font="13">(71)</text>
<text top="303" left="240" width="4" height="16" font="0"> </text>
<text top="304" left="356" width="122" height="15" font="5">Cohort/2002-2005</text>
<text top="303" left="478" width="4" height="16" font="0"> </text>
<text top="304" left="627" width="54" height="15" font="5">157/154</text>
<text top="303" left="681" width="4" height="16" font="0"> </text>
<text top="304" left="762" width="329" height="15" font="5">30-d outcomes: death 3.2% vs. 4.5% (p=NS); MI </text>
<text top="323" left="762" width="337" height="15" font="5">4.5% vs. 1.9%,(p=NS); revascularization 0.6% vs. </text>
<text top="342" left="762" width="88" height="15" font="5">0.6% (p=NS)</text>
<text top="341" left="850" width="4" height="16" font="0"> </text>
<text top="304" left="1121" width="269" height="15" font="5">1-2 y follow-up: death 13.4% vs. 12.3% </text>
<text top="323" left="1121" width="248" height="15" font="5">(p=0.8); MI 8.3% vs. 4.5% (p=0.17); </text>
<text top="342" left="1121" width="225" height="15" font="5">revascularization 25.5% vs. 2.6% </text>
<text top="361" left="1121" width="286" height="15" font="5">(p=0.0001); PCI vs. CABG mortality HR:  </text>
<text top="380" left="1121" width="254" height="15" font="5">0.95 (95% CI: 0.51 to 1.77, p=0.861); </text>
<text top="399" left="1121" width="283" height="15" font="5">cardiac mortality HR: 0.99, (95% CI: 0.49 </text>
<text top="418" left="1121" width="281" height="15" font="5">to 2.04, p=0.994); MI  HR: 0.53 (95% CI: </text>
<text top="437" left="1121" width="148" height="15" font="5">0.21 to 1.32; p=0.170)</text>
<text top="436" left="1269" width="4" height="16" font="0"> </text>
<text top="456" left="1121" width="4" height="16" font="0"> </text>
<text top="478" left="108" width="129" height="15" font="5">Rodés-Cabau et al. </text>
<text top="478" left="237" width="36" height="15" font="13">(178)</text>
<text top="477" left="273" width="4" height="16" font="0"> </text>
<text top="478" left="356" width="126" height="15" font="5">Cohort/2002-2008 </text>
<text top="477" left="482" width="4" height="16" font="0"> </text>
<text top="478" left="627" width="54" height="15" font="5">104/145</text>
<text top="477" left="681" width="4" height="16" font="0"> </text>
<text top="478" left="762" width="330" height="15" font="5">30-d outcomes: MACCE 18.3% vs. 27.6%; death </text>
<text top="497" left="762" width="356" height="15" font="5">6.7% vs. 8.3%; MI 12.5% vs. 17.2%; stroke 1.0% vs. </text>
<text top="515" left="762" width="109" height="15" font="5">5.5% (all p=NS)</text>
<text top="514" left="871" width="4" height="16" font="0"> </text>
<text top="478" left="1121" width="285" height="15" font="5">1-2-y follow-up: MACCE 43.3% vs. 35%; </text>
<text top="497" left="1121" width="283" height="15" font="5">death 16.3% vs. 12.4%; MI 23.1% 19.3%; </text>
<text top="515" left="1121" width="266" height="15" font="5">revascularization 9.6% vs. 4.8%; stroke </text>
<text top="535" left="1121" width="304" height="15" font="5">8.75 vs. 6.2% (all NS).                                     </text>
<text top="553" left="1121" width="241" height="15" font="5">Survival free of cardiac death or MI </text>
<text top="573" left="1121" width="277" height="15" font="5">adjusted HR: 1.28 (95% CI: 0.64 to 2.56; </text>
<text top="591" left="1121" width="271" height="15" font="5">p=0.47); MACCE-free survival adjusted </text>
<text top="610" left="1121" width="265" height="15" font="5">HR: 1.11(95% CI: 0.59 to 2.0; p= 0.73).</text>
<text top="609" left="1386" width="4" height="16" font="0"> </text>
<text top="630" left="1121" width="4" height="16" font="0"> </text>
<text top="651" left="108" width="108" height="15" font="5">Sanmartín et al. </text>
<text top="651" left="216" width="28" height="15" font="13">(73)</text>
<text top="650" left="244" width="4" height="16" font="0"> </text>
<text top="651" left="356" width="122" height="15" font="5">Cohort/2000-2005</text>
<text top="650" left="478" width="4" height="16" font="0"> </text>
<text top="651" left="627" width="46" height="15" font="5">96/245</text>
<text top="650" left="673" width="4" height="16" font="0"> </text>
<text top="651" left="762" width="357" height="15" font="5">30-d outcomes: MACCE after surgery 2.1% vs. 9.0% </text>
<text top="670" left="762" width="62" height="15" font="5">(p=0.03).</text>
<text top="669" left="824" width="4" height="16" font="0"> </text>
<text top="651" left="1121" width="283" height="15" font="5">1-y follow-up: MACCE 10.4% vs. 11.4%, </text>
<text top="670" left="1121" width="266" height="15" font="5">(p=0.50), repeat revascularization 5.2% </text>
<text top="689" left="1121" width="119" height="15" font="5">vs. 0.8% (p=0.02)</text>
<text top="688" left="1240" width="4" height="16" font="0"> </text>
</page>
<page number="27" position="absolute" top="0" left="0" height="918" width="1512">
<text top="59" left="108" width="4" height="15" font="0"> </text>
<text top="59" left="459" width="4" height="15" font="0"> </text>
<text top="59" left="810" width="4" height="15" font="0"> </text>
<text top="59" left="864" width="4" height="15" font="0"> </text>
<text top="59" left="918" width="4" height="15" font="0"> </text>
<text top="59" left="972" width="4" height="15" font="0"> </text>
<text top="59" left="1026" width="4" height="15" font="0"> </text>
<text top="59" left="1080" width="4" height="15" font="0"> </text>
<text top="59" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="108" width="613" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="825" left="810" width="4" height="15" font="0"> </text>
<text top="825" left="864" width="4" height="15" font="0"> </text>
<text top="825" left="918" width="4" height="15" font="0"> </text>
<text top="825" left="972" width="4" height="15" font="0"> </text>
<text top="825" left="1026" width="4" height="15" font="0"> </text>
<text top="825" left="1080" width="4" height="15" font="0"> </text>
<text top="825" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="1188" width="4" height="15" font="0"> </text>
<text top="825" left="1242" width="22" height="15" font="0">27 </text>
<text top="847" left="108" width="4" height="15" font="0"> </text>
<text top="112" left="108" width="64" height="15" font="5">Wu et al. </text>
<text top="112" left="172" width="27" height="15" font="13">(60)</text>
<text top="111" left="200" width="4" height="16" font="0"> </text>
<text top="112" left="356" width="122" height="15" font="5">Cohort/2000-2004</text>
<text top="111" left="478" width="4" height="16" font="0"> </text>
<text top="112" left="627" width="54" height="15" font="5">135/135</text>
<text top="111" left="681" width="4" height="16" font="0"> </text>
<text top="112" left="762" width="304" height="15" font="5">30-d outcomes: death 5.2% vs. 2.2% (p=0.33)</text>
<text top="111" left="1066" width="4" height="16" font="0"> </text>
<text top="112" left="1121" width="280" height="15" font="5">1-y follow-up: death 16.1% vs. 5.9% OR: </text>
<text top="131" left="1121" width="182" height="15" font="5">3.06 (95% CI: 0.99 to 9.45)</text>
<text top="130" left="1304" width="4" height="16" font="0"> </text>
<text top="150" left="1121" width="284" height="15" font="5">2-y follow-up: death 18.0% vs. 5.9%; HR: </text>
<text top="169" left="1121" width="246" height="15" font="5">3.1 (95% CI: 1.42 to 7.14; p=0.005); </text>
<text top="188" left="1121" width="113" height="15" font="5">revascularization</text>
<text top="185" left="1234" width="3" height="9" font="19"> </text>
<text top="188" left="1237" width="144" height="15" font="5">37.3% vs. 6.3%; HR: </text>
<text top="207" left="1121" width="234" height="15" font="5">6.7; (95% CI: 3.0 to 14.3; p&lt;0.001)</text>
<text top="206" left="1355" width="4" height="16" font="0"> </text>
<text top="226" left="108" width="821" height="12" font="17">CABG indicates coronary artery bypass grafting; CI, confidence interval; d, day; HR, hazard ratio; LEMANS, Study of Unprotected Left Main Stenting</text>
<text top="223" left="929" width="2" height="8" font="21"> </text>
<text top="226" left="931" width="417" height="12" font="17">Versus Bypass Surgery; LM, left main; MACCE, Major adverse cardiac and </text>
<text top="242" left="108" width="1283" height="12" font="17">cardiovascular events; MAE, major adverse events; MAIN-COMPARE, Revascularization for Unprotected Left Main Coronary Artery Stenosis: Comparison of Percutaneous Coronary Angioplasty versus Surgical Revascularization; MI, </text>
<text top="257" left="108" width="1266" height="12" font="17">myocardial infarction; NS, not significant; OR, odds ratio; pts, patients; PCI, percutaneous coronary intervention; RR, relative risk; SYNTAX, Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery; </text>
<text top="273" left="108" width="270" height="12" font="17">TVR, target vessel revascularization; and y, year. </text>
</page>
<page number="28" position="absolute" top="0" left="0" height="918" width="1512">
	<fontspec id="23" size="7" family="Times" color="#000000"/>
<text top="59" left="108" width="4" height="15" font="0"> </text>
<text top="59" left="459" width="4" height="15" font="0"> </text>
<text top="59" left="810" width="4" height="15" font="0"> </text>
<text top="59" left="864" width="4" height="15" font="0"> </text>
<text top="59" left="918" width="4" height="15" font="0"> </text>
<text top="59" left="972" width="4" height="15" font="0"> </text>
<text top="59" left="1026" width="4" height="15" font="0"> </text>
<text top="59" left="1080" width="4" height="15" font="0"> </text>
<text top="59" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="108" width="613" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="825" left="810" width="4" height="15" font="0"> </text>
<text top="825" left="864" width="4" height="15" font="0"> </text>
<text top="825" left="918" width="4" height="15" font="0"> </text>
<text top="825" left="972" width="4" height="15" font="0"> </text>
<text top="825" left="1026" width="4" height="15" font="0"> </text>
<text top="825" left="1080" width="4" height="15" font="0"> </text>
<text top="825" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="1188" width="4" height="15" font="0"> </text>
<text top="825" left="1242" width="22" height="15" font="0">28 </text>
<text top="847" left="108" width="4" height="15" font="0"> </text>
<text top="112" left="108" width="863" height="16" font="2"><b>Data Supplement 10. Forest Plot of 1-Year MACCE Rates After PCI or CABG for Unprotected Left Main CAD<i> </i></b></text>
<text top="552" left="1188" width="4" height="15" font="5"> </text>
<text top="567" left="108" width="557" height="14" font="7">References: (62-67, 69, 70, 72, 177, 178). OR &gt;1 suggest an advantage of CABG over PCI.  </text>
<text top="584" left="108" width="894" height="14" font="7">CABG indicates coronary artery bypass surgery; CAD, coronary artery disease; CI, confidence interval; LEMANS, Study of Unprotected Left Main </text>
<text top="601" left="108" width="50" height="14" font="7">Stenting</text>
<text top="598" left="158" width="2" height="9" font="23"> </text>
<text top="601" left="161" width="802" height="14" font="7">Versus Bypass Surgery; MAIN-COMPARE, Revascularization for Unprotected Left Main Coronary Artery Stenosis: Comparison of </text>
<text top="618" left="108" width="920" height="14" font="7">Percutaneous Coronary Angioplasty versus Surgical Revascularization; MACCE, major adverse cardiac and cerebrovascular event; OR, odds ratio; PCI, </text>
<text top="636" left="108" width="882" height="14" font="7">percutaneous coronary intervention; SYNTAX, Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery; and W, </text>
<text top="653" left="108" width="62" height="14" font="7">weighted. </text>
</page>
<page number="29" position="absolute" top="0" left="0" height="918" width="1512">
<text top="59" left="108" width="4" height="15" font="0"> </text>
<text top="59" left="459" width="4" height="15" font="0"> </text>
<text top="59" left="810" width="4" height="15" font="0"> </text>
<text top="59" left="864" width="4" height="15" font="0"> </text>
<text top="59" left="918" width="4" height="15" font="0"> </text>
<text top="59" left="972" width="4" height="15" font="0"> </text>
<text top="59" left="1026" width="4" height="15" font="0"> </text>
<text top="59" left="1080" width="4" height="15" font="0"> </text>
<text top="59" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="108" width="613" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="825" left="810" width="4" height="15" font="0"> </text>
<text top="825" left="864" width="4" height="15" font="0"> </text>
<text top="825" left="918" width="4" height="15" font="0"> </text>
<text top="825" left="972" width="4" height="15" font="0"> </text>
<text top="825" left="1026" width="4" height="15" font="0"> </text>
<text top="825" left="1080" width="4" height="15" font="0"> </text>
<text top="825" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="1188" width="4" height="15" font="0"> </text>
<text top="825" left="1242" width="22" height="15" font="0">29 </text>
<text top="847" left="108" width="4" height="15" font="0"> </text>
<text top="112" left="108" width="865" height="16" font="2"><b>Data Supplement 11. Forest Plot of 1-Year Mortality Rates After PCI or CABG for Unprotected Left Main CAD</b></text>
<text top="113" left="973" width="4" height="15" font="5"> </text>
<text top="590" left="1181" width="4" height="15" font="5"> </text>
<text top="605" left="108" width="577" height="14" font="7">References: (60, 62-67, 69-72, 75, 177, 178). OR &gt;1 suggest an advantage of CABG over PCI.  </text>
<text top="622" left="108" width="944" height="14" font="7">CABG indicates coronary artery bypass surgery; CAD, coronary artery disease; CI, confidence interval; LEMANS, Study of Unprotected Left Main Stenting</text>
<text top="619" left="1052" width="2" height="9" font="23"> </text>
<text top="622" left="1054" width="152" height="14" font="7">Versus Bypass Surgery;  </text>
<text top="639" left="108" width="1102" height="14" font="7">MACCE, major adverse cardiac and cerebrovascular event; MAIN-COMPARE, Revascularization for Unprotected Left Main Coronary Artery Stenosis: Comparison of Percutaneous  </text>
<text top="656" left="108" width="1169" height="14" font="7">Coronary Angioplasty versus Surgical Revascularization; OR, odds ratio; SYNTAX, Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery; and W, weighted. </text>
<text top="674" left="108" width="4" height="14" font="7"> </text>
<text top="674" left="324" width="4" height="14" font="7"> </text>
</page>
<page number="30" position="absolute" top="0" left="0" height="918" width="1512">
<text top="59" left="108" width="4" height="15" font="0"> </text>
<text top="59" left="459" width="4" height="15" font="0"> </text>
<text top="59" left="810" width="4" height="15" font="0"> </text>
<text top="59" left="864" width="4" height="15" font="0"> </text>
<text top="59" left="918" width="4" height="15" font="0"> </text>
<text top="59" left="972" width="4" height="15" font="0"> </text>
<text top="59" left="1026" width="4" height="15" font="0"> </text>
<text top="59" left="1080" width="4" height="15" font="0"> </text>
<text top="59" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="108" width="613" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="825" left="810" width="4" height="15" font="0"> </text>
<text top="825" left="864" width="4" height="15" font="0"> </text>
<text top="825" left="918" width="4" height="15" font="0"> </text>
<text top="825" left="972" width="4" height="15" font="0"> </text>
<text top="825" left="1026" width="4" height="15" font="0"> </text>
<text top="825" left="1080" width="4" height="15" font="0"> </text>
<text top="825" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="1188" width="4" height="15" font="0"> </text>
<text top="825" left="1242" width="22" height="15" font="0">30 </text>
<text top="847" left="108" width="4" height="15" font="0"> </text>
<text top="113" left="108" width="4" height="15" font="5"> </text>
<text top="112" left="112" width="869" height="16" font="2"><b>Data Supplement 12. Forest Plot of 2-Year Mortality Rates After PCI or CABG for Unprotected Left Main CAD </b></text>
<text top="493" left="1186" width="4" height="15" font="5"> </text>
<text top="508" left="108" width="534" height="14" font="7">References: (60, 63, 71, 72, 177-179). OR &gt;1 suggest an advantage of CABG over PCI.  </text>
<text top="525" left="108" width="1192" height="14" font="7">CABG indicates coronary artery bypass surgery; CAD, coronary artery disease; CI, confidence interval; MAIN-COMPARE, Revascularization for Unprotected Left Main Coronary Artery Stenosis:  </text>
<text top="543" left="108" width="1199" height="14" font="7">Comparison of Percutaneous Coronary Angioplasty versus Surgical Revascularization; OR, odds ratio; PCI, percutaneous coronary intervention; SYNTAX, Synergy Between Percutaneous Coronary  </text>
<text top="561" left="108" width="394" height="14" font="7">Intervention with TAXUS and Cardiac Surgery; and W, weighted</text>
<text top="560" left="502" width="8" height="15" font="5">. </text>
</page>
<page number="31" position="absolute" top="0" left="0" height="918" width="1512">
<text top="59" left="108" width="4" height="15" font="0"> </text>
<text top="59" left="459" width="4" height="15" font="0"> </text>
<text top="59" left="810" width="4" height="15" font="0"> </text>
<text top="59" left="864" width="4" height="15" font="0"> </text>
<text top="59" left="918" width="4" height="15" font="0"> </text>
<text top="59" left="972" width="4" height="15" font="0"> </text>
<text top="59" left="1026" width="4" height="15" font="0"> </text>
<text top="59" left="1080" width="4" height="15" font="0"> </text>
<text top="59" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="108" width="613" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="825" left="810" width="4" height="15" font="0"> </text>
<text top="825" left="864" width="4" height="15" font="0"> </text>
<text top="825" left="918" width="4" height="15" font="0"> </text>
<text top="825" left="972" width="4" height="15" font="0"> </text>
<text top="825" left="1026" width="4" height="15" font="0"> </text>
<text top="825" left="1080" width="4" height="15" font="0"> </text>
<text top="825" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="1188" width="4" height="15" font="0"> </text>
<text top="825" left="1242" width="22" height="15" font="0">31 </text>
<text top="847" left="108" width="4" height="15" font="0"> </text>
<text top="130" left="108" width="881" height="16" font="2"><b>Data Supplement 13. Forest Plot of 3-Year Mortality Rates After PCI or CABG (for Unprotected Left Main CAD) </b></text>
<text top="438" left="1188" width="4" height="15" font="5"> </text>
<text top="453" left="108" width="435" height="14" font="7">References: (72, 74).  OR &gt;1 suggest an advantage of CABG over PCI.  </text>
<text top="470" left="108" width="1192" height="14" font="7">CABG indicates coronary artery bypass surgery; CAD, coronary artery disease; CI, confidence interval; MAIN-COMPARE, Revascularization for Unprotected Left Main Coronary Artery Stenosis:  </text>
<text top="488" left="108" width="986" height="14" font="7">Comparison of Percutaneous Coronary Angioplasty versus Surgical Revascularization; OR, odds ratio; PCI, percutaneous coronary intervention; and W, weighted.  </text>
<text top="504" left="108" width="3" height="12" font="17"> </text>
<text top="521" left="108" width="4" height="16" font="2"><b> </b></text>
<text top="521" left="324" width="4" height="16" font="2"><b> </b></text>
</page>
<page number="32" position="absolute" top="0" left="0" height="918" width="1512">
<text top="59" left="108" width="4" height="15" font="0"> </text>
<text top="59" left="459" width="4" height="15" font="0"> </text>
<text top="59" left="810" width="4" height="15" font="0"> </text>
<text top="59" left="864" width="4" height="15" font="0"> </text>
<text top="59" left="918" width="4" height="15" font="0"> </text>
<text top="59" left="972" width="4" height="15" font="0"> </text>
<text top="59" left="1026" width="4" height="15" font="0"> </text>
<text top="59" left="1080" width="4" height="15" font="0"> </text>
<text top="59" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="108" width="613" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="825" left="810" width="4" height="15" font="0"> </text>
<text top="825" left="864" width="4" height="15" font="0"> </text>
<text top="825" left="918" width="4" height="15" font="0"> </text>
<text top="825" left="972" width="4" height="15" font="0"> </text>
<text top="825" left="1026" width="4" height="15" font="0"> </text>
<text top="825" left="1080" width="4" height="15" font="0"> </text>
<text top="825" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="1188" width="4" height="15" font="0"> </text>
<text top="825" left="1242" width="22" height="15" font="0">32 </text>
<text top="847" left="108" width="4" height="15" font="0"> </text>
<text top="112" left="108" width="869" height="16" font="2"><b>Data Supplement 14. Forest Plot of 5-Year Mortality Rates After PCI or CABG for Unprotected Left Main CAD </b></text>
<text top="132" left="108" width="4" height="15" font="5"> </text>
<text top="460" left="1188" width="4" height="15" font="5"> </text>
<text top="475" left="108" width="432" height="14" font="7">References: (66, 72). OR &gt;1 suggest an advantage of CABG over PCI.  </text>
<text top="492" left="108" width="1091" height="14" font="7">CABG indicates coronary artery bypass surgery; CAD, coronary artery disease; CI, confidence interval; MAIN-COMPARE, Revascularization for Unprotected Left Main Coronary  </text>
<text top="510" left="108" width="1075" height="14" font="7">Artery Stenosis: Comparison of Percutaneous Coronary Angioplasty versus Surgical Revascularization; OR, odds ratio; PCI, percutaneous coronary intervention; and W, weighted</text>
<text top="511" left="1184" width="7" height="12" font="17">. </text>
<text top="528" left="108" width="4" height="16" font="2"><b> </b></text>
<text top="528" left="324" width="4" height="16" font="2"><b> </b></text>
</page>
<page number="33" position="absolute" top="0" left="0" height="918" width="1512">
<text top="59" left="108" width="4" height="15" font="0"> </text>
<text top="59" left="459" width="4" height="15" font="0"> </text>
<text top="59" left="810" width="4" height="15" font="0"> </text>
<text top="59" left="864" width="4" height="15" font="0"> </text>
<text top="59" left="918" width="4" height="15" font="0"> </text>
<text top="59" left="972" width="4" height="15" font="0"> </text>
<text top="59" left="1026" width="4" height="15" font="0"> </text>
<text top="59" left="1080" width="4" height="15" font="0"> </text>
<text top="59" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="108" width="613" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="825" left="810" width="4" height="15" font="0"> </text>
<text top="825" left="864" width="4" height="15" font="0"> </text>
<text top="825" left="918" width="4" height="15" font="0"> </text>
<text top="825" left="972" width="4" height="15" font="0"> </text>
<text top="825" left="1026" width="4" height="15" font="0"> </text>
<text top="825" left="1080" width="4" height="15" font="0"> </text>
<text top="825" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="1188" width="4" height="15" font="0"> </text>
<text top="825" left="1242" width="22" height="15" font="0">33 </text>
<text top="847" left="108" width="4" height="15" font="0"> </text>
<text top="112" left="108" width="1238" height="16" font="2"><b>Data Supplement 15. Outcomes of PCI Versus CABG for Patients With Single-Vessel Coronary Disease Involving the Proximal Left Anterior Descending Artery </b></text>
<text top="133" left="195" width="51" height="15" font="4"><b>Author</b></text>
<text top="132" left="247" width="4" height="16" font="2"><b> </b></text>
<text top="133" left="376" width="108" height="15" font="4"><b>Type of Study/ </b></text>
<text top="132" left="484" width="4" height="16" font="2"><b> </b></text>
<text top="152" left="352" width="152" height="15" font="4"><b>Years of Recruitment</b></text>
<text top="151" left="504" width="4" height="16" font="2"><b> </b></text>
<text top="133" left="539" width="81" height="15" font="4"><b>Number of </b></text>
<text top="152" left="549" width="61" height="15" font="4"><b>Patients </b></text>
<text top="171" left="537" width="81" height="15" font="4"><b>PCI/CABG</b></text>
<text top="170" left="618" width="4" height="16" font="2"><b> </b></text>
<text top="133" left="718" width="343" height="15" font="4"><b>Short-Term Results for                                           </b></text>
<text top="152" left="734" width="133" height="15" font="4"><b>PCI Versus CABG</b></text>
<text top="151" left="867" width="4" height="16" font="2"><b> </b></text>
<text top="133" left="1104" width="166" height="15" font="4"><b>Long-Term Results for </b></text>
<text top="132" left="1271" width="4" height="16" font="2"><b> </b></text>
<text top="152" left="1119" width="133" height="15" font="4"><b>PCI Versus CABG</b></text>
<text top="151" left="1252" width="4" height="16" font="2"><b> </b></text>
<text top="191" left="108" width="118" height="15" font="5">Greenbaum et al. </text>
<text top="191" left="225" width="27" height="15" font="13">(97)</text>
<text top="190" left="253" width="4" height="16" font="0"> </text>
<text top="191" left="335" width="137" height="15" font="5">Retrospective cohort</text>
<text top="190" left="472" width="4" height="16" font="0"> </text>
<text top="210" left="335" width="71" height="15" font="5">1986-1994</text>
<text top="209" left="407" width="4" height="16" font="0"> </text>
<text top="191" left="521" width="54" height="15" font="5">754/149</text>
<text top="190" left="575" width="4" height="16" font="0"> </text>
<text top="191" left="635" width="319" height="15" font="5">At 1 y, HR for event-free survival for CABG to </text>
<text top="210" left="635" width="135" height="15" font="5">PCI: 0.20; p&lt;0.0001</text>
<text top="209" left="770" width="4" height="16" font="0"> </text>
<text top="191" left="967" width="420" height="15" font="5">At 2 to 7 y, HR for event-free survival for CABG to PCI: 0.62; </text>
<text top="210" left="967" width="39" height="15" font="5">p=NS</text>
<text top="209" left="1006" width="4" height="16" font="0"> </text>
<text top="241" left="108" width="74" height="15" font="5">Goy et al. (</text>
<text top="241" left="182" width="29" height="15" font="13">104,</text>
<text top="241" left="211" width="4" height="15" font="5"> </text>
<text top="241" left="215" width="25" height="15" font="13">105</text>
<text top="241" left="240" width="8" height="15" font="5">, </text>
<text top="241" left="248" width="25" height="15" font="13">180</text>
<text top="241" left="273" width="6" height="15" font="5">)</text>
<text top="240" left="278" width="4" height="16" font="0"> </text>
<text top="241" left="335" width="87" height="15" font="5">Randomized </text>
<text top="240" left="423" width="4" height="16" font="0"> </text>
<text top="260" left="335" width="71" height="15" font="5">1994-1998</text>
<text top="259" left="407" width="4" height="16" font="0"> </text>
<text top="241" left="521" width="38" height="15" font="5">68/66</text>
<text top="240" left="559" width="4" height="16" font="0"> </text>
<text top="241" left="635" width="335" height="15" font="5">At 2.4 y: death, MI, revascularization 31% vs. 7% </text>
<text top="260" left="635" width="236" height="15" font="5">(p&lt;0.001); death or MI 12% vs. 7%</text>
<text top="259" left="871" width="4" height="16" font="0"> </text>
<text top="241" left="967" width="231" height="15" font="5">At 5 y: death 9% vs. 3% (p=0.09). </text>
<text top="240" left="1198" width="4" height="16" font="0"> </text>
<text top="260" left="967" width="239" height="15" font="5">At 10 y: death 10% vs. 10% (p=1.0)</text>
<text top="259" left="1206" width="4" height="16" font="0"> </text>
<text top="292" left="108" width="102" height="15" font="5">Cisowski et al. </text>
<text top="292" left="210" width="36" height="15" font="13">(100)</text>
<text top="291" left="246" width="4" height="16" font="0"> </text>
<text top="292" left="335" width="87" height="15" font="5">Randomized </text>
<text top="291" left="423" width="4" height="16" font="0"> </text>
<text top="310" left="335" width="71" height="15" font="5">2000-2001</text>
<text top="309" left="407" width="4" height="16" font="0"> </text>
<text top="292" left="521" width="38" height="15" font="5">50/50</text>
<text top="291" left="559" width="4" height="16" font="0"> </text>
<text top="292" left="635" width="229" height="15" font="5">At 6 mo: death or MI:  0% vs. 0%;</text>
<text top="291" left="864" width="4" height="16" font="0"> </text>
<text top="310" left="635" width="262" height="15" font="5"> revascularization 12% vs. 2% (p&lt;0.05)</text>
<text top="309" left="897" width="4" height="16" font="0"> </text>
<text top="292" left="967" width="29" height="15" font="5">N/A</text>
<text top="291" left="995" width="4" height="16" font="0"> </text>
<text top="338" left="108" width="97" height="15" font="5">Diegeler et al. </text>
<text top="338" left="205" width="36" height="15" font="13">(101)</text>
<text top="337" left="241" width="4" height="16" font="0"> </text>
<text top="338" left="335" width="87" height="15" font="5">Randomized </text>
<text top="337" left="423" width="4" height="16" font="0"> </text>
<text top="357" left="335" width="76" height="15" font="5">1997- 2001</text>
<text top="356" left="411" width="4" height="16" font="0"> </text>
<text top="338" left="521" width="54" height="15" font="5">110/110</text>
<text top="337" left="575" width="4" height="16" font="0"> </text>
<text top="338" left="635" width="279" height="15" font="5">At 6 mo: death or MI 3% vs. 6% (p=NS); </text>
<text top="357" left="635" width="258" height="15" font="5">revascularization 29% vs. 8% (p=0.02)</text>
<text top="356" left="893" width="4" height="16" font="0"> </text>
<text top="338" left="967" width="29" height="15" font="5">N/A</text>
<text top="337" left="995" width="4" height="16" font="0"> </text>
<text top="385" left="108" width="92" height="15" font="5">Drenth et al. (</text>
<text top="385" left="200" width="25" height="15" font="13">102</text>
<text top="385" left="225" width="8" height="15" font="5">, </text>
<text top="385" left="233" width="25" height="15" font="13">137</text>
<text top="385" left="257" width="6" height="15" font="5">)</text>
<text top="384" left="263" width="4" height="16" font="0"> </text>
<text top="385" left="335" width="83" height="15" font="5">Randomized</text>
<text top="384" left="418" width="4" height="16" font="0"> </text>
<text top="404" left="335" width="55" height="15" font="5">1997-99</text>
<text top="403" left="390" width="4" height="16" font="0"> </text>
<text top="385" left="521" width="38" height="15" font="5">51/51</text>
<text top="384" left="559" width="4" height="16" font="0"> </text>
<text top="385" left="635" width="287" height="15" font="5">At 6 mo: death or MI 6% vs. 10% (p=NS); </text>
<text top="404" left="635" width="242" height="15" font="5">revascularization 4% vs. 8% (p=NS)</text>
<text top="403" left="877" width="4" height="16" font="0"> </text>
<text top="385" left="967" width="29" height="15" font="5">N/A</text>
<text top="384" left="995" width="4" height="16" font="0"> </text>
<text top="434" left="108" width="88" height="15" font="5">Reeves et al. </text>
<text top="434" left="196" width="36" height="15" font="13">(166)</text>
<text top="433" left="232" width="4" height="16" font="0"> </text>
<text top="434" left="335" width="83" height="15" font="5">Randomized</text>
<text top="433" left="418" width="4" height="16" font="0"> </text>
<text top="453" left="335" width="71" height="15" font="5">1999-2001</text>
<text top="452" left="407" width="4" height="16" font="0"> </text>
<text top="434" left="521" width="38" height="15" font="5">50/50</text>
<text top="433" left="559" width="4" height="16" font="0"> </text>
<text top="434" left="635" width="233" height="15" font="5">In-hospital: death or MI 0% vs. 0%</text>
<text top="433" left="868" width="4" height="16" font="0"> </text>
<text top="434" left="967" width="394" height="15" font="5">At 1.5 y: death 0% vs. 2% (p=NS); MI 4% vs. 0% (p=NS); </text>
<text top="453" left="967" width="246" height="15" font="5">revascularization 4% vs. 0% (p=NS).</text>
<text top="452" left="1213" width="4" height="16" font="0"> </text>
<text top="472" left="967" width="410" height="15" font="5">Survival analysis for MIDCAB vs. PTCA HR: 0.77 (95% CI: </text>
<text top="491" left="967" width="140" height="15" font="5">0.38 to 1.57; p=0.47)</text>
<text top="490" left="1106" width="4" height="16" font="0"> </text>
<text top="510" left="967" width="4" height="16" font="0"> </text>
<text top="531" left="108" width="83" height="15" font="5">Thiele et al. </text>
<text top="531" left="191" width="36" height="15" font="13">(138)</text>
<text top="530" left="226" width="4" height="16" font="0"> </text>
<text top="550" left="108" width="4" height="16" font="0"> </text>
<text top="531" left="335" width="83" height="15" font="5">Randomized</text>
<text top="530" left="418" width="4" height="16" font="0"> </text>
<text top="550" left="335" width="71" height="15" font="5">1997-2001</text>
<text top="549" left="407" width="4" height="16" font="0"> </text>
<text top="531" left="521" width="54" height="15" font="5">110/110</text>
<text top="530" left="575" width="4" height="16" font="0"> </text>
<text top="531" left="635" width="29" height="15" font="5">N/A</text>
<text top="530" left="663" width="4" height="16" font="0"> </text>
<text top="531" left="967" width="417" height="15" font="5">At 5 y: death 10% vs. 12%  (p=0.54); MI 5% vs. 7% (p=0.46); </text>
<text top="550" left="967" width="279" height="15" font="5">revascularization: 32% vs. 10% (p&lt;0.001)</text>
<text top="549" left="1246" width="4" height="16" font="0"> </text>
<text top="577" left="108" width="77" height="15" font="5">Hong et al. </text>
<text top="577" left="185" width="36" height="15" font="13">(106)</text>
<text top="576" left="221" width="4" height="16" font="0"> </text>
<text top="577" left="335" width="83" height="15" font="5">Randomized</text>
<text top="576" left="418" width="4" height="16" font="0"> </text>
<text top="596" left="335" width="33" height="15" font="5">2003</text>
<text top="595" left="368" width="4" height="16" font="0"> </text>
<text top="577" left="521" width="46" height="15" font="5">119/70</text>
<text top="576" left="567" width="4" height="16" font="0"> </text>
<text top="577" left="635" width="320" height="15" font="5">In-hospital: death or MI 5.1% vs. 4.3% (p=1.00)</text>
<text top="576" left="955" width="4" height="16" font="0"> </text>
<text top="577" left="967" width="316" height="15" font="5">At 6 mo: death or MI:  6.8% vs. 10.1% (p=NS);</text>
<text top="576" left="1283" width="4" height="16" font="0"> </text>
<text top="596" left="967" width="267" height="15" font="5">revascularization 5.9% vs. 1.7% (p=NS)</text>
<text top="595" left="1233" width="4" height="16" font="0"> </text>
<text top="626" left="108" width="64" height="15" font="5">MASS I (</text>
<text top="626" left="172" width="25" height="15" font="13">109</text>
<text top="626" left="197" width="8" height="15" font="5">, </text>
<text top="626" left="205" width="25" height="15" font="13">181</text>
<text top="626" left="230" width="10" height="15" font="5">) </text>
<text top="626" left="335" width="83" height="15" font="5">Randomized</text>
<text top="625" left="418" width="4" height="16" font="0"> </text>
<text top="645" left="335" width="4" height="16" font="0"> </text>
<text top="626" left="521" width="38" height="15" font="5">72/70</text>
<text top="625" left="559" width="4" height="16" font="0"> </text>
<text top="626" left="635" width="29" height="15" font="5">N/A</text>
<text top="625" left="663" width="4" height="16" font="0"> </text>
<text top="626" left="967" width="402" height="15" font="5">At 3 y: death, MI or revascularization 24% vs. 3% (p=0.006)</text>
<text top="625" left="1369" width="4" height="16" font="0"> </text>
<text top="666" left="108" width="87" height="15" font="5">Fraund et al. </text>
<text top="666" left="195" width="36" height="15" font="13">(103)</text>
<text top="665" left="231" width="4" height="16" font="0"> </text>
<text top="666" left="335" width="46" height="15" font="5">Cohort</text>
<text top="665" left="381" width="4" height="16" font="0"> </text>
<text top="685" left="335" width="71" height="15" font="5">1998-2001</text>
<text top="684" left="407" width="4" height="16" font="0"> </text>
<text top="666" left="521" width="54" height="15" font="5">256/206</text>
<text top="665" left="575" width="4" height="16" font="0"> </text>
<text top="666" left="635" width="299" height="15" font="5">In-hospital death or MI 0.8% vs. 2 % (p=NS)</text>
<text top="665" left="934" width="4" height="16" font="0"> </text>
<text top="666" left="967" width="286" height="15" font="5">At 3 y: death or MI 4.7% vs. 5.8% (p=NS);</text>
<text top="665" left="1253" width="4" height="16" font="0"> </text>
<text top="685" left="967" width="287" height="15" font="5"> revascularization 7.8% vs. 28.9% (p&lt;0.01)</text>
<text top="684" left="1254" width="4" height="16" font="0"> </text>
</page>
<page number="34" position="absolute" top="0" left="0" height="918" width="1512">
<text top="59" left="108" width="4" height="15" font="0"> </text>
<text top="59" left="459" width="4" height="15" font="0"> </text>
<text top="59" left="810" width="4" height="15" font="0"> </text>
<text top="59" left="864" width="4" height="15" font="0"> </text>
<text top="59" left="918" width="4" height="15" font="0"> </text>
<text top="59" left="972" width="4" height="15" font="0"> </text>
<text top="59" left="1026" width="4" height="15" font="0"> </text>
<text top="59" left="1080" width="4" height="15" font="0"> </text>
<text top="59" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="108" width="613" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="825" left="810" width="4" height="15" font="0"> </text>
<text top="825" left="864" width="4" height="15" font="0"> </text>
<text top="825" left="918" width="4" height="15" font="0"> </text>
<text top="825" left="972" width="4" height="15" font="0"> </text>
<text top="825" left="1026" width="4" height="15" font="0"> </text>
<text top="825" left="1080" width="4" height="15" font="0"> </text>
<text top="825" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="1188" width="4" height="15" font="0"> </text>
<text top="825" left="1242" width="22" height="15" font="0">34 </text>
<text top="847" left="108" width="4" height="15" font="0"> </text>
<text top="112" left="108" width="92" height="15" font="5">Ben-Gal et al.</text>
<text top="112" left="200" width="31" height="15" font="13"> (99)</text>
<text top="111" left="232" width="4" height="16" font="0"> </text>
<text top="112" left="335" width="137" height="15" font="5">Matched cases from </text>
<text top="131" left="335" width="127" height="15" font="5">prospective cohort </text>
<text top="130" left="462" width="4" height="16" font="0"> </text>
<text top="150" left="335" width="71" height="15" font="5">2002-2003</text>
<text top="149" left="407" width="4" height="16" font="0"> </text>
<text top="169" left="335" width="129" height="15" font="5">(PCI were all DES)</text>
<text top="168" left="464" width="4" height="16" font="0"> </text>
<text top="112" left="521" width="38" height="15" font="5">83/83</text>
<text top="111" left="559" width="4" height="16" font="0"> </text>
<text top="112" left="635" width="215" height="15" font="5">30 d death: 0% vs. 1.1% (p=NS)</text>
<text top="111" left="850" width="4" height="16" font="0"> </text>
<text top="112" left="967" width="433" height="15" font="5">At 22 mo: death 1.1% vs. 5.5% (p=NS); revascularization 16.8% </text>
<text top="131" left="967" width="398" height="15" font="5">vs. 3.6% (p=0.005); independent predictors of MACE (Cox </text>
<text top="150" left="967" width="419" height="15" font="5">analysis) were assignment to the Cypher group (HR:  4.1; 95% </text>
<text top="169" left="967" width="433" height="15" font="5">CI: 1.26 to 13.16), multivessel disease (HR: 4.3; 95% CI: 1.44 to </text>
<text top="188" left="967" width="372" height="15" font="5">13.16), and prior PCI (HR: 4.36; 95% CI: 1.28 to 14.90)</text>
<text top="187" left="1339" width="4" height="16" font="0"> </text>
<text top="207" left="967" width="4" height="16" font="0"> </text>
<text top="229" left="108" width="109" height="15" font="5">Toutouzas et al. </text>
<text top="229" left="217" width="36" height="15" font="13">(182)</text>
<text top="228" left="253" width="4" height="16" font="0"> </text>
<text top="229" left="335" width="46" height="15" font="5">Cohort</text>
<text top="228" left="381" width="4" height="16" font="0"> </text>
<text top="229" left="521" width="54" height="15" font="5">147/110</text>
<text top="228" left="575" width="4" height="16" font="0"> </text>
<text top="229" left="635" width="318" height="15" font="5">Inhospital: death or MI or revascularization 0% </text>
<text top="248" left="635" width="45" height="15" font="5">vs. 0%</text>
<text top="247" left="680" width="4" height="16" font="0"> </text>
<text top="229" left="967" width="432" height="15" font="5">At 2 y: death:  2.0% vs. 1.8% (p=NS); MI 0% vs. 0.9%; (p=NS); </text>
<text top="248" left="967" width="254" height="15" font="5">revascularization  2% vs. 0% (p=0.51)</text>
<text top="247" left="1220" width="4" height="16" font="0"> </text>
<text top="274" left="108" width="1288" height="12" font="17">CABG indicates coronary artery bypass graft; CI, confidence interval; d, day; DES, drug-eluting stents; HR, hazard ratio; MASS, Medicine, Angioplasty, or Surgery Study; MIDCAB, minimally invasive direct coronary artery bypass ;MI, </text>
<text top="290" left="108" width="894" height="12" font="17">myocardial infarction; mo, month; NS, not significant; PCI, percutaneous coronary intervention; PTCA, percutaneous transluminal coronary angioplasty and y, year. </text>
<text top="306" left="108" width="4" height="16" font="2"><b> </b></text>
<text top="327" left="108" width="4" height="16" font="2"><b> </b></text>
<text top="348" left="108" width="689" height="16" font="2"><b>Data Supplement 16. Cohort Studies Comparing CABG to PCI in Patients With Diabetes </b></text>
<text top="369" left="231" width="51" height="15" font="4"><b>Author</b></text>
<text top="368" left="282" width="4" height="16" font="2"><b> </b></text>
<text top="369" left="503" width="104" height="15" font="4"><b>Type of Study/</b></text>
<text top="368" left="607" width="4" height="16" font="2"><b> </b></text>
<text top="388" left="482" width="146" height="15" font="4"><b>Year of Recruitment</b></text>
<text top="387" left="628" width="4" height="16" font="2"><b> </b></text>
<text top="369" left="743" width="222" height="15" font="4"><b>Number of Patients PCI/CABG</b></text>
<text top="368" left="965" width="4" height="16" font="2"><b> </b></text>
<text top="369" left="1054" width="299" height="15" font="4"><b>Long-Term Results for PCI Versus CABG</b></text>
<text top="368" left="1353" width="4" height="16" font="2"><b> </b></text>
<text top="407" left="108" width="99" height="15" font="5">Barsness et al. </text>
<text top="407" left="207" width="36" height="15" font="13">(122)</text>
<text top="406" left="243" width="4" height="16" font="0"> </text>
<text top="426" left="108" width="4" height="16" font="0"> </text>
<text top="407" left="406" width="137" height="15" font="5">Retrospective cohort</text>
<text top="406" left="543" width="4" height="16" font="0"> </text>
<text top="426" left="406" width="71" height="15" font="5">1984-1990</text>
<text top="425" left="478" width="4" height="16" font="0"> </text>
<text top="407" left="705" width="173" height="15" font="5">770 pts with diabetes total</text>
<text top="406" left="878" width="4" height="16" font="0"> </text>
<text top="407" left="1004" width="402" height="15" font="5">At 5 y: Similar mortality for PCI and CABG pts: unadjusted </text>
<text top="426" left="1004" width="290" height="15" font="5">86% vs. 89%; p=NS; adjusted 92% vs. 93%</text>
<text top="425" left="1294" width="4" height="16" font="0"> </text>
<text top="474" left="108" width="110" height="15" font="5">Weintraub et al. </text>
<text top="474" left="218" width="36" height="15" font="13">(120)</text>
<text top="473" left="254" width="4" height="16" font="0"> </text>
<text top="493" left="108" width="4" height="16" font="0"> </text>
<text top="474" left="406" width="46" height="15" font="5">Cohort</text>
<text top="473" left="452" width="4" height="16" font="0"> </text>
<text top="493" left="406" width="71" height="15" font="5">1981-1994</text>
<text top="492" left="478" width="4" height="16" font="0"> </text>
<text top="474" left="705" width="67" height="15" font="5">834/1,805</text>
<text top="473" left="771" width="4" height="16" font="0"> </text>
<text top="474" left="1004" width="400" height="15" font="5">At 10 y: death:  64% vs. 53%; p=0.045 for insulin-requiring </text>
<text top="493" left="1004" width="379" height="15" font="5">pts with diabetes ONLY                                                     </text>
<text top="492" left="1383" width="4" height="16" font="0"> </text>
<text top="512" left="1004" width="394" height="15" font="5">Insulin-requiring subgroup multivariate HR: 1.35; 95% CI: </text>
<text top="531" left="1004" width="221" height="15" font="5">1.01 to 1.79 for PTCA vs. CABG</text>
<text top="530" left="1225" width="4" height="16" font="0"> </text>
<text top="551" left="108" width="75" height="15" font="5">Niles et al. </text>
<text top="551" left="183" width="36" height="15" font="13">(118)</text>
<text top="550" left="219" width="4" height="16" font="0"> </text>
<text top="570" left="108" width="4" height="16" font="0"> </text>
<text top="551" left="406" width="137" height="15" font="5">Retrospective cohort</text>
<text top="550" left="543" width="4" height="16" font="0"> </text>
<text top="569" left="406" width="71" height="15" font="5">1992-1996</text>
<text top="568" left="478" width="4" height="16" font="0"> </text>
<text top="551" left="705" width="186" height="15" font="5">2,766 pts with diabetes total</text>
<text top="550" left="891" width="4" height="16" font="0"> </text>
<text top="551" left="1004" width="395" height="15" font="5">At 2 y: higher mortality in PCI pts (HR: 2.0; p=0.038) with </text>
<text top="569" left="1004" width="393" height="15" font="5">3-vessel disease. Trend to higher mortality in PCI pts (HR: </text>
<text top="588" left="1004" width="357" height="15" font="5">1.3; p=0.2) with 2-vessel disease, compared to CABG</text>
<text top="587" left="1361" width="4" height="16" font="0"> </text>
<text top="625" left="108" width="135" height="15" font="5">Van Domburg et al. </text>
<text top="625" left="243" width="27" height="15" font="13">(92)</text>
<text top="624" left="271" width="4" height="16" font="0"> </text>
<text top="625" left="406" width="46" height="15" font="5">Cohort</text>
<text top="624" left="452" width="4" height="16" font="0"> </text>
<text top="644" left="406" width="71" height="15" font="5">1970-1985</text>
<text top="643" left="478" width="4" height="16" font="0"> </text>
<text top="625" left="705" width="38" height="15" font="5">76/82</text>
<text top="624" left="743" width="4" height="16" font="0"> </text>
<text top="625" left="1004" width="406" height="15" font="5">At 20 y: survival similar for PCI vs. CABG pts                       </text>
<text top="644" left="1004" width="391" height="15" font="5">Mortality for CABG vs. PTCA  RR: 1.03; 95% CI: 0.87 to </text>
<text top="663" left="1004" width="29" height="15" font="5">1.24</text>
<text top="662" left="1033" width="4" height="16" font="0"> </text>
<text top="682" left="1004" width="4" height="16" font="0"> </text>
<text top="703" left="108" width="85" height="15" font="5">Brener et al. </text>
<text top="703" left="193" width="36" height="15" font="13">(115)</text>
<text top="702" left="229" width="4" height="16" font="0"> </text>
<text top="722" left="108" width="4" height="16" font="0"> </text>
<text top="703" left="406" width="137" height="15" font="5">Retrospective cohort</text>
<text top="702" left="543" width="4" height="16" font="0"> </text>
<text top="722" left="406" width="71" height="15" font="5">1995-1999</text>
<text top="721" left="478" width="4" height="16" font="0"> </text>
<text top="703" left="705" width="67" height="15" font="5">265/2,054</text>
<text top="702" left="771" width="4" height="16" font="0"> </text>
<text top="703" left="1004" width="335" height="15" font="5">At 6 y: deaths for NIDDM: 21% vs. 17%; p=0.008</text>
<text top="702" left="1339" width="4" height="16" font="0"> </text>
<text top="722" left="1004" width="405" height="15" font="5">Deaths for IDDM:  31% vs. 23%; p&lt;0.0001                            </text>
<text top="741" left="1004" width="330" height="15" font="5">Unadjusted HR: 1.13; 95% CI: 1.0  to 1.4; p=0.07</text>
<text top="740" left="1334" width="4" height="16" font="0"> </text>
<text top="760" left="1004" width="4" height="16" font="0"> </text>
</page>
<page number="35" position="absolute" top="0" left="0" height="918" width="1512">
<text top="59" left="108" width="4" height="15" font="0"> </text>
<text top="59" left="459" width="4" height="15" font="0"> </text>
<text top="59" left="810" width="4" height="15" font="0"> </text>
<text top="59" left="864" width="4" height="15" font="0"> </text>
<text top="59" left="918" width="4" height="15" font="0"> </text>
<text top="59" left="972" width="4" height="15" font="0"> </text>
<text top="59" left="1026" width="4" height="15" font="0"> </text>
<text top="59" left="1080" width="4" height="15" font="0"> </text>
<text top="59" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="108" width="613" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="825" left="810" width="4" height="15" font="0"> </text>
<text top="825" left="864" width="4" height="15" font="0"> </text>
<text top="825" left="918" width="4" height="15" font="0"> </text>
<text top="825" left="972" width="4" height="15" font="0"> </text>
<text top="825" left="1026" width="4" height="15" font="0"> </text>
<text top="825" left="1080" width="4" height="15" font="0"> </text>
<text top="825" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="1188" width="4" height="15" font="0"> </text>
<text top="825" left="1242" width="22" height="15" font="0">35 </text>
<text top="847" left="108" width="4" height="15" font="0"> </text>
<text top="112" left="108" width="83" height="15" font="5">Javaid et al. </text>
<text top="112" left="191" width="36" height="15" font="13">(117)</text>
<text top="111" left="226" width="4" height="16" font="0"> </text>
<text top="112" left="406" width="137" height="15" font="5">Retrospective cohort</text>
<text top="111" left="543" width="4" height="16" font="0"> </text>
<text top="131" left="406" width="56" height="15" font="5">DES era</text>
<text top="130" left="462" width="4" height="16" font="0"> </text>
<text top="112" left="705" width="173" height="15" font="5">601 pts with diabetes total</text>
<text top="111" left="878" width="4" height="16" font="0"> </text>
<text top="131" left="705" width="54" height="15" font="5">344/257</text>
<text top="130" left="759" width="4" height="16" font="0"> </text>
<text top="112" left="1004" width="349" height="15" font="5">At 1 y: death, stroke, MI, revascularization HR: 3.5; </text>
<text top="131" left="1004" width="186" height="15" font="5">(p&lt;0.001) for 2-vessel CAD</text>
<text top="130" left="1190" width="4" height="16" font="0"> </text>
<text top="150" left="1004" width="243" height="15" font="5">HR: 4.8 (p&lt;0.001) for 3-vessel CAD</text>
<text top="149" left="1246" width="4" height="16" font="0"> </text>
<text top="179" left="108" width="76" height="15" font="5">Hueb et al. </text>
<text top="179" left="184" width="36" height="15" font="13">(110)</text>
<text top="178" left="220" width="4" height="16" font="0"> </text>
<text top="198" left="108" width="4" height="16" font="0"> </text>
<text top="179" left="406" width="46" height="15" font="5">Cohort</text>
<text top="178" left="452" width="4" height="16" font="0"> </text>
<text top="198" left="406" width="71" height="15" font="5">1995-2000</text>
<text top="197" left="478" width="4" height="16" font="0"> </text>
<text top="179" left="705" width="54" height="15" font="5">120/221</text>
<text top="178" left="759" width="4" height="16" font="0"> </text>
<text top="179" left="1004" width="401" height="15" font="5">At 5 y: incidence of cardiac death 11.1% vs. 11.8% (p=NS), </text>
<text top="198" left="1004" width="406" height="15" font="5">revascularization 27.5% vs. 3.2% (p&lt;0.001)                            </text>
<text top="217" left="1004" width="382" height="15" font="5">The incidence of cardiac death was NS different between </text>
<text top="236" left="1004" width="136" height="15" font="5">PCI and MT groups </text>
<text top="235" left="1140" width="4" height="16" font="0"> </text>
<text top="256" left="108" width="65" height="15" font="5">Bair et al.</text>
<text top="256" left="173" width="32" height="15" font="13"> (82)</text>
<text top="255" left="204" width="4" height="16" font="0"> </text>
<text top="256" left="406" width="145" height="15" font="5">Subset of large cohort</text>
<text top="255" left="552" width="4" height="16" font="0"> </text>
<text top="275" left="406" width="71" height="15" font="5">1992-2000</text>
<text top="274" left="478" width="4" height="16" font="0"> </text>
<text top="256" left="705" width="67" height="15" font="5">353/1,267</text>
<text top="255" left="771" width="4" height="16" font="0"> </text>
<text top="256" left="1004" width="214" height="15" font="5">At 15 y: death HR: 0.81; p=0.03</text>
<text top="255" left="1218" width="4" height="16" font="0"> </text>
<text top="302" left="108" width="92" height="15" font="5">Hannan et al. </text>
<text top="302" left="200" width="27" height="15" font="13">(85)</text>
<text top="301" left="227" width="4" height="16" font="0"> </text>
<text top="322" left="108" width="4" height="16" font="0"> </text>
<text top="302" left="406" width="145" height="15" font="5">Subset of large cohort</text>
<text top="301" left="552" width="4" height="16" font="0"> </text>
<text top="321" left="406" width="71" height="15" font="5">2003-2004</text>
<text top="320" left="478" width="4" height="16" font="0"> </text>
<text top="302" left="705" width="79" height="15" font="5">2,844/3,256</text>
<text top="301" left="784" width="4" height="16" font="0"> </text>
<text top="302" left="1004" width="390" height="15" font="5">At 18 mo: death HR: 1.03, p=0.75; death or MI HR: 1.19;  </text>
<text top="321" left="1004" width="47" height="15" font="5">p=0.07</text>
<text top="320" left="1050" width="4" height="16" font="0"> </text>
<text top="352" left="108" width="1290" height="12" font="17">CABG indicates coronary artery bypass graft; CAD, coronary artery disease; CI, confidence interval; DES, drug-eluting stent; HR, hazard ratio; IDDM, insulin-dependent diabetes mellitus; MI, myocardial infarction; MT, medical therapy; </text>
<text top="368" left="108" width="1147" height="12" font="17">NIDDM, noninsulin-dependent diabetes mellitus; NS, not significant; pts, patients; PCI, percutaneous coronary intervention; PTCA, percutaneous transluminal coronary angioplasty; RR, relative risk, and y, year. </text>
<text top="384" left="108" width="4" height="15" font="5"> </text>
<text top="421" left="108" width="4" height="15" font="5"> </text>
<text top="458" left="108" width="738" height="16" font="2"><b>Data Supplement 17. RCTs of PCI With CABG in Patients With Multivessel CAD and Diabetes </b></text>
<text top="479" left="222" width="51" height="15" font="4"><b>Author</b></text>
<text top="478" left="273" width="4" height="16" font="2"><b> </b></text>
<text top="479" left="431" width="178" height="15" font="4"><b>Type of Study in Year of </b></text>
<text top="498" left="474" width="89" height="15" font="4"><b>Recruitment</b></text>
<text top="497" left="562" width="4" height="16" font="2"><b> </b></text>
<text top="479" left="676" width="81" height="15" font="4"><b>Number of </b></text>
<text top="498" left="668" width="98" height="15" font="4"><b>Patients PCI/ </b></text>
<text top="517" left="691" width="48" height="15" font="4"><b>CABG</b></text>
<text top="516" left="739" width="4" height="16" font="2"><b> </b></text>
<text top="479" left="820" width="270" height="15" font="4"><b>Primary Endpoint for PCI and CABG</b></text>
<text top="478" left="1090" width="4" height="16" font="2"><b> </b></text>
<text top="479" left="1229" width="76" height="15" font="4"><b>Comments</b></text>
<text top="478" left="1305" width="4" height="16" font="2"><b> </b></text>
<text top="537" left="108" width="71" height="15" font="5">SYNTAX </text>
<text top="537" left="179" width="36" height="15" font="13">(183)</text>
<text top="536" left="215" width="4" height="16" font="0"> </text>
<text top="537" left="387" width="159" height="15" font="5">Randomized 2005-2007</text>
<text top="536" left="546" width="4" height="16" font="0"> </text>
<text top="537" left="650" width="108" height="15" font="5">Overall 903/897</text>
<text top="536" left="757" width="4" height="16" font="0"> </text>
<text top="555" left="650" width="85" height="15" font="5">DM 231/221</text>
<text top="554" left="734" width="4" height="16" font="0"> </text>
<text top="537" left="781" width="343" height="15" font="5">DM: 12-mo death, stroke, MI, or revascularization: </text>
<text top="555" left="781" width="338" height="15" font="5">26.0% vs. 14.2% (HR: 1.83, 95% CI: 1.22 to 1.73; </text>
<text top="575" left="781" width="60" height="15" font="5">p=0.003)</text>
<text top="574" left="841" width="4" height="16" font="0"> </text>
<text top="537" left="1129" width="247" height="15" font="5">Criterion for noninferiority of PCI to </text>
<text top="555" left="1129" width="241" height="15" font="5">CABG was not met in overall study.</text>
<text top="554" left="1370" width="4" height="16" font="0"> </text>
<text top="604" left="108" width="63" height="15" font="5">CARDIa </text>
<text top="604" left="171" width="36" height="15" font="13">(123)</text>
<text top="603" left="206" width="4" height="16" font="0"> </text>
<text top="604" left="387" width="159" height="15" font="5">Randomized 2002-2007</text>
<text top="603" left="546" width="4" height="16" font="0"> </text>
<text top="604" left="650" width="85" height="15" font="5">DM 256/254</text>
<text top="603" left="734" width="4" height="16" font="0"> </text>
<text top="604" left="781" width="313" height="15" font="5">DM: 1-y death, stroke or MI: 13.0% vs. 10.5% </text>
<text top="623" left="781" width="279" height="15" font="5">([OR: 1.25, 95% CI: 0.75 to 2.09; p=0.39)</text>
<text top="622" left="1060" width="4" height="16" font="0"> </text>
<text top="604" left="1129" width="247" height="15" font="5">Criterion for noninferiority of PCI to </text>
<text top="623" left="1129" width="134" height="15" font="5">CABG was not met.</text>
<text top="622" left="1263" width="4" height="16" font="0"> </text>
<text top="659" left="108" width="68" height="15" font="5">BARI 2D </text>
<text top="659" left="176" width="36" height="15" font="13">(112)</text>
<text top="658" left="211" width="4" height="16" font="0"> </text>
<text top="659" left="387" width="184" height="15" font="5">Prestratified/randomized to </text>
<text top="678" left="387" width="224" height="15" font="5">revascularization-medical therapy</text>
<text top="677" left="611" width="4" height="16" font="0"> </text>
<text top="659" left="650" width="85" height="15" font="5">DM 798/807</text>
<text top="658" left="734" width="4" height="16" font="0"> </text>
<text top="659" left="781" width="149" height="15" font="5">Death from any cause:</text>
<text top="658" left="930" width="4" height="16" font="0"> </text>
<text top="682" left="797" width="125" height="14" font="5">•  Medical:  87.8%</text>
<text top="678" left="922" width="4" height="16" font="0"> </text>
<text top="702" left="797" width="189" height="14" font="5">•  Revascularization:  88.3%</text>
<text top="698" left="987" width="4" height="16" font="0"> </text>
<text top="722" left="797" width="63" height="14" font="5">•  P=0.97</text>
<text top="718" left="860" width="4" height="16" font="0"> </text>
<text top="659" left="1129" width="178" height="15" font="5">5-y freedom from MACE: </text>
<text top="658" left="1307" width="4" height="16" font="0"> </text>
<text top="682" left="1140" width="242" height="14" font="5">•  PCI vs. medical (77.0% vs. 78.9; </text>
<text top="701" left="1160" width="56" height="15" font="5">p=0.15) </text>
<text top="726" left="1140" width="224" height="14" font="5">•  CABG vs. medical (77.6% vs. </text>
<text top="746" left="1160" width="107" height="15" font="5">69.5%; p=0.01) </text>
<text top="771" left="1140" width="158" height="14" font="5">•   interaction p=0.002 </text>
</page>
<page number="36" position="absolute" top="0" left="0" height="918" width="1512">
<text top="59" left="108" width="4" height="15" font="0"> </text>
<text top="59" left="459" width="4" height="15" font="0"> </text>
<text top="59" left="810" width="4" height="15" font="0"> </text>
<text top="59" left="864" width="4" height="15" font="0"> </text>
<text top="59" left="918" width="4" height="15" font="0"> </text>
<text top="59" left="972" width="4" height="15" font="0"> </text>
<text top="59" left="1026" width="4" height="15" font="0"> </text>
<text top="59" left="1080" width="4" height="15" font="0"> </text>
<text top="59" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="108" width="613" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="825" left="810" width="4" height="15" font="0"> </text>
<text top="825" left="864" width="4" height="15" font="0"> </text>
<text top="825" left="918" width="4" height="15" font="0"> </text>
<text top="825" left="972" width="4" height="15" font="0"> </text>
<text top="825" left="1026" width="4" height="15" font="0"> </text>
<text top="825" left="1080" width="4" height="15" font="0"> </text>
<text top="825" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="1188" width="4" height="15" font="0"> </text>
<text top="825" left="1242" width="22" height="15" font="0">36 </text>
<text top="847" left="108" width="4" height="15" font="0"> </text>
<text top="112" left="108" width="61" height="15" font="5">ARTS I (</text>
<text top="112" left="169" width="25" height="15" font="13">121</text>
<text top="112" left="194" width="8" height="15" font="5">, </text>
<text top="112" left="202" width="25" height="15" font="13">162</text>
<text top="112" left="227" width="8" height="15" font="5">, </text>
<text top="112" left="236" width="25" height="15" font="13">184</text>
<text top="112" left="260" width="6" height="15" font="5">)</text>
<text top="111" left="266" width="4" height="16" font="0"> </text>
<text top="112" left="387" width="159" height="15" font="5">Randomized 1997-1998</text>
<text top="111" left="546" width="4" height="16" font="0"> </text>
<text top="112" left="650" width="108" height="15" font="5">Overall 600/605</text>
<text top="111" left="757" width="4" height="16" font="0"> </text>
<text top="131" left="650" width="77" height="15" font="5">DM 112/96</text>
<text top="130" left="726" width="4" height="16" font="0"> </text>
<text top="112" left="781" width="340" height="15" font="5">Overall: 5-y overall freedom from death, stroke, or </text>
<text top="131" left="781" width="324" height="15" font="5">MI 18.2% vs. 14.9% (RR: 1.22; 95% CI: 0.95 to </text>
<text top="150" left="781" width="90" height="15" font="5">1.58; p=0.14)</text>
<text top="149" left="870" width="4" height="16" font="0"> </text>
<text top="169" left="781" width="296" height="15" font="5">DM: 1-y freedom from death, stroke, MI, or </text>
<text top="188" left="781" width="308" height="15" font="5">revascularization (63.4% vs. 84.4%; p&lt; 0.001)</text>
<text top="187" left="1089" width="4" height="16" font="0"> </text>
<text top="113" left="1129" width="4" height="16" font="0"> </text>
<text top="208" left="108" width="64" height="15" font="5">MASS II </text>
<text top="208" left="172" width="36" height="15" font="13">(110)</text>
<text top="207" left="208" width="4" height="16" font="0"> </text>
<text top="208" left="387" width="159" height="15" font="5">Randomized 1995-2000</text>
<text top="207" left="546" width="4" height="16" font="0"> </text>
<text top="208" left="650" width="108" height="15" font="5">Overall 205/203</text>
<text top="207" left="757" width="4" height="16" font="0"> </text>
<text top="227" left="650" width="68" height="15" font="5">DM 56/59</text>
<text top="226" left="718" width="4" height="16" font="0"> </text>
<text top="208" left="781" width="250" height="15" font="5">DM: 1-y death 5.3% vs. 6.8% (p=0.5)</text>
<text top="207" left="1031" width="4" height="16" font="0"> </text>
<text top="208" left="1129" width="4" height="16" font="0"> </text>
<text top="269" left="108" width="1268" height="12" font="17">*ARTS indicates Arterial Revascularization Therapies Study; BARI 2D, Bypass Angioplasty Revascularization Investigation 2 Diabetes; CABG, coronary artery bypass graft; CAD, coronary artery disease; CARDIA, Coronary Artery </text>
<text top="284" left="108" width="1268" height="12" font="17">Revascularization in Diabetes; CI,  confidence interval; DM, diabetes mellitus; HR, hazard ratio; LAD, left anterior descending artery; LOE, level of evidence; MACE, major adverse cardiac event; MASS II, Medicine, Angioplasty, or </text>
<text top="300" left="108" width="1291" height="12" font="17">Surgery Study (MASS II); OR, odds ratio; MI, myocardial infarction; PCI, percutaneous coronary intervention; RR, relative risk; SYNTAX, Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery; and y, </text>
<text top="315" left="108" width="30" height="12" font="17">year. </text>
<text top="332" left="108" width="4" height="15" font="5"> </text>
<text top="350" left="108" width="4" height="15" font="5"> </text>
<text top="370" left="108" width="4" height="16" font="0"> </text>
<text top="390" left="108" width="4" height="16" font="0"> </text>
<text top="411" left="716" width="84" height="16" font="0">References </text>
<text top="432" left="756" width="4" height="16" font="0"> </text>
<text top="452" left="108" width="4" height="14" font="7"> </text>
<text top="452" left="137" width="1255" height="14" font="7">1.   Sabharwal NK, Stoykova B, Taneja AK, et al. A randomized trial of exercise treadmill ECG versus stress SPECT myocardial perfusion imaging as an initial diagnostic strategy in stable patients with chest </text>
<text top="469" left="162" width="439" height="14" font="7">pain and suspected CAD: cost analysis. J Nucl Cardiol. 2007;14:174-86. </text>
<text top="486" left="108" width="4" height="14" font="7"> </text>
<text top="486" left="137" width="1223" height="14" font="7">2.   Shaw LJ, Mieres JH, Hendel RH, et al. Comparative Effectiveness of exercise electrocardiography with or without myocardial perfusion single photon emission computed tomography in women with </text>
<text top="504" left="162" width="995" height="14" font="7">suspected coronary artery disease: results from the What Is the Optimal Method for Ischemia Evaluation in Women (WOMEN) trial. Circulation. 2011;124:1239-49. </text>
<text top="521" left="108" width="4" height="14" font="7"> </text>
<text top="521" left="137" width="874" height="14" font="7">3.   Kwok Y, Kim C, Grady D, et al. Meta-analysis of exercise testing to detect coronary artery disease in women. Am J Cardiol. 1999;83:660-6. </text>
<text top="538" left="108" width="4" height="14" font="7"> </text>
<text top="538" left="137" width="1018" height="14" font="7">4.   Gianrossi R, Detrano R, Mulvihill D, et al. Exercise-induced ST depression in the diagnosis of coronary artery disease. A meta-analysis. Circulation. 1989;80:87-98. </text>
<text top="555" left="108" width="4" height="14" font="7"> </text>
<text top="555" left="137" width="955" height="14" font="7">5.   Underwood SR, Anagnostopoulos C, Cerqueira M, et al. Myocardial perfusion scintigraphy: the evidence. Eur J Nucl Med Mol Imaging. 2004;31:261-91. </text>
<text top="573" left="108" width="4" height="14" font="7"> </text>
<text top="573" left="137" width="1233" height="14" font="7">6.   Underwood SR, Shaw LJ, Anagnostopoulos C, et al. Myocardial perfusion scintigraphy and cost effectiveness of diagnosis and management of coronary heart disease. Heart. 2004;90 Suppl 5:v34-v36. </text>
<text top="590" left="108" width="4" height="14" font="7"> </text>
<text top="590" left="137" width="1227" height="14" font="7">7.   Nucifora G, Schuijf JD, van Werkhoven JM, et al. Relationship between obstructive coronary artery disease and abnormal stress testing in patients with paroxysmal or persistent atrial fibrillation. Int J </text>
<text top="607" left="162" width="232" height="14" font="7">Cardiovasc Imaging. 2011;27:777-85. </text>
<text top="624" left="108" width="4" height="14" font="7"> </text>
<text top="624" left="137" width="938" height="14" font="7">8.   Underwood SR, Godman B, Salyani S, et al. Economics of myocardial perfusion imaging in Europe--the EMPIRE Study. Eur Heart J. 1999;20:157-66. </text>
<text top="642" left="108" width="4" height="14" font="7"> </text>
<text top="642" left="137" width="1053" height="14" font="7">9.   Marcassa C, Bax JJ, Bengel F, et al. Clinical value, cost-effectiveness, and safety of myocardial perfusion scintigraphy: a position statement. Eur Heart J. 2008;29:557-63. </text>
<text top="659" left="108" width="4" height="14" font="7"> </text>
<text top="659" left="130" width="1120" height="14" font="7">10.   Fleischmann KE, Hunink MG, Kuntz KM, et al. Exercise echocardiography or exercise SPECT imaging? A meta-analysis of diagnostic test performance. JAMA. 1998;280:913-20. </text>
<text top="676" left="108" width="4" height="14" font="7"> </text>
<text top="676" left="130" width="961" height="14" font="7">11.   Garber AM, Solomon NA. Cost-effectiveness of alternative test strategies for the diagnosis of coronary artery disease. Ann Intern Med. 1999;130:719-28. </text>
<text top="693" left="108" width="4" height="14" font="7"> </text>
<text top="693" left="130" width="1251" height="14" font="7">12.   Imran MB, Palinkas A, Picano E. Head-to-head comparison of dipyridamole echocardiography and stress perfusion scintigraphy for the detection of coronary artery disease: a meta-analysis. Comparison </text>
<text top="711" left="162" width="477" height="14" font="7">between stress echo and scintigraphy. Int J Cardiovasc Imaging. 2003;19:23-8. </text>
<text top="728" left="108" width="4" height="14" font="7"> </text>
<text top="728" left="130" width="1240" height="14" font="7">13.   Biagini E, Shaw LJ, Poldermans D, et al. Accuracy of non-invasive techniques for diagnosis of coronary artery disease and prediction of cardiac events in patients with left bundle branch block: a meta-</text>
<text top="745" left="162" width="352" height="14" font="7">analysis. Eur J Nucl Med Mol Imaging. 2006;33:1442-51. </text>
<text top="762" left="108" width="4" height="14" font="7"> </text>
<text top="762" left="130" width="1235" height="14" font="7">14.   Nandalur KR, Dwamena BA, Choudhri AF, et al. Diagnostic performance of stress cardiac magnetic resonance imaging in the detection of coronary artery disease: a meta-analysis. J Am Coll Cardiol. </text>
<text top="780" left="162" width="111" height="14" font="7">2007;50:1343-53. </text>
</page>
<page number="37" position="absolute" top="0" left="0" height="918" width="1512">
<text top="59" left="108" width="4" height="15" font="0"> </text>
<text top="59" left="459" width="4" height="15" font="0"> </text>
<text top="59" left="810" width="4" height="15" font="0"> </text>
<text top="59" left="864" width="4" height="15" font="0"> </text>
<text top="59" left="918" width="4" height="15" font="0"> </text>
<text top="59" left="972" width="4" height="15" font="0"> </text>
<text top="59" left="1026" width="4" height="15" font="0"> </text>
<text top="59" left="1080" width="4" height="15" font="0"> </text>
<text top="59" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="108" width="613" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="825" left="810" width="4" height="15" font="0"> </text>
<text top="825" left="864" width="4" height="15" font="0"> </text>
<text top="825" left="918" width="4" height="15" font="0"> </text>
<text top="825" left="972" width="4" height="15" font="0"> </text>
<text top="825" left="1026" width="4" height="15" font="0"> </text>
<text top="825" left="1080" width="4" height="15" font="0"> </text>
<text top="825" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="1188" width="4" height="15" font="0"> </text>
<text top="825" left="1242" width="22" height="15" font="0">37 </text>
<text top="847" left="108" width="4" height="15" font="0"> </text>
<text top="111" left="108" width="4" height="14" font="7"> </text>
<text top="111" left="130" width="1055" height="14" font="7">15.   Geleijnse ML, Krenning BJ, Soliman OI, et al. Dobutamine stress echocardiography for the detection of coronary artery disease in women. Am J Cardiol. 2007;99:714-7. </text>
<text top="129" left="108" width="4" height="14" font="7"> </text>
<text top="129" left="130" width="1248" height="14" font="7">16.   Picano E, Molinaro S, Pasanisi E. The diagnostic accuracy of pharmacological stress echocardiography for the assessment of coronary artery disease: a meta-analysis. Cardiovasc Ultrasound. 2008;6:30. </text>
<text top="146" left="108" width="4" height="14" font="7"> </text>
<text top="146" left="130" width="1247" height="14" font="7">17.   Mahajan N, Polavaram L, Vankayala H, et al. Diagnostic accuracy of myocardial perfusion imaging and stress echocardiography for the diagnosis of left main and triple vessel coronary artery disease: a </text>
<text top="163" left="162" width="312" height="14" font="7">comparative meta-analysis. Heart. 2010;96:956-66. </text>
<text top="180" left="108" width="4" height="14" font="7"> </text>
<text top="180" left="130" width="1260" height="14" font="7">18.   Budoff MJ, Dowe D, Jollis JG, et al. Diagnostic performance of 64-multidetector row coronary computed tomographic angiography for evaluation of coronary artery stenosis in individuals without known </text>
<text top="197" left="162" width="1235" height="14" font="7">coronary artery disease: results from the prospective multicenter ACCURACY (Assessment by Coronary Computed Tomographic Angiography of Individuals Undergoing Invasive Coronary Angiography) </text>
<text top="215" left="162" width="260" height="14" font="7">trial. J Am Coll Cardiol. 2008;52:1724-32. </text>
<text top="232" left="108" width="4" height="14" font="7"> </text>
<text top="232" left="130" width="884" height="14" font="7">19.   Miller JM, Rochitte CE, Dewey M, et al. Diagnostic performance of coronary angiography by 64-row CT. N Engl J Med. 2008;359:2324-36. </text>
<text top="249" left="108" width="4" height="14" font="7"> </text>
<text top="249" left="130" width="1260" height="14" font="7">20.   Meijboom WB, Meijs MF, Schuijf JD, et al. Diagnostic accuracy of 64-slice computed tomography coronary angiography: a prospective, multicenter, multivendor study. J Am Coll Cardiol. 2008;52:2135-</text>
<text top="266" left="162" width="22" height="14" font="7">44. </text>
<text top="284" left="108" width="4" height="14" font="7"> </text>
<text top="284" left="130" width="1266" height="14" font="7">21.   Mowatt G, Cook JA, Hillis GS, et al. 64-Slice computed tomography angiography in the diagnosis and assessment of coronary artery disease: systematic review and meta-analysis. Heart. 2008;94:1386-93. </text>
<text top="301" left="108" width="4" height="14" font="7"> </text>
<text top="301" left="130" width="1064" height="14" font="7">22.   Janne dB, Siebert U, Cury R, et al. A systematic review on diagnostic accuracy of CT-based detection of significant coronary artery disease. Eur J Radiol. 2008;65:449-61. </text>
<text top="318" left="108" width="4" height="14" font="7"> </text>
<text top="318" left="130" width="1262" height="14" font="7">23.   Schuetz GM, Zacharopoulou NM, Schlattmann P, et al. Meta-analysis: noninvasive coronary angiography using computed tomography versus magnetic resonance imaging. Ann Intern Med. 2010;152:167-</text>
<text top="336" left="162" width="22" height="14" font="7">77. </text>
<text top="353" left="108" width="4" height="14" font="7"> </text>
<text top="353" left="130" width="1251" height="14" font="7">24.   Hamon M, Biondi-Zoccai GG, Malagutti P, et al. Diagnostic performance of multislice spiral computed tomography of coronary arteries as compared with conventional invasive coronary angiography: a </text>
<text top="370" left="162" width="326" height="14" font="7">meta-analysis. J Am Coll Cardiol. 2006;48:1896-910. </text>
<text top="387" left="108" width="4" height="14" font="7"> </text>
<text top="387" left="130" width="1252" height="14" font="7">25.   Schuijf JD, Bax JJ, Shaw LJ, et al. Meta-analysis of comparative diagnostic performance of magnetic resonance imaging and multislice computed tomography for noninvasive coronary angiography. Am </text>
<text top="404" left="162" width="161" height="14" font="7">Heart J. 2006;151:404-11. </text>
<text top="422" left="108" width="4" height="14" font="7"> </text>
<text top="422" left="130" width="984" height="14" font="7">26.   Sun Z, Jiang W. Diagnostic value of multislice computed tomography angiography in coronary artery disease: a meta-analysis. Eur J Radiol. 2006;60:279-86. </text>
<text top="439" left="108" width="4" height="14" font="7"> </text>
<text top="439" left="130" width="1061" height="14" font="7">27.   Stein PD, Beemath A, Kayali F, et al. Multidetector computed tomography for the diagnosis of coronary artery disease: a systematic review. Am J Med. 2006;119:203-16. </text>
<text top="456" left="108" width="4" height="14" font="7"> </text>
<text top="456" left="130" width="1084" height="14" font="7">28.   Jones CM, Athanasiou T, Dunne N, et al. Multi-detector computed tomography in coronary artery bypass graft assessment: a meta-analysis. Ann Thorac Surg. 2007;83:341-8. </text>
<text top="473" left="108" width="4" height="14" font="7"> </text>
<text top="473" left="130" width="1157" height="14" font="7">29.   Hamon M, Lepage O, Malagutti P, et al. Diagnostic performance of 16- and 64-section spiral CT for coronary artery bypass graft assessment: meta-analysis. Radiology. 2008;247:679-86. </text>
<text top="491" left="108" width="4" height="14" font="7"> </text>
<text top="491" left="130" width="1274" height="14" font="7">30.   Carrabba N, Schuijf JD, de Graaf FR, et al. Diagnostic accuracy of 64-slice computed tomography coronary angiography for the detection of in-stent restenosis: a meta-analysis. J Nucl Cardiol. 2010;17:470-</text>
<text top="508" left="162" width="15" height="14" font="7">8. </text>
<text top="525" left="108" width="4" height="14" font="7"> </text>
<text top="525" left="130" width="1079" height="14" font="7">31.   Sun Z, Almutairi AM. Diagnostic accuracy of 64 multislice CT angiography in the assessment of coronary in-stent restenosis: a meta-analysis. Eur J Radiol. 2010;73:266-73. </text>
<text top="543" left="108" width="4" height="14" font="7"> </text>
<text top="543" left="130" width="1269" height="14" font="7">32.   Korosoglou G, Elhmidi Y, Steen H, et al. Prognostic value of high-dose dobutamine stress magnetic resonance imaging in 1,493 consecutive patients: assessment of myocardial wall motion and perfusion. J </text>
<text top="560" left="162" width="219" height="14" font="7">Am Coll Cardiol. 2010;56:1225-34. </text>
<text top="577" left="108" width="4" height="14" font="7"> </text>
<text top="577" left="130" width="867" height="14" font="7">33.   Kelle S, Chiribiri A, Vierecke J, et al. Long-term prognostic value of dobutamine stress CMR. JACC Cardiovasc Imaging. 2011;4:161-72. </text>
<text top="594" left="108" width="4" height="14" font="7"> </text>
<text top="594" left="130" width="1253" height="14" font="7">34.   Bingham SE, Hachamovitch R. Incremental prognostic significance of combined cardiac magnetic resonance imaging, adenosine stress perfusion, delayed enhancement, and left ventricular function over </text>
<text top="611" left="162" width="560" height="14" font="7">preimaging information for the prediction of adverse events. Circulation. 2011;123:1509-18. </text>
<text top="629" left="108" width="4" height="14" font="7"> </text>
<text top="629" left="130" width="1235" height="14" font="7">35.   Jahnke C, Nagel E, Gebker R, et al. Prognostic value of cardiac magnetic resonance stress tests: adenosine stress perfusion and dobutamine stress wall motion imaging. Circulation. 2007;115:1769-76. </text>
<text top="646" left="108" width="4" height="14" font="7"> </text>
<text top="646" left="130" width="1244" height="14" font="7">36.   Coelho-Filho OR, Seabra LF, Mongeon F-P. Stress Myocardial Perfusion Imaging by CMR Provides Strong Prognastic Value to Cardiac Events Regardless of Patient's Sex. JACC Cardiovasc Imaging. </text>
<text top="663" left="162" width="96" height="14" font="7">2011;4:850-61. </text>
<text top="680" left="108" width="4" height="14" font="7"> </text>
<text top="680" left="130" width="1230" height="14" font="7">37.   Bodi V, Sanchis J, Lopez-Lereu MP, et al. Prognostic value of dipyridamole stress cardiovascular magnetic resonance imaging in patients with known or suspected coronary artery disease. J Am Coll </text>
<text top="698" left="162" width="156" height="14" font="7">Cardiol. 2007;50:1174-9. </text>
<text top="715" left="108" width="4" height="14" font="7"> </text>
<text top="715" left="130" width="898" height="14" font="7">38.   Hundley WG, Morgan TM, Neagle CM, et al. Magnetic resonance imaging determination of cardiac prognosis. Circulation. 2002;106:2328-33. </text>
<text top="732" left="108" width="4" height="14" font="7"> </text>
<text top="732" left="130" width="1264" height="14" font="7">39.   Wallace EL, Morgan TM, Walsh TF, et al. Dobutamine cardiac magnetic resonance results predict cardiac prognosis in women with known or suspected ischemic heart disease. JACC Cardiovasc Imaging. </text>
<text top="750" left="162" width="103" height="14" font="7">2009;2:299-307. </text>
<text top="767" left="108" width="4" height="14" font="7"> </text>
<text top="767" left="130" width="1278" height="14" font="7">40.   Hartlage G, Janik M, Anadiotis A, et al. Prognostic value of adenosine stress cardiovascular magnetic resonance and dobutamine stress echocardiography in patients with low-risk chest pain. Int J Cardiovasc </text>
<text top="784" left="162" width="95" height="14" font="7">Imaging. 2011. </text>
</page>
<page number="38" position="absolute" top="0" left="0" height="918" width="1512">
<text top="59" left="108" width="4" height="15" font="0"> </text>
<text top="59" left="459" width="4" height="15" font="0"> </text>
<text top="59" left="810" width="4" height="15" font="0"> </text>
<text top="59" left="864" width="4" height="15" font="0"> </text>
<text top="59" left="918" width="4" height="15" font="0"> </text>
<text top="59" left="972" width="4" height="15" font="0"> </text>
<text top="59" left="1026" width="4" height="15" font="0"> </text>
<text top="59" left="1080" width="4" height="15" font="0"> </text>
<text top="59" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="108" width="613" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="825" left="810" width="4" height="15" font="0"> </text>
<text top="825" left="864" width="4" height="15" font="0"> </text>
<text top="825" left="918" width="4" height="15" font="0"> </text>
<text top="825" left="972" width="4" height="15" font="0"> </text>
<text top="825" left="1026" width="4" height="15" font="0"> </text>
<text top="825" left="1080" width="4" height="15" font="0"> </text>
<text top="825" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="1188" width="4" height="15" font="0"> </text>
<text top="825" left="1242" width="22" height="15" font="0">38 </text>
<text top="847" left="108" width="4" height="15" font="0"> </text>
<text top="111" left="108" width="4" height="14" font="7"> </text>
<text top="111" left="130" width="1262" height="14" font="7">41.   Steel K, Broderick R, Gandla V, et al. Complementary prognostic values of stress myocardial perfusion and late gadolinium enhancement imaging by cardiac magnetic resonance in patients with known or </text>
<text top="129" left="162" width="409" height="14" font="7">suspected coronary artery disease. Circulation. 2009;120:1390-400. </text>
<text top="146" left="108" width="4" height="14" font="7"> </text>
<text top="146" left="130" width="920" height="14" font="7">42.   Pilz G, Jeske A, Klos M, et al. Prognostic value of normal adenosine-stress cardiac magnetic resonance imaging. Am J Cardiol. 2008;101:1408-12. </text>
<text top="163" left="108" width="4" height="14" font="7"> </text>
<text top="163" left="130" width="1241" height="14" font="7">43.   Lo KY, Leung KF, Chu CM, et al. Prognostic value of adenosine stress myocardial perfusion by cardiac magnetic resonance imaging in patients with known or suspected coronary artery disease. QJM. </text>
<text top="180" left="162" width="111" height="14" font="7">2011;104:425-32. </text>
<text top="197" left="108" width="4" height="14" font="7"> </text>
<text top="197" left="130" width="1263" height="14" font="7">44.   Dall'Armellina E, Morgan TM, Mandapaka S, et al. Prediction of cardiac events in patients with reduced left ventricular ejection fraction with dobutamine cardiovascular magnetic resonance assessment of </text>
<text top="215" left="162" width="373" height="14" font="7">wall motion score index. J Am Coll Cardiol. 2008;52:279-86. </text>
<text top="232" left="108" width="4" height="14" font="7"> </text>
<text top="232" left="130" width="1200" height="14" font="7">45.   Ingkanisorn WP, Kwong RY, Bohme NS, et al. Prognosis of negative adenosine stress magnetic resonance in patients presenting to an emergency department with chest pain. J Am Coll Cardiol. </text>
<text top="249" left="162" width="111" height="14" font="7">2006;47:1427-32. </text>
<text top="266" left="108" width="4" height="14" font="7"> </text>
<text top="266" left="130" width="1195" height="14" font="7">46.   Lerakis S, McLean DS, Anadiotis AV, et al. Prognostic value of adenosine stress cardiovascular magnetic resonance in patients with low-risk chest pain. J Cardiovasc Magn Reson. 2009;11:37. </text>
<text top="284" left="108" width="4" height="14" font="7"> </text>
<text top="284" left="130" width="1250" height="14" font="7">47.   Doesch C, Seeger A, Doering J, et al. Risk stratification by adenosine stress cardiac magnetic resonance in patients with coronary artery stenoses of intermediate angiographic severity. JACC Cardiovasc </text>
<text top="301" left="162" width="153" height="14" font="7">Imaging. 2009;2:424-33. </text>
<text top="318" left="108" width="4" height="14" font="7"> </text>
<text top="318" left="130" width="1269" height="14" font="7">48.   Bernhardt P, Spiess J, Levenson B, et al. Combined assessment of myocardial perfusion and late gadolinium enhancement in patients after percutaneous coronary intervention or bypass grafts: a multicenter </text>
<text top="336" left="162" width="685" height="14" font="7">study of an integrated cardiovascular magnetic resonance protocol. JACC Cardiovasc Imaging. 2009;2:1292-300. </text>
<text top="353" left="108" width="4" height="14" font="7"> </text>
<text top="353" left="130" width="1268" height="14" font="7">49.   Schwitter J, Wacker CM, van Rossum AC, et al. MR-IMPACT: comparison of perfusion-cardiac magnetic resonance with single-photon emission computed tomography for the detection of coronary artery </text>
<text top="370" left="162" width="507" height="14" font="7">disease in a multicentre, multivendor, randomized trial. Eur Heart J. 2008;29:480-9. </text>
<text top="387" left="108" width="4" height="14" font="7"> </text>
<text top="387" left="130" width="1238" height="14" font="7">50.   Nagel E, Lehmkuhl HB, Bocksch W, et al. Noninvasive diagnosis of ischemia-induced wall motion abnormalities with the use of high-dose dobutamine stress MRI: comparison with dobutamine stress </text>
<text top="404" left="162" width="293" height="14" font="7">echocardiography. Circulation. 1999;99:763-70. </text>
<text top="422" left="108" width="4" height="14" font="7"> </text>
<text top="422" left="130" width="1042" height="14" font="7">51.   Greenwood JP, Maredia N, Radjenovic A, et al. Clinical evaluation of magnetic resonance imaging in coronary heart disease: the CE-MARC study. Trials. 2009;10:62. </text>
<text top="439" left="108" width="4" height="14" font="7"> </text>
<text top="439" left="130" width="1231" height="14" font="7">52.   Hamon M, Fau G, Nee G, et al. Meta-analysis of the diagnostic performance of stress perfusion cardiovascular magnetic resonance for detection of coronary artery disease. J Cardiovasc Magn Reson. </text>
<text top="456" left="162" width="76" height="14" font="7">2010;12:29. </text>
<text top="473" left="108" width="4" height="14" font="7"> </text>
<text top="473" left="130" width="1269" height="14" font="7">53.   Caracciolo EA, Davis KB, Sopko G, et al. Comparison of surgical and medical group survival in patients with left main coronary artery disease. Long-term CASS experience. Circulation. 1995;91:2325-34. </text>
<text top="491" left="108" width="4" height="14" font="7"> </text>
<text top="491" left="130" width="1114" height="14" font="7">54.   Taylor HA, Deumite NJ, Chaitman BR, et al. Asymptomatic left main coronary artery disease in the Coronary Artery Surgery Study (CASS) registry. Circulation. 1989;79:1171-9. </text>
<text top="508" left="108" width="4" height="14" font="7"> </text>
<text top="508" left="130" width="1229" height="14" font="7">55.   Chaitman BR, Fisher LD, Bourassa MG, et al. Effect of coronary bypass surgery on survival patterns in subsets of patients with left main coronary artery disease. Report of the Collaborative Study in </text>
<text top="525" left="162" width="401" height="14" font="7">Coronary Artery Surgery (CASS). Am J Cardiol. 1981;48:765-77. </text>
<text top="543" left="108" width="4" height="14" font="7"> </text>
<text top="543" left="130" width="1273" height="14" font="7">56.   Takaro T, Hultgren HN, Lipton MJ, et al. The VA cooperative randomized study of surgery for coronary arterial occlusive disease II. Subgroup with significant left main lesions. Circulation. 1976;54:III107-</text>
<text top="560" left="162" width="45" height="14" font="7">III117. </text>
<text top="577" left="108" width="4" height="14" font="7"> </text>
<text top="577" left="130" width="1231" height="14" font="7">57.   Takaro T, Peduzzi P, Detre KM, et al. Survival in subgroups of patients with left main coronary artery disease. Veterans Administration Cooperative Study of Surgery for Coronary Arterial Occlusive </text>
<text top="594" left="162" width="225" height="14" font="7">Disease. Circulation. 1982;66:14-22. </text>
<text top="611" left="108" width="4" height="14" font="7"> </text>
<text top="611" left="130" width="1245" height="14" font="7">58.   Yusuf S, Zucker D, Peduzzi P, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists </text>
<text top="629" left="162" width="249" height="14" font="7">Collaboration. Lancet. 1994;344:563-70. </text>
<text top="646" left="108" width="4" height="14" font="7"> </text>
<text top="646" left="130" width="1212" height="14" font="7">59.   Dzavik V, Ghali WA, Norris C, et al. Long-term survival in 11,661 patients with multivessel coronary artery disease in the era of stenting: a report from the Alberta Provincial Project for Outcome </text>
<text top="663" left="162" width="604" height="14" font="7">Assessment in Coronary Heart Disease (APPROACH) Investigators. Am Heart J. 2001;142:119-26. </text>
<text top="680" left="108" width="4" height="14" font="7"> </text>
<text top="680" left="130" width="1172" height="14" font="7">60.   Wu C, Hannan EL, Walford G, et al. Utilization and outcomes of unprotected left main coronary artery stenting and coronary artery bypass graft surgery. Ann Thorac Surg. 2008;86:1153-9. </text>
<text top="698" left="108" width="4" height="14" font="7"> </text>
<text top="698" left="130" width="1275" height="14" font="7">61.   Kappetein A, Feldman T, Mack M. Comparison of coronary artery bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial. </text>
<text top="715" left="162" width="113" height="14" font="7">Eur Heart J. 2011. </text>
<text top="732" left="108" width="4" height="14" font="7"> </text>
<text top="732" left="130" width="1256" height="14" font="7">62.   Morice MC, Serruys PW, Kappetein AP, et al. Outcomes in patients with de novo left main disease treated with either percutaneous coronary intervention using paclitaxel-eluting stents or coronary artery </text>
<text top="750" left="162" width="1016" height="14" font="7">bypass graft treatment in the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial. Circulation. 2010;121:2645-53. </text>
<text top="767" left="108" width="4" height="14" font="7"> </text>
<text top="767" left="130" width="1149" height="14" font="7">63.   Buszman PE, Kiesz SR, Bochenek A, et al. Acute and late outcomes of unprotected left main stenting in comparison with surgical revascularization. J Am Coll Cardiol. 2008;51:538-45. </text>
</page>
<page number="39" position="absolute" top="0" left="0" height="918" width="1512">
<text top="59" left="108" width="4" height="15" font="0"> </text>
<text top="59" left="459" width="4" height="15" font="0"> </text>
<text top="59" left="810" width="4" height="15" font="0"> </text>
<text top="59" left="864" width="4" height="15" font="0"> </text>
<text top="59" left="918" width="4" height="15" font="0"> </text>
<text top="59" left="972" width="4" height="15" font="0"> </text>
<text top="59" left="1026" width="4" height="15" font="0"> </text>
<text top="59" left="1080" width="4" height="15" font="0"> </text>
<text top="59" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="108" width="613" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="825" left="810" width="4" height="15" font="0"> </text>
<text top="825" left="864" width="4" height="15" font="0"> </text>
<text top="825" left="918" width="4" height="15" font="0"> </text>
<text top="825" left="972" width="4" height="15" font="0"> </text>
<text top="825" left="1026" width="4" height="15" font="0"> </text>
<text top="825" left="1080" width="4" height="15" font="0"> </text>
<text top="825" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="1188" width="4" height="15" font="0"> </text>
<text top="825" left="1242" width="22" height="15" font="0">39 </text>
<text top="847" left="108" width="4" height="15" font="0"> </text>
<text top="111" left="108" width="4" height="14" font="7"> </text>
<text top="111" left="130" width="1241" height="14" font="7">64.   Boudriot E, Thiele H, Walther T, et al. Randomized comparison of percutaneous coronary intervention with sirolimus-eluting stents versus coronary artery bypass grafting in unprotected left main stem </text>
<text top="129" left="162" width="276" height="14" font="7">stenosis. J Am Coll Cardiol. 2011;57:538-45. </text>
<text top="146" left="108" width="4" height="14" font="7"> </text>
<text top="146" left="130" width="1215" height="14" font="7">65.   Chieffo A, Morici N, Maisano F, et al. Percutaneous treatment with drug-eluting stent implantation versus bypass surgery for unprotected left main stenosis: a single-center experience. Circulation. </text>
<text top="163" left="162" width="111" height="14" font="7">2006;113:2542-7. </text>
<text top="180" left="108" width="4" height="14" font="7"> </text>
<text top="180" left="130" width="1274" height="14" font="7">66.   Chieffo A, Magni V, Latib A, et al. 5-year outcomes following percutaneous coronary intervention with drug-eluting stent implantation versus coronary artery bypass graft for unprotected left main coronary </text>
<text top="197" left="162" width="475" height="14" font="7">artery lesions the milan experience. JACC Cardiovasc Interv. 2010;3:595-601. </text>
<text top="215" left="108" width="4" height="14" font="7"> </text>
<text top="215" left="130" width="1253" height="14" font="7">67.   Lee MS, Kapoor N, Jamal F, et al. Comparison of coronary artery bypass surgery with percutaneous coronary intervention with drug-eluting stents for unprotected left main coronary artery disease. J Am </text>
<text top="232" left="162" width="185" height="14" font="7">Coll Cardiol. 2006;47:864-70. </text>
<text top="249" left="108" width="4" height="14" font="7"> </text>
<text top="249" left="130" width="1252" height="14" font="7">68.   Lee MS, Bokhoor P, Park SJ, et al. Unprotected left main coronary disease and ST-segment elevation myocardial infarction: a contemporary review and argument for percutaneous coronary intervention. </text>
<text top="266" left="162" width="243" height="14" font="7">JACC Cardiovasc Interv. 2010;3:791-5. </text>
<text top="284" left="108" width="4" height="14" font="7"> </text>
<text top="284" left="130" width="1252" height="14" font="7">69.   Naik H, White AJ, Chakravarty T, et al. A meta-analysis of 3,773 patients treated with percutaneous coronary intervention or surgery for unprotected left main coronary artery stenosis. JACC Cardiovasc </text>
<text top="301" left="162" width="139" height="14" font="7">Interv. 2009;2:739-47. </text>
<text top="318" left="108" width="4" height="14" font="7"> </text>
<text top="318" left="130" width="1267" height="14" font="7">70.   White AJ, Kedia G, Mirocha JM, et al. Comparison of coronary artery bypass surgery and percutaneous drug-eluting stent implantation for treatment of left main coronary artery stenosis. JACC Cardiovasc </text>
<text top="336" left="162" width="139" height="14" font="7">Interv. 2008;1:236-45. </text>
<text top="353" left="108" width="4" height="14" font="7"> </text>
<text top="353" left="130" width="1274" height="14" font="7">71.   Palmerini T, Marzocchi A, Marrozzini C, et al. Comparison between coronary angioplasty and coronary artery bypass surgery for the treatment of unprotected left main coronary artery stenosis (the Bologna </text>
<text top="370" left="162" width="240" height="14" font="7">Registry). Am J Cardiol. 2006;98:54-9. </text>
<text top="387" left="108" width="4" height="14" font="7"> </text>
<text top="387" left="130" width="1230" height="14" font="7">72.   Park DW, Seung KB, Kim YH, et al. Long-term safety and efficacy of stenting versus coronary artery bypass grafting for unprotected left main coronary artery disease: 5-year results from the MAIN-</text>
<text top="404" left="162" width="1218" height="14" font="7">COMPARE (Revascularization for Unprotected Left Main Coronary Artery Stenosis: Comparison of Percutaneous Coronary Angioplasty Versus Surgical Revascularization) registry. J Am Coll Cardiol. </text>
<text top="422" left="162" width="103" height="14" font="7">2010;56:117-24. </text>
<text top="439" left="108" width="4" height="14" font="7"> </text>
<text top="439" left="130" width="1049" height="14" font="7">73.   Sanmartin M, Baz JA, Claro R, et al. Comparison of drug-eluting stents versus surgery for unprotected left main coronary artery disease. Am J Cardiol. 2007;100:970-3. </text>
<text top="456" left="108" width="4" height="14" font="7"> </text>
<text top="456" left="130" width="1267" height="14" font="7">74.   Brener SJ, Galla JM, Bryant R. I, et al. Comparison of percutaneous versus surgical revascularization of severe unprotected left main coronary stenosis in matched patients. Am J Cardiol. 2008;101:169-72. </text>
<text top="473" left="108" width="4" height="14" font="7"> </text>
<text top="473" left="130" width="1237" height="14" font="7">75.   Makikallio TH, Niemela M, Kervinen K, et al. Coronary angioplasty in drug eluting stent era for the treatment of unprotected left main stenosis compared to coronary artery bypass grafting. Ann Med. </text>
<text top="491" left="162" width="103" height="14" font="7">2008;40:437-43. </text>
<text top="508" left="108" width="4" height="14" font="7"> </text>
<text top="508" left="130" width="856" height="14" font="7">76.   Varnauskas E. Twelve-year follow-up of survival in the randomized European Coronary Surgery Study. N Engl J Med. 1988;319:332-7. </text>
<text top="525" left="108" width="4" height="14" font="7"> </text>
<text top="525" left="130" width="1230" height="14" font="7">77.   Jones RH, Kesler K, Phillips HR, III, et al. Long-term survival benefits of coronary artery bypass grafting and percutaneous transluminal angioplasty in patients with coronary artery disease. J Thorac </text>
<text top="543" left="162" width="225" height="14" font="7">Cardiovasc Surg. 1996;111:1013-25. </text>
<text top="560" left="108" width="4" height="14" font="7"> </text>
<text top="560" left="130" width="1257" height="14" font="7">78.   Hueb W, Lopes N, Gersh BJ, et al. Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel </text>
<text top="577" left="162" width="332" height="14" font="7">coronary artery disease. Circulation. 2010;122:949-57. </text>
<text top="594" left="108" width="4" height="14" font="7"> </text>
<text top="594" left="130" width="1242" height="14" font="7">79.   Myers WO, Schaff HV, Gersh BJ, et al. Improved survival of surgically treated patients with triple vessel coronary artery disease and severe angina pectoris. A report from the Coronary Artery Surgery </text>
<text top="611" left="162" width="410" height="14" font="7">Study (CASS) registry. J Thorac Cardiovasc Surg. 1989;97:487-95. </text>
<text top="629" left="108" width="4" height="14" font="7"> </text>
<text top="629" left="130" width="1079" height="14" font="7">80.   Smith PK, Califf RM, Tuttle RH, et al. Selection of surgical or percutaneous coronary intervention provides differential longevity benefit. Ann Thorac Surg. 2006;82:1420-8. </text>
<text top="646" left="108" width="4" height="14" font="7"> </text>
<text top="646" left="130" width="939" height="14" font="7">81.   Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503-16. </text>
<text top="663" left="108" width="4" height="14" font="7"> </text>
<text top="663" left="130" width="1239" height="14" font="7">82.   Bair TL, Muhlestein JB, May HT, et al. Surgical revascularization is associated with improved long-term outcomes compared with percutaneous stenting in most subgroups of patients with multivessel </text>
<text top="680" left="162" width="632" height="14" font="7">coronary artery disease: results from the Intermountain Heart Registry. Circulation. 2007;116:I226-I231. </text>
<text top="698" left="108" width="4" height="14" font="7"> </text>
<text top="698" left="130" width="1252" height="14" font="7">83.   Booth J, Clayton T, Pepper J, et al. Randomized, controlled trial of coronary artery bypass surgery versus percutaneous coronary intervention in patients with multivessel coronary artery disease: six-year </text>
<text top="715" left="162" width="473" height="14" font="7">follow-up from the Stent or Surgery Trial (SoS). Circulation. 2008;118:381-8. </text>
<text top="732" left="108" width="4" height="14" font="7"> </text>
<text top="732" left="130" width="1217" height="14" font="7">84.   Hannan EL, Racz MJ, McCallister BD, et al. A comparison of three-year survival after coronary artery bypass graft surgery and percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. </text>
<text top="750" left="162" width="96" height="14" font="7">1999;33:63-72. </text>
<text top="767" left="108" width="4" height="14" font="7"> </text>
<text top="767" left="130" width="987" height="14" font="7">85.   Hannan EL, Wu C, Walford G, et al. Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease. N Engl J Med. 2008;358:331-41. </text>
</page>
<page number="40" position="absolute" top="0" left="0" height="918" width="1512">
<text top="59" left="108" width="4" height="15" font="0"> </text>
<text top="59" left="459" width="4" height="15" font="0"> </text>
<text top="59" left="810" width="4" height="15" font="0"> </text>
<text top="59" left="864" width="4" height="15" font="0"> </text>
<text top="59" left="918" width="4" height="15" font="0"> </text>
<text top="59" left="972" width="4" height="15" font="0"> </text>
<text top="59" left="1026" width="4" height="15" font="0"> </text>
<text top="59" left="1080" width="4" height="15" font="0"> </text>
<text top="59" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="108" width="613" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="825" left="810" width="4" height="15" font="0"> </text>
<text top="825" left="864" width="4" height="15" font="0"> </text>
<text top="825" left="918" width="4" height="15" font="0"> </text>
<text top="825" left="972" width="4" height="15" font="0"> </text>
<text top="825" left="1026" width="4" height="15" font="0"> </text>
<text top="825" left="1080" width="4" height="15" font="0"> </text>
<text top="825" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="1188" width="4" height="15" font="0"> </text>
<text top="825" left="1242" width="22" height="15" font="0">40 </text>
<text top="847" left="108" width="4" height="15" font="0"> </text>
<text top="111" left="108" width="4" height="14" font="7"> </text>
<text top="111" left="130" width="1218" height="14" font="7">86.   Malenka DJ, Leavitt BJ, Hearne MJ, et al. Comparing long-term survival of patients with multivessel coronary disease after CABG or PCI: analysis of BARI-like patients in northern New England. </text>
<text top="129" left="162" width="203" height="14" font="7">Circulation. 2005;112:I371-I376. </text>
<text top="146" left="108" width="4" height="14" font="7"> </text>
<text top="146" left="130" width="1220" height="14" font="7">87.   Bravata DM, Gienger AL, McDonald KM, et al. Systematic review: the comparative effectiveness of percutaneous coronary interventions and coronary artery bypass graft surgery. Ann Intern Med. </text>
<text top="163" left="162" width="111" height="14" font="7">2007;147:703-16. </text>
<text top="180" left="108" width="4" height="14" font="7"> </text>
<text top="180" left="130" width="1272" height="14" font="7">88.   Daemen J, Boersma E, Flather M, et al. Long-term safety and efficacy of percutaneous coronary intervention with stenting and coronary artery bypass surgery for multivessel coronary artery disease: a meta-</text>
<text top="197" left="162" width="748" height="14" font="7">analysis with 5-year patient-level data from the ARTS, ERACI-II, MASS-II, and SoS trials. Circulation. 2008;118:1146-54. </text>
<text top="215" left="108" width="4" height="14" font="7"> </text>
<text top="215" left="130" width="1240" height="14" font="7">89.   Rodriguez A, Rodriguez AM, Baldi J, et al. Coronary stenting versus coronary bypass surgery in patients with multiple vessel disease and significant proximal LAD stenosis: results from the ERACI II </text>
<text top="232" left="162" width="177" height="14" font="7">study. Heart. 2003;89:184-8. </text>
<text top="249" left="108" width="4" height="14" font="7"> </text>
<text top="249" left="130" width="1261" height="14" font="7">90.   Mercado N, Maier W, Boersma E, et al. Clinical and angiographic outcome of patients with mild coronary lesions treated with balloon angioplasty or coronary stenting. Implications for mechanical plaque </text>
<text top="266" left="162" width="229" height="14" font="7">sealing. Eur Heart J. 2003;24:541-51. </text>
<text top="284" left="108" width="4" height="14" font="7"> </text>
<text top="284" left="130" width="1100" height="14" font="7">91.   The RITA Investigators. Coronary angioplasty versus coronary artery bypass surgery: the Randomized Intervention Treatment of Angina (RITA) trial. Lancet. 1993;341:573-80. </text>
<text top="301" left="108" width="4" height="14" font="7"> </text>
<text top="301" left="130" width="1224" height="14" font="7">92.   van Domburg RT, Foley DP, Breeman A, et al. Coronary artery bypass graft surgery and percutaneous transluminal coronary angioplasty. Twenty-year clinical outcome. Eur Heart J. 2002;23:543-9. </text>
<text top="318" left="108" width="4" height="14" font="7"> </text>
<text top="318" left="130" width="979" height="14" font="7">93.   Hannan EL, Racz MJ, Walford G, et al. Long-term outcomes of coronary-artery bypass grafting versus stent implantation. N Engl J Med. 2005;352:2174-83. </text>
<text top="336" left="108" width="4" height="14" font="7"> </text>
<text top="336" left="130" width="1267" height="14" font="7">94.   Berger PB, Velianou JL, Aslanidou VH, et al. Survival following coronary angioplasty versus coronary artery bypass surgery in anatomic subsets in which coronary artery bypass surgery improves survival </text>
<text top="353" left="162" width="892" height="14" font="7">compared with medical therapy. Results from the Bypass Angioplasty Revascularization Investigation (BARI). J Am Coll Cardiol. 2001;38:1440-9. </text>
<text top="370" left="108" width="4" height="14" font="7"> </text>
<text top="370" left="130" width="894" height="14" font="7">95.   Cecil WT, Kasteridis P, Barnes JW, Jr., et al. A meta-analysis update: percutaneous coronary interventions. Am J Manag Care. 2008;14:521-8. </text>
<text top="387" left="108" width="4" height="14" font="7"> </text>
<text top="387" left="130" width="1263" height="14" font="7">96.   Pitt B, Waters D, Brown WV, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J </text>
<text top="404" left="162" width="131" height="14" font="7">Med. 1999;341:70-6. </text>
<text top="422" left="108" width="4" height="14" font="7"> </text>
<text top="422" left="130" width="1263" height="14" font="7">97.   Greenbaum AB, Califf RM, Jones RH, et al. Comparison of medicine alone, coronary angioplasty, and left internal mammary artery-coronary artery bypass for one-vessel proximal left anterior descending </text>
<text top="439" left="162" width="338" height="14" font="7">coronary artery disease. Am J Cardiol. 2000;86:1322-6. </text>
<text top="456" left="108" width="4" height="14" font="7"> </text>
<text top="456" left="130" width="1254" height="14" font="7">98.   Aziz O, Rao C, Panesar SS, et al. Meta-analysis of minimally invasive internal thoracic artery bypass versus percutaneous revascularisation for isolated lesions of the left anterior descending artery. BMJ. </text>
<text top="473" left="162" width="91" height="14" font="7">2007;334:617. </text>
<text top="491" left="108" width="4" height="14" font="7"> </text>
<text top="491" left="130" width="1271" height="14" font="7">99.   Ben-Gal Y, Mohr R, Braunstein R, et al. Revascularization of left anterior descending artery with drug-eluting stents: comparison with minimally invasive direct coronary artery bypass surgery. Ann Thorac </text>
<text top="508" left="162" width="147" height="14" font="7">Surg. 2006;82:2067-71. </text>
<text top="525" left="108" width="1272" height="14" font="7">  100.   Cisowski M, Drzewiecka-Gerber A, Ulczok R, et al. Primary direct stenting versus endoscopic atraumatic coronary artery bypass surgery in patients with proximal stenosis of the left anterior descending </text>
<text top="543" left="162" width="483" height="14" font="7">coronary artery--a prospective, randomised study. Kardiol Pol. 2004;61:253-61. </text>
<text top="560" left="108" width="1207" height="14" font="7">  101.   Diegeler A, Thiele H, Falk V, et al. Comparison of stenting with minimally invasive bypass surgery for stenosis of the left anterior descending coronary artery. N Engl J Med. 2002;347:561-6. </text>
<text top="577" left="108" width="1299" height="14" font="7">  102.   Drenth DJ, Veeger NJ, Middel B, et al. Comparison of late (four years) functional health status between percutaneous transluminal angioplasty intervention and off-pump left internal mammary artery bypass </text>
<text top="594" left="162" width="790" height="14" font="7">grafting for isolated high-grade narrowing of the proximal left anterior descending coronary artery. Am J Cardiol. 2004;94:1414-7. </text>
<text top="611" left="108" width="1237" height="14" font="7">  103.   Fraund S, Herrmann G, Witzke A, et al. Midterm follow-up after minimally invasive direct coronary artery bypass grafting versus percutaneous coronary intervention techniques. Ann Thorac Surg. </text>
<text top="629" left="162" width="111" height="14" font="7">2005;79:1225-31. </text>
<text top="646" left="108" width="1224" height="14" font="7">  104.   Goy JJ, Eeckhout E, Burnand B, et al. Coronary angioplasty versus left internal mammary artery grafting for isolated proximal left anterior descending artery stenosis. Lancet. 1994;343:1449-53. </text>
<text top="663" left="108" width="1276" height="14" font="7">  105.   Goy JJ, Kaufmann U, Hurni M, et al. 10-year follow-up of a prospective randomized trial comparing bare-metal stenting with internal mammary artery grafting for proximal, isolated de novo left anterior </text>
<text top="680" left="162" width="772" height="14" font="7">coronary artery stenosis the SIMA (Stenting versus Internal Mammary Artery grafting) trial. J Am Coll Cardiol. 2008;52:815-7. </text>
<text top="698" left="108" width="1253" height="14" font="7">  106.   Hong SJ, Lim DS, Seo HS, et al. Percutaneous coronary intervention with drug-eluting stent implantation vs. minimally invasive direct coronary artery bypass (MIDCAB) in patients with left anterior </text>
<text top="715" left="162" width="487" height="14" font="7">descending coronary artery stenosis. Catheter Cardiovasc Interv. 2005;64:75-81. </text>
<text top="732" left="108" width="1294" height="14" font="7">  107.   Jaffery Z, Kowalski M, Weaver WD, et al. A meta-analysis of randomized control trials comparing minimally invasive direct coronary bypass grafting versus percutaneous coronary intervention for stenosis </text>
<text top="750" left="162" width="533" height="14" font="7">of the proximal left anterior descending artery. Eur J Cardiothorac Surg. 2007;31:691-7. </text>
<text top="767" left="108" width="1267" height="14" font="7">  108.   Kapoor JR, Gienger AL, Ardehali R, et al. Isolated disease of the proximal left anterior descending artery comparing the effectiveness of percutaneous coronary interventions and coronary artery bypass </text>
<text top="784" left="162" width="303" height="14" font="7">surgery. JACC Cardiovasc Interv. 2008;1:483-91. </text>
</page>
<page number="41" position="absolute" top="0" left="0" height="918" width="1512">
<text top="59" left="108" width="4" height="15" font="0"> </text>
<text top="59" left="459" width="4" height="15" font="0"> </text>
<text top="59" left="810" width="4" height="15" font="0"> </text>
<text top="59" left="864" width="4" height="15" font="0"> </text>
<text top="59" left="918" width="4" height="15" font="0"> </text>
<text top="59" left="972" width="4" height="15" font="0"> </text>
<text top="59" left="1026" width="4" height="15" font="0"> </text>
<text top="59" left="1080" width="4" height="15" font="0"> </text>
<text top="59" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="108" width="613" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="825" left="810" width="4" height="15" font="0"> </text>
<text top="825" left="864" width="4" height="15" font="0"> </text>
<text top="825" left="918" width="4" height="15" font="0"> </text>
<text top="825" left="972" width="4" height="15" font="0"> </text>
<text top="825" left="1026" width="4" height="15" font="0"> </text>
<text top="825" left="1080" width="4" height="15" font="0"> </text>
<text top="825" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="1188" width="4" height="15" font="0"> </text>
<text top="825" left="1242" width="22" height="15" font="0">41 </text>
<text top="847" left="108" width="4" height="15" font="0"> </text>
<text top="111" left="108" width="1255" height="14" font="7">  109.   Hueb WA, Bellotti G, de Oliveira SA, et al. The Medicine, Angioplasty or Surgery Study (MASS): a prospective, randomized trial of medical therapy, balloon angioplasty or bypass surgery for single </text>
<text top="129" left="162" width="521" height="14" font="7">proximal left anterior descending artery stenoses. J Am Coll Cardiol. 1995;26:1600-5. </text>
<text top="146" left="108" width="1030" height="14" font="7">  110.   Hueb W, Gersh BJ, Costa F, et al. Impact of diabetes on five-year outcomes of patients with multivessel coronary artery disease. Ann Thorac Surg. 2007;83:93-9. </text>
<text top="163" left="108" width="1228" height="14" font="7">  111.   Sorajja P, Chareonthaitawee P, Rajagopalan N, et al. Improved survival in asymptomatic diabetic patients with high-risk SPECT imaging treated with coronary artery bypass grafting. Circulation. </text>
<text top="180" left="162" width="128" height="14" font="7">2005;112:I311-I316. </text>
<text top="197" left="108" width="977" height="14" font="7">  112.   Frye RL, August P, Brooks MM, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360:2503-15. </text>
<text top="215" left="108" width="1218" height="14" font="7">  113.   The BARI Investigators. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty </text>
<text top="232" left="162" width="425" height="14" font="7">Revascularization Investigation (BARI). Circulation. 1997;96:1761-9. </text>
<text top="249" left="108" width="841" height="14" font="7">  114.   The BARI Investigators. The final 10-year follow-up results from the BARI randomized trial. J Am Coll Cardiol. 2007;49:1600-6. </text>
<text top="266" left="108" width="1285" height="14" font="7">  115.   Brener SJ, Lytle BW, Casserly IP, et al. Propensity analysis of long-term survival after surgical or percutaneous revascularization in patients with multivessel coronary artery disease and high-risk features. </text>
<text top="284" left="162" width="186" height="14" font="7">Circulation. 2004;109:2290-5. </text>
<text top="301" left="108" width="1292" height="14" font="7">  116.   Hlatky MA, Boothroyd DB, Bravata DM, et al. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data </text>
<text top="318" left="162" width="325" height="14" font="7">from ten randomised trials. Lancet. 2009;373:1190-7. </text>
<text top="336" left="108" width="1249" height="14" font="7">  117.   Javaid A, Steinberg DH, Buch AN, et al. Outcomes of coronary artery bypass grafting versus percutaneous coronary intervention with drug-eluting stents for patients with multivessel coronary artery </text>
<text top="353" left="162" width="254" height="14" font="7">disease. Circulation. 2007;116:I200-I206. </text>
<text top="370" left="108" width="1264" height="14" font="7">  118.   Niles NW, McGrath PD, Malenka D, et al. Survival of patients with diabetes and multivessel coronary artery disease after surgical or percutaneous coronary revascularization: results of a large regional </text>
<text top="387" left="162" width="715" height="14" font="7">prospective study. Northern New England Cardiovascular Disease Study Group. J Am Coll Cardiol. 2001;37:1008-15. </text>
<text top="404" left="108" width="1285" height="14" font="7">  119.   Pell JP, Pell AC, Jeffrey RR, et al. Comparison of survival following coronary artery bypass grafting vs. percutaneous coronary intervention in diabetic and non-diabetic patients: retrospective cohort study </text>
<text top="422" left="162" width="298" height="14" font="7">of 6320 procedures. Diabet Med. 2004;21:790-2. </text>
<text top="439" left="108" width="1281" height="14" font="7">  120.   Weintraub WS, Stein B, Kosinski A, et al. Outcome of coronary bypass surgery versus coronary angioplasty in diabetic patients with multivessel coronary artery disease. J Am Coll Cardiol. 1998;31:10-9. </text>
<text top="456" left="108" width="1262" height="14" font="7">  121.   Abizaid A, Costa MA, Centemero M, et al. Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the Arterial </text>
<text top="473" left="162" width="466" height="14" font="7">Revascularization Therapy Study (ARTS) trial. Circulation. 2001;104:533-8. </text>
<text top="491" left="108" width="1129" height="14" font="7">  122.   Barsness GW, Peterson ED, Ohman EM, et al. Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty. Circulation. 1997;96:2551-6. </text>
<text top="508" left="108" width="1276" height="14" font="7">  123.   Kapur A, Hall RJ, Malik IS, et al. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery </text>
<text top="525" left="162" width="441" height="14" font="7">Revascularization in Diabetes) trial. J Am Coll Cardiol. 2010;55:432-40. </text>
<text top="543" left="108" width="1191" height="14" font="7">  124.   Benzer W, Hofer S, Oldridge NB. Health-related quality of life in patients with coronary artery disease after different treatments for angina in routine clinical practice. Herz. 2003;28:421-8. </text>
<text top="560" left="108" width="1016" height="14" font="7">  125.   Bonaros N, Schachner T, Ohlinger A, et al. Assessment of health-related quality of life after coronary revascularization. Heart Surg Forum. 2005;8:E380-E385. </text>
<text top="577" left="108" width="1260" height="14" font="7">  126.   Favarato ME, Hueb W, Boden WE, et al. Quality of life in patients with symptomatic multivessel coronary artery disease: a comparative post hoc analyses of medical, angioplasty or surgical strategies-</text>
<text top="594" left="162" width="283" height="14" font="7">MASS II trial. Int J Cardiol. 2007;116:364-70. </text>
<text top="611" left="108" width="1106" height="14" font="7">  127.   Hofer S, Doering S, Rumpold G, et al. Determinants of health-related quality of life in patients with coronary artery disease. Eur J Cardiovasc Prev Rehabil. 2006;13:398-406. </text>
<text top="629" left="108" width="856" height="14" font="7">  128.   Lukkarinen H, Hentinen M. Treatments of coronary artery disease improve quality of life in the long term. Nurs Res. 2006;55:26-33. </text>
<text top="646" left="108" width="1293" height="14" font="7">  129.   Pocock SJ, Henderson RA, Seed P, et al. Quality of life, employment status, and anginal symptoms after coronary angioplasty or bypass surgery. 3-year follow-up in the Randomized Intervention Treatment </text>
<text top="663" left="162" width="328" height="14" font="7">of Angina (RITA) Trial. Circulation. 1996;94:135-42. </text>
<text top="680" left="108" width="944" height="14" font="7">  130.   Weintraub WS, Spertus JA, Kolm P, et al. Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med. 2008;359:677-87. </text>
<text top="698" left="108" width="1248" height="14" font="7">  131.   Hambrecht R, Walther C, Mobius-Winkler S, et al. Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease: a randomized trial. Circulation. </text>
<text top="715" left="162" width="111" height="14" font="7">2004;109:1371-8. </text>
<text top="732" left="108" width="1236" height="14" font="7">  132.   Pocock SJ, Henderson RA, Clayton T, et al. Quality of life after coronary angioplasty or continued medical treatment for angina: three-year follow-up in the RITA-2 trial. Randomized Intervention </text>
<text top="750" left="162" width="355" height="14" font="7">Treatment of Angina. J Am Coll Cardiol. 2000;35:907-14. </text>
<text top="767" left="108" width="1221" height="14" font="7">  133.   Wijeysundera HC, Nallamothu BK, Krumholz HM, et al. Meta-analysis: effects of percutaneous coronary intervention versus medical therapy on angina relief. Ann Intern Med. 2010;152:370-9. </text>
</page>
<page number="42" position="absolute" top="0" left="0" height="918" width="1512">
<text top="59" left="108" width="4" height="15" font="0"> </text>
<text top="59" left="459" width="4" height="15" font="0"> </text>
<text top="59" left="810" width="4" height="15" font="0"> </text>
<text top="59" left="864" width="4" height="15" font="0"> </text>
<text top="59" left="918" width="4" height="15" font="0"> </text>
<text top="59" left="972" width="4" height="15" font="0"> </text>
<text top="59" left="1026" width="4" height="15" font="0"> </text>
<text top="59" left="1080" width="4" height="15" font="0"> </text>
<text top="59" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="108" width="613" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="825" left="810" width="4" height="15" font="0"> </text>
<text top="825" left="864" width="4" height="15" font="0"> </text>
<text top="825" left="918" width="4" height="15" font="0"> </text>
<text top="825" left="972" width="4" height="15" font="0"> </text>
<text top="825" left="1026" width="4" height="15" font="0"> </text>
<text top="825" left="1080" width="4" height="15" font="0"> </text>
<text top="825" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="1188" width="4" height="15" font="0"> </text>
<text top="825" left="1242" width="22" height="15" font="0">42 </text>
<text top="847" left="108" width="4" height="15" font="0"> </text>
<text top="111" left="108" width="1277" height="14" font="7">  134.   Takagi H, Kawai N, Umemoto T. Meta-analysis of four randomized controlled trials on long-term outcomes of coronary artery bypass grafting versus percutaneous coronary intervention with stenting for </text>
<text top="129" left="162" width="425" height="14" font="7">multivessel coronary artery disease. Am J Cardiol. 2008;101:1259-62. </text>
<text top="146" left="108" width="1244" height="14" font="7">  135.   Parisi AF, Folland ED, Hartigan P. A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. Veterans Affairs ACME Investigators. N Engl J Med. </text>
<text top="163" left="162" width="96" height="14" font="7">1992;326:10-6. </text>
<text top="180" left="108" width="1276" height="14" font="7">  136.   Cisowski M, Drzewiecki J, Drzewiecka-Gerber A, et al. Primary stenting versus MIDCAB: preliminary report-comparision of two methods of revascularization in single left anterior descending coronary </text>
<text top="197" left="162" width="348" height="14" font="7">artery stenosis. Ann Thorac Surg. 2002;74:S1334-S1339. </text>
<text top="215" left="108" width="1284" height="14" font="7">  137.   Drenth DJ, Veeger NJ, Winter JB, et al. A prospective randomized trial comparing stenting with off-pump coronary surgery for high-grade stenosis in the proximal left anterior descending coronary artery: </text>
<text top="232" left="162" width="360" height="14" font="7">three-year follow-up. J Am Coll Cardiol. 2002;40:1955-60. </text>
<text top="249" left="108" width="1288" height="14" font="7">  138.   Thiele H, Neumann-Schniedewind P, Jacobs S, et al. Randomized comparison of minimally invasive direct coronary artery bypass surgery versus sirolimus-eluting stenting in isolated proximal left anterior </text>
<text top="266" left="162" width="451" height="14" font="7">descending coronary artery stenosis. J Am Coll Cardiol. 2009;53:2324-31. </text>
<text top="284" left="108" width="1039" height="14" font="7">  139.   Gurfinkel EP, Perez dlH, Brito VM, et al. Invasive vs non-invasive treatment in acute coronary syndromes and prior bypass surgery. Int J Cardiol. 2007;119:65-72. </text>
<text top="301" left="108" width="1043" height="14" font="7">  140.   Pfautsch P, Frantz E, Ellmer A, et al. [Long-term outcome of therapy of recurrent myocardial ischemia after surgical revascularization]. Z Kardiol. 1999;88:489-97. </text>
<text top="318" left="108" width="1185" height="14" font="7">  141.   Subramanian S, Sabik JFI, Houghtaling PL, et al. Decision-making for patients with patent left internal thoracic artery grafts to left anterior descending. Ann Thorac Surg. 2009;87:1392-8. </text>
<text top="336" left="108" width="1151" height="14" font="7">  142.   Weintraub WS, Jones EL, Morris DC, et al. Outcome of reoperative coronary bypass surgery versus coronary angioplasty after previous bypass surgery. Circulation. 1997;95:868-77. </text>
<text top="353" left="108" width="1222" height="14" font="7">  143.   Stephan WJ, O'Keefe JH, Jr., Piehler JM, et al. Coronary angioplasty versus repeat coronary artery bypass grafting for patients with previous bypass surgery. J Am Coll Cardiol. 1996;28:1140-6. </text>
<text top="370" left="108" width="1279" height="14" font="7">  144.   The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med. 1996;335:217-</text>
<text top="387" left="162" width="22" height="14" font="7">25. </text>
<text top="404" left="108" width="1252" height="14" font="7">  145.   Writing Group for the Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Five-year clinical and functional outcome comparing bypass surgery and angioplasty in patients with </text>
<text top="422" left="162" width="532" height="14" font="7">multivessel coronary disease. A multicenter randomized trial. JAMA. 1997;277:715-21. </text>
<text top="439" left="108" width="1286" height="14" font="7">  146.   Multicenter, dose-ranging study of efegatran sulfate versus heparin with thrombolysis for acute myocardial infarction: The Promotion of Reperfusion in Myocardial Infarction Evolution (PRIME) trial. Am </text>
<text top="456" left="162" width="161" height="14" font="7">Heart J. 2002;143:95-105. </text>
<text top="473" left="108" width="1213" height="14" font="7">  147.   King SBI, Lembo NJ, Weintraub WS, et al. A randomized trial comparing coronary angioplasty with coronary bypass surgery. Emory Angioplasty versus Surgery Trial (EAST). N Engl J Med. </text>
<text top="491" left="162" width="118" height="14" font="7">1994;331:1044-50. </text>
<text top="508" left="108" width="1007" height="14" font="7">  148.   King SBI, Kosinski AS, Guyton RA, et al. Eight-year mortality in the Emory Angioplasty versus Surgery Trial (EAST). J Am Coll Cardiol. 2000;35:1116-21. </text>
<text top="525" left="108" width="1298" height="14" font="7">  149.   Hamm CW, Reimers J, Ischinger T, et al. A randomized study of coronary angioplasty compared with bypass surgery in patients with symptomatic multivessel coronary disease. German Angioplasty Bypass </text>
<text top="543" left="162" width="397" height="14" font="7">Surgery Investigation (GABI). N Engl J Med. 1994;331:1037-43. </text>
<text top="560" left="108" width="1238" height="14" font="7">  150.   Carrie D, Elbaz M, Puel J, et al. Five-year outcome after coronary angioplasty versus bypass surgery in multivessel coronary artery disease: results from the French Monocentric Study. Circulation. </text>
<text top="577" left="162" width="83" height="14" font="7">1997;96:II-6. </text>
<text top="594" left="108" width="1295" height="14" font="7">  151.   Henderson RA, Pocock SJ, Sharp SJ, et al. Long-term results of RITA-1 trial: clinical and cost comparisons of coronary angioplasty and coronary-artery bypass grafting. Randomised Intervention Treatment </text>
<text top="611" left="162" width="235" height="14" font="7">of Angina. Lancet. 1998;352:1419-25. </text>
<text top="629" left="108" width="1230" height="14" font="7">  152.   Rodriguez A, Mele E, Peyregne E, et al. Three-year follow-up of the Argentine Randomized Trial of Percutaneous Transluminal Coronary Angioplasty Versus Coronary Artery Bypass Surgery in </text>
<text top="646" left="162" width="415" height="14" font="7">Multivessel Disease (ERACI). J Am Coll Cardiol. 1996;27:1178-84. </text>
<text top="663" left="108" width="1277" height="14" font="7">  153.   Rodriguez A, Bernardi V, Navia J, et al. Argentine Randomized Study: Coronary Angioplasty with Stenting versus Coronary Bypass Surgery in patients with Multiple-Vessel Disease (ERACI II): 30-day </text>
<text top="680" left="162" width="545" height="14" font="7">and one-year follow-up results. ERACI II Investigators. J Am Coll Cardiol. 2001;37:51-8. </text>
<text top="698" left="108" width="1295" height="14" font="7">  154.   Hueb W, Soares PR, Gersh BJ, et al. The medicine, angioplasty, or surgery study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: one-</text>
<text top="715" left="162" width="305" height="14" font="7">year results. J Am Coll Cardiol. 2004;43:1743-51. </text>
<text top="732" left="108" width="985" height="14" font="7">  155.   CABRI Trial Participants. First-year results of CABRI (Coronary Angioplasty versus Bypass Revascularisation Investigation). Lancet. 1995;346:1179-84. </text>
<text top="750" left="108" width="1226" height="14" font="7">  156.   Wahrborg P. Quality of life after coronary angioplasty or bypass surgery. 1-year follow-up in the Coronary Angioplasty versus Bypass Revascularization investigation (CABRI) trial. Eur Heart J. </text>
<text top="767" left="162" width="96" height="14" font="7">1999;20:653-8. </text>
</page>
<page number="43" position="absolute" top="0" left="0" height="918" width="1512">
<text top="59" left="108" width="4" height="15" font="0"> </text>
<text top="59" left="459" width="4" height="15" font="0"> </text>
<text top="59" left="810" width="4" height="15" font="0"> </text>
<text top="59" left="864" width="4" height="15" font="0"> </text>
<text top="59" left="918" width="4" height="15" font="0"> </text>
<text top="59" left="972" width="4" height="15" font="0"> </text>
<text top="59" left="1026" width="4" height="15" font="0"> </text>
<text top="59" left="1080" width="4" height="15" font="0"> </text>
<text top="59" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="108" width="613" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="825" left="810" width="4" height="15" font="0"> </text>
<text top="825" left="864" width="4" height="15" font="0"> </text>
<text top="825" left="918" width="4" height="15" font="0"> </text>
<text top="825" left="972" width="4" height="15" font="0"> </text>
<text top="825" left="1026" width="4" height="15" font="0"> </text>
<text top="825" left="1080" width="4" height="15" font="0"> </text>
<text top="825" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="1188" width="4" height="15" font="0"> </text>
<text top="825" left="1242" width="22" height="15" font="0">43 </text>
<text top="847" left="108" width="4" height="15" font="0"> </text>
<text top="111" left="108" width="1289" height="14" font="7">  157.   Goy JJ, Kaufmann U, Goy-Eggenberger D, et al. A prospective randomized trial comparing stenting to internal mammary artery grafting for proximal, isolated de novo left anterior coronary artery stenosis: </text>
<text top="129" left="162" width="543" height="14" font="7">the SIMA trial. Stenting vs Internal Mammary Artery. Mayo Clin Proc. 2000;75:1116-23. </text>
<text top="146" left="108" width="1284" height="14" font="7">  158.   Morrison DA, Sethi G, Sacks J, et al. Percutaneous coronary intervention versus coronary artery bypass graft surgery for patients with medically refractory myocardial ischemia and risk factors for adverse </text>
<text top="163" left="162" width="1210" height="14" font="7">outcomes with bypass: a multicenter, randomized trial. Investigators of the Department of Veterans Affairs Cooperative Study #385, the Angina With Extremely Serious Operative Mortality Evaluation </text>
<text top="180" left="162" width="307" height="14" font="7">(AWESOME). J Am Coll Cardiol. 2001;38:143-9. </text>
<text top="197" left="108" width="1228" height="14" font="7">  159.   Stroupe KT, Morrison DA, Hlatky MA, et al. Cost-effectiveness of coronary artery bypass grafts versus percutaneous coronary intervention for revascularization of high-risk patients. Circulation. </text>
<text top="215" left="162" width="111" height="14" font="7">2006;114:1251-7. </text>
<text top="232" left="108" width="1261" height="14" font="7">  160.   Rodriguez AE, Baldi J, Fernandez PC, et al. Five-year follow-up of the Argentine randomized trial of coronary angioplasty with stenting versus coronary bypass surgery in patients with multiple vessel </text>
<text top="249" left="162" width="337" height="14" font="7">disease (ERACI II). J Am Coll Cardiol. 2005;46:582-8. </text>
<text top="266" left="108" width="1275" height="14" font="7">  161.   The SoS Investigators. Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): a </text>
<text top="284" left="162" width="329" height="14" font="7">randomised controlled trial. Lancet. 2002;360:965-70. </text>
<text top="301" left="108" width="1293" height="14" font="7">  162.   Serruys PW, Ong AT, van Herwerden LA, et al. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization </text>
<text top="318" left="162" width="481" height="14" font="7">Therapies Study (ARTS) randomized trial. J Am Coll Cardiol. 2005;46:575-81. </text>
<text top="336" left="108" width="1269" height="14" font="7">  163.   Thiele H, Oettel S, Jacobs S, et al. Comparison of bare-metal stenting with minimally invasive bypass surgery for stenosis of the left anterior descending coronary artery: a 5-year follow-up. Circulation. </text>
<text top="353" left="162" width="118" height="14" font="7">2005;112:3445-50. </text>
<text top="370" left="108" width="1249" height="14" font="7">  164.   Pohl T, Giehrl W, Reichart B, et al. Retroinfusion-supported stenting in high-risk patients for percutaneous intervention and bypass surgery: results of the prospective randomized myoprotect I study. </text>
<text top="387" left="162" width="272" height="14" font="7">Catheter Cardiovasc Interv. 2004;62:323-30. </text>
<text top="404" left="108" width="1128" height="14" font="7">  165.   Eefting F, Nathoe H, van Dijk D, et al. Randomized comparison between stenting and off-pump bypass surgery in patients referred for angioplasty. Circulation. 2003;108:2870-6. </text>
<text top="422" left="108" width="1259" height="14" font="7">  166.   Reeves BC, Angelini GD, Bryan AJ, et al. A multi-centre randomised controlled trial of minimally invasive direct coronary bypass grafting versus percutaneous transluminal coronary angioplasty with </text>
<text top="439" left="162" width="691" height="14" font="7">stenting for proximal stenosis of the left anterior descending coronary artery. Health Technol Assess. 2004;8:1-43. </text>
<text top="456" left="108" width="1093" height="14" font="7">  167.   Kim JW, Lim DS, Sun K, et al. Stenting or MIDCAB using ministernotomy for revascularization of proximal left anterior descending artery? Int J Cardiol. 2005;99:437-41. </text>
<text top="473" left="108" width="1201" height="14" font="7">  168.   Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009;360:961-72. </text>
<text top="491" left="108" width="198" height="14" font="7">  169.   SYNTAX Score. 2011; </text>
<text top="508" left="108" width="1279" height="14" font="7">  170.   Park DW, Yun SC, Lee SW, et al. Long-term mortality after percutaneous coronary intervention with drug-eluting stent implantation versus coronary artery bypass surgery for the treatment of multivessel </text>
<text top="525" left="162" width="340" height="14" font="7">coronary artery disease. Circulation. 2008;117:2079-86. </text>
<text top="543" left="108" width="1205" height="14" font="7">  171.   Briguori C, Condorelli G, Airoldi F, et al. Comparison of coronary drug-eluting stents versus coronary artery bypass grafting in patients with diabetes mellitus. Am J Cardiol. 2007;99:779-84. </text>
<text top="560" left="108" width="1280" height="14" font="7">  172.   Yang ZK, Shen WF, Zhang RY, et al. Coronary artery bypass surgery versus percutaneous coronary intervention with drug-eluting stent implantation in patients with multivessel coronary disease. J Interv </text>
<text top="577" left="162" width="141" height="14" font="7">Cardiol. 2007;20:10-6. </text>
<text top="594" left="108" width="1050" height="14" font="7">  173.   Lee MS, Jamal F, Kedia G, et al. Comparison of bypass surgery with drug-eluting stents for diabetic patients with multivessel disease. Int J Cardiol. 2007;123:34-42. </text>
<text top="611" left="108" width="1295" height="14" font="7">  174.   Yang JH, Gwon HC, Cho SJ, et al. Comparison of coronary artery bypass grafting with drug-eluting stent implantation for the treatment of multivessel coronary artery disease. Ann Thorac Surg. 2008;85:65-</text>
<text top="629" left="162" width="22" height="14" font="7">70. </text>
<text top="646" left="108" width="1270" height="14" font="7">  175.   Varani E, Balducelli M, Vecchi G, et al. Comparison of multiple drug-eluting stent percutaneous coronary intervention and surgical revascularization in patients with multivessel coronary artery disease: </text>
<text top="663" left="162" width="521" height="14" font="7">one-year clinical results and total treatment costs. J Invasive Cardiol. 2007;19:469-75. </text>
<text top="680" left="108" width="976" height="14" font="7">  176.   Tarantini G, Ramondo A, Napodano M, et al. PCI versus CABG for multivessel coronary disease in diabetics. Catheter Cardiovasc Interv. 2009;73:50-8. </text>
<text top="698" left="108" width="990" height="14" font="7">  177.   Seung KB, Park DW, Kim YH, et al. Stents versus coronary-artery bypass grafting for left main coronary artery disease. N Engl J Med. 2008;358:1781-92. </text>
<text top="715" left="108" width="1261" height="14" font="7">  178.   Rodes-Cabau J, Deblois J, Bertrand OF, et al. Nonrandomized comparison of coronary artery bypass surgery and percutaneous coronary intervention for the treatment of unprotected left main coronary </text>
<text top="732" left="162" width="385" height="14" font="7">artery disease in octogenarians. Circulation. 2008;118:2374-81. </text>
<text top="750" left="108" width="537" height="14" font="7">  179.   Serruys P. Left main lessons from SYNTAX: interventional perspectives. 2009; </text>
<text top="767" left="108" width="1283" height="14" font="7">  180.   Goy JJ, Eeckhout E, Moret C, et al. Five-year outcome in patients with isolated proximal left anterior descending coronary artery stenosis treated by angioplasty or left internal mammary artery grafting. A </text>
<text top="784" left="162" width="283" height="14" font="7">prospective trial. Circulation. 1999;99:3255-9. </text>
</page>
<page number="44" position="absolute" top="0" left="0" height="918" width="1512">
<text top="59" left="108" width="4" height="15" font="0"> </text>
<text top="59" left="459" width="4" height="15" font="0"> </text>
<text top="59" left="810" width="4" height="15" font="0"> </text>
<text top="59" left="864" width="4" height="15" font="0"> </text>
<text top="59" left="918" width="4" height="15" font="0"> </text>
<text top="59" left="972" width="4" height="15" font="0"> </text>
<text top="59" left="1026" width="4" height="15" font="0"> </text>
<text top="59" left="1080" width="4" height="15" font="0"> </text>
<text top="59" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="108" width="613" height="15" font="0">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="825" left="810" width="4" height="15" font="0"> </text>
<text top="825" left="864" width="4" height="15" font="0"> </text>
<text top="825" left="918" width="4" height="15" font="0"> </text>
<text top="825" left="972" width="4" height="15" font="0"> </text>
<text top="825" left="1026" width="4" height="15" font="0"> </text>
<text top="825" left="1080" width="4" height="15" font="0"> </text>
<text top="825" left="1134" width="4" height="15" font="0"> </text>
<text top="825" left="1188" width="4" height="15" font="0"> </text>
<text top="825" left="1242" width="22" height="15" font="0">44 </text>
<text top="847" left="108" width="4" height="15" font="0"> </text>
<text top="111" left="108" width="1290" height="14" font="7">  181.   Hueb WA, Soares PR, Almeida De OS, et al. Five-year follow-op of the medicine, angioplasty, or surgery study (MASS): A prospective, randomized trial of medical therapy, balloon angioplasty, or bypass </text>
<text top="129" left="162" width="677" height="14" font="7">surgery for single proximal left anterior descending coronary artery stenosis. Circulation. 1999;100:II107-II113. </text>
<text top="146" left="108" width="1298" height="14" font="7">  182.   Toutouzas K, Patsa C, Vaina S, et al. Drug eluting stents versus coronary artery bypass surgery in patients with isolated proximal lesion in left anterior descending artery suffering from chronic stable angina. </text>
<text top="163" left="162" width="265" height="14" font="7">Catheter Cardiovasc Interv. 2007;70:832-7. </text>
<text top="180" left="108" width="1264" height="14" font="7">  183.   Banning AP, Westaby S, Morice MC, et al. Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease: comparison of outcomes with cardiac surgery and paclitaxel-eluting </text>
<text top="197" left="162" width="270" height="14" font="7">stents. J Am Coll Cardiol. 2010;55:1067-75. </text>
<text top="215" left="108" width="1099" height="14" font="7">  184.   Serruys PW, Unger F, Sousa JE, et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med. 2001;344:1117-24. </text>
<text top="233" left="108" width="4" height="16" font="0"> </text>
<text top="253" left="108" width="4" height="16" font="0"> </text>
</page>
</pdf2xml>
